0000004977afl:AflacJapanMemberafl:ClosedblockMember2022-12-31

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

☒

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, ~~2022~~2023

☐

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission File Number: 001-07434

Aflac Incorporated

(Exact name of registrant as specified in its charter)

Georgia

58-1167100

(State or other jurisdiction of incorporation or organization)

(I.R.S. Employer Identification No.)

1932 Wynnton Road

Columbus,

Georgia

31999

(Address of principal executive offices)

(ZIP Code)

706. 323.3431

(Registrant's telephone number, including area code)


(Former name, former address and former fiscal year, if changed since last report)

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, $.10 par value per share

AFL

New York Stock Exchange

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. þ Yes ¨ No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). þ Yes ¨ No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.


Large accelerated filer	þ	Accelerated filer	☐
Non-accelerated filer	¨	Smaller reporting company	☐
		Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). ☐ Yes þ No

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date. ~~644,164,538~~604,226,995 shares of the issuer's common stock were outstanding as of April 21, ~~2022.~~2023.

Aflac Incorporated and Subsidiaries

Quarterly Report on Form 10-Q

For the Quarter Ended March 31, ~~2022~~2023

Table of Contents


PART I.		FINANCIAL INFORMATION:	Page

	Item 1.	Financial Statements (Unaudited)

		Consolidated Statements of Earnings Three Months Ended March 31, ~~2022~~2023 and ~~2021~~2022	1

		Consolidated Statements of Comprehensive Income (Loss) Three Months Ended March 31, ~~2022~~2023 and ~~2021~~2022	2

		Consolidated Balance Sheets March 31, ~~2022,~~2023, and December 31, ~~2021~~2022	3

		Consolidated Statements of Shareholders' Equity Three Months Ended March 31, ~~2022~~2023 and ~~2021~~2022	4

		Consolidated Statements of Cash Flows Three Months Ended March 31, ~~2022~~2023 and ~~2021~~2022	5

		Notes to the Consolidated Financial Statements	6

	Item 2.	Management's Discussion and Analysis of Financial Condition and Results of Operations	6375

	Item 3.	Quantitative and Qualitative Disclosures about Market Risk	94107

	Item 4.	Controls and Procedures	94107

PART II.		OTHER INFORMATION:

	~~Item 1A.~~	~~Risk Factors~~	95

	Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	96108



	Item 6.	Exhibits	97109

Glossary of Selected Terms			99110

Items other than those listed above are omitted because they are not required or are not applicable.

PART I. FINANCIAL INFORMATION

Item 1. Financial Statements.

Aflac Incorporated and Subsidiaries

Consolidated Statements of Earnings


		Three Months Ended March 31,						Three Months Ended March 31,
(In millions, except for share and per-share amounts - Unaudited)	(In millions, except for share and per-share amounts - Unaudited)		2022	2021			(In millions, except for share and per-share amounts - Unaudited)				2023		2022
Revenues:	Revenues:											Revenues:
Net earned premiums, principally supplemental health insurance	Net earned premiums, principally supplemental health insurance				$	4,178			$	4,593		Net earned premiums, principally supplemental health insurance		$	3,688	$	4,079
Net investment income	Net investment income				903				925			Net investment income		943		903
Net investment gains (losses)	Net investment gains (losses)				122				307			Net investment gains (losses)		123		122
Other income (loss)	Other income (loss)				69				44			Other income (loss)		46		69
Total revenues	Total revenues				5,272				5,869			Total revenues		4,800		5,173
Benefits and expenses:	Benefits and expenses:											Benefits and expenses:
Benefits and claims, net					2,487				2,735
Benefits and claims, excluding reserve remeasurement												Benefits and claims, excluding reserve remeasurement		2,203		2,517
Reserve remeasurement (gains) losses												Reserve remeasurement (gains) losses		(53)		(34)
Total benefits and claims, net												Total benefits and claims, net		2,150		2,483
Acquisition and operating expenses:	Acquisition and operating expenses:											Acquisition and operating expenses:
Amortization of deferred policy acquisition costs	Amortization of deferred policy acquisition costs				322				311			Amortization of deferred policy acquisition costs		205		207
Insurance commissions	Insurance commissions				300				326			Insurance commissions		280		300
Insurance and other expenses	Insurance and other expenses				831				832			Insurance and other expenses		775		833
Interest expense	Interest expense				56				62			Interest expense		48		56
Total acquisition and operating expenses	Total acquisition and operating expenses				1,509				1,531			Total acquisition and operating expenses		1,308		1,396
Total benefits and expenses	Total benefits and expenses				3,996				4,266			Total benefits and expenses		3,458		3,879
Earnings before income taxes	Earnings before income taxes				1,276				1,603			Earnings before income taxes		1,342		1,294
Income taxes	Income taxes				244				310			Income taxes		154		247
Net earnings	Net earnings				$	1,032			$	1,293		Net earnings		$	1,188	$	1,047
Net earnings per share:	Net earnings per share:											Net earnings per share:
Basic	Basic				$	1.59			$	1.88		Basic		$	1.94	$	1.61
Diluted	Diluted				1.58				1.87			Diluted		1.94		1.60
Weighted-average outstanding common shares used in computing earnings per share (In thousands):	Weighted-average outstanding common shares used in computing earnings per share (In thousands):											Weighted-average outstanding common shares used in computing earnings per share (In thousands):
Basic	Basic				649,753				688,938			Basic		611,205		649,753
Diluted	Diluted				652,827				691,940			Diluted		613,950		652,827
Cash dividends per share	Cash dividends per share				$	.40			$	.33		Cash dividends per share		$	.42	$	.40

Prior-year amounts have been adjusted for the adoption of accounting guidance on January 1, 2023 related to accounting for long-duration insurance contracts.

See the accompanying Notes to the Consolidated Financial Statements.

Aflac Incorporated and Subsidiaries

Consolidated Statements of Comprehensive Income (Loss)


		Three Months Ended March 31,						Three Months Ended March 31,
(In millions - Unaudited)	(In millions - Unaudited)		2022	2021			(In millions - Unaudited)				2023		2022
Net earnings	Net earnings				$	1,032			$	1,293		Net earnings		$	1,188	$	1,047
Other comprehensive income (loss) before income taxes:	Other comprehensive income (loss) before income taxes:											Other comprehensive income (loss) before income taxes:
Unrealized foreign currency translation gains (losses) during period	Unrealized foreign currency translation gains (losses) during period				(467)				(581)			Unrealized foreign currency translation gains (losses) during period		(43)		(452)
Unrealized gains (losses) on fixed maturity securities:	Unrealized gains (losses) on fixed maturity securities:											Unrealized gains (losses) on fixed maturity securities:
Unrealized holding gains (losses) on fixed maturity securities during period	Unrealized holding gains (losses) on fixed maturity securities during period				(4,752)				(2,003)			Unrealized holding gains (losses) on fixed maturity securities during period		2,578		(4,752)
Reclassification adjustment for (gains) losses on fixed maturity securities included in net earnings	Reclassification adjustment for (gains) losses on fixed maturity securities included in net earnings				(77)				20			Reclassification adjustment for (gains) losses on fixed maturity securities included in net earnings		(57)		(77)
Unrealized gains (losses) on derivatives during period	Unrealized gains (losses) on derivatives during period				1				0			Unrealized gains (losses) on derivatives during period		1		1
Effect of changes in discount rate assumptions during period												Effect of changes in discount rate assumptions during period		(3,537)		5,347
Pension liability adjustment during period	Pension liability adjustment during period				3				5			Pension liability adjustment during period		9		3
Total other comprehensive income (loss) before income taxes	Total other comprehensive income (loss) before income taxes				(5,292)				(2,559)			Total other comprehensive income (loss) before income taxes		(1,049)		70
Income tax expense (benefit) related to items of other comprehensive income (loss)	Income tax expense (benefit) related to items of other comprehensive income (loss)				(1,012)				(432)			Income tax expense (benefit) related to items of other comprehensive income (loss)		(200)		110
Other comprehensive income (loss), net of income taxes	Other comprehensive income (loss), net of income taxes				(4,280)				(2,127)			Other comprehensive income (loss), net of income taxes		(849)		(40)
Total comprehensive income (loss)	Total comprehensive income (loss)				$	(3,248)			$	(834)		Total comprehensive income (loss)		$	339	$	1,007

Prior-year amounts have been adjusted for the adoption of accounting guidance on January 1, 2023 related to accounting for long-duration insurance contracts.

See the accompanying Notes to the Consolidated Financial Statements.

Aflac Incorporated and Subsidiaries

Consolidated Balance Sheets


(In millions, except for share and per-share amounts)		March 31, 2022 (Unaudited)			December 31, 2021
(In millions, except for share and per-share amounts - Unaudited)								(In millions, except for share and per-share amounts - Unaudited)	March 31, 2023			December 31, 2022
Assets:	Assets:							Assets:
Investments and cash:	Investments and cash:							Investments and cash:
Fixed maturity securities available for sale, at fair value, (no allowance for credit losses in 2022 and 2021, amortized cost $78,241 in 2022 and $82,105 in 2021)			$	85,795		$	94,206
Fixed maturity securities available for sale - consolidated variable interest entities, at fair value (amortized cost $3,223 in 2022 and $3,264 in 2021)			4,170			4,490
Fixed maturity securities held to maturity, at amortized cost, net of allowance for credit losses of $8 in 2022 and $8 in 2021 (fair value $24,585 in 2022 and $26,869 in 2021)			20,672			22,000
Fixed maturity securities available for sale, at fair value, (no allowance for credit losses in 2023 and 2022, amortized cost $72,084 in 2023 and $72,246 in 2022)								Fixed maturity securities available for sale, at fair value, (no allowance for credit losses in 2023 and 2022, amortized cost $72,084 in 2023 and $72,246 in 2022)		$	74,174		$	71,936
Fixed maturity securities available for sale - consolidated variable interest entities, at fair value (amortized cost $3,222 in 2023 and $3,223 in 2022)								Fixed maturity securities available for sale - consolidated variable interest entities, at fair value (amortized cost $3,222 in 2023 and $3,223 in 2022)		3,925			3,805
Fixed maturity securities held to maturity, at amortized cost, net of allowance for credit losses of $6 in 2023 and $7 in 2022 (fair value $21,616 in 2023 and $21,210 in 2022)								Fixed maturity securities held to maturity, at amortized cost, net of allowance for credit losses of $6 in 2023 and $7 in 2022 (fair value $21,616 in 2023 and $21,210 in 2022)		18,936			19,056
Equity securities, at fair value	Equity securities, at fair value		1,415			1,603		Equity securities, at fair value		1,087			1,091
Commercial mortgage and other loans, net of allowance for credit losses of $158 in 2022 and $174 in 2021 (includes $10,027 in 2022 and $9,740 in 2021 of consolidated variable interest entities)			12,312			11,786
Other investments (includes $1,624 in 2022 and $1,535 in 2021 of consolidated variable interest entities)			3,960			3,842
Commercial mortgage and other loans, net of allowance for credit losses of $223 in 2023 and $192 in 2022 (includes $10,684 in 2023 and $10,832 in 2022 of consolidated variable interest entities)								Commercial mortgage and other loans, net of allowance for credit losses of $223 in 2023 and $192 in 2022 (includes $10,684 in 2023 and $10,832 in 2022 of consolidated variable interest entities)		13,328			13,496
Other investments (includes $2,049 in 2023 and $1,909 in 2022 of consolidated variable interest entities)								Other investments (includes $2,049 in 2023 and $1,909 in 2022 of consolidated variable interest entities)		5,241			4,070
Cash and cash equivalents	Cash and cash equivalents		4,275			5,051		Cash and cash equivalents		3,809			3,943
Total investments and cash	Total investments and cash		132,599			142,978		Total investments and cash		120,500			117,397
Receivables	Receivables		730			693		Receivables		789			647
Accrued investment income	Accrued investment income		683			737		Accrued investment income		701			745
Deferred policy acquisition costs	Deferred policy acquisition costs		9,082			9,525		Deferred policy acquisition costs		9,267			9,239
Property and equipment, at cost less accumulated depreciation	Property and equipment, at cost less accumulated depreciation		538			538		Property and equipment, at cost less accumulated depreciation		528			530
Other	Other		3,414			3,071		Other		3,181			3,180
Total assets	Total assets		$	147,046		$	157,542	Total assets		$	134,966		$	131,738
Liabilities and shareholders’ equity:	Liabilities and shareholders’ equity:							Liabilities and shareholders’ equity:
Liabilities:	Liabilities:							Liabilities:
Policy liabilities:	Policy liabilities:							Policy liabilities:
Future policy benefits	Future policy benefits		$	85,866		$	90,588	Future policy benefits		$	91,293		$	88,241
Unpaid policy claims	Unpaid policy claims		4,754			4,836		Unpaid policy claims		229			201
Unearned premiums	Unearned premiums		2,318			2,576		Unearned premiums		1,743			1,825
Other policyholders’ funds	Other policyholders’ funds		6,705			7,072		Other policyholders’ funds		6,668			6,643
Total policy liabilities	Total policy liabilities		99,643			105,072		Total policy liabilities		99,933			96,910
Income taxes	Income taxes		3,503			4,339		Income taxes		647			698
Payables for return of cash collateral on loaned securities	Payables for return of cash collateral on loaned securities		2,198			2,162		Payables for return of cash collateral on loaned securities		3,460			1,809
Notes payable and lease obligations	Notes payable and lease obligations		7,768			7,956		Notes payable and lease obligations		7,420			7,442
Other	Other		4,407			4,760		Other		3,722			4,739
Total liabilities	Total liabilities		117,519			124,289		Total liabilities		115,182			111,598
Commitments and contingent liabilities (Note 12)			0			0
Commitments and contingent liabilities (Note 13)								Commitments and contingent liabilities (Note 13)
Shareholders’ equity:	Shareholders’ equity:							Shareholders’ equity:
Common stock of $.10 par value. In thousands: authorized 1,900,000 shares in 2022 and 2021; issued 1,353,780 shares in 2022 and 1,352,739 shares in 2021			135			135
Common stock of $.10 par value. In thousands: authorized 1,900,000 shares in 2023 and 2022; issued 1,355,012 shares in 2023 and 1,354,079 shares in 2022								Common stock of $.10 par value. In thousands: authorized 1,900,000 shares in 2023 and 2022; issued 1,355,012 shares in 2023 and 1,354,079 shares in 2022		135			135
Additional paid-in capital	Additional paid-in capital		2,560			2,529		Additional paid-in capital		2,665			2,641
Retained earnings	Retained earnings		42,413			41,381		Retained earnings		45,555			44,367
Accumulated other comprehensive income (loss):	Accumulated other comprehensive income (loss):							Accumulated other comprehensive income (loss):
Unrealized foreign currency translation gains (losses)	Unrealized foreign currency translation gains (losses)		(2,482)			(2,013)		Unrealized foreign currency translation gains (losses)		(3,618)			(3,564)
Unrealized gains (losses) on fixed maturity securities	Unrealized gains (losses) on fixed maturity securities		5,787			9,602		Unrealized gains (losses) on fixed maturity securities		1,289			(702)
Unrealized gains (losses) on derivatives	Unrealized gains (losses) on derivatives		(29)			(30)		Unrealized gains (losses) on derivatives		(26)			(27)
Effect of changes in discount rate assumptions								Effect of changes in discount rate assumptions		(4,894)			(2,100)
Pension liability adjustment	Pension liability adjustment		(163)			(166)		Pension liability adjustment		(29)			(36)
Treasury stock, at average cost	Treasury stock, at average cost		(18,694)			(18,185)		Treasury stock, at average cost		(21,293)			(20,574)
Total shareholders’ equity	Total shareholders’ equity		29,527			33,253		Total shareholders’ equity		19,784			20,140
Total liabilities and shareholders’ equity	Total liabilities and shareholders’ equity		$	147,046		$	157,542	Total liabilities and shareholders’ equity		$	134,966		$	131,738

Prior-year amounts have been adjusted for the adoption of accounting guidance on January 1, 2023 related to accounting for long-duration insurance contracts.

See the accompanying Notes to the Consolidated Financial Statements.

Aflac Incorporated and Subsidiaries

Consolidated Statements of Shareholders’ Equity


(In millions, except for per share amounts - Unaudited)	Common Stock		Additional Paid-in Capital		Retained Earnings		Accumulated Other Comprehensive Income (Loss)		Treasury Stock		Total Shareholders' Equity
Balance at December 31, 2022	$	135	$	2,641	$	44,367	$	(6,429)	$	(20,574)	$	20,140
Net earnings	0		0		1,188		0		0		1,188
Unrealized foreign currency translation gains (losses) during period, net of income taxes	0		0		0		(54)		0		(54)
Unrealized gains (losses) on fixed maturity securities during period, net of income taxes and reclassification adjustments	0		0		0		1,991		0		1,991
Unrealized gains (losses) on derivatives during period, net of income taxes	0		0		0		1		0		1
Effect of changes in discount rate assumptions during period, net of income taxes	0		0		0		(2,794)		0		(2,794)
Pension liability adjustment during period, net of income taxes	0		0		0		7		0		7
Dividends to shareholders (1) ($.00 per share)	0		0		0		0		0		0
Exercise of stock options	0		3		0		0		0		3
Share-based compensation	0		14		0		0		0		14
Purchases of treasury stock	0		0		0		0		(732)		(732)
Treasury stock reissued	0		7		0		0		13		20
Balance at March 31, 2023	$	135	$	2,665	$	45,555	$	(7,278)	$	(21,293)	$	19,784


(In millions, except for per share amounts - Unaudited)	Common Stock		Additional Paid-in Capital		Retained Earnings		Accumulated Other Comprehensive Income (Loss)		Treasury Stock		Total Shareholders' Equity
Balance at December 31, 2021	$	135	$	2,529	$	40,963	$	(8,411)	$	(18,185)	$	17,031
Net earnings	0		0		1,047		0		0		1,047
Unrealized foreign currency translation gains (losses) during period, net of income taxes	0		0		0		(453)		0		(453)
Unrealized gains (losses) on fixed maturity securities during period, net of income taxes and reclassification adjustments	0		0		0		(3,815)		0		(3,815)
Unrealized gains (losses) on derivatives during period, net of income taxes	0		0		0		1		0		1
Effect of changes in discount rate assumptions during period, net of income taxes	0		0		0		4,224		0		4,224
Pension liability adjustment during period, net of income taxes	0		0		0		3		0		3
Dividends to shareholders (1) ($.00 per share)	0		0		0		0		0		0
Exercise of stock options	0		6		0		0		0		6
Share-based compensation	0		13		0		0		0		13
Purchases of treasury stock	0		0		0		0		(523)		(523)
Treasury stock reissued	0		12		0		0		14		26
Balance at March 31, 2022	$	135	$	2,560	$	42,010	$	(8,451)	$	(18,694)	$	17,560

(1) Dividends to shareholders are recorded in the period in which they are declared.

Prior-year amounts have been adjusted for the adoption of accounting guidance on January 1, 2023 related to accounting for long-duration insurance contracts.

See the accompanying Notes to the Consolidated Financial Statements.

Aflac Incorporated and Subsidiaries

Consolidated Statements of ~~Shareholders’ Equity~~

(In millions, except for per share amounts - Unaudited) Common Stock Additional Paid-in Capital Retained Earnings Accumulated Other Comprehensive Income (Loss) Treasury Stock Total Shareholders'
Equity
Balance at December 31, 2021 $ 135 $ 2,529 $ 41,381 $ 7,393 $ (18,185) $ 33,253
Net earnings 0 0 1,032 0 0 1,032
Unrealized foreign currency translation
   gains (losses) during period, net of
   income taxes 0 0 0 (469) 0 (469)
Unrealized gains (losses) on fixed maturity
   securities during period, net of income
   taxes and reclassification adjustments 0 0 0 (3,815) 0 (3,815)
Unrealized gains (losses) on derivatives
   during period, net of income taxes 0 0 0 1 0 1
Pension liability adjustment during period,
   net of income taxes 0 0 0 3 0 3
Dividends to shareholders (1)
  ($.00 per share)
0 0 0 0 0 0
Exercise of stock options 0 6 0 0 0 6
Share-based compensation 0 13 0 0 0 13
Purchases of treasury stock 0 0 0 0 (523) (523)
Treasury stock reissued 0 12 0 0 14 26
Balance at March 31, 2022 $ 135 $ 2,560 $ 42,413 $ 3,113 $ (18,694) $ 29,527

(In millions, except for per share amounts - Unaudited) Common Stock Additional Paid-in Capital Retained Earnings Accumulated Other Comprehensive Income (Loss) Treasury Stock Total Shareholders'
Equity
Balance at December 31, 2020 $ 135 $ 2,410 $ 37,984 $ 8,934 $ (15,904) $ 33,559
Net earnings 0 0 1,293 0 0 1,293
Unrealized foreign currency translation
   gains (losses) during period, net of
   income taxes 0 0 0 (565) 0 (565)
Unrealized gains (losses) on fixed maturity
   securities during period, net of income
   taxes and reclassification adjustments 0 0 0 (1,567) 0 (1,567)
Unrealized gains (losses) on derivatives
   during period, net of income taxes 0 0 0 1 0 1
Pension liability adjustment during period,
   net of income taxes 0 0 0 4 0 4
Dividends to shareholders (1)
  ($.00 per share)
0 0 0 0 0 0
Exercise of stock options 0 9 0 0 0 9
Share-based compensation 0 9 0 0 0 9
Purchases of treasury stock 0 0 0 0 (668) (668)
Treasury stock reissued 0 10 0 0 18 28
Balance at March 31, 2021 $ 135 $ 2,438 $ 39,277 $ 6,807 $ (16,554) $ 32,103

~~(1)~~ ~~Dividends to shareholders are recorded in the period in which they are declared.~~

~~See the accompanying Notes to the Consolidated Financial Statements.~~

~~Aflac Incorporated and Subsidiaries~~

~~Consolidated Statements of~~ Cash Flows
   Three Months Ended March 31,
(In millions - Unaudited) 2022 2021
Cash flows from operating activities:
Net earnings $ 1,032 $ 1,293
Adjustments to reconcile net earnings to net cash provided (used) by operating activities:
Change in receivables and advance premiums (30) (19)
Capitalization of deferred policy acquisition costs (255) (262)
Amortization of deferred policy acquisition costs 322 311
Increase in policy liabilities 198 204
Change in income tax liabilities 321 331
Net investment (gains) losses (122) (307)
Other, net (206) (185)
Net cash provided (used) by operating activities 1,260 1,366
Cash flows from investing activities:
Proceeds from investments sold or matured:
Available-for-sale fixed maturity securities 545 651
Equity securities 102 123
Commercial mortgage and other loans 638 725
Costs of investments acquired:
Available-for-sale fixed maturity securities (707) (2,475)
Equity securities (114) (126)
Commercial mortgage and other loans (1,161) (956)
Other investments, net (138) (201)
Settlement of derivatives, net (558) 116
Cash received (pledged or returned) as collateral, net 142 1,206
Other, net 41 (32)
Net cash provided (used) by investing activities (1,210) (969)
Cash flows from financing activities:
Purchases of treasury stock (500) (650)
Proceeds from borrowings 0 400
Dividends paid to shareholders (250) (219)
Change in investment-type contracts, net (21) (12)
Treasury stock reissued 9 9
Other, net 25

2
Net cash provided (used) by financing activities (737) (470)
Effect of exchange rate changes on cash and cash equivalents (89) (78)
Net change in cash and cash equivalents (776) (151)
Cash and cash equivalents, beginning of period 5,051 5,141
Cash and cash equivalents, end of period $ 4,275 $ 4,990
Supplemental disclosures of cash flow information:
Income taxes paid $ (77) $ (20)
Interest paid 37 35
Noncash interest 19 27
Noncash financing activities:
Lease obligations 73 20
Treasury stock issued for:
   Associate stock bonus 3 7
   Shareholder dividend reinvestment 9 8
   Share-based compensation grants 5 4


	Three Months Ended March 31,
(In millions - Unaudited)	2023			2022
Cash flows from operating activities:
Net earnings		$	1,188		$	1,047
Adjustments to reconcile net earnings to net cash provided (used) by operating activities:
Change in receivables and advance premiums		(34)			(29)
Capitalization of deferred policy acquisition costs		(270)			(255)
Amortization of deferred policy acquisition costs		205			207
Increase in policy liabilities		(361)			143
Change in income tax liabilities		154			325
Net investment (gains) losses		(123)			(122)
Other, net		(51)			(56)
Net cash provided (used) by operating activities		708			1,260
Cash flows from investing activities:
Proceeds from investments sold or matured:
Available-for-sale fixed maturity securities		949			545
Equity securities		126			102

Commercial mortgage and other loans		418			638
Costs of investments acquired:
Available-for-sale fixed maturity securities		(1,090)			(707)
Equity securities		(134)			(114)
Commercial mortgage and other loans		(315)			(1,161)
Other investments, net		(1,074)			(138)
Settlement of derivatives, net		(480)			(558)
Cash received (pledged or returned) as collateral, net		1,756			142
Other, net		(51)			41
Net cash provided (used) by investing activities		105			(1,210)
Cash flows from financing activities:
Purchases of treasury stock		(700)			(500)


Dividends paid to shareholders		(248)			(250)
Change in investment-type contracts, net		(28)			(21)
Treasury stock reissued		2			9
Other, net		41			25
Net cash provided (used) by financing activities		(933)			(737)
Effect of exchange rate changes on cash and cash equivalents		(14)			(89)
Net change in cash and cash equivalents		(134)			(776)
Cash and cash equivalents, beginning of period		3,943			5,051
Cash and cash equivalents, end of period		$	3,809		$	4,275
Supplemental disclosures of cash flow information:
Income taxes paid		$	0		$	(77)
Interest paid		37			37
Noncash interest		11			19
Noncash financing activities:
Lease obligations		18			73
Treasury stock issued for:
Associate stock bonus		4			3
Shareholder dividend reinvestment		9			9
Share-based compensation grants		5			5

Prior-year amounts have been adjusted for the adoption of accounting guidance on January 1, 2023 related to accounting for long-duration insurance contracts.

See the accompanying Notes to the Consolidated Financial Statements.

Aflac Incorporated and Subsidiaries

Notes to the Consolidated Financial Statements

~~(Interim period data – Unaudited)~~(Unaudited)

1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Description of Business

Aflac Incorporated (the Parent Company) and its subsidiaries (collectively, the Company) primarily sell supplemental health and life insurance in the United States (U.S.) and Japan. The Company's insurance business is marketed and administered through American Family Life Assurance Company of Columbus (Aflac) in the U.S. and through Aflac Life Insurance Japan Ltd. (ALIJ) in Japan. The Company’s operations consist of 2two reportable business segments: Aflac U.S., which includes Aflac, and Aflac Japan, which includes ALIJ. American Family Life Assurance Company of New York (Aflac New York) is a wholly owned subsidiary of Aflac. Most of Aflac's policies are individually underwritten and marketed through independent agents. With the exception of dental and vision products administered by ~~Argus Dental & Vision,~~Aflac Benefits Solutions, Inc. ~~(Argus)~~(ABS) and certain group life insurance products, Aflac U.S. markets and administers group products through Continental American Insurance Company (CAIC), branded as Aflac Group Insurance. Additionally, Aflac U.S. markets its consumer markets products through Tier One Insurance Company (TOIC). The Company's insurance operations in the U.S. and Japan service the two markets for the Company's insurance business. The Parent Company, other operating business units that are not individually reportable, and business activities, including reinsurance activities, not included in Aflac Japan or Aflac U.S. are included in Corporate and other. Aflac Japan's revenues, including net gains and losses on its investment portfolio, accounted for ~~71%~~62% and 70% of the Company's total revenues in the three-month periods ended March 31, ~~2022~~2023 and ~~2021,~~2022, respectively. The percentage of the Company's total assets attributable to Aflac Japan was 81% at March 31, ~~2022,~~2023, compared with ~~82%~~80% at December 31, ~~2021.~~2022.

In 2022, the Company established Aflac Re Bermuda Ltd. (Aflac Re), a Bermuda domiciled insurer that reinsures certain policies issued by ALIJ. Aflac Re is subject to regulation in Bermuda, where the Bermuda Monetary Authority (BMA) has broad administrative powers relating to granting and revoking licenses to transact reinsurance business, approval of specific reinsurance transactions, capital requirements and solvency standards, limitations on dividends to shareholders, the nature of and limitations on investments, and the filing of financial statements in accordance with prescribed or permitted accounting practices. Financial results from Aflac Re are included in Corporate and other.

Basis of Presentation

The Company prepares its financial statements in accordance with U.S. generally accepted accounting principles (U.S. GAAP). These principles are established primarily by the Financial Accounting Standards Board (FASB). In these Notes to the Consolidated Financial Statements, references to U.S. GAAP issued by the FASB are derived from the FASB Accounting Standards CodificationTM (ASC). The preparation of financial statements in conformity with U.S. GAAP requires the Company to make estimates based on currently available information when recording transactions resulting from business operations. The most significant items on the Company's balance sheet that involve a greater degree of accounting estimates and actuarial determinations subject to changes in the future are the valuation of investments and derivatives, deferred policy acquisition costs (DAC), liabilities for future policy benefits, and ~~unpaid policy claims, and~~ income taxes. These accounting estimates and actuarial determinations are sensitive to market conditions, investment yields, interest rates, mortality, morbidity, commission and other acquisition expenses, and terminations by policyholders. As additional information becomes available, or actual amounts are determinable, the recorded estimates are revised and reflected in operating results. Although some variability is inherent in these estimates, the Company believes the amounts provided are reasonable and reflective of the best estimates of management.

The unaudited consolidated financial statements include the accounts of the Parent Company, its subsidiaries and those entities required to be consolidated under applicable accounting standards. All material intercompany accounts and transactions have been eliminated.

In the opinion of management, the accompanying unaudited consolidated financial statements of the Company contain all adjustments, consisting of normal recurring accruals, which are necessary to fairly present the consolidated balance sheets as of March 31, ~~2022~~2023 and December 31, ~~2021,~~2022, and the consolidated statements of earnings and comprehensive income (loss), shareholders' equity and cash flows for the three-month periods ended March 31, ~~2022~~2023 and ~~2021.~~2022. Results of operations for interim periods are not necessarily indicative of results for the entire year. As a result, these financial statements should be read in conjunction with the financial statements and notes thereto included in the Company's annual report on Form 10-K for the year ended December 31, ~~2021 (2021~~2022 (2022 Annual Report).

~~Market Conditions:~~ The impact of the Coronavirus Disease 2019 (COVID-19) global pandemic on the Company continues to evolve and the continued path of the global economic recovery remains uncertain given the potential longer term impacts of the pandemic. For example, economic conditions have acted as headwinds to sales in the first quarter of 2022, particularly in Japan, pressuring premium growth rates. Further, in the U.S., supply shortages, upward pressure on wages to attract employees and higher commodity prices have all driven near-term increases in inflation. Central bank and government efforts to control inflation, as well the impacts of the Russia-Ukraine conflict, including volatility in energy prices and additional disruptions in the global supply chain, could lead to slower economic growth in Japan and the U.S. Additionally, rising energy prices, along with increased widening of the differential between U.S. and Japan interest rates, have contributed to a weakening of the yen, which has the effect of suppressing the Company's current period results in relation to the comparable prior period.

~~Reclassifications~~: Certain reclassifications have been made to prior-year amounts to conform to current-year reporting classifications. These reclassifications had no impact on net earnings or total shareholders' equity.Significant Accounting Policies

~~New~~The Company revised the following accounting policies as a result of the adoption of amended accounting guidance effective January 1, 2023 and certain reclassifications. Refer to Recently Adopted Accounting Pronouncements

~~Accounting Pronouncements Pending Adoption~~

below for details of the adoption of ASU 2018-12 Financial Services - Insurance: Targeted Improvements to the Accounting for Long-Duration ~~Contracts, as clarified~~Contracts. In conjunction with the adoption of ASU 2018-12, the Company changed its practice of recording the change in the deferred profit liability on products with limited payment features from the benefits and ~~amended by:~~

~~ASU 2019-09 Financial Services - Insurance: Effective Date~~

~~ASU 2020-11 Financial Services - Insurance: Effective Date and Early Application~~claims, net line item to the net earned premiums line item in the consolidated statement of earnings. This reclassification had no impact on net earnings. The change in presentation has been made for all comparative periods presented. All other categories of significant accounting policies remain unchanged from the 2022 Annual Report.

~~In August 2018,~~Insurance Revenue and Expense Recognition: Substantially all of the ~~FASB issued amendments that will significantly change how insurers account for~~supplemental health and life insurance policies the Company issues are classified as long-duration contracts. The ~~amendments will change existing recognition, measurement, presentation, and disclosure requirements. Issues addressed~~contract provisions generally cannot be changed or canceled during the contract period; however, the Company may adjust premiums for supplemental health policies issued in the ~~new guidance include: 1) a requirement~~U.S. within prescribed guidelines and with the approval of state insurance regulatory authorities.

Insurance premiums for most of the Company's health and life policies, including cancer, accident, hospital, critical illness, supplemental dental and vision, term life, whole life, long-term care and disability, are recognized as earned premiums over the premium-paying periods of the contracts when due from policyholders. When earned premiums are reported, the related amounts of benefits and expenses are charged against such revenues. This association is accomplished by means of annual increases or decreases to ~~review and, if there is a change, update assumptions for~~ the liability for future policy benefits (LFPB) ~~at least annually,~~ and ~~to update~~ the ~~discount rate assumption quarterly, 2) accounting for market risk benefits at fair value, 3) simplified~~deferral and subsequent amortization ~~for deferred~~of policy acquisition ~~costs, and 4) enhanced financial statement presentation and disclosures.~~costs.

~~In November 2019,~~Premiums from the ~~FASB issued~~Company's products with limited-pay features, including cancer, medical and nursing care, term life, whole life, WAYS, and child endowment, are collected over a significantly shorter period than the contract term (i.e., the period during which benefits are provided). Premiums for these products are recognized as earned premiums over the premium-paying periods when due from policyholders. Any gross premium in excess of the net premium is deferred and recorded as a deferred profit liability, which is subsequently amortized in net earned premiums such that profits are recognized in a constant relationship with insurance in force. Benefits are recorded as an ~~amendment extending~~expense when they are incurred. An LFPB is recorded when premiums are recognized using the effective date for public business entities that meet the definition of a Securities and Exchange Commission (SEC) filer, excluding entities eligible to be small reporting companies as defined by the SEC, by one year.net premium method.

~~In November 2020, the FASB issued~~Policyholders also have an ~~amendment providing an additional year deferral~~option to pay discounted advanced premiums for all insurance entities due to the impact of COVID-19. The amendments are now effective for the Company for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2022. Early applicationcertain of the ~~amendments is permitted.~~Company's products. Advanced premiums are deferred and recognized when due from policyholders over the otherwise required contractual premium payment period.

Benefit expense is bifurcated between benefits and claims and reserve remeasurement (gains) losses. The ~~Company continues~~net premium ratio (NPR) is used to ~~evaluate~~measure benefit expense and is calculated as the ~~impact~~ratio of ~~adoption~~the present value of actual and ~~has determined that~~future expected benefits and expenses to the ~~adoption will have a significant impact on~~present value of actual and future expected gross premiums. A revised NPR is calculated as of the ~~Company’s financial position, results~~beginning of operations, and disclosures. The requirement to update assumptions for LFPB will have a significant impact on the Company's results of operations, systems, processes and controls and the requirement to update discount rates will have a significant impact on its equity.each reporting period using updated future cash flow expectations.

~~As part of working toward implementation of~~Reserve remeasurement (gains) losses represent the updated standard, the Company has made progress on key accounting policy decisions, including processes to identify insurance policy groupings (cohorts) for LFPB measurement and DAC amortization purposes, applicable discount rates, development of liability cash flow and claim expense assumptions, and DAC amortization methodology.

~~The Company will not early adopt the updated standard and has selected the modified retrospective transition method, which requires the amended guidance be applied~~difference between two reserve measures both calculated as of the beginning of the ~~earliest~~current reporting period ~~presented beginning on~~using the ~~January 1, 2021 transition date (Transition Date). The modified retrospective transition method generally results in applying~~same locked-in discount rates. One reserve measure uses the ~~guidance to contracts on the basis of existing carrying values~~NPR as of the ~~Transition Date. On~~end of the ~~Transition Date the Company calculates the ratio of expected benefits less existing carrying values to gross premiums (net premium ratio) using updated assumptions~~prior reporting period, and the ~~discount rate immediately before the Transition Date. For any cohorts that have a net premium ratio greater than 100% on the Transition Date, the net premium ratio will be capped at 100%. The Company~~second uses the net premium ratio calculated on the Transition Date (and capped at 100% if required) to calculate the LFPB using two different discount rates: i) the discount rate used immediately before the Transition Date,revised NPR. Benefits and ii) the discount rate determined by reference to the Transition Date market level yields for upper-medium-grade (low credit risk) fixed income instruments (as of December 31, 2020). For cohorts with their net premium ratio capped at 100% on the Transition Date, any difference between the LFPB calculated using the discount rate immediately before the Transition Date and the existing carrying value as of the Transition Date is recorded as an adjustment (decrease) to opening retained earnings. For all cohorts on the Transition Date,claims represent the difference in the ~~LFPB~~liability balance calculated as of the beginning of the current reporting period and the end of the current reporting period both using the ~~two different~~revised NPR and the locked-in discount ~~rates (i.e.,~~rates. The locked-in interest accretion rate utilized for accretion of interest expense on insurance reserves is the original discount rate used ~~immediately before the Transition Date and the updated discount rate as of the Transition Date) is recorded in accumulated other comprehensive income (AOCI) net of tax~~ at ~~transition.~~contract issue date.

~~When~~Advertising expense is reported as incurred in insurance and other expenses in the ~~Company adopts~~consolidated statement of earnings.

Deferred Policy Acquisition Costs: Certain direct and incremental costs of acquiring insurance contracts are deferred and amortized on a grouped-contract basis over the expected term of the related contracts, using a constant-level basis. For life and health products issued in Japan, the constant-level basis used is units in force, which is a proxy for face amount, and insurance in force, respectively. For life and health products issued in the U.S., the constant-level basis used is face amount and number of policies in force, respectively. Amortization is computed using the same contract groupings (also referred to as cohorts) and mortality and termination assumptions that are used in computing the LFPB, and these assumptions are reviewed and updated ~~standard beginning January 1, 2023, opening equity will be adjusted for~~at least annually. The effects of changes in assumptions are recognized prospectively over the ~~Transition Date impacts to AOCI and retained earnings and prior periods presented (years 2021 and 2022) will be restated following~~remaining contract term as a revision of the ~~updated standard. Based~~future amortization pattern, while current period amortization is calculated based on the ~~modified retrospective transition method,~~actual experience during the ~~Company currently estimates that~~quarter. Deferred costs include the ~~Transition Date impact from adoption is likely~~excess of current-year commissions over ultimate renewal-year commissions and certain incremental direct policy issue, underwriting and sales expenses directly related to ~~result in a decrease in AOCI in a range between $18 billion and $20 billion and a decrease in retained earnings of approximately $0.3 billion. The variability around the impact of adoption~~successful policy acquisition.

For some products, policyholders can elect to modify product benefits, features, rights or coverages by exchanging a contract for a new contract or by amendment, endorsement, or rider to a contract, or by the election of a feature or coverage within a contract. These transactions are known as internal replacements. The Company performs a two-stage analysis of the internal replacements to determine if the modification is substantive to the base policy. The stages of evaluation are as follows: 1) determine if the modification is integrated with the base policy, and 2) if it is integrated, determine if the resulting contract is substantially changed.

For internal replacement transactions where the resulting contract is substantially unchanged, unamortized deferred acquisition costs from the original policy continue to be amortized over the expected life of the cohort, and the costs of replacing the policy are accounted for as policy maintenance costs and expensed as incurred.

For an internal replacement transaction that results in a policy that is substantially changed, the policy is treated as lapsed for amortization purposes, and the costs of acquiring the new policy are capitalized and amortized in accordance with the Company's accounting policies for deferred acquisition costs.

Riders can be considered internal replacements that are either integrated or non-integrated resulting in either substantially changed or substantially unchanged treatment. Riders are evaluated based on the specific facts and circumstances of the rider and are considered an expansion of the existing benefits with additional premium required. Non-integrated riders to existing contracts do not change the Company's profit expectations for the related products and are treated as a new policy establishment for incremental coverage.

Policy Liabilities

~~results from~~: For long-duration insurance contracts, the Company ~~making~~calculates an integrated reserve that represents all payments under the contract including future expected claims and unpaid policy claims and related expenses. The liability for future policy benefits is measured using the net level premium method.

Long-duration insurance contracts issued by the Company are grouped into annual calendar-year cohorts based on the contract issue date, reportable segment, legal entity and product type. Limited-pay contracts are grouped into separate cohorts from other traditional products in the same manner and are further separated based on their premium payment structures.

The LFPB is determined as the present value of future policy benefits to be paid to or on the behalf of policyholders and certain related expenses less the present value of future net premiums receivable under the Company’s insurance contracts, where future net premiums receivable are future gross premiums receivable under the contract multiplied by the NPR.

Future policy benefits are calculated using assumptions and estimates ~~primarily related~~including mortality, morbidity, termination (also referred to as lapses), expense, and discount rates. The assumptions and estimates that the ~~determination~~Company uses depend on its judgment regarding the likelihood of ~~Transition Date market level yields.~~future events and are inherently uncertain.

Cash flow assumptions (mortality, morbidity, and termination) are established at policy inception and are evaluated each quarter to determine if an update is needed. To facilitate a more detailed review of cash flow assumptions, experience studies are performed annually during the third quarter. Changes in cash flow assumptions are the result of applying the updated best estimate assumptions as of the beginning of the reporting period and are recognized in reserve remeasurement (gains) losses in the consolidated statement of earnings. Expense assumptions are established at policy inception and determined for each issue-year cohort as a percentage of paid claims. These expense assumptions are locked-in and remain unchanged over the term of the insurance policy. Actual experience is reflected in the calculation of future policy benefits each quarter, and changes in the liability due to actual experience are recognized in reserve remeasurement (gains) losses in the consolidated statement of earnings.

The Company has ~~advanced and continues to refine the design of~~designed its discount rate methodology for ~~both~~ the U.S. and Japan insurance business. The methodology incorporates constructing a discount rate curve separately for discounting cash flows used to calculate the U.S. and Japan ~~LFPB, with each curve intended to be~~LFPBs, reflective of the ~~currency, tenor and~~ characteristics of the insurance ~~liabilities.~~liabilities, such as currency and tenor. Discount rates comprising each curve ~~will be~~are determined by reference to upper-medium grade (low credit risk) fixed-income instrument yields that ~~are intended to~~

reflect the duration characteristics of the corresponding insurance liabilities. The Company ~~intends to use~~uses for these yields single-A rated fixed income instruments with credit ratings based on international rating standards. Where only local ratings are available, the Company ~~intends to select~~selects the fixed-income instruments with local ratings that are equivalent to a single-A rating based on international rating standards. The methodology ~~will be~~is designed to prioritize observable inputs based on market data available in the local debt markets where the respective policies were issued in the currency in which the policies are denominated. For the discount rates applicable to tenors for which the single-A debt market is not liquid or there is little or no observable market data, the Company ~~will use~~uses various estimation techniques consistent with the fair value guidance in ASC 820, which include, but are not limited to: (i) for tenors where there is less observable market data and/or the observable market data is available for similar instruments, estimating tenor-specific single-A credit spreads and applying them to risk-free government ~~rates;~~rates; (ii) for tenors where there is very limited or no observable single-A or similar market data, interpolation and extrapolation techniques. ~~Discount rates will be updated each reporting period.~~

Long duration insurance contracts issued by the Company will be grouped into annual calendar-year cohorts based on the contract issue date, reportable segment, legal entity and product type. Limited pay contracts will be grouped into separate cohorts from other traditional products in the same manner and will be further separated based on their premium payment structures. Riders will be combined with base policies with similar insurance coverage types and the same contract issue years.

~~In addition to the preliminary policy elections related to cohorts and LFPB~~The locked-in discount ~~rates directly impacting Transition Date AOCI, the Company has also advanced the following accounting policies relevant to the post-Transition Date accounting:~~

•Cash flow assumptions underlying insurance liabilities will be evaluated as to whether an update is needed at least annually in the same fiscal quarter each year. To facilitate the review, experience studies will be performed annually in the consistent quarter year-to-year to substantiate assumptions, including mortality, morbidity, and terminations in future periods.

•~~Locked-in discount rates~~rate used for the computation of interest accretion on ~~LFPB for policies issued on or after January 1, 2021 will be~~LFPBs is determined separately for each issue-year cohort as a single discount rate, calculated as the weighted-average of monthly upper-medium grade ~~(low-credit~~(low credit risk) fixed-income instrument forward curves ~~over~~in the calendar year, determined using the methodology described above and weighted using issued annualized premiums for each issue month. The single discount rate for each issue-year cohort is determined by solving for a rate that produces an equivalent net premium ratio to the forward curve and will remain unchanged after the calendar year of issue. ~~Locked-in~~

Unearned premiums consist primarily of discounted advance premiums on deposit from policyholders in conjunction with their purchase of certain Aflac Japan limited-pay insurance products. These advanced premiums are deferred upon collection and recognized as earned premiums over the contractual premium payment period.

The other policyholders’ funds liability consists primarily of the fixed annuity line of business in Aflac Japan which has fixed benefits and premiums.

For internal replacements that are determined to be substantially changed, policy liabilities related to the original policy that was replaced are immediately released, and policy liabilities are established for the new insurance contract. The policy reserves are evaluated based on the new policy features, and changes are recognized at the date of contract change/modification. For internal replacements that are substantially unchanged, no changes to the reserves are recognized. For modifications that are not integrated with the base policy, new coverage is recognized as a separately issued contract within the current cohort.

Reclassifications: Certain reclassifications have been made to prior-year amounts to conform to current-year reporting classifications. These reclassifications had no impact on net earnings or total shareholders' equity.

New Accounting Pronouncements

Recently Adopted Accounting Pronouncements

ASU 2018-12 Financial Services - Insurance: Targeted Improvements to the Accounting for Long-Duration Contracts, as clarified and amended by:

ASU 2019-09 Financial Services - Insurance: Effective Date

ASU 2020-11 Financial Services - Insurance: Effective Date and Early Application

In August 2018, the FASB issued amendments that significantly changed how insurers account for long-duration contracts. The Company adopted the standard on January 1, 2023 using a modified retrospective transition method which resulted in applying the amended guidance as of the beginning of the earliest period presented on the January 1, 2021 transition date (Transition Date). The modified retrospective transition method generally results in applying the guidance to contracts on the basis of existing carrying values as of the Transition Date. On the Transition Date, the Company calculated the ratio of the present value of future expected benefits and expenses less existing carrying values to the present value of future expected gross premiums (Transition Date NPR) using updated assumptions and the discount rate immediately before the Transition Date. The Company capped the Transition Date NPR at 100% for any cohorts with a Transition Date NPR greater than 100%. The Company calculated the LFPB using the Transition Date NPR (capped at 100% if required) and two different discount rates: (i) the discount rate used immediately before the Transition Date, and (ii) the discount rate determined by reference to the Transition Date market level yields for upper-medium grade (low credit risk) fixed income instruments (as of December 31, 2020). For cohorts with their Transition Date NPR capped at 100%, the Company recorded as an adjustment (decrease) to opening retained earnings any difference between the LFPB calculated using the discount rate immediately before the Transition Date and the existing carrying value as of the Transition Date. For all cohorts on the Transition Date, the Company recorded in accumulated other comprehensive

income (AOCI) net of tax, the difference in the LFPB calculated using the two different discount rates (i.e., the discount rate used immediately before the Transition Date and the updated discount rate as of the Transition Date).

Upon adoption, the Company adjusted opening equity for the Transition Date impacts to AOCI and retained earnings and adjusted prior periods presented (years 2021 and 2022) following the updated standard. Based upon the modified retrospective transition method, the Transition Date impact from adoption resulted in a decrease in AOCI of approximately $18.6 billion and a decrease in retained earnings (RE) of approximately $0.3 billion.

See Note 6 and Note 7 of the Notes to the Consolidated Financial Statements for expanded disclosures for DAC and future policy benefits, respectively, required as a result of the amended guidance.

Transition Impact to Shareholder's Equity

The following table presents the cumulative transition impact as of January 1, 2021 to the Company’s Shareholder’s Equity as a result of the adoption of ASU 2018-12, using the modified retrospective transition method.


(In millions - Unaudited)	Common Stock		Additional Paid-in Capital		Retained Earnings		Accumulated Other Comprehensive Income (Loss)		Treasury Stock		Total Shareholders' Equity
Balance at December 31, 2020	$	135	$	2,410	$	37,984	$	8,934	$	(15,904)	$	33,559
Cumulative effect of change in accounting principle, ASU 2018-12, net of income taxes	0		0		(324)		(18,570)		0		(18,894)
Balance at January 1, 2021	$	135	$	2,410	$	37,660	$	(9,636)	$	(15,904)	$	14,665

The following table presents the transition impacts as of January 1, 2021 to the Company's AOCI and RE as a result of the adoption of ASU 2018-12 by reporting segment and disaggregated by product type, using the modified retrospective transition method.


(In millions - Unaudited)	Impact to Retained Earnings			Impact to AOCI
Transition impacts:
Aflac Japan
Cancer		$	0		$	14,529
Medical and other health		1			2,382
Life insurance		0			3,314
Other (1)		398			433
Aflac U.S.
Accident		0			92
Disability		0			149
Critical care		4			2,258
Hospital indemnity		0			223
Dental/vision		0			65
Life insurance		5			149
Other		2			218
Reinsurance		0			(305)
Transition impact before income taxes		410			23,507
Less: income taxes		86			4,937
Total transition impact, net of income taxes		$	324		$	18,570

(1) Impact to retained earnings is driven primarily by capping the Transition Date NPR on Care products.

Transition Impact on the Liability for Future Policy Benefits

The Company adopted ASU 2018-12 using the modified retrospective transition method. The tables below present the disaggregated transition impacts to the Company’s LFPB as a result of adoption, split between the changes in the present

value of expected net premiums and the present value of expected future policy benefits as of the Transition Date and the LFPB rollforward for the year ended December 31, 2021. The locked-in discount rates on the policies held at the Transition Date reflect the locked-in rates in existence immediately before the Transition Date. See Note 7 of the Notes to the Consolidated Financial Statements for additional information.

•~~For DAC amortization,~~Under the modified retrospective transition method, the NPR for future policy benefits existing as of the Transition Date considers the carryover basis of those liabilities, which equals the future policy benefits and unpaid policy claims balance as of December 31, 2020. If the revised Transition Date NPR for a cohort is greater than 100%, the Company ~~has made a preliminary policy election~~capped the Transition Date NPR at 100% and increased the LFPB with an offsetting decrease to group insurance policies into cohorts that are consistent with the groupings used in estimating the associated LFPB. DAC will be amortized on a constant-level basis for the grouped contracts over the expected remaining term of the related contracts. For both life and health products issued by Aflac Japan, the constant-level basis used will be units in force, which is a proxy for face amount and insurance in force, respectively. For life products issued by Aflac U.S., the constant level basis used will be face amount of policies in force; for health products issued by Aflac U.S., the constant level basis used will be the number of policies in force.

•The Company has made a preliminary entity-wide election to use locked-in claim expense assumptions determined for each issue-year cohort as a percentage of incurred claims; these assumptions would remain unchanged over the term of the insurance policy.opening retained earnings.

The ~~Company has created a governance framework~~LFPB recorded in the consolidated balance sheet includes the deferred profit liability for limited-payment contracts. This deferred profit liability is not included in the Transition Date and ~~a plan~~LFPB rollforwards. For products with limited-payment features, to ~~support implementation of~~ the ~~updated standard. As part of its implementation plan,~~extent the transition date adjustment related to updating cash flow assumptions is favorable, the Company ~~has also advanced~~increased the modernization of its actuarial technology platform to enhance its modeling, data management, experience study and analytical capabilities, increase the end-to-end automation of key reporting and analytical processes and optimize its control framework. The Company has also put in place internal controls related to the new processes created as part of implementing the updated standard and will continue to refine and maturate these internal controls until the formal implementation in the first quarter of 2023.deferred profit liability.

811

The following table presents the transition impacts to the present value of expected net premiums by reporting segment and disaggregated by product type due to the cumulative effect of the change in accounting principle as a result of the adoption of ASU 2018-12 using the modified retrospective transition method.


	Transition Impact at January 1, 2021
	Aflac Japan								Aflac U.S.
(In millions)	Cancer		Medical and Other Health		Life Insurance		Other		Accident		Disability		Critical Care		Hospital Indemnity		Dental/Vision		Life Insurance		Other
Present value of expected premiums:
Balance at December 31, 2020	$	25,601	$	21,270	$	12,440	$	2,080	$	3,350	$	1,921	$	5,898	$	1,376	$	281	$	710	$	154
Impact to retained earnings from capping Transition Date NPR	0		(1)		0		(398)		0		0		(4)		0		0		(5)		(2)
Impact of deferred profit liability	15		7		36		26		0		0		0		0		0		0		0
Beginning balance at original discount rate	25,616		21,276		12,476		1,708		3,350		1,921		5,894		1,376		281		705		152
Effect of change in discount rate assumptions	3,982		2,598		908		148		479		197		1,048		154		41		78		27
Balance at January 1, 2021	$	29,598	$	23,874	$	13,384	$	1,856	$	3,829	$	2,118	$	6,942	$	1,530	$	322	$	783	$	179

The following table presents the changes in the present value of expected net premiums by reporting segment and disaggregated by product type for the year ended December 31, 2021.


	December 31, 2021
	Aflac Japan								Aflac U.S.
(In millions)	Cancer		Medical and Other Health		Life Insurance		Other		Accident		Disability		Critical Care		Hospital Indemnity		Dental/Vision		Life Insurance		Other
Present value of expected premiums:
Balance at January 1, 2021	$	29,598	$	23,874	$	13,384	$	1,856	$	3,829	$	2,118	$	6,942	$	1,530	$	322	$	783	$	179
Beginning balance at original discount rate (1)	25,616		21,276		12,476		1,708		3,350		1,921		5,894		1,376		281		705		152
Effect of changes in cash flow assumptions	32		88		40		1		(163)		(129)		(302)		0		(26)		31		0
Effect of actual variances from expected experience	(134)		(449)		(135)		(11)		(109)		(38)		(290)		(32)		(14)		34		(3)
Adjusted beginning of period balance	25,514		20,915		12,381		1,698		3,078		1,754		5,302		1,344		241		770		149
Issuances	1,116		1,132		284		55		365		345		552		263		39		112		0
Interest accrual	586		439		202		27		116		61		210		45		10		25		6
Net premium earned (2)	(2,206)		(1,692)		(1,609)		(151)		(552)		(393)		(665)		(268)		(47)		(124)		(19)
Foreign currency translation	(2,539)		(2,111)		(1,194)		(167)		0		0		0		0		0		0		0
Other	(1)		(2)		0		(1)		(8)		(7)		(8)		(4)		(2)		(3)		(1)
Ending balance at original discount rate	22,470		18,681		10,064		1,461		2,999		1,760		5,391		1,380		241		780		135
Effect of changes in discount rate assumptions	3,423		2,493		783		125		284		102		632		87		23		54		18
Balance at December 31, 2021	$	25,893	$	21,174	$	10,847	$	1,586	$	3,283	$	1,862	$	6,023	$	1,467	$	264	$	834	$	153

(1) Includes the adjustment for capping the Transition Date NPR.

(2) Net premiums earned represent the portion of gross premiums collected from policyholders that is used to fund expected benefit payments.

The following table presents the transition impacts to the present value of expected future policy benefits by reporting segment and disaggregated by product type due to the cumulative effect of the change in accounting principle as a result of the adoption of ASU 2018-12 using the modified retrospective transition method.


	Transition Impact at January 1, 2021
	Aflac Japan								Aflac U.S.
(In millions)	Cancer		Medical and Other Health		Life Insurance		Other		Accident		Disability		Critical Care		Hospital Indemnity		Dental/Vision		Life Insurance		Other
Present value of expected future policy benefits:
Balance at December 31, 2020	$	64,056	$	34,638	$	43,729	$	7,620	$	3,818	$	2,919	$	13,427	$	2,258	$	599	$	1,562	$	661
Effect of change in discount rate assumptions	18,511		4,980		4,222		581		571		346		3,306		377		106		227		245
Balance at January 1, 2021	$	82,567	$	39,618	$	47,951	$	8,201	$	4,389	$	3,265	$	16,733	$	2,635	$	705	$	1,789	$	906

The ~~Company continues testing its~~following table presents the changes in the present value of expected future policy benefits by reporting segment and ~~disclosure capabilities~~disaggregated by product type for the year ended December 31, 2021.


	December 31, 2021
	Aflac Japan								Aflac U.S.
(In millions)	Cancer		Medical and Other Health		Life Insurance		Other		Accident		Disability		Critical Care		Hospital Indemnity		Dental/Vision		Life Insurance		Other
Present value of expected future policy benefits:
Balance at January 1, 2021	$	82,567	$	39,618	$	47,951	$	8,201	$	4,389	$	3,265	$	16,733	$	2,635	$	705	$	1,789	$	906
Beginning balance at original discount rate	64,056		34,638		43,729		7,620		3,818		2,919		13,427		2,258		599		1,562		661
Effect of changes in cash flow assumptions	24		85		31		(11)		(178)		(143)		(326)		(3)		(29)		31		0
Effect of actual variances from expected experience	(149)		(458)		(139)		(15)		(115)		(41)		(304)		(36)		(15)		34		(3)
Adjusted beginning of period balance	63,931		34,265		43,621		7,594		3,525		2,735		12,797		2,219		555		1,627		658
Issuances	1,133		1,155		287		62		372		355		563		271		40		115		0
Interest accrual	2,014		769		833		129		137		100		553		85		23		58		33
Benefit payments	(3,894)		(1,313)		(1,373)		(238)		(439)		(520)		(834)		(275)		(69)		(107)		(46)
Foreign currency translation	(6,377)		(3,478)		(4,366)		(760)		0		0		0		0		0		0		0
Other	0		0		0		0		(1)		0		0		0		0		1		0
Ending balance at original discount rate	56,807		31,398		39,002		6,787		3,594		2,670		13,079		2,300		549		1,694		645
Effect of changes in discount rate assumptions	15,940		4,623		3,718		535		355		201		2,309		252		67		149		192
Balance at December 31, 2021	72,747		36,021		42,720		7,322		3,949		2,871		15,388		2,552		616		1,843		837
Net liability for future policy benefits	46,854		14,847		31,873		5,736		666		1,009		9,365		1,085		352		1,009		684
Less: reinsurance recoverable	0		2,150		0		0		0		0		0		0		0		10		0
Net liability for future policy benefits after reinsurance recoverable	$	46,854	$	12,697	$	31,873	$	5,736	$	666	$	1,009	$	9,365	$	1,085	$	352	$	999	$	684

The following table presents a reconciliation of the rollforwards by reporting segment and disaggregated by product type for the year ended December 31, 2021 to the liability for future policy benefits as of December 31, 2021 under the ~~new ASU~~amended guidance. The deferred profit liability for ~~post-Transition Date accounting periods.~~limited-payment contracts and reinsurance is presented together with the LFPB in the Consolidated Balance Sheets and has been included as a reconciling item in the table below.


(In millions)	December 31, 2021
Balances included in future policy benefits rollforward:
Aflac Japan
Cancer		$	46,854
Medical and other health		14,847
Life insurance		31,873
Other		5,736
Aflac U.S.
Accident		666
Disability		1,009
Critical care		9,365
Hospital indemnity		1,085
Dental/vision		352
Life insurance		1,009
Other		684
Corporate and other		30
Deferred profit liability - limited-payment contracts		1,595
Deferred profit liability - reinsurance		859
Total		$	115,964

The ~~Company currently has no products with market risk benefits.~~adoption of ASU 2018-12 did not have an impact on the Company's balance for deferred policy acquisition costs upon adoption.

Accounting Pronouncements Pending Adoption

ASU 2023-02 Investments - Equity Method and Joint Ventures (Topic 323): Accounting for Investments in Tax Credit Structures Using the Proportional Amortization Method

In March 2023, the FASB issued amendments to permit reporting entities to elect to account for their tax equity investments, regardless of the tax credit program from which the income tax credits are received, using the proportional amortization method if certain conditions are met. Under the proportional amortization method, an entity amortizes the initial cost of the investment in proportion to the income tax credits and other income tax benefits received and recognizes the net amortization and income tax credits and other income tax benefits in the income statement as a component of income tax expense (benefit).

The amendments are effective for public business entities for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted and if an entity adopts the amendments in an interim period, it shall adopt them as of the beginning of the fiscal year that includes that interim period.

The adoption of this guidance is not expected to have a significant impact on the Company's financial position, results of operations, or disclosures.

Recent accounting guidance not discussed above is not applicable, did not have, or is not expected to have a material impact to the Company's business.

For additional information on new accounting pronouncements and recent accounting guidance and their impact, if any, on the Company's financial position, results of operations or disclosures, see Note 1 of the Notes to the Consolidated Financial Statements in the ~~2021~~2022 Annual Report.

2. BUSINESS SEGMENT INFORMATION

The Company consists of 2two reportable insurance business segments: Aflac Japan and Aflac U.S., both of which sell supplemental health and life insurance. In addition, the Parent Company, other operating business units that are not individually reportable, and business activities, including reinsurance ~~retrocession~~ activities, not included in Aflac Japan or Aflac U.S. are included in Corporate and other.

The Company does not allocate corporate overhead expenses to business segments. Consistent with U.S. GAAP accounting guidance for segment reporting, the Company evaluates and manages its business segments using a financial performance measure called pretax adjusted earnings. Adjusted earnings are adjusted revenues less benefits and adjusted expenses. The adjustments to both revenues and expenses account for certain items that cannot be predicted or that are outside management’s control. Adjusted revenues are U.S. GAAP total revenues excluding net investment gains and losses, except for amortized hedge costs/income related to foreign currency exposure management strategies and net interest cash flows from derivatives associated with certain investment strategies. Adjusted expenses are U.S. GAAP total acquisition and operating expenses including the impact of interest cash flows from derivatives associated with notes payable but excluding any nonrecurring or other items not associated with the normal course of the Company’s insurance operations and that do not reflect the Company's underlying business performance. The Company excludes income taxes related to operations to arrive at pretax adjusted earnings. Information regarding operations by reportable segment and Corporate and other, follows:


		Three Months Ended March 31,						Three Months Ended March 31,
(In millions)	(In millions)		2022		2021		(In millions)		2023		2022
Revenues:	Revenues:						Revenues:
Aflac Japan:	Aflac Japan:						Aflac Japan:
Net earned premiums	Net earned premiums		$	2,724	$	3,123	Net earned premiums		$	2,170	$	2,625

Adjusted net investment income (1),(2)	Adjusted net investment income (1),(2)		680		705		Adjusted net investment income (1),(2)		611		680
Other income	Other income		9		13		Other income		9		9
Total adjusted revenue Aflac Japan	Total adjusted revenue Aflac Japan		3,413		3,841		Total adjusted revenue Aflac Japan		2,790		3,314
Aflac U.S.:	Aflac U.S.:						Aflac U.S.:
Net earned premiums	Net earned premiums		1,413		1,422		Net earned premiums		1,428		1,413

Adjusted net investment income (3)	Adjusted net investment income (3)		184		176		Adjusted net investment income (3)		197		184
Other income	Other income		42		30		Other income		35		42
Total adjusted revenue Aflac U.S.	Total adjusted revenue Aflac U.S.		1,639		1,628		Total adjusted revenue Aflac U.S.		1,660		1,639
Corporate and other (4),(5)	Corporate and other (4),(5)		74		83		Corporate and other (4),(5)		129		74
Total adjusted revenues	Total adjusted revenues		5,126		5,552		Total adjusted revenues		4,579		5,027
Net investment gains (losses) (1),(2),(3),(4)	Net investment gains (losses) (1),(2),(3),(4)		146		317		Net investment gains (losses) (1),(2),(3),(4)		221		146
Total revenues	Total revenues		$	5,272	$	5,869	Total revenues		$	4,800	$	5,173

(1) Amortized hedge costs of ~~$26~~$58 and ~~$19~~$26 for the three-month periods ended March 31, ~~2022,~~2023, and ~~2021,~~2022, respectively, related to certain foreign currency exposure management strategies have been reclassified from net investment gains (losses) and reported as a deduction from net investment income when analyzing operations.

(2) Net interest cash flows from derivatives associated with certain investment strategies of ~~$(10)~~$(62) and ~~$(8)~~$(10) for the three-month periods ended March 31, ~~2022~~2023, and ~~2021,~~2022, respectively, have been reclassified from net investment gains (losses) and included in adjusted earnings as a component of net investment income when analyzing operations.

(3) Net interest cash flows from derivatives associated with certain investment strategies of $(7) and $1 for the three-month ~~period~~periods ended March 31, 2023, and 2022, have been reclassified from net investment gains (losses) and included in adjusted earnings as a component of net investment income when analyzing operations.

(4) Amortized hedge income of ~~$11~~$29 and ~~$17~~$11 for the three-month periods ended March 31, ~~2022,~~2023, and ~~2021,~~2022, respectively, related to certain foreign currency exposure management strategies has been reclassified from net investment gains (losses) and reported as an increase to net investment income when analyzing operations.

(5) The change in value of federal historic rehabilitation and solar investments in partnerships of $51 and $12 for the three-month ~~period~~periods ended March 31, 2023, and 2022, respectively, is included as a reduction to net investment income. Tax credits on these investments of $52 and $16 for the three-month ~~period~~periods ended March 31, 2023, and 2022, respectively, have been recorded as an income tax benefit in the consolidated statement of earnings. See Note 3 of the Notes to the Consolidated Financial Statements for additional information on these investments.

Prior-year amounts have been adjusted for the adoption of accounting guidance on January 1, 2023 related to accounting for long-duration insurance contracts.

1015


		Three Months Ended March 31,						Three Months Ended March 31,
(In millions)	(In millions)		2022		2021		(In millions)		2023		2022
Pretax earnings:	Pretax earnings:						Pretax earnings:
Aflac Japan (1),(2)	Aflac Japan (1),(2)		$	862	$	887	Aflac Japan (1),(2)		$	788	$	870
Aflac U.S. (3)	Aflac U.S. (3)		325		445		Aflac U.S. (3)		352		333
Corporate and other (4),(5),(6)	Corporate and other (4),(5),(6)		(44)		(26)		Corporate and other (4),(5),(6)		(7)		(42)
Pretax adjusted earnings (7)	Pretax adjusted earnings (7)		1,143		1,306		Pretax adjusted earnings (7)		1,133		1,161
Net investment gains (losses) (1),(2),(3),(4),(5)	Net investment gains (losses) (1),(2),(3),(4),(5)		134		304		Net investment gains (losses) (1),(2),(3),(4),(5)		209		134
Other income (loss)	Other income (loss)		(1)		(7)		Other income (loss)		0		(1)
Total earnings before income taxes	Total earnings before income taxes		$	1,276	$	1,603	Total earnings before income taxes		$	1,342	$	1,294
Income taxes applicable to pretax adjusted earnings	Income taxes applicable to pretax adjusted earnings		$	216	$	248	Income taxes applicable to pretax adjusted earnings		$	180	$	219
Effect of foreign currency translation on after-tax adjusted earnings	Effect of foreign currency translation on after-tax adjusted earnings		(37)		13		Effect of foreign currency translation on after-tax adjusted earnings		(41)		(35)

(4) Amortized hedge income of ~~$11~~$29 and ~~$17~~$11 for the three-month periods ended March 31, ~~2022,~~2023, and ~~2021,~~2022, respectively, related to certain foreign currency exposure management strategies has been reclassified from net investment gains (losses) and reported as an increase in net investment income when analyzing operations.

(5) A gain of ~~$13~~$12 and ~~$14~~$13 for the three-month periods ended March 31, ~~2022,~~2023, and ~~2021,~~2022, respectively, related to the interest rate component of the change in fair value of foreign currency swaps on notes payable has been reclassified from net investment gains (losses) and included in adjusted earnings when analyzing operations.

(6) The change in value of federal historic rehabilitation and solar investments in partnerships of $51 and $12 for the three-month ~~period~~periods ended March 31, 2023, and 2022, respectively, is included as a reduction to net investment income. Tax credits on these investments of $52 and $16 for the three-month ~~period~~periods ended March 31, 2023, and 2022, respectively, have been recorded as an income tax benefit in the consolidated statement of earnings. See Note 3 of the Notes to the Consolidated Financial Statements for additional information on these investments.

(7) Includes ~~$41~~$34 and ~~$45~~$41 for the three-month periods ended March 31, ~~2022,~~2023, and ~~2021,~~2022, respectively, of interest expense on debt.

Prior-year amounts have been adjusted for the adoption of accounting guidance on January 1, 2023 related to accounting for long-duration insurance contracts.

Assets were as follows:


(In millions)	(In millions)	March 31, 2022			December 31, 2021			(In millions)	March 31, 2023			December 31, 2022
Assets:	Assets:							Assets:
Aflac Japan	Aflac Japan		$	119,270		$	128,536	Aflac Japan		$	108,762		$	105,734
Aflac U.S.	Aflac U.S.		21,944			23,106		Aflac U.S.		21,385			21,002
Corporate and other	Corporate and other		5,832			5,900		Corporate and other		4,819			5,002
Total assets	Total assets		$	147,046		$	157,542	Total assets		$	134,966		$	131,738

Prior-year amounts have been adjusted for the adoption of accounting guidance on January 1, 2023 related to accounting for long-duration insurance contracts.

1116

3. INVESTMENTS

Investment Holdings

The amortized cost for the Company's investments in fixed maturity securities, the cost for equity securities and the fair values of these investments are shown in the following tables.


		March 31, 2022											March 31, 2023
(In millions)	(In millions)	Amortized Cost		Allowance for Credit Losses		Gross Unrealized Gains		Gross Unrealized Losses		Fair Value		(In millions)	Amortized Cost		Allowance for Credit Losses		Gross Unrealized Gains		Gross Unrealized Losses		Fair Value
Securities available for sale, carried at fair value through other comprehensive income:	Securities available for sale, carried at fair value through other comprehensive income:											Securities available for sale, carried at fair value through other comprehensive income:
Fixed maturity securities:	Fixed maturity securities:											Fixed maturity securities:
Yen-denominated:	Yen-denominated:											Yen-denominated:
Japan government and agencies	Japan government and agencies	$	28,492	$	0	$	2,403	$	345	$	30,550	Japan government and agencies	$	25,264	$	0	$	1,534	$	1,079	$	25,719
Municipalities	Municipalities	1,120		0		259		15		1,364		Municipalities	1,028		0		152		42		1,138
Mortgage- and asset-backed securities	Mortgage- and asset-backed securities	280		0		14		3		291		Mortgage- and asset-backed securities	238		0		9		8		239
Public utilities	Public utilities	4,240		0		629		17		4,852		Public utilities	3,979		0		351		63		4,267
Sovereign and supranational	Sovereign and supranational	714		0		64		0		778		Sovereign and supranational	543		0		31		3		571
Banks/financial institutions	Banks/financial institutions	6,607		0		530		168		6,969		Banks/financial institutions	6,313		0		337		427		6,223
Other corporate	Other corporate	6,588		0		1,089		77		7,600		Other corporate	6,402		0		705		309		6,798
Total yen-denominated	Total yen-denominated	48,041		0		4,988		625		52,404		Total yen-denominated	43,767		0		3,119		1,931		44,955
U.S. dollar-denominated:	U.S. dollar-denominated:											U.S. dollar-denominated:
U.S. government and agencies	U.S. government and agencies	160		0		5		3		162		U.S. government and agencies	179		0		0		5		174
Municipalities	Municipalities	1,316		0		112		16		1,412		Municipalities	1,280		0		53		55		1,278
Mortgage- and asset-backed securities	Mortgage- and asset-backed securities	1,055		0		43		23		1,075		Mortgage- and asset-backed securities	2,307		0		90		69		2,328
Public utilities	Public utilities	3,783		0		583		29		4,337		Public utilities	3,479		0		315		128		3,666
Sovereign and supranational	Sovereign and supranational	213		0		52		8		257		Sovereign and supranational	132		0		36		11		157
Banks/financial institutions	Banks/financial institutions	3,217		0		526		26		3,717		Banks/financial institutions	2,966		0		316		85		3,197
Other corporate	Other corporate	23,679		0		3,129		207		26,601		Other corporate	21,196		0		1,946		798		22,344
Total U.S. dollar-denominated	Total U.S. dollar-denominated	33,423		0		4,450		312		37,561		Total U.S. dollar-denominated	31,539		0		2,756		1,151		33,144
Total securities available for sale	Total securities available for sale	$	81,464	$	0	$	9,438	$	937	$	89,965	Total securities available for sale	$	75,306	$	0	$	5,875	$	3,082	$	78,099

1217


		December 31, 2021											December 31, 2022
(In millions)	(In millions)	Amortized Cost		Allowance for Credit Losses		Gross Unrealized Gains		Gross Unrealized Losses		Fair Value		(In millions)	Amortized Cost		Allowance for Credit Losses		Gross Unrealized Gains		Gross Unrealized Losses		Fair Value
Securities available for sale, carried at fair value through other comprehensive income:	Securities available for sale, carried at fair value through other comprehensive income:											Securities available for sale, carried at fair value through other comprehensive income:
Fixed maturity securities:	Fixed maturity securities:											Fixed maturity securities:
Yen-denominated:	Yen-denominated:											Yen-denominated:
Japan government and agencies	Japan government and agencies	$	30,335	$	0	$	3,343	$	61	$	33,617	Japan government and agencies	$	25,418	$	0	$	1,259	$	1,724	$	24,953
Municipalities	Municipalities	1,192		0		322		5		1,509		Municipalities	1,034		0		124		61		1,097
Mortgage- and asset-backed securities	Mortgage- and asset-backed securities	300		0		19		1		318		Mortgage- and asset-backed securities	241		0		8		12		237
Public utilities	Public utilities	4,462		0		906		2		5,366		Public utilities	3,932		0		301		108		4,125
Sovereign and supranational	Sovereign and supranational	760		0		82		0		842		Sovereign and supranational	659		0		24		5		678
Banks/financial institutions	Banks/financial institutions	6,963		0		787		72		7,678		Banks/financial institutions	6,348		0		324		531		6,141
Other corporate	Other corporate	7,148		0		1,535		26		8,657		Other corporate	6,288		0		555		408		6,435
Total yen-denominated	Total yen-denominated	51,160		0		6,994		167		57,987		Total yen-denominated	43,920		0		2,595		2,849		43,666
U.S. dollar-denominated:	U.S. dollar-denominated:											U.S. dollar-denominated:
U.S. government and agencies	U.S. government and agencies	196		0		8		1		203		U.S. government and agencies	169		0		0		8		161
Municipalities	Municipalities	1,340		0		189		2		1,527		Municipalities	1,269		0		43		89		1,223
Mortgage- and asset-backed securities	Mortgage- and asset-backed securities	897		0		33		2		928		Mortgage- and asset-backed securities	1,926		0		67		84		1,909
Public utilities	Public utilities	3,781		0		909		5		4,685		Public utilities	3,481		0		240		180		3,541
Sovereign and supranational	Sovereign and supranational	222		0		57		6		273		Sovereign and supranational	133		0		35		12		156
Banks/financial institutions	Banks/financial institutions	3,169		0		747		3		3,913		Banks/financial institutions	2,992		0		271		105		3,158
Other corporate	Other corporate	24,604		0		4,629		53		29,180		Other corporate	21,579		0		1,549		1,201		21,927
Total U.S. dollar-denominated	Total U.S. dollar-denominated	34,209		0		6,572		72		40,709		Total U.S. dollar-denominated	31,549		0		2,205		1,679		32,075
Total securities available for sale	Total securities available for sale	$	85,369	$	0	$	13,566	$	239	$	98,696	Total securities available for sale	$	75,469	$	0	$	4,800	$	4,528	$	75,741


		March 31, 2022													March 31, 2023
(In millions)	(In millions)	Amortized Cost		Allowance for Credit Losses		Net Carrying Amount		Gross Unrealized Gains		Gross Unrealized Losses		Fair Value		(In millions)	Amortized Cost		Allowance for Credit Losses		Net Carrying Amount		Gross Unrealized Gains		Gross Unrealized Losses		Fair Value
Securities held to maturity, carried at amortized cost:	Securities held to maturity, carried at amortized cost:													Securities held to maturity, carried at amortized cost:
Fixed maturity securities:	Fixed maturity securities:													Fixed maturity securities:
Yen-denominated:	Yen-denominated:													Yen-denominated:
Japan government and agencies	Japan government and agencies	$	19,817	$	3	$	19,814	$	3,712	$	0	$	23,526	Japan government and agencies	$	18,154	$	2	$	18,152	$	2,548	$	0	$	20,700
Municipalities	Municipalities	315		0		315		83		0		398		Municipalities	285		0		285		56		0		341

Public utilities	Public utilities	41		1		40		10		0		50		Public utilities	37		0		37		5		0		42
Sovereign and supranational	Sovereign and supranational	487		4		483		101		0		584		Sovereign and supranational	447		4		443		67		0		510

Other corporate	Other corporate	20		0		20		7		0		27		Other corporate	19		0		19		4		0		23
Total yen-denominated	Total yen-denominated	20,680		8		20,672		3,913		0		24,585		Total yen-denominated	18,942		6		18,936		2,680		0		21,616
Total securities held to maturity	Total securities held to maturity	$	20,680	$	8	$	20,672	$	3,913	$	0	$	24,585	Total securities held to maturity	$	18,942	$	6	$	18,936	$	2,680	$	0	$	21,616

1318


		December 31, 2021													December 31, 2022
(In millions)	(In millions)	Amortized Cost		Allowance for Credit Losses		Net Carrying Amount		Gross Unrealized Gains		Gross Unrealized Losses		Fair Value		(In millions)	Amortized Cost		Allowance for Credit Losses		Net Carrying Amount		Gross Unrealized Gains		Gross Unrealized Losses		Fair Value
Securities held to maturity, carried at amortized cost:	Securities held to maturity, carried at amortized cost:													Securities held to maturity, carried at amortized cost:
Fixed maturity securities:	Fixed maturity securities:													Fixed maturity securities:
Yen-denominated:	Yen-denominated:													Yen-denominated:
Japan government and agencies	Japan government and agencies	$	21,089	$	3	$	21,086	$	4,613	$	0	$	25,699	Japan government and agencies	$	18,269	$	2	$	18,267	$	2,045	$	0	$	20,312
Municipalities	Municipalities	335		0		335		101		0		436		Municipalities	287		0		287		48		0		335
Public utilities	Public utilities	44		1		43		12		0		55		Public utilities	38		1		37		4		0		41
Sovereign and supranational	Sovereign and supranational	518		4		514		136		0		650		Sovereign and supranational	450		4		446		54		0		500
Other corporate	Other corporate	22		0		22		7		0		29		Other corporate	19		0		19		3		0		22
Total yen-denominated	Total yen-denominated	22,008		8		22,000		4,869		0		26,869		Total yen-denominated	19,063		7		19,056		2,154		0		21,210
Total securities held to maturity	Total securities held to maturity	$	22,008	$	8	$	22,000	$	4,869	$	0	$	26,869	Total securities held to maturity	$	19,063	$	7	$	19,056	$	2,154	$	0	$	21,210


(In millions)	(In millions)	March 31, 2022			December 31, 2021			(In millions)	March 31, 2023			December 31, 2022
Equity securities, carried at fair value through net earnings:	Equity securities, carried at fair value through net earnings:	Fair Value			Fair Value			Equity securities, carried at fair value through net earnings:	Fair Value			Fair Value
Equity securities:	Equity securities:							Equity securities:
Yen-denominated	Yen-denominated		$	711		$	744	Yen-denominated		$	679		$	670
U.S. dollar-denominated	U.S. dollar-denominated		663			817		U.S. dollar-denominated		360			374
Other currencies	Other currencies		41			42		Other currencies		48			47
Total equity securities	Total equity securities		$	1,415		$	1,603	Total equity securities		$	1,087		$	1,091

The methods of determining the fair values of the Company's investments in fixed maturity securities and equity securities are described in Note 5.

During the first quarter of ~~2022~~2023 and ~~2021,~~2022, respectively, the Company did not reclassify any investments from the held-to-maturity category to the available-for-sale category.

Contractual and Economic Maturities

The contractual and economic maturities of the Company's investments in fixed maturity securities at March 31, ~~2022,~~2023, were as follows:

1419


(In millions)	(In millions)	Amortized Cost (1)			Fair Value			(In millions)	Amortized Cost (1)			Fair Value
Available for sale:	Available for sale:							Available for sale:
Due in one year or less	Due in one year or less		$	1,335		$	1,427	Due in one year or less		$	1,690		$	1,765
Due after one year through five years	Due after one year through five years		7,876			8,406		Due after one year through five years		6,964			7,350
Due after five years through 10 years	Due after five years through 10 years		12,472			14,056		Due after five years through 10 years		15,878			17,289
Due after 10 years	Due after 10 years		58,446			64,710		Due after 10 years		48,230			49,128
Mortgage- and asset-backed securities	Mortgage- and asset-backed securities		1,335			1,366		Mortgage- and asset-backed securities		2,544			2,567
Total fixed maturity securities available for sale	Total fixed maturity securities available for sale		$	81,464		$	89,965	Total fixed maturity securities available for sale		$	75,306		$	78,099
Held to maturity:	Held to maturity:							Held to maturity:
Due in one year or less	Due in one year or less		$	0		$	0	Due in one year or less		$	0		$	0
Due after one year through five years	Due after one year through five years		41			44		Due after one year through five years		40			42
Due after five years through 10 years	Due after five years through 10 years		10,846			12,429		Due after five years through 10 years		10,067			11,271
Due after 10 years	Due after 10 years		9,785			12,112		Due after 10 years		8,829			10,303
Mortgage- and asset-backed securities	Mortgage- and asset-backed securities		0			0		Mortgage- and asset-backed securities		0			0
Total fixed maturity securities held to maturity	Total fixed maturity securities held to maturity		$	20,672		$	24,585	Total fixed maturity securities held to maturity		$	18,936		$	21,616

(1) Net of allowance for credit losses

Economic maturities are used for certain debt instruments with no stated maturity where the expected maturity date is based on the combination of features in the financial instrument such as the right to call or prepay obligations or changes in coupon rates.

Investment Concentrations

The Company's process for investing in credit-related investments begins with an independent approach to underwriting each issuer's fundamental credit quality. The Company evaluates independently those factors that it believes could influence an issuer's ability to make payments under the contractual terms of the Company's instruments. This includes a thorough analysis of a variety of items including the issuer's country of domicile (including political, legal, and financial considerations); the industry in which the issuer competes (with an analysis of industry structure, end-market dynamics, and regulation); company specific issues (such as management, assets, earnings, cash generation, and capital needs); and contractual provisions of the instrument (such as financial covenants and position in the capital structure). The Company further evaluates the investment considering broad business and portfolio management objectives, including asset/liability needs, portfolio diversification, and expected income.

Investment exposures that individually exceeded 10% of shareholders' equity were as follows:

March 31, 2022

December 31, 2021

March 31, 2023

December 31, 2022

(In millions)

Credit
Rating

Amortized
Cost

Fair
Value

Credit
Rating

Amortized
Cost

Fair
Value

(In millions)

Credit
Rating

Amortized
Cost

Fair
Value

Credit
Rating

Amortized
Cost

Fair
Value

Japan National Government(1)

A+

$47,146

$52,760

A+

$50,186

$57,862

Japan National Government(1)

A+

$42,355

$45,299

A+

$42,618

$44,178

(1)Japan Government Bonds (JGBs) or JGB-backed securities

1520

Net Investment Gains and Losses

Information regarding pretax net gains and losses from investments is as follows:


		Three Months Ended March 31,						Three Months Ended March 31,
(In millions)	(In millions)		2022		2021		(In millions)		2023		2022
Net investment gains (losses):	Net investment gains (losses):						Net investment gains (losses):
Sales and redemptions:	Sales and redemptions:						Sales and redemptions:
Fixed maturity securities available for sale:	Fixed maturity securities available for sale:						Fixed maturity securities available for sale:
Gross gains from sales	Gross gains from sales		$	70	$	2	Gross gains from sales		$	1	$	70
Gross losses from sales	Gross losses from sales		(3)		(1)		Gross losses from sales		(3)		(3)
Foreign currency gains (losses)	Foreign currency gains (losses)		10		(12)		Foreign currency gains (losses)		59		10
Other investments:	Other investments:						Other investments:
Gross gains from sales	Gross gains from sales		9		0		Gross gains from sales		0		9
Total sales and redemptions	Total sales and redemptions		86		(11)		Total sales and redemptions		57		86
Equity securities	Equity securities		(156)		(68)		Equity securities		(3)		(156)

Credit losses:	Credit losses:						Credit losses:
Fixed maturity securities available for sale			0		11

Fixed maturity securities held to maturity	Fixed maturity securities held to maturity		0		1		Fixed maturity securities held to maturity		1		0
Commercial mortgage and other loans	Commercial mortgage and other loans		16		27		Commercial mortgage and other loans		(31)		16
Impairment losses			0		(20)

Loan commitments	Loan commitments		7		5		Loan commitments		3		7
Reinsurance recoverables and other	Reinsurance recoverables and other		2		(2)		Reinsurance recoverables and other		(3)		2
Total credit losses	Total credit losses		25		22		Total credit losses		(30)		25
Derivatives and other:	Derivatives and other:						Derivatives and other:
Derivative gains (losses)	Derivative gains (losses)		(466)		(287)		Derivative gains (losses)		17		(466)
Foreign currency gains (losses)	Foreign currency gains (losses)		633		651		Foreign currency gains (losses)		82		633
Total derivatives and other	Total derivatives and other		167		364		Total derivatives and other		99		167
Total net investment gains (losses)	Total net investment gains (losses)		$	122	$	307	Total net investment gains (losses)		$	123	$	122

The unrealized holding ~~gains,~~losses, net of ~~losses,~~gains, recorded as a component of net investment gains and losses for the three-month period ended March 31, ~~2022,~~2023, that relate to equity securities still held at the March 31, ~~2022~~2023 reporting date, were ~~$157~~$5 million.

Unrealized Investment Gains and Losses

Effect on Shareholders’ Equity

The net effect on shareholders’ equity of unrealized gains and losses from fixed maturity securities was as follows:


(In millions)	(In millions)	March 31, 2022			December 31, 2021			(In millions)	March 31, 2023			December 31, 2022
Unrealized gains (losses) on securities available for sale	Unrealized gains (losses) on securities available for sale		$	8,501		$	13,330	Unrealized gains (losses) on securities available for sale		$	2,793		$	272
Deferred income taxes	Deferred income taxes		(2,714)			(3,728)		Deferred income taxes		(1,504)			(974)
Shareholders’ equity, unrealized gains (losses) on fixed maturity securities	Shareholders’ equity, unrealized gains (losses) on fixed maturity securities		$	5,787		$	9,602	Shareholders’ equity, unrealized gains (losses) on fixed maturity securities		$	1,289		$	(702)

Gross Unrealized Loss Aging

The following tables show the fair values and gross unrealized losses of the Company's available-for-sale investments for the periods ended March 31, ~~2022~~2023 and December 31, ~~2021,~~2022, aggregated by investment category and length of time that individual securities have been in a continuous unrealized loss position.

1621


		March 31, 2022																			March 31, 2023
		Total						Less than 12 months						12 months or longer										Total								Less than 12 months								12 months or longer
(In millions)	(In millions)	Fair Value			Unrealized Losses			Fair Value			Unrealized Losses			Fair Value			Unrealized Losses						(In millions)	Fair Value				Unrealized Losses				Fair Value				Unrealized Losses				Fair Value				Unrealized Losses
Fixed maturity securities available for sale:	Fixed maturity securities available for sale:																			Fixed maturity securities available for sale:
U.S. government and agencies:	U.S. government and agencies:																			U.S. government and agencies:
U.S. dollar-denominated	U.S. dollar-denominated		$	1		$	3		$	0		$	3		$	1			$	0			U.S. dollar-denominated		$	149			$	5			$	62			$	1			$	87			$	4
Japan government and agencies:	Japan government and agencies:																			Japan government and agencies:
Yen-denominated	Yen-denominated		7,780			345			4,264			123			3,516				222				Yen-denominated		8,845				1,079				565				77				8,280				1,002
Municipalities:	Municipalities:																			Municipalities:
U.S. dollar-denominated	U.S. dollar-denominated		258			16			243			14			15				2				U.S. dollar-denominated		817				55				356				13				461				42
Yen-denominated	Yen-denominated		216			15			96			4			120				11				Yen-denominated		303				42				57				4				246				38
Mortgage- and asset- backed securities:	Mortgage- and asset- backed securities:																			Mortgage- and asset- backed securities:
U.S. dollar-denominated	U.S. dollar-denominated		549			23			533			23			16				0				U.S. dollar-denominated		1,007				69				753				58				254				11
Yen-denominated	Yen-denominated		79			3			49			0			30				3				Yen-denominated		70				8				5				0				65				8
Public utilities:	Public utilities:																			Public utilities:
U.S. dollar-denominated	U.S. dollar-denominated		535			29			459			23			76				6				U.S. dollar-denominated		1,380				128				776				53				604				75
Yen-denominated	Yen-denominated		598			17			546			14			52				3				Yen-denominated		726				63				37				2				689				61
Sovereign and supranational:	Sovereign and supranational:																			Sovereign and supranational:
U.S. dollar-denominated	U.S. dollar-denominated		34			8			5			1			29				7				U.S. dollar-denominated		31				11				0				0				31				11

Yen-denominated																		Yen-denominated				72					3				35				3				37				0
Banks/financial institutions:	Banks/financial institutions:																			Banks/financial institutions:
U.S. dollar-denominated	U.S. dollar-denominated		590			26			535			21			55				5				U.S. dollar-denominated		982				85				448				17				534				68
Yen-denominated	Yen-denominated		3,594			168			2,576			86			1,018				82				Yen-denominated		3,907				427				736				43				3,171				384
Other corporate:	Other corporate:																			Other corporate:
U.S. dollar-denominated	U.S. dollar-denominated		3,835			207			3,011			118			824				89				U.S. dollar-denominated		8,128				798				3,297				119				4,831				679
Yen-denominated	Yen-denominated		1,453			77			1,209			47			244				30				Yen-denominated		2,064				309				753				72				1,311				237
Total	Total		$	19,522		$	937		$	13,526		$	477		$	5,996			$	460			Total		$	28,481			$	3,082			$	7,880			$	462			$	20,601			$	2,620

1722


		December 31, 2021																			December 31, 2022
		Total						Less than 12 months						12 months or longer										Total								Less than 12 months								12 months or longer
(In millions)	(In millions)	Fair Value			Unrealized Losses			Fair Value			Unrealized Losses			Fair Value			Unrealized Losses						(In millions)	Fair Value				Unrealized Losses				Fair Value				Unrealized Losses				Fair Value				Unrealized Losses
Fixed maturity securities available for sale:	Fixed maturity securities available for sale:																			Fixed maturity securities available for sale:
U.S. government and agencies:	U.S. government and agencies:																			U.S. government and agencies:
U.S. dollar-denominated	U.S. dollar-denominated		$	1		$	1		$	0		$	1		$	1			$	0			U.S. dollar-denominated		$	159			$	8			$	85			$	3			$	74			$	5
Japan government and agencies:	Japan government and agencies:																			Japan government and agencies:
Yen-denominated	Yen-denominated		2,868			61			445			3			2,423				58				Yen-denominated		8,856				1,724				3,733				580				5,123				1,144
Municipalities:	Municipalities:																			Municipalities:
U.S. dollar-denominated	U.S. dollar-denominated		82			2			79			2			3				0				U.S. dollar-denominated		854				89				735				57				119				32
Yen-denominated	Yen-denominated		187			5			53			0			134				5				Yen-denominated		286				61				150				26				136				35
Mortgage- and asset- backed securities:	Mortgage- and asset- backed securities:																			Mortgage- and asset- backed securities:
U.S. dollar-denominated	U.S. dollar-denominated		278			2			278			2			0				0				U.S. dollar-denominated		936				84				640				42				296				42
Yen-denominated	Yen-denominated		33			1			0			0			33				1				Yen-denominated		62				12				38				6				24				6
Public utilities:	Public utilities:																			Public utilities:
U.S. dollar-denominated	U.S. dollar-denominated		130			5			70			2			60				3				U.S. dollar-denominated		1,852				180				1,667				144				185				36
Yen-denominated	Yen-denominated		26			2			0			0			26				2				Yen-denominated		880				108				576				61				304				47
Sovereign and supranational:	Sovereign and supranational:																			Sovereign and supranational:
U.S. dollar-denominated	U.S. dollar-denominated		37			6			6			1			31				5				U.S. dollar-denominated		30				12				0				0				30				12
Yen-denominated																		Yen-denominated				71					5				34				4				37				1
Banks/financial institutions:	Banks/financial institutions:																			Banks/financial institutions:
U.S. dollar-denominated	U.S. dollar-denominated		292			3			274			3			18				0				U.S. dollar-denominated		1,147				105				786				58				361				47
Yen-denominated	Yen-denominated		2,074			72			1,011			16			1,063				56				Yen-denominated		3,957				531				1,760				174				2,197				357
Other corporate:	Other corporate:																			Other corporate:
U.S. dollar-denominated	U.S. dollar-denominated		1,365			53			458			8			907				45				U.S. dollar-denominated		10,529				1,201				8,636				785				1,893				416
Yen-denominated	Yen-denominated		541			26			274			4			267				22				Yen-denominated		2,090				408				1,507				273				583				135
Total	Total		$	7,914		$	239		$	2,948		$	42		$	4,966			$	197			Total		$	31,709			$	4,528			$	20,347			$	2,213			$	11,362			$	2,315

Analysis of Securities in Unrealized Loss Positions

The unrealized losses on the Company's fixed maturity securities investments have been primarily related to general market changes in interest rates, foreign exchange rates, and/or the levels of credit spreads rather than specific concerns with the issuer's ability to pay interest and repay principal. In the first quarter of 2023, interest rates for longer durations have declined which is the primary driver of the decrease in unrealized losses. However, compared to the prior year, interest rates have risen significantly which is the primary driver contributing to the increase in unrealized losses 12 months or longer.

For any of its fixed maturity securities with significant declines in fair value, the Company performs detailed analyses to identify whether the drivers of the declines are due to general market drivers, such as the recent rise in interest rates, or due to credit-related factors. Identifying the drivers of the declines in fair value helps to align and allocate the Company‘s resources to securities with real credit-related concerns that could impact ultimate collection of principal and interest. For any significant declines in fair value ~~of its fixed maturity securities,~~determined to be non-interest rate or market related, the Company performs a more focused review of the related issuers' specific credit profile.

For corporate issuers, the Company evaluates their assets, business profile including industry dynamics and competitive positioning, financial statements and other available financial data. For non-corporate issuers, the Company analyzes all sources of credit support, including issuer-specific factors. The Company utilizes information available in the public domain and, for certain private placement issuers, from consultations with the issuers directly. The Company also considers ratings from Nationally Recognized Statistical Rating Organizations (NRSROs), as well as the specific

characteristics of the security it owns including seniority in the issuer's capital structure, covenant protections, or other relevant features. From these reviews, the Company evaluates the issuers' continued ability to service the Company's investment through payment of interest and principal.

Assuming no credit-related factors develop, unrealized gains and losses on fixed maturity securities are expected to diminish as investments near maturity. Based on its credit analysis, the Company believes that the issuers of its fixed maturity investments in the sectors shown in the table above have the ability to service their obligations to the Company, and the Company does not intend to sell the investments and it is not more likely than not that the Company will be required to sell the investments before recovery of their amortized cost bases, which may be at maturity.

However, from time to time the Company identifies certain available-for-sale fixed maturity securities where the amortized cost basis exceeds the present value of the cash flows expected to be collected due to credit related factors and as a result, a credit allowance will be estimated. Based on an evaluation of its securities currently in an unrealized loss position, the Company has determined that those securities had not incurred a credit loss and therefore, should not have a credit loss allowance as of March 31, 2023. Refer to the Allowance forCredit Losses section below for additional information.

Commercial Mortgage and Other Loans

The Company classifies its transitional real estate loans (TREs), commercial mortgage loans (CMLs) and middle market loans (MMLs) as held-for-investment and includes them in the commercial mortgage and other loans line on the consolidated balance sheets. The Company carries them on the balance sheet at amortized cost less an estimated allowance for credit losses.

The following table reflects the composition of the carrying value for commercial mortgage and other loans by property type as of the periods presented.


(In millions)	(In millions)	March 31, 2022				December 31, 2021				(In millions)	March 31, 2023				December 31, 2022
		Amortized Cost		% of Total		Amortized Cost		% of Total			Amortized Cost		% of Total		Amortized Cost		% of Total
Commercial Mortgage and other loans:	Commercial Mortgage and other loans:									Commercial Mortgage and other loans:
Transitional real estate loans:	Transitional real estate loans:									Transitional real estate loans:
Office	Office	$	2,017	16.2	%	$	2,001	16.7	%	Office	$	2,142	15.8	%	$	2,158	15.8	%
Retail	Retail	267		2.1		267		2.2		Retail	465		3.4		493		3.6
Apartments/Multi-Family	Apartments/Multi-Family	2,135		17.1		1,893		15.8		Apartments/Multi-Family	2,616		19.3		2,701		19.7
Industrial	Industrial	101		.8		94		.8		Industrial	416		3.1		123		.9
Hospitality	Hospitality	834		6.7		876		7.3		Hospitality	825		6.1		803		5.9
Other	Other	237		1.9		228		1.9		Other	236		1.7		231		1.7
Total transitional real estate loans	Total transitional real estate loans	5,591		44.8		5,359		44.7		Total transitional real estate loans	6,700		49.4		6,509		47.6
Commercial mortgage loans:	Commercial mortgage loans:									Commercial mortgage loans:
Office	Office	395		3.2		398		3.3		Office	380		2.8		388		2.8
Retail	Retail	330		2.6		332		2.8		Retail	308		2.3		310		2.3
Apartments/Multi-Family	Apartments/Multi-Family	633		5.1		649		5.4		Apartments/Multi-Family	610		4.5		630		4.6
Industrial	Industrial	521		4.2		525		4.4		Industrial	469		3.5		694		5.1

Total commercial mortgage loans	Total commercial mortgage loans	1,879		15.1		1,904		15.9		Total commercial mortgage loans	1,767		13.1		2,022		14.8
Middle market loans	Middle market loans	5,000		40.1		4,697		39.4		Middle market loans	5,084		37.5		5,157		37.6
Total commercial mortgage and other loans	Total commercial mortgage and other loans	$	12,470	100.0	%	$	11,960	100.0	%	Total commercial mortgage and other loans	$	13,551	100.0	%	$	13,688	100.0	%
Allowance for credit losses	Allowance for credit losses	(158)				(174)				Allowance for credit losses	(223)				(192)
Total net commercial mortgage and other loans	Total net commercial mortgage and other loans	$	12,312			$	11,786			Total net commercial mortgage and other loans	$	13,328			$	13,496

CMLs and TREs were secured by properties entirely within the U.S. (with the largest concentrations in California ~~(22%~~(20%), Texas (12%) and Florida ~~(9%~~(10%)). ~~Middle market loans~~MMLs are issued only to companies domiciled within the U.S. and Canada.

Transitional Real Estate Loans

TREs are commercial mortgage loans that are typically relatively short-term floating rate instruments secured by a first lien on the property. These loans provide funding for properties undergoing a change in their physical characteristics and/or economic profile and do not typically require any principal repayment prior to the maturity date. ~~This loan portfolio is generally considered to be investment grade.~~

As of March 31, ~~2022,~~2023, the Company had ~~$693~~$709 million in outstanding commitments to fund TREs. These commitments are contingent on the final underwriting and due diligence to be performed.

Commercial Mortgage Loans

CMLs are typically fixed rate loans on commercial real estate with partial repayment of principal over the life of the loan with the remaining outstanding principal being repaid upon maturity. This loan portfolio is generally considered higher quality investment grade loans. ~~As of March 31, 2022, the Company had no outstanding commitments to fund CMLs. These commitments are contingent on the final underwriting and due diligence to be performed.~~

Middle Market Loans

MMLs are typically first lien senior secured cash flow loans to small to mid-size companies for working capital, refinancing, acquisition, and recapitalization. These loans are generally considered to be below investment grade. The carrying value for MMLs included ~~$16~~$21 million and ~~$11~~$28 million for a short term credit facility that is reflected in other liabilities on the consolidated balance sheets, as of March 31, ~~2022,~~2023, and December 31, ~~2021,~~2022, respectively.

As of March 31, ~~2022,~~2023, the Company had commitments of approximately ~~$1.2 billion~~$748 million to fund future MMLs. These commitments are contingent upon the availability of ~~middle market loans~~MMLs that meet the Company's underwriting criteria.

Credit Quality Indicators

For TREs, the Company’s key credit quality indicator is loan-to-value (LTV). Given that ~~TRE loans~~TREs involve properties undergoing ~~renovation or construction,~~a repositioning of their commercial profile, LTV provides the most insight into the credit risk of the loan. The Company monitors the performance of the loans periodically, but not less frequently than quarterly. The monitoring process also focuses on higher risk loans, which include those that are delinquent or for which foreclosure or deed-in-lieu of foreclosure is anticipated.

For CMLs, the Company’s key credit quality indicators include LTV and debt service coverage ratios (DSCR). LTV is calculated by dividing the current outstanding loan balance by the most recent estimated property value. DSCR is the most recently available operating income of the underlying property compared to the required debt service of the loan.

For MMLs and held-to-maturity fixed maturity securities, the Company’s key credit quality indicator is credit ratings. The Company’s held-to-maturity portfolio is composed of investment grade securities that are senior unsecured instruments, while its MMLs generally have below-investment-grade ratings but are typically senior secured instruments. The Company monitors the credit ratings periodically, but not less frequently than quarterly.

For the Company’s reinsurance recoverable balance, the key credit quality indicator is the credit rating of the Company’s reinsurance counterparty. The Company uses external credit ratings focused on the reinsurer’s financial strength and credit worthiness. As of March 31, ~~2022,~~2023, the Company's reinsurance counterparties were rated A+. The Company monitors the credit ratings periodically, but not less frequently than quarterly.

2025

The following tables present as of March 31, ~~2022~~2023 the amortized cost basis of TREs, CMLs and MMLs by year of origination and credit quality ~~indicator~~.indicator.


Transitional Real Estate Loans	Transitional Real Estate Loans													Transitional Real Estate Loans
(In millions)	(In millions)	2022		2021		2020		2019		2018		Prior		Total		(In millions)	2023		2022		2021		2020		2019		Prior		Total
Loan-to-Value Ratio:	Loan-to-Value Ratio:															Loan-to-Value Ratio:
0%-59.99%	0%-59.99%	$	294	$	598	$	36	$	318	$	86	$	0	$	1,332	0%-59.99%	$	77	$	692	$	588	$	36	$	153	$	10	$	1,556
60%-69.99%	60%-69.99%	161		693		137		624		417		50		2,082		60%-69.99%	42		663		707		135		490		430		2,467
70%-79.99%	70%-79.99%	145		1,031		156		493		227		1		2,053		70%-79.99%	0		882		947		98		365		146		2,438
80% or greater	80% or greater	0		124		0		0		0		0		124		80% or greater	0		77		162		0		0		0		239
Total	Total	$	600	$	2,446	$	329	$	1,435	$	730	$	51	$	5,591	Total	$	119	$	2,314	$	2,404	$	269	$	1,008	$	586	$	6,700


Commercial Mortgage Loans	Commercial Mortgage Loans																Commercial Mortgage Loans
(In millions)	(In millions)	2022		2021		2020		2019		2018		Prior		Total		Weighted-Average DSCR	(In millions)	2023		2022		2021		2020		2019		Prior		Total		Weighted-Average DSCR
Loan-to-Value Ratio:	Loan-to-Value Ratio:																Loan-to-Value Ratio:
0%-59.99%	0%-59.99%	$	0	$	303	$	47	$	518	$	154	$	599	$	1,621	2.48	0%-59.99%	$	0	$	0	$	299	$	46	$	507	$	599	$	1,451	2.52
60%-69.99%	60%-69.99%	0		34		0		86		0		113		233		1.87	60%-69.99%	0		0		15		0		45		169		229		2.00
70%-79.99%	70%-79.99%	0		0		0		0		0		25		25		1.78	70%-79.99%	0		0		0		0		39		24		63		2.21
80% or greater	80% or greater	0		0		0		0		0		0		0		0.00	80% or greater	0		0		0		0		0		24		24		1.41
Total	Total	0		337		47		604		154		737		1,879		2.39	Total	$	0	$	0	$	314	$	46	$	591	$	816	$	1,767	2.43

Weighted Average DSCR	Weighted Average DSCR	0.00		2.87		1.93		2.39		2.10		2.28					Weighted Average DSCR	0.00				2.93		1.93		2.45		2.24


Middle Market Loans	Middle Market Loans																	Middle Market Loans
(In millions)	(In millions)	2022		2021		2020		2019		2018		Prior		Revolving Loans		Total		(In millions)	2023		2022		2021		2020		2019		Prior		Revolving Loans		Total
Credit Ratings:	Credit Ratings:																	Credit Ratings:
BBB	BBB	$	0	$	117	$	58	$	37	$	23	$	0	$	81	$	316	BBB	$	7	$	75	$	142	$	70	$	37	$	17	$	134	$	482
BB	BB	42		337		299		187		111		59		296		1,331		BB	1		347		444		299		171		128		381		1,771
B	B	99		889		513		624		262		275		292		2,954		B	20		230		661		382		464		406		297		2,460
CCC	CCC	0		0		22		64		87		124		75		372		CCC	0		0		21		39		111		128		57		356
CC	CC	0		0		0		0		0		26		1		27		CC	0		0		0		0		0		14		1		15
C and lower	C and lower	0		0		0		0		0		0		0		0		C and lower	0		0		0		0		0		0		0		0
Total	Total	$	141	$	1,343	$	892	$	912	$	483	$	484	$	745	$	5,000	Total	$	28	$	652	$	1,268	$	790	$	783	$	693	$	870	$	5,084

Loan Modifications

The Company granted certain loan modifications in its MML and TRE portfolios during the three-month period ended March 31, 2023. As of March 31, 2023, these loan modifications did not have a material impact on the Company’s results of operations.

Allowance for Credit Losses

The Company calculates its allowance for credit losses for held-to-maturity fixed maturity securities, loan receivables, loan commitments and reinsurance recoverable by grouping assets with similar risk characteristics when there is not a specific expectation of a loss for an individual asset. For held-to-maturity fixed maturity securities, MMLs, and MML commitments, the Company groups assets by credit ratings, industry, and country. The Company groups CMLs and TREs and respective loan commitments by property type, property location and the property’s LTV and ~~debt service coverage ratios.~~DSCR. The credit allowance for the reinsurance recoverable balance is estimated using a probability-of-default (PD) / loss-given-default (LGD) method.

The credit allowance for held-to-maturity fixed maturity securities and loan receivables is estimated using a PD / LGD method, discounted for the time value of money. For held-to-maturity fixed maturity securities, available-for-sale fixed

maturity securities and loan receivables, the Company includes the change in present value due to the passage of time in the change in the allowance for credit losses. The Company’s methodology for estimating credit losses utilizes the contractual maturity date of the financial asset, adjusted when necessary to reflect the expected timing of repayment (such as prepayment options, renewal options, call options, or extension options). The Company applies reasonable and

supportable forecasts of macroeconomic variables that impact the determination of PD/LGD over a two-year period for held-to-maturity fixed maturity securities and MMLs. The Company reverts to historical loss information over one year, following the two-year forecast period. For the CML and TRE portfolio, the Company applies reasonable and supportable forecasts of macroeconomic variables as well as national and local real-estate market factors to estimate future credit losses where the market factors revert back to historical levels over time with the period being dependent on current market conditions, projected market conditions and difference in the current and historical market levels for each factor. The Company continuously monitors the estimation methodology, due to changes in portfolio composition, changes in underwriting practices and significant events or conditions and makes adjustments as necessary.

The Company’s held-to-maturity fixed maturity portfolio includes Japan Government and Agency securities of ~~$19.7~~$18.0 billion amortized cost as of March 31, ~~2022~~2023 that meet the requirements for zero-credit-loss expectation and therefore these asset classes have been excluded from the current expected credit loss measurement.

An investment in an available-for-sale fixed maturity security ismay be impaired if the fair value falls below amortized cost. The Company regularly reviews its fixed maturity security investments portfolio for declines in fair value. The Company's debt impairment model focuses on the ultimate collection of the cash flows from its investments and whether the Company has the intent to sell or if it is more likely than not the Company would be required to sell the security prior to recovery of its amortized cost. The determination of the amount of impairments under this model is based upon the Company's periodic evaluation and assessment of known and inherent risks associated with the respective securities. Such evaluations and assessments are revised as conditions change and new information becomes available.

When determining the Company's intention to sell a security prior to recovery of its fair value to amortized cost, the Company evaluates facts and circumstances such as, but not limited to, future cash flow needs, decisions to reposition its security portfolio, and risk profile of individual investment holdings. The Company performs ongoing analyses of its liquidity needs, which includes cash flow testing of its policy liabilities, debt maturities, projected dividend payments, and other cash flow and liquidity needs.

The Company’s methodology for estimating credit losses for available-for-sale fixed maturity securities utilizes the discounted cash flow model, based on past events, current market conditions and future economic conditions, as well as industry analysis and credit ratings of the fixed maturity securities. In addition, the Company evaluates the specific issuer’s probability of default and expected recovery of its position in the event of default based on the underlying financial condition and assets of the borrower as well as seniority and/or security of other debt holders in the issuer when developing management’s best estimate of expected cash flows.

The Company granted certain loan modifications in its MML and TRE portfolios during the three-month period ended March 31, 2022. As of March 31, 2022, these loan modifications did not have a material impact on the Company’s results of operations.

~~The Company had no troubled debt restructurings (TDRs) during the three-month periods ended March 31, 2022 and March 31, 2021, respectively.~~

~~The Company~~ designates nonaccrual status for a nonperforming loan or debt security or a loan that is not generating its stated interest rate because of nonpayment of periodic interest by the borrower. The Company applies the cash basis method to record any payments received on non-accrual assets. The Company resumes the accrual of interest on fixed maturity securities and loans that are currently making contractual payments or for those that are not current where the borrower has paid timely (less than 30 days outstanding).

As of March 31, ~~2022~~2023 and December 31, ~~2021,~~2022, the Company had an immaterial amount of loans and fixed maturity securities on nonaccrual status.

2227

The following table presents the roll forward of the allowance for credit losses by portfolio segment.


(in millions)		Transitional Real Estate Loans		Commercial Mortgage Loans		Middle Market Loans		Held to Maturity Securities		Available for Sale Securities		Reinsurance Recoverables
(In millions)														(In millions)	Transitional Real Estate Loans		Commercial Mortgage Loans		Middle Market Loans		Held to Maturity Securities		Available for Sale Securities		Reinsurance Recoverables

Three Months Ended March 31, 2023:														Three Months Ended March 31, 2023:
Balance at December 31, 2022														Balance at December 31, 2022	$	(54)	$	(9)	$	(129)	$	(7)	$	0	$	(8)
(Addition to) release of allowance for credit losses														(Addition to) release of allowance for credit losses	(11)		0		(20)		1		0		(3)
Write-offs, net of recoveries														Write-offs, net of recoveries	0		0		0		0		0		0
Change in foreign exchange														Change in foreign exchange	0		0		0		0		0		0
Balance at March 31, 2023														Balance at March 31, 2023	$	(65)	$	(9)	$	(149)	$	(6)	$	0	$	(11)
Three Months Ended March 31, 2022:	Three Months Ended March 31, 2022:													Three Months Ended March 31, 2022:
Balance at December 31, 2021	Balance at December 31, 2021	$	(68)	$	(10)	$	(96)	$	(8)	$	0	$	(13)	Balance at December 31, 2021	$	(68)	$	(10)	$	(96)	$	(8)	$	0	$	(13)
(Addition to) release of allowance for credit losses	(Addition to) release of allowance for credit losses	16		2		(2)		0		0		2		(Addition to) release of allowance for credit losses	16		2		(2)		0		0		2

Change in foreign exchange	Change in foreign exchange	0		0		0		0		0		2		Change in foreign exchange	0		0		0		0		0		2
Balance at March 31, 2022	Balance at March 31, 2022	$	(52)	$	(8)	$	(98)	$	(8)	$	0	$	(9)	Balance at March 31, 2022	$	(52)	$	(8)	$	(98)	$	(8)	$	0	$	(9)
Three Months Ended March 31, 2021:
Balance at December 31, 2020		$	(63)	$	(33)	$	(85)	$	(9)	$	(38)	$	(11)

(Addition to) release of allowance for credit losses		16		9		2		1		0		(2)
Write-offs, net of recoveries		0		0		0		0		11		0
Balance at March 31, 2021		$	(47)	$	(24)	$	(83)	$	(8)	$	(27)	$	(13)

During the first quarter of 2023, the Company identified certain TREs collateralized with commercial real estate properties with an amortized cost of $521 million in anticipation of potential foreclosure or deed-in lieu foreclosure transactions. The Company established a credit allowance of $10 million for those amortized loans of $345 million for which the fair value of the collateral was below the amortized cost of the loans.

For assets that are subject to the credit loss measurement, the change in credit loss allowance will be significantly impacted by purchases and sales in those assets during the period as well as entering into new non-cancelable loan commitments. The estimate of credit losses for loan commitments as of March 31, ~~2022~~2023 was ~~$24~~$21 million.

Other Investments

The table below reflects the composition of the carrying value for other investments as of the periods presented.


(In millions)	(In millions)	March 31, 2022			December 31, 2021			(In millions)	March 31, 2023			December 31, 2022
Other investments:	Other investments:							Other investments:
Policy loans	Policy loans		$	224		$	236	Policy loans		$	214		$	214
Short-term investments (1)	Short-term investments (1)		1,747			1,726		Short-term investments (1)		2,561			1,532
Limited partnerships	Limited partnerships		1,964			1,858		Limited partnerships		2,432			2,290
Other	Other		25			22		Other		34			34
Total other investments	Total other investments		$	3,960		$	3,842	Total other investments		$	5,241		$	4,070

(1) Includes securities lending collateral

The Parent Company invests in partnerships that specialize in rehabilitating historic structures or the installation of solar equipment in order to receive federal historic rehabilitation and solar tax credits. These investments are classified as limited partnerships and included in other investments in the consolidated balance sheet. The change in value of each investment is recorded as a reduction to net investment income. Tax credits generated by these investments are recorded as an income tax benefit in the consolidated statement of earnings.

As of March 31, ~~2022,~~2023, the Company had ~~$1.7~~$2.0 billion in outstanding commitments to fund alternative investments in limited partnerships.

Variable Interest Entities (VIEs)

As a condition of its involvement or investment in a VIE, the Company enters into certain protective rights and covenants that preclude changes in the structure of the VIE that would alter the creditworthiness of the Company's investment or its beneficial interest in the VIE.

For those VIEs other than certain unit trust structures, the Company's involvement is passive in nature. The Company ~~has~~is not, nor has it been, required to purchase any securities issued in the future by these VIEs.

The Company's ownership interest in VIEs is limited to holding the obligations issued by them. The Company has no direct or contingent obligations to fund the limited activities of these VIEs, nor does it have any direct or indirect financial guarantees related to the limited activities of these VIEs. The Company has not provided any assistance or any other type of financing support to any of the VIEs it invests in, nor does it have any intention to do so in the future. For those VIEs in which the Company holds debt obligations, the weighted-average lives of the Company's notes are very similar to the underlying collateral held by these VIEs where applicable.

The Company's risk of loss related to its interests in any of its VIEs is limited to the carrying value of the related investments held in the VIE.

VIEs - Consolidated

The following table presents the cost or amortized cost, fair value and balance sheet caption in which the assets and liabilities of consolidated VIEs are reported.

Investments in Consolidated Variable Interest Entities


		March 31, 2022						December 31, 2021							March 31, 2023						December 31, 2022
(In millions)	(In millions)	Amortized Cost (1)			Fair Value			Amortized Cost (1)			Fair Value			(In millions)	Amortized Cost (1)			Fair Value			Amortized Cost (1)			Fair Value
Assets:	Assets:													Assets:
Fixed maturity securities, available for sale	Fixed maturity securities, available for sale		$	3,223		$	4,170		$	3,264		$	4,490	Fixed maturity securities, available for sale		$	3,222		$	3,925		$	3,223		$	3,805

Commercial mortgage and other loans	Commercial mortgage and other loans		10,027			10,082			9,740			9,910		Commercial mortgage and other loans		10,684			10,688			10,832			10,762
Other investments (2)	Other investments (2)		1,624			1,624			1,535			1,535		Other investments (2)		2,049			2,049			1,909			1,909
Other assets (3)	Other assets (3)		75			75			78			78		Other assets (3)		63			63			62			62
Total assets of consolidated VIEs	Total assets of consolidated VIEs		$	14,949		$	15,951		$	14,617		$	16,013	Total assets of consolidated VIEs		$	16,018		$	16,725		$	16,026		$	16,538
Liabilities:	Liabilities:													Liabilities:
Other liabilities (3)	Other liabilities (3)		$	427		$	427		$	414		$	414	Other liabilities (3)		$	399		$	399		$	390		$	390
Total liabilities of consolidated VIEs	Total liabilities of consolidated VIEs		$	427		$	427		$	414		$	414	Total liabilities of consolidated VIEs		$	399		$	399		$	390		$	390

(1) Net of allowance for credit losses

(2) Consists entirely of alternative investments in limited partnerships

(3) Consists entirely of derivatives

The Company is substantively the only investor in the consolidated VIEs listed in the table above. As the sole investor in these VIEs, the Company has the power to direct the activities of a variable interest entity that most significantly impact the entity's economic performance and is therefore considered to be the primary beneficiary of the VIEs that it consolidates. The Company also participates in substantially all of the variability created by these VIEs. The activities of these VIEs are limited to holding invested assets and foreign currency swaps, as appropriate, and utilizing the cash flows from these securities to service its investment. Neither the Company nor any of its creditors are able to obtain the underlying collateral of the VIEs unless there is an event of default or other specified event. For those VIEs that contain a swap, the Company is not a direct counterparty to the swap contracts and has no control over them. The Company's loss exposure to these VIEs is limited to its original investment. The Company's consolidated VIEs do not rely on outside or ongoing sources of funding to support their activities beyond the underlying collateral and swap contracts, if applicable. With the exception of its investment in unit trust structures, the underlying collateral assets and funding of the Company's consolidated VIEs are generally static in nature.

Investments in Unit Trust Structures

The Company also utilizes unit trust structures in its Aflac Japan segment to invest in various asset classes. As the sole investor of these VIEs, the Company is required to consolidate these trusts under U.S. GAAP.

2429

VIEs - Not Consolidated

The table below reflects the amortized cost, fair value and balance sheet caption in which the Company's investment in VIEs not consolidated are reported.

Investments in Variable Interest Entities Not Consolidated


		March 31, 2022						December 31, 2021							March 31, 2023						December 31, 2022
(In millions)	(In millions)	Amortized Cost			Fair Value			Amortized Cost			Fair Value			(In millions)	Amortized Cost			Fair Value			Amortized Cost			Fair Value
Assets:	Assets:													Assets:
Fixed maturity securities, available for sale	Fixed maturity securities, available for sale		$	4,513		$	5,260		$	4,779		$	5,864	Fixed maturity securities, available for sale		$	3,890		$	4,274		$	3,998		$	4,259
Other investments (1)	Other investments (1)		340			340			323			323		Other investments (1)		383			383			381			381
Total investments in VIEs not consolidated	Total investments in VIEs not consolidated		$	4,853		$	5,600		$	5,102		$	6,187	Total investments in VIEs not consolidated		$	4,273		$	4,657		$	4,379		$	4,640

(1) Consists entirely of alternative investments in limited partnerships

Certain investments in VIEs that the Company is not required to consolidate are investments that are in the form of debt obligations from the VIEs that are irrevocably and unconditionally guaranteed by their corporate parents or sponsors. These VIEs are the primary financing vehicles used by their corporate sponsors to raise financing in the capital markets. The variable interests created by these VIEs are principally or solely a result of the debt instruments issued by them. The Company does not have the power to direct the activities that most significantly impact the entity's economic performance, nor does it have the obligation to absorb losses of the entity or the right to receive benefits from the entity. As such, the Company is not the primary beneficiary of these VIEs and is therefore not required to consolidate them.

The Company holds alternative investments in limited partnerships that have been determined to be VIEs. These partnerships invest in private equity and structured investments. The Company’s maximum exposure to loss on these investments is limited to the amount of its investment. The Company is not the primary beneficiary of these VIEs and is therefore not required to consolidate them. The Company classifies these investments as Other investments in the consolidated balance sheets.

Securities Lending and Pledged Securities

The Company lends fixed maturity and public equity securities to financial institutions in short-term security-lending transactions. These short-term security-lending arrangements increase investment income with minimal risk. The Company receives cash or other securities as collateral for such loans. The Company's security lending policy requires that the fair value of the securities received as collateral be 102% or more of the fair value of the loaned securities and that unrestricted cash received as collateral be 100% or more of the fair value of the loaned securities. The securities loaned continue to be carried as investment assets on the Company's balance sheet during the terms of the loans and are not reported as sales. For loans involving unrestricted cash or securities as collateral, the collateral is reported as an asset with a corresponding liability for the return of the collateral. For loans where the Company receives as collateral securities that the Company is not permitted to sell or repledge, the collateral is not reflected on the consolidated financial statements.

2530

Details of collateral by loaned security type and remaining maturity of the agreements were as follows:


Securities Lending Transactions Accounted for as Secured Borrowings	Securities Lending Transactions Accounted for as Secured Borrowings												Securities Lending Transactions Accounted for as Secured Borrowings
Remaining Contractual Maturity of the Agreements	Remaining Contractual Maturity of the Agreements												Remaining Contractual Maturity of the Agreements
		March 31, 2022						December 31, 2021							March 31, 2023						December 31, 2022
(In millions)	(In millions)	Overnight and Continuous(1)		Up to 30 days		Total			Overnight and Continuous(1)		Up to 30 days		Total			(In millions)	Overnight and Continuous(1)		Up to 30 days			Total		Overnight and Continuous(1)		Up to 30 days		Total
Securities lending transactions:	Securities lending transactions:															Securities lending transactions:
Fixed maturity securities:	Fixed maturity securities:															Fixed maturity securities:
Japan government and agencies	Japan government and agencies	$	0	$	1,127	$	1,127		$	0	$	920	$	920		Japan government and agencies	$	0	$	2,912		$	2,912	$	0	$	1,087	$	1,087

Public utilities	Public utilities	16		0		16			40		0		40			Public utilities	4		0			4		12		0		12
Sovereign and supranational		2		0		2			2		0		2

Banks/financial institutions	Banks/financial institutions	116		0		116			88		0		88			Banks/financial institutions	60		0			60		89		0		89
Other corporate	Other corporate	937		0		937			1,112		0		1,112			Other corporate	484		0			484		621		0		621

Total borrowings	Total borrowings	$	1,071	$	1,127	$	2,198		$	1,242	$	920	$	2,162		Total borrowings	$	548	$	2,912		$	3,460	$	722	$	1,087	$	1,809
Gross amount of recognized liabilities for securities lending transactions	Gross amount of recognized liabilities for securities lending transactions					$	2,198						$	2,162		Gross amount of recognized liabilities for securities lending transactions						$	3,460					$	1,809

(1) The related loaned security, under the Company's U.S. securities lending program, can be returned to the Company at the transferee's discretion; therefore, they are classified as Overnight and Continuous.

In connection with securities lending, in addition to cash collateral received, the Company received from counterparties securities collateral of ~~$7.0~~$5.9 billion and $6.8 billion at March 31, ~~2022~~2023 and December 31, ~~2021,~~2022, respectively, which may not be sold or re-pledged, unless the counterparty is in default. Such securities collateral is not reflected on the consolidated financial statements.

The Company did 0tnot have any repurchase agreements or repurchase-to-maturity transactions outstanding as of March 31, ~~2022,~~2023, and December 31, ~~2021,~~2022, respectively.

Certain fixed maturity securities can be pledged as collateral as part of derivative transactions, or pledged to support state deposit requirements on certain investment programs. For additional information regarding pledged securities related to derivative transactions, see Note 4.

4. DERIVATIVE INSTRUMENTS

The Company's freestanding derivative financial instruments have historically consisted of:

•foreign currency forwards and options used in hedging foreign exchange risk on U.S. dollar-denominated investments in Aflac Japan's portfolio, with options used on a standalone basis and/or in a collar ~~strategy~~strategy;

•foreign currency forwards and options used to economically hedge certain portions of forecasted cash flows denominated in yen and hedge the Company's long term exposure to a weakening ~~yen~~yen;

•cross-currency interest rate swaps, also referred to as foreign currency swaps, associated with certain senior notes and subordinated ~~debentures~~debentures;

•foreign currency swaps that are associated with variable interest entity (VIE) bond purchase commitments, and investments in special-purpose entities, including VIEs where the Company is the primary ~~beneficiary~~beneficiary;

•interest rate swaps used to economically hedge interest rate fluctuations in certain variable-rate ~~investments~~investments;

•interest rate swaptions used to hedge changes in the fair value associated with interest rate fluctuations for certain U.S. dollar-denominated available-for-sale fixed-maturity ~~securities~~securities; and

•bond purchase commitments at the inception of investments in consolidated VIEs.

Some of the Company's derivatives are designated as cash flow hedges, fair value hedges or net investment hedges; however, other derivatives do not qualify for hedge accounting or the Company elects not to designate them as accounting hedges.

Derivative Types

Foreign currency forwards and options are executed for the Aflac Japan segment in order to hedge the currency risk on the carrying value of certain U.S. dollar-denominated investments. The average maturity of these forwards and options can change depending on factors such as market conditions and types of investments being held. In situations where the maturity of the forwards and options is shorter than the underlying investment being hedged, the Company may enter into new forwards and options near maturity of the existing derivative in order to continue hedging the underlying investment. In forward transactions, Aflac Japan agrees with another party to buy a fixed amount of yen and sell a corresponding amount of U.S. dollars at a specified future date. The Company also uses one-sided foreign currency put options to mitigate the settlement risk on U.S. dollar-denominated assets related to extreme foreign currency rate changes. From time to time, Aflac Japan also executes foreign currency option transactions in a collar strategy, where Aflac Japan agrees with another party to simultaneously purchase put options and sell call options. In the purchased put transactions, Aflac Japan obtains the option to buy a fixed amount of yen and sell a corresponding amount of U.S. dollars at a specified future date. In the sold call transactions, Aflac Japan agrees to sell a fixed amount of yen and buy a corresponding amount of U.S. dollars at a specified future date. The combination of purchasing the put option and selling the call option results in no net premium being paid (i.e. a costless or zero-cost collar). ~~In 2021, the Company moved to a strategy that contains one-sided put options, fewer foreign currency forwards and no collars.~~

From time to time, the Company may also enter into foreign currency forwards and options to hedge the currency risk associated with the net investment in Aflac Japan. In these forward transactions, the Company agrees with another party to buy a fixed amount of U.S. dollars and sell a corresponding amount of yen at a specified price at a specified future date. In the option transactions, the Company may use a combination of foreign currency options to protect expected future cash flows by simultaneously purchasing yen put options (options that protect against a weakening yen) and selling yen call options (options that limit participation in a strengthening yen). The combination of these two actions create a zero-cost collar. Additionally, the Company enters into purchased options to hedge cash flows from the net investment in Aflac Japan.

The Company enters into foreign currency swaps pursuant to which it exchanges an initial principal amount in one currency for an initial principal amount of another currency, with an agreement to re-exchange the principal amounts at a future date. There may also be periodic exchanges of payments at specified intervals based on the agreed upon rates and notional amounts. Foreign currency swaps are used primarily in the consolidated VIEs in the Company's Aflac Japan portfolio to convert foreign-denominated cash flows to yen, the functional currency of Aflac Japan, in order to minimize cash flow fluctuations. The Company also uses foreign currency swaps to economically convert certain of its U.S. dollar-denominated senior note and subordinated debenture principal and interest obligations into yen-denominated obligations.

In order to reduce investment income volatility from its variable-rate investments, the Company enters into receive–fixed, pay–floating interest rate swaps. These derivatives are cleared and settled through a central clearinghouse.

Swaptions are used to mitigate the adverse impact resulting from significant changes in the fair value of U.S. dollar-denominated available-for-sale securities due to fluctuation in interest rates. In a payer swaption, the Company pays a premium to obtain the right, but not the obligation, to enter into a swap contract where it will pay a fixed rate and receive a floating rate. Interest rate swaption collars are combinations of two swaption positions. In order to maximize the efficiency of the collars while minimizing cost, a collar strategy is used whereby the Company purchases a long payer swaption (the Company purchases an option that allows it to enter into a swap where the Company will pay the fixed rate and receive the floating rate of the swap) and sells a short receiver swaption (the Company sells an option that provides the counterparty with the right to enter into a swap where the Company will receive the fixed rate and pay the floating rate of the swap). The combination of purchasing the long payer swaption and selling the short receiver swaption results in no net premium being paid (i.e. a costless or zero-cost collar).

Bond purchase commitments result from repackaged bond structures that are consolidated VIEs whereby there is a delay in the trade date and settlement date of the bond within the structure to ensure completion of all necessary legal agreements to support the consolidated VIE that issues the repackaged bond. Since the Company has a commitment to purchase the underlying bond at a specified price, the agreement meets the definition of a derivative where the value is derived based on the current market value of the bond compared to the fixed purchase price to be paid on the settlement date.

Derivative Balance Sheet Classification

The table below summarizes the balance sheet classification of the Company's derivative fair value amounts, as well as the gross asset and liability fair value amounts. The fair value amounts presented do not include income accruals. Derivative assets are included in “Other Assets,” while derivative liabilities are included in “Other Liabilities” within the Company’s Consolidated Balance Sheets. The notional amount of derivative contracts represents the basis upon which pay or receive amounts are calculated and are not reflective of exposure or credit risk.


			March 31, 2022									December 31, 2021										March 31, 2023									December 31, 2022
(In millions)	(In millions)				Asset Derivatives			Liability Derivatives						Asset Derivatives			Liability Derivatives			(In millions)				Asset Derivatives			Liability Derivatives						Asset Derivatives			Liability Derivatives
Hedge Designation/ Derivative Type	Hedge Designation/ Derivative Type	Notional Amount			Fair Value			Fair Value			Notional Amount			Fair Value			Fair Value			Hedge Designation/ Derivative Type	Notional Amount			Fair Value			Fair Value			Notional Amount			Fair Value			Fair Value
Cash flow hedges:	Cash flow hedges:																			Cash flow hedges:
Foreign currency swaps - VIE	Foreign currency swaps - VIE		$	18		$	0		$	2		$	18		$	0		$	2	Foreign currency swaps - VIE		$	18		$	0		$	3		$	18		$	0		$	3
Total cash flow hedges	Total cash flow hedges		18			0			2			18			0			2		Total cash flow hedges		18			0			3			18			0			3
Fair value hedges:	Fair value hedges:																			Fair value hedges:
Foreign currency forwards			0			0			0			62			0			5

Foreign currency options	Foreign currency options		9,004			4			0			8,829			5			0		Foreign currency options		7,743			20			0			7,940			45			0

Total fair value hedges	Total fair value hedges		9,004			4			0			8,891			5			5		Total fair value hedges		7,743			20			0			7,940			45			0
Net investment hedge:	Net investment hedge:																			Net investment hedge:
Foreign currency forwards	Foreign currency forwards		5,012			487			0			4,996			341			0		Foreign currency forwards		4,956			359			43			4,982			383			85
Foreign currency options	Foreign currency options		1,908			0			0			1,949			0			0		Foreign currency options		2,235			3			0			2,630			7			0
Total net investment hedge	Total net investment hedge		6,920			487			0			6,945			341			0		Total net investment hedge		7,191			362			43			7,612			390			85
Non-qualifying strategies:	Non-qualifying strategies:																			Non-qualifying strategies:
Foreign currency swaps	Foreign currency swaps		1,900			66			5			2,250			59			13		Foreign currency swaps		1,900			55			0			1,900			66			0
Foreign currency swaps - VIE	Foreign currency swaps - VIE		3,367			75			425			3,151			78			412		Foreign currency swaps - VIE		3,466			63			396			3,420			62			387
Foreign currency forwards	Foreign currency forwards		10,472			490			812			15,953			450			1,133		Foreign currency forwards		3,701			0			133			5,049			17			640
Foreign currency options	Foreign currency options		4,456			4			0			2,746			3			0		Foreign currency options		5,717			23			0			5,521			30			0

Interest rate swaps	Interest rate swaps		3,500			0			216			3,500			0			54		Interest rate swaps		17,730			26			483			17,730			7			583

Total non-qualifying strategies	Total non-qualifying strategies		23,695			635			1,458			27,600			590			1,612		Total non-qualifying strategies		32,514			167			1,012			33,620			182			1,610
Total derivatives	Total derivatives		$	39,637		$	1,126		$	1,460		$	43,454		$	936		$	1,619	Total derivatives		$	47,466		$	549		$	1,058		$	49,190		$	617		$	1,698

Cash Flow Hedges

For certain variable-rate U.S. dollar-denominated available-for-sale securities held by Aflac Japan via consolidated VIEs, foreign currency swaps are used to swap the U.S. Dollar (USD) variable rate interest and principal payments to fixed rate Japanese Yen (JPY) interest and principal payments. The Company has designated foreign currency swaps as a hedge of the variability in cash flows of a forecasted transaction or of amounts to be received or paid related to a recognized asset (“cash flow” hedge). The remaining maximum length of time for which these cash flows are hedged is approximately ~~five~~four years. The derivatives in the Company's consolidated VIEs that are not designated as accounting hedges are discussed in the "non-qualifying strategies" section of this note.

Fair Value Hedges

The Company designates and accounts for certain foreign currency forwards, options, and interest rate swaptions as fair value hedges when they meet the requirements for hedge accounting. The Company recognizes gains and losses on these derivatives as well as the offsetting gain or loss on the related hedged items in current earnings.

Foreign currency forwards and options hedge the foreign currency exposure of certain U.S. dollar-denominated available-for-sale fixed-maturity investments held in Aflac Japan. The change in the fair value of the foreign currency forwards related to the changes in the difference between the spot rate and the forward price is excluded from the assessment of hedge effectiveness. The change in fair value of the foreign currency option related to the time value of the option is recognized in current earnings and is excluded from the assessment of hedge effectiveness.

Interest rate swaptions hedge the interest rate exposure of certain U.S. dollar-denominated available-for-sale securities held in Aflac Japan. For these hedging relationships, the Company excludes time value from the assessment of hedge

effectiveness and recognizes changes in the intrinsic value of the swaptions in current earnings within net investment income. The change in the time value of the swaptions is recognized in other comprehensive income (loss) and amortized into earnings (net investment income) over its legal term.

The following table presents the gains and losses on derivatives and the related hedged items in fair value hedges.

Fair Value Hedging Relationships


(In millions)	(In millions)		Hedging Derivatives						Hedged Items				(In millions)		Hedging Derivatives						Hedged Items
Hedging Derivatives	Hedging Derivatives	Hedged Items	Total Gains (Losses)		Gains (Losses) Excluded from Effectiveness Testing(1)		Gains (Losses) Included in Effectiveness Testing(2)		Gains (Losses)(2)		Net Investment Gains (Losses) Recognized for Fair Value Hedge		Hedging Derivatives	Hedged Items	Total Gains (Losses)		Gains (Losses) Excluded from Effectiveness Testing(1)		Gains (Losses) Included in Effectiveness Testing(2)		Gains (Losses)(2)		Net Investment Gains (Losses) Recognized for Fair Value Hedge
Three Months Ended March 31, 2022:

Three Months Ended March 31, 2023:													Three Months Ended March 31, 2023:

Foreign currency options	Foreign currency options	Fixed maturity securities	$	(15)	$	(15)	$	0	$	0	$	0	Foreign currency options	Fixed maturity securities	$	(39)	$	(39)	$	0	$	0	$	0

Total gains (losses)	Total gains (losses)		$	(15)	$	(15)	$	0	$	0	$	0	Total gains (losses)		$	(39)	$	(39)	$	0	$	0	$	0

Three Months Ended March 31, 2021:
Foreign currency forwards		Fixed maturity securities	$	(4)	$	0	$	(4)	$	4	$	0
Three Months Ended March 31, 2022:													Three Months Ended March 31, 2022:

Foreign currency options	Foreign currency options	Fixed maturity securities	(60)		(3)		(57)		59		2		Foreign currency options	Fixed maturity securities	(15)		(15)		0		0		0

Total gains (losses)	Total gains (losses)		$	(64)	$	(3)	$	(61)	$	63	$	2	Total gains (losses)		$	(15)	$	(15)	$	0	$	0	$	0

(1) Gains (losses) excluded from effectiveness testing includes the forward point on foreign currency forwards and time value change on foreign currency options which are reported in the consolidated statement of earnings as net investment gains (losses). It also includes the change in the fair value of the interest rate swaptions related to the time value of the swaptions which is recognized as a component of other comprehensive income (loss).

(2) Gains and losses on foreign currency forwards and options and related hedged items are reported in the consolidated statement of earnings as net investment gains (losses). For interest rate swaptions and related hedged items, gains and losses included in the hedge assessment, premium amortization and time value amortization while the hedge items are still outstanding are reported within net investment income. The time value gains and losses for interest rate swaptions when the related hedged items are redeemed are reported in net investment gains and losses consistent with the impact of the hedged item. For the three-month periods ended March 31, ~~2022~~2023 and ~~2021,~~2022, gains and losses included in the hedge assessment on interest rate swaptions and related hedged items were immaterial.

The following table shows the carrying amounts of assets designated and qualifying as hedged items in fair value hedges of interest rate risk and the related cumulative hedge adjustment included in the carrying amount.


(In millions)	(In millions)	Carrying Amount of the Hedged Assets/(Liabilities)(1)					Cumulative Amount of Fair Value Hedging Adjustment Included in the Carrying Amount of Hedged Assets/(Liabilities)				(In millions)	Carrying Amount of the Hedged Assets/(Liabilities)(1)					Cumulative Amount of Fair Value Hedging Adjustment Included in the Carrying Amount of Hedged Assets/(Liabilities)
			March 31, 2022		December 31, 2021		March 31, 2022		December 31, 2021				March 31, 2023		December 31, 2022		March 31, 2023		December 31, 2022
Fixed maturity securities	Fixed maturity securities		$	2,843	$	3,038	$	202	$	205	Fixed maturity securities		$	2,068	$	2,360	$	186	$	189

(1) The balance includes hedging adjustment on discontinued hedging relationships of ~~$202~~$186 in ~~2022~~2023 and ~~$205~~$189 in ~~2021.~~2022.

Net Investment Hedge

The Company's investment in Aflac Japan is affected by changes in the yen/dollar exchange rate. To mitigate this exposure, the Parent Company's yen-denominated liabilities (see Note 8)9) have been designated as non-derivative hedges and certain foreign currency forwards and options have been designated as derivative hedges of the foreign currency exposure of the Company's net investment in Aflac Japan.

The Company's net investment hedge was effective during the three-month periods ended March 31, ~~2022~~2023 and ~~2021,~~2022, respectively.

2934

Non-qualifying Strategies

For the Company's derivative instruments in consolidated VIEs that do not qualify for hedge accounting treatment, all changes in their fair value are reported in current period earnings within net investment gains (losses). The amount of gain or loss recognized in earnings for the Company's VIEs is attributable to the derivatives in those investment structures. While the change in value of the swaps is recorded through current period earnings, the change in value of the available-for-sale fixed maturity securities associated with these swaps is recorded through other comprehensive income.

As of March 31, ~~2022,~~2023, the Parent Company had $1.9 billion notional amount of cross-currency interest rate swap agreements related to certain of its U.S. dollar-denominated senior notes to effectively convert a portion of the interest on the notes from U.S dollar to Japanese yen. Changes in the values of these swaps are recorded through current period earnings. For additional information regarding these swaps, see Note 9 of the Notes to the Consolidated Financial Statements in the ~~2021~~2022 Annual Report.

The Company uses foreign exchange forwards and options to economically mitigate the currency risk of some of its U.S. dollar-denominated loan receivables held within the Aflac Japan segment. These arrangements are not designated as accounting hedges, as the foreign currency remeasurement of the loan receivables impacts current period earnings, and substantially offsets gains and losses from foreign exchange forwards within net investment gains (losses). The Company also has certain foreign exchange forwards on U.S. dollar-denominated available-for-sale securities where hedge accounting is not being applied.

The Company uses interest rate swaps to economically convert the variable rate investment income to a fixed rate on certain variable-rate investments.

3035

Impact of Derivatives and Hedging Instruments

The following table summarizes the impact to earnings and other comprehensive income (loss) from all derivatives and hedging instruments.

Three Months Ended March 31,
2022 2021
(In millions)
Net Investment Income(1)
Net Investment
Gains (Losses)
Other
Comprehensive
Income (Loss)(2)
Net Investment Income(1)
Net Investment
Gains (Losses)
Other
Comprehensive
Income (Loss)(2)
Qualifying hedges:
  Cash flow hedges:
       Foreign currency swaps - VIE $ 0 $ (1) $ 1 $ 0 $ (1) $ 0
  Total cash flow hedges 0 (1) (3) 1 0 (1) (3) 0
  Fair value hedges:
       Foreign currency options(3)
(15) (1)
  Total fair value hedges 0 (15) 0 0 (1) 0
  Net investment hedge:
       Non-derivative hedging
         instruments 0 199 0 188
       Foreign currency forwards (76) 301 18 335
       Foreign currency options (1) 0 (2) 0
  Total net investment hedge (77) 500 16 523
  Non-qualifying strategies:
       Foreign currency swaps 28 87
       Foreign currency swaps - VIE 23 29
       Foreign currency forwards (241) (432)
       Foreign currency options (10) 16
       Interest rate swaps (156) 0
Forward bond purchase
  commitment - VIE (17) (1)
  Total non-qualifying strategies (373) (301)
          Total $ 0 $ (466) $ 501 $ 0 $ (287) $ 523


	Three Months Ended March 31,
	2023										2022
(In millions)	Net Investment Income(1)			Net Investment Gains (Losses)				Other Comprehensive Income (Loss)(2)			Net Investment Income(1)			Net Investment Gains (Losses)				Other Comprehensive Income (Loss)(2)
Qualifying hedges:
Cash flow hedges:
Foreign currency swaps - VIE		$	0		$	(1)			$	1		$	0		$	(1)			$	1
Total cash flow hedges		0			(1)		(3)		1			0			(1)		(3)		1
Fair value hedges:

Foreign currency options(3)					(39)										(15)

Total fair value hedges		0			(39)				0			0			(15)				0
Net investment hedge:
Non-derivative hedging instruments					0				25						0				199
Foreign currency forwards					90				29						(76)				301
Foreign currency options					(3)				0						(1)				0
Total net investment hedge					87				54						(77)				500
Non-qualifying strategies:
Foreign currency swaps					1										28
Foreign currency swaps - VIE					(27)										23
Foreign currency forwards					(51)										(241)
Foreign currency options					(19)										(10)
Interest rate swaps					69										(156)
Forward bond purchase commitment - VIE					(3)										(17)
Total non-qualifying strategies					(30)										(373)
Total		$	0		$	17			$	55		$	0		$	(466)			$	501

(1) Interest expense/income on cash flow hedges are recorded in net investment income. For interest rate swaptions classified as fair value hedges, the change in the time value of the swaptions is recognized in other comprehensive income (loss) and amortized into net investment income over its legal term. If the swaption is early terminated but the hedge item is still outstanding, the amortization of disposal amount of the swaptions is recorded in net investment income over the remaining life of the hedged items.

(2) Gains and losses on cash flow hedges and the change in the fair value of interest rate swaptions related to the time value of the swaptions in fair value hedges are recorded as unrealized gains (losses). Gains and losses on net investment hedges related to changes in foreign currency spot rates are recorded in the unrealized foreign currency translation gains (losses) line in the consolidated statement of comprehensive income (loss).

(3) Impact of cash flow hedges reported as net investment gains (losses) includes $1 of losses reclassified from accumulated other comprehensive income (loss) into earnings during the three-month period ended March 31, ~~2022,~~2023, and ~~an immaterial amount~~$1 of losses during the three-month period ended March 31, ~~2021.~~2022. In addition, an immaterial amount of losses were reclassified from accumulated other comprehensive income (loss) into earnings during the three-month period ended March 31, ~~2022,~~2023, and an immaterial amount during the three-month period ended March 31, ~~2021,~~2022, related to fair value hedges excluded component. Impact shown net of effect of hedged items (see Fair Value Hedges section of this Note 4 for further detail).

As of March 31, ~~2022,~~2023, $5 million of deferred losses on derivative instruments recorded in accumulated other comprehensive income are expected to be reclassified into earnings during the next twelve months.

Credit Risk Assumed through Derivatives

For the foreign currency swaps associated with the Company's VIE investments for which it is the primary beneficiary, the Company bears the risk of loss due to counterparty default even though it is not a direct counterparty to those contracts.

The Company is a direct counterparty to the foreign currency swaps that it has entered into in connection with certain of its senior notes and subordinated debentures; foreign currency forwards; and foreign currency options, and therefore the Company is exposed to credit risk in the event of nonperformance by the counterparties in those contracts. The risk of counterparty default for the Company's foreign currency swaps, certain foreign currency forwards, and foreign currency options is mitigated by collateral posting requirements that counterparties to those transactions must meet.

3136

As of March 31, ~~2022,~~2023, all of the Company's derivative agreement counterparties were investment grade.

The Company engages in over-the-counter (OTC) bilateral derivative transactions directly with unaffiliated third parties under International Swaps and Derivatives Association, Inc. (ISDA) agreements and other documentation. Most of the ISDA agreements also include Credit Support Annexes (CSAs) provisions, which generally provide for two-way collateral postings at the first dollar of exposure. The Company mitigates the risk that counterparties to transactions might be unable to fulfill their contractual obligations by monitoring counterparty credit exposure and collateral value while generally requiring that collateral be posted at the outset of the transaction. In addition, a significant portion of the derivative transactions have provisions that give the counterparty the right to terminate the transaction upon a downgrade of the Company's financial strength rating. The actual amount of payments that the Company could be required to make depends on market conditions, the fair value of outstanding affected transactions, and other factors prevailing at and after the time of the downgrade.

The Company also engages in OTC cleared derivative transactions through regulated central clearing counterparties. These positions are marked to market and margined on a daily basis (both initial margin and variation margin), and the Company has minimal exposure to credit-related losses in the event of nonperformance by counterparties to these derivatives.

Collateral posted by the Company to third parties for derivative transactions can generally be repledged or resold by the counterparties. The aggregate fair value of all derivative instruments with credit-risk-related contingent features that were in a net liability position by counterparty was approximately ~~$713~~$767 million and ~~$904 million~~$1.3 billion as of March 31, ~~2022,~~2023, and December 31, ~~2021,~~2022, respectively. If the credit-risk-related contingent features underlying these agreements had been triggered on March 31, ~~2022,~~2023, the Company estimates that it would be required to post a maximum of ~~$264~~$222 million of additional collateral to these derivative counterparties. The Company is generally allowed to sell or repledge collateral obtained from its derivative counterparties, although it does not typically exercise such rights. (See the Offsetting tables below for collateral posted or received as of the reported balance sheet dates.)

Offsetting of Financial Instruments and Derivatives

Most of the Company's derivative instruments are subject to enforceable master netting arrangements that provide for the net settlement of all derivative contracts between the Parent Company or its subsidiaries and the respective counterparty in the event of default or upon the occurrence of certain termination events. Collateral support agreements with the master netting arrangements generally provide that the Company will receive or pledge financial collateral at the first dollar of exposure.

The Company has securities lending agreements with unaffiliated financial institutions that post collateral to the Company in return for the use of its fixed maturity and public equity securities (see Note 3). When the Company has entered into securities lending agreements with the same counterparty, the agreements generally provide for net settlement in the event of default by the counterparty. This right of set-off allows the Company to keep and apply collateral received if the counterparty failed to return the securities borrowed from the Company as contractually agreed.

The tables below summarize the Company's derivatives and securities lending transactions, and as reflected in the tables, in accordance with U.S. GAAP, the Company's policy is to not offset these financial instruments in the Consolidated Balance Sheets.

3237

Offsetting of Financial Assets and Derivative Assets


March 31, 2022
March 31, 2023																			March 31, 2023
											Gross Amounts Not Offset in Balance Sheet																												Gross Amounts Not Offset in Balance Sheet
(In millions)	(In millions)	Gross Amount of Recognized Assets			Gross Amount Offset in Balance Sheet			Net Amount of Assets Presented in Balance Sheet			Financial Instruments			Securities Collateral		Cash Collateral Received					Net Amount				(In millions)	Gross Amount of Recognized Assets				Gross Amount Offset in Balance Sheet				Net Amount of Assets Presented in Balance Sheet					Financial Instruments				Securities Collateral		Cash Collateral Received				Net Amount
Derivative assets:	Derivative assets:																			Derivative assets:
Derivative assets subject to a master netting agreement or offsetting arrangement	Derivative assets subject to a master netting agreement or offsetting arrangement																			Derivative assets subject to a master netting agreement or offsetting arrangement
OTC - bilateral	OTC - bilateral		$	1,051		$	0		$	1,051		$	(503)	$	(3)		$	(532)					$	13	OTC - bilateral			$	460			$	0			$	460			$	(71)		$	(61)			$	(326)		$	2

OTC - cleared																			OTC - cleared			26					0				26				(26)			0				0				0
Total derivative assets subject to a master netting agreement or offsetting arrangement	Total derivative assets subject to a master netting agreement or offsetting arrangement		1,051			0			1,051			(503)		(3)			(532)						13		Total derivative assets subject to a master netting agreement or offsetting arrangement			486				0				486				(97)			(61)				(326)			2
Derivative assets not subject to a master netting agreement or offsetting arrangement	Derivative assets not subject to a master netting agreement or offsetting arrangement																			Derivative assets not subject to a master netting agreement or offsetting arrangement
OTC - bilateral	OTC - bilateral		75						75														75		OTC - bilateral			63								63														63

Total derivative assets not subject to a master netting agreement or offsetting arrangement	Total derivative assets not subject to a master netting agreement or offsetting arrangement		75						75														75		Total derivative assets not subject to a master netting agreement or offsetting arrangement			63								63														63
Total derivative assets	Total derivative assets		1,126			0			1,126			(503)		(3)			(532)						88		Total derivative assets			549				0				549				(97)			(61)				(326)			65
Securities lending and similar arrangements	Securities lending and similar arrangements		2,218			0			2,218			0		0			(2,218)						0		Securities lending and similar arrangements			3,418				0				3,418				0			0				(3,418)			0
Total	Total		$	3,344		$	0		$	3,344		$	(503)	$	(3)		$	(2,750)					$	88	Total			$	3,967			$	0			$	3,967			$	(97)		$	(61)			$	(3,744)		$	65

3338


December 31, 2021
December 31, 2022																			December 31, 2022
											Gross Amounts Not Offset in Balance Sheet																												Gross Amounts Not Offset in Balance Sheet
(In millions)	(In millions)	Gross Amount of Recognized Assets			Gross Amount Offset in Balance Sheet			Net Amount of Assets Presented in Balance Sheet			Financial Instruments			Securities Collateral		Cash Collateral Received					Net Amount				(In millions)	Gross Amount of Recognized Assets				Gross Amount Offset in Balance Sheet				Net Amount of Assets Presented in Balance Sheet					Financial Instruments				Securities Collateral		Cash Collateral Received				Net Amount
Derivative assets:	Derivative assets:																			Derivative assets:
Derivative assets subject to a master netting agreement or offsetting arrangement	Derivative assets subject to a master netting agreement or offsetting arrangement																			Derivative assets subject to a master netting agreement or offsetting arrangement
OTC - bilateral	OTC - bilateral		$	858		$	0		$	858		$	(471)	$	(53)		$	(334)					$	0	OTC - bilateral			$	548			$	0			$	548			$	(167)		$	(60)			$	(320)		$	1

OTC - cleared																			OTC - cleared			7					0				7				(7)			0				0				0
Total derivative assets subject to a master netting agreement or offsetting arrangement	Total derivative assets subject to a master netting agreement or offsetting arrangement		858			0			858			(471)		(53)			(334)						0		Total derivative assets subject to a master netting agreement or offsetting arrangement			555				0				555				(174)			(60)				(320)			1
Derivative assets not subject to a master netting agreement or offsetting arrangement	Derivative assets not subject to a master netting agreement or offsetting arrangement																			Derivative assets not subject to a master netting agreement or offsetting arrangement
OTC - bilateral	OTC - bilateral		78						78														78		OTC - bilateral			62								62														62

Total derivative assets not subject to a master netting agreement or offsetting arrangement	Total derivative assets not subject to a master netting agreement or offsetting arrangement		78						78														78		Total derivative assets not subject to a master netting agreement or offsetting arrangement			62								62														62
Total derivative assets	Total derivative assets		936			0			936			(471)		(53)			(334)						78		Total derivative assets			617				0				617				(174)			(60)				(320)			63
Securities lending and similar arrangements	Securities lending and similar arrangements		2,124			0			2,124			0		0			(2,124)						0		Securities lending and similar arrangements			1,788				0				1,788				0			0				(1,788)			0
Total	Total		$	3,060		$	0		$	3,060		$	(471)	$	(53)		$	(2,458)					$	78	Total			$	2,405			$	0			$	2,405			$	(174)		$	(60)			$	(2,108)		$	63

3439

Offsetting of Financial Liabilities and Derivative Liabilities


March 31, 2022
March 31, 2023																			March 31, 2023
											Gross Amounts Not Offset in Balance Sheet																							Gross Amounts Not Offset in Balance Sheet
(In millions)	(In millions)	Gross Amount of Recognized Liabilities			Gross Amount Offset in Balance Sheet			Net Amount of Liabilities Presented in Balance Sheet			Financial Instruments			Securities Collateral		Cash Collateral Pledged					Net Amount			(In millions)	Gross Amount of Recognized Liabilities			Gross Amount Offset in Balance Sheet			Net Amount of Liabilities Presented in Balance Sheet			Financial Instruments			Securities Collateral		Cash Collateral Pledged			Net Amount
Derivative liabilities:	Derivative liabilities:																			Derivative liabilities:
Derivative liabilities subject to a master netting agreement or offsetting arrangement	Derivative liabilities subject to a master netting agreement or offsetting arrangement																			Derivative liabilities subject to a master netting agreement or offsetting arrangement
OTC - bilateral	OTC - bilateral		$	817		$	0		$	817		$	(503)	$	(278)		$	(21)				$	15	OTC - bilateral		$	176		$	0		$	176		$	(71)	$	(80)		$	(9)		$	16
OTC - cleared	OTC - cleared		216			0			216			0		0			(150)					66		OTC - cleared		483			0			483			(26)		0			(456)			1
Total derivative liabilities subject to a master netting agreement or offsetting arrangement	Total derivative liabilities subject to a master netting agreement or offsetting arrangement		1,033			0			1,033			(503)		(278)			(171)					81		Total derivative liabilities subject to a master netting agreement or offsetting arrangement		659			0			659			(97)		(80)			(465)			17
Derivative liabilities not subject to a master netting agreement or offsetting arrangement	Derivative liabilities not subject to a master netting agreement or offsetting arrangement																			Derivative liabilities not subject to a master netting agreement or offsetting arrangement
OTC - bilateral	OTC - bilateral		427						427													427		OTC - bilateral		399						399											399

Total derivative liabilities not subject to a master netting agreement or offsetting arrangement	Total derivative liabilities not subject to a master netting agreement or offsetting arrangement		427						427													427		Total derivative liabilities not subject to a master netting agreement or offsetting arrangement		399						399											399
Total derivative liabilities	Total derivative liabilities		1,460			0			1,460			(503)		(278)			(171)					508		Total derivative liabilities		1,058			0			1,058			(97)		(80)			(465)			416
Securities lending and similar arrangements	Securities lending and similar arrangements		2,198			0			2,198			(2,218)		0			0					(20)		Securities lending and similar arrangements		3,460			0			3,460			(3,418)		0			0			42
Total	Total		$	3,658		$	0		$	3,658		$	(2,721)	$	(278)		$	(171)				$	488	Total		$	4,518		$	0		$	4,518		$	(3,515)	$	(80)		$	(465)		$	458

3540


December 31, 2021
December 31, 2022																			December 31, 2022
											Gross Amounts Not Offset in Balance Sheet																							Gross Amounts Not Offset in Balance Sheet
(In millions)	(In millions)	Gross Amount of Recognized Liabilities			Gross Amount Offset in Balance Sheet			Net Amount of Liabilities Presented in Balance Sheet			Financial Instruments			Securities Collateral		Cash Collateral Pledged					Net Amount			(In millions)	Gross Amount of Recognized Liabilities			Gross Amount Offset in Balance Sheet			Net Amount of Liabilities Presented in Balance Sheet			Financial Instruments			Securities Collateral		Cash Collateral Pledged			Net Amount
Derivative liabilities:	Derivative liabilities:																			Derivative liabilities:
Derivative liabilities subject to a master netting agreement or offsetting arrangement	Derivative liabilities subject to a master netting agreement or offsetting arrangement																			Derivative liabilities subject to a master netting agreement or offsetting arrangement
OTC - bilateral	OTC - bilateral		$	1,151		$	0		$	1,151		$	(471)	$	(662)		$	(14)				$	4	OTC - bilateral		$	725		$	0		$	725		$	(167)	$	(506)		$	(52)		$	0
OTC - cleared	OTC - cleared		54			0			54			0		0			(35)					19		OTC - cleared		583			0			583			(7)		0			(577)			(1)
Total derivative liabilities subject to a master netting agreement or offsetting arrangement	Total derivative liabilities subject to a master netting agreement or offsetting arrangement		1,205			0			1,205			(471)		(662)			(49)					23		Total derivative liabilities subject to a master netting agreement or offsetting arrangement		1,308			0			1,308			(174)		(506)			(629)			(1)
Derivative liabilities not subject to a master netting agreement or offsetting arrangement	Derivative liabilities not subject to a master netting agreement or offsetting arrangement																			Derivative liabilities not subject to a master netting agreement or offsetting arrangement
OTC - bilateral	OTC - bilateral		414						414													414		OTC - bilateral		390						390											390

Total derivative liabilities not subject to a master netting agreement or offsetting arrangement	Total derivative liabilities not subject to a master netting agreement or offsetting arrangement		414						414													414		Total derivative liabilities not subject to a master netting agreement or offsetting arrangement		390						390											390
Total derivative liabilities	Total derivative liabilities		1,619			0			1,619			(471)		(662)			(49)					437		Total derivative liabilities		1,698			0			1,698			(174)		(506)			(629)			389
Securities lending and similar arrangements	Securities lending and similar arrangements		2,162			0			2,162			(2,124)		0			0					38		Securities lending and similar arrangements		1,809			0			1,809			(1,788)		0			0			21
Total	Total		$	3,781		$	0		$	3,781		$	(2,595)	$	(662)		$	(49)				$	475	Total		$	3,507		$	0		$	3,507		$	(1,962)	$	(506)		$	(629)		$	410

For additional information on the Company's financial instruments, see the accompanying Notes 1, 3 and 5 and Notes 1, 3 and 5 of the Notes to the Consolidated Financial Statements in the ~~2021~~2022 Annual Report.

5. FAIR VALUE MEASUREMENTS

Fair Value Hierarchy

U.S. GAAP specifies a hierarchy of valuation techniques based on whether the inputs to those valuation techniques are observable or unobservable. These two types of inputs create three valuation hierarchy levels. Level 1 valuations reflect quoted market prices for identical assets or liabilities in active markets. Level 2 valuations reflect quoted market prices for similar assets or liabilities in an active market, quoted market prices for identical or similar assets or liabilities in non-active markets or model-derived valuations in which all significant valuation inputs are observable in active markets. Level 3 valuations reflect valuations in which one or more of the significant inputs are not observable in an active market.

The following tables present the fair value hierarchy levels of the Company's assets and liabilities that are measured and carried at fair value on a recurring basis.

March 31, 2022
(In millions) Quoted Prices in
Active Markets
for Identical
Assets
(Level 1) Significant
Observable
Inputs
(Level 2) Significant
Unobservable
Inputs
(Level 3) Total
Fair
Value
Assets:
Securities available for sale, carried at
fair value:
Fixed maturity securities:
Government and agencies $ 29,547 $ 1,165 $ 0 $ 30,712
Municipalities 0 2,776 0 2,776
Mortgage- and asset-backed securities 0 1,048 318 1,366
Public utilities 0 8,604 585 9,189
Sovereign and supranational 0 994 41 1,035
Banks/financial institutions 0 10,626 60 10,686
Other corporate 0 33,911 290 34,201
Total fixed maturity securities 29,547 59,124 1,294 89,965
Equity securities 1,166 83 166 1,415
Other investments 1,747 0 0 1,747
Cash and cash equivalents 4,275 0 0 4,275
Other assets:
Foreign currency swaps 0 141 0 141
Foreign currency forwards 0 977 0 977
Foreign currency options 0 8 0 8
Total other assets 0 1,126 0 1,126
Total assets $ 36,735 $ 60,333 $ 1,460 $ 98,528
Liabilities:
Other liabilities:
Foreign currency swaps $ 0 $ 432 $ 0 $ 432
Foreign currency forwards 0 812 0 812
Interest rate swaps 0 216 0 216
Total liabilities $ 0 $ 1,460 $ 0 $ 1,460

3741


	March 31, 2023
(In millions)	Quoted Prices in Active Markets for Identical Assets (Level 1)			Significant Observable Inputs (Level 2)			Significant Unobservable Inputs (Level 3)			Total Fair Value
Assets:
Securities available for sale, carried at fair value:
Fixed maturity securities:
Government and agencies		$	24,903		$	990		$	0		$	25,893
Municipalities		0			2,416			0			2,416
Mortgage- and asset-backed securities		0			2,149			418			2,567
Public utilities		0			7,583			350			7,933
Sovereign and supranational		0			691			37			728
Banks/financial institutions		0			9,259			161			9,420
Other corporate		0			28,389			753			29,142
Total fixed maturity securities		24,903			51,477			1,719			78,099
Equity securities		806			60			221			1,087
Other investments		2,561			0			0			2,561
Cash and cash equivalents		3,809			0			0			3,809
Other assets:
Foreign currency swaps		0			118			0			118
Foreign currency forwards		0			359			0			359
Foreign currency options		0			46			0			46
Interest rate swaps		0			26			0			26


Total other assets		0			549			0			549
Total assets		$	32,079		$	52,086		$	1,940		$	86,105
Liabilities:
Other liabilities:
Foreign currency swaps		$	0		$	399		$	0		$	399
Foreign currency forwards		0			176			0			176

Interest rate swaps		0			483			0			483


Total liabilities		$	0		$	1,058		$	0		$	1,058


		December 31, 2021													December 31, 2022
(In millions)	(In millions)	Quoted Prices in Active Markets for Identical Assets (Level 1)			Significant Observable Inputs (Level 2)			Significant Unobservable Inputs (Level 3)			Total Fair Value			(In millions)	Quoted Prices in Active Markets for Identical Assets (Level 1)			Significant Observable Inputs (Level 2)			Significant Unobservable Inputs (Level 3)			Total Fair Value
Assets:	Assets:													Assets:
Securities available for sale, carried at fair value:	Securities available for sale, carried at fair value:													Securities available for sale, carried at fair value:
Fixed maturity securities:	Fixed maturity securities:													Fixed maturity securities:
Government and agencies	Government and agencies		$	32,532		$	1,288		$	0		$	33,820	Government and agencies		$	24,158		$	956		$	0		$	25,114
Municipalities	Municipalities		0			3,036			0			3,036		Municipalities		0			2,320			0			2,320
Mortgage- and asset-backed securities	Mortgage- and asset-backed securities		0			955			291			1,246		Mortgage- and asset-backed securities		0			1,803			343			2,146
Public utilities	Public utilities		0			9,558			493			10,051		Public utilities		0			7,169			497			7,666
Sovereign and supranational	Sovereign and supranational		0			1,072			43			1,115		Sovereign and supranational		0			797			37			834
Banks/financial institutions	Banks/financial institutions		0			11,546			45			11,591		Banks/financial institutions		0			9,140			159			9,299
Other corporate	Other corporate		0			37,411			426			37,837		Other corporate		0			27,620			742			28,362
Total fixed maturity securities	Total fixed maturity securities		32,532			64,866			1,298			98,696		Total fixed maturity securities		24,158			49,805			1,778			75,741
Equity securities	Equity securities		1,340			90			173			1,603		Equity securities		822			60			209			1,091
Other investments	Other investments		1,726			0			0			1,726		Other investments		1,532			0			0			1,532
Cash and cash equivalents	Cash and cash equivalents		5,051			0			0			5,051		Cash and cash equivalents		3,943			0			0			3,943
Other assets:	Other assets:													Other assets:
Foreign currency swaps	Foreign currency swaps		0			137			0			137		Foreign currency swaps		0			128			0			128
Foreign currency forwards	Foreign currency forwards		0			791			0			791		Foreign currency forwards		0			400			0			400
Foreign currency options	Foreign currency options		0			8			0			8		Foreign currency options		0			82			0			82

Interest rate swaps														Interest rate swaps		0			7			0			7
Total other assets	Total other assets		0			936			0			936		Total other assets		0			617			0			617
Total assets	Total assets		$	40,649		$	65,892		$	1,471		$	108,012	Total assets		$	30,455		$	50,482		$	1,987		$	82,924
Liabilities:	Liabilities:													Liabilities:
Other liabilities:	Other liabilities:													Other liabilities:
Foreign currency swaps	Foreign currency swaps		$	0		$	427		$	0		$	427	Foreign currency swaps		$	0		$	390		$	0		$	390
Foreign currency forwards	Foreign currency forwards		0			1,138			0			1,138		Foreign currency forwards		0			725			0			725
Interest rate swaps	Interest rate swaps		0			54			0			54		Interest rate swaps		0			583			0			583

Total liabilities	Total liabilities		$	0		$	1,619		$	0		$	1,619	Total liabilities		$	0		$	1,698		$	0		$	1,698

3843

The following tables present the carrying amount and fair value categorized by fair value hierarchy level for the Company's financial instruments that are not carried at fair value.


		March 31, 2022																March 31, 2023
(In millions)	(In millions)	Carrying Value			Quoted Prices in Active Markets for Identical Assets (Level 1)			Significant Observable Inputs (Level 2)			Significant Unobservable Inputs (Level 3)			Total Fair Value			(In millions)	Carrying Value			Quoted Prices in Active Markets for Identical Assets (Level 1)			Significant Observable Inputs (Level 2)			Significant Unobservable Inputs (Level 3)			Total Fair Value
Assets:	Assets:																Assets:
Securities held to maturity, carried at amortized cost:	Securities held to maturity, carried at amortized cost:																Securities held to maturity, carried at amortized cost:
Fixed maturity securities:	Fixed maturity securities:																Fixed maturity securities:
Government and agencies	Government and agencies		$	19,814		$	23,315		$	211		$	0		$	23,526	Government and agencies		$	18,152		$	20,517		$	183		$	0		$	20,700
Municipalities	Municipalities		315			0			398			0			398		Municipalities		285			0			341			0			341

Public utilities	Public utilities		40			0			50			0			50		Public utilities		37			0			42			0			42
Sovereign and supranational	Sovereign and supranational		483			0			584			0			584		Sovereign and supranational		443			0			510			0			510

Other corporate	Other corporate		20			0			27			0			27		Other corporate		19			0			23			0			23
Commercial mortgage and other loans	Commercial mortgage and other loans		12,312			0			0			12,356			12,356		Commercial mortgage and other loans		13,328			0			0			13,052			13,052
Other investments (1)	Other investments (1)		25			0			25			0			25		Other investments (1)		34			0			34			0			34
Total assets	Total assets		$	33,009		$	23,315		$	1,295		$	12,356		$	36,966	Total assets		$	32,298		$	20,517		$	1,133		$	13,052		$	34,702
Liabilities:	Liabilities:																Liabilities:
Other policyholders’ funds	Other policyholders’ funds		$	6,705		$	0		$	0		$	6,595		$	6,595	Other policyholders’ funds		$	6,668		$	0		$	0		$	6,569		$	6,569
Notes payable (excluding leases)	Notes payable (excluding leases)		7,628			0			7,602			244			7,846		Notes payable (excluding leases)		7,270			0			6,175			797			6,972
Total liabilities	Total liabilities		$	14,333		$	0		$	7,602		$	6,839		$	14,441	Total liabilities		$	13,938		$	0		$	6,175		$	7,366		$	13,541

(1) Excludes policy loans of ~~$224~~$214 and equity method investments of ~~$1,964,~~$2,432, at carrying value

3944


		December 31, 2021																December 31, 2022
(In millions)	(In millions)	Carrying Value			Quoted Prices in Active Markets for Identical Assets (Level 1)			Significant Observable Inputs (Level 2)			Significant Unobservable Inputs (Level 3)			Total Fair Value			(In millions)	Carrying Value			Quoted Prices in Active Markets for Identical Assets (Level 1)			Significant Observable Inputs (Level 2)			Significant Unobservable Inputs (Level 3)			Total Fair Value
Assets:	Assets:																Assets:
Securities held to maturity, carried at amortized cost:	Securities held to maturity, carried at amortized cost:																Securities held to maturity, carried at amortized cost:
Fixed maturity securities:	Fixed maturity securities:																Fixed maturity securities:
Government and agencies	Government and agencies		$	21,086		$	25,469		$	230		$	0		$	25,699	Government and agencies		$	18,267		$	20,132		$	180		$	0		$	20,312
Municipalities	Municipalities		335			0			436			0			436		Municipalities		287			0			335			0			335

Public utilities	Public utilities		43			0			55			0			55		Public utilities		37			0			41			0			41
Sovereign and supranational	Sovereign and supranational		514			0			650			0			650		Sovereign and supranational		446			0			500			0			500

Other corporate	Other corporate		22			0			29			0			29		Other corporate		19			0			22			0			22
Commercial mortgage and other loans	Commercial mortgage and other loans		11,786			0			0			11,996			11,996		Commercial mortgage and other loans		13,496			0			0			13,212			13,212
Other investments (1)	Other investments (1)		22			0			22			0			22		Other investments (1)		34			0			34			0			34
Total assets	Total assets		$	33,808		$	25,469		$	1,422		$	11,996		$	38,887	Total assets		$	32,586		$	20,132		$	1,112		$	13,212		$	34,456
Liabilities:	Liabilities:																Liabilities:
Other policyholders’ funds	Other policyholders’ funds		$	7,072		$	0		$	0		$	6,957		$	6,957	Other policyholders’ funds		$	6,643		$	0		$	0		$	6,543		$	6,543
Notes payable (excluding leases)	Notes payable (excluding leases)		7,839			0			8,280			259			8,539		Notes payable (excluding leases)		7,295			0			6,024			802			6,826
Total liabilities	Total liabilities		$	14,911		$	0		$	8,280		$	7,216		$	15,496	Total liabilities		$	13,938		$	0		$	6,024		$	7,345		$	13,369

(1) Excludes policy loans of ~~$236~~$214 and equity method investments of ~~$1,858,~~$2,290, at carrying value

Prior-year amounts have been adjusted for the adoption of accounting guidance on January 1, 2023 related to accounting for long-duration insurance contracts.

Fair Value of Financial Instruments

Fixed maturity and equity securities

The Company determines the fair values of fixed maturity securities and public ~~and privately-issued~~ equity securities using the following approaches or techniques: price quotes and valuations from third party pricing vendors (including quoted market prices readily available from public exchange markets), in-house valuations and non-binding price quotes the Company obtains from outside brokers.

~~A third party pricing vendor has developed valuation models to determine~~The fair values of ~~privately issued securities. Starting in June 2021, these~~the Company’s public fixed maturity securities are generally based on prices provided by third-party pricing vendors. The Company utilizes internally generated valuations or broker quotes for privately-issued fixed maturity securities or fixed maturity securities where there is no price available from a third-party pricing vendor. For internally generated valuations, the Company utilizes valuation models developed by a third-party pricing vendor. The models and associated processes and controls ~~were transitioned to and~~are executed by Company personnel.

These models are discounted cash flow (DCF) valuation models but also use information from related markets, specifically public bond markets and the credit default swap (CDS) market, to estimate expected cash flows. ~~These~~The models take into consideration any unique characteristics of the securities and make various adjustments to arrive at an appropriate issuer-specific loss adjusted credit ~~curve.~~curve using the most appropriate comparable security(ies) of the issuer and issuer-specific CDS spreads. This credit curve is then used with the relevant recovery rates to estimate expected cash flows and modeling of additional features, including illiquidity adjustments, if necessary, to price the security by discounting those loss adjusted cash flows. In cases where a credit curve cannot be developed from market information for the specific ~~security features,~~issuer, the valuation methodology takes into consideration other market observable inputs, including:

1) the most appropriate comparable security(ies) of ~~the issuer~~a guarantor and/or parent

2) ~~issuer-specific~~ CDS spreads of a guarantor and/or parent

3) bonds ~~or CDS spreads~~ of comparable issuers with similar characteristics such as rating, geography, or sector

4) CDS spreads of an appropriate index or of comparable issuers with similar characteristics such as rating, geography, or sector

5) bond indices that are comparative in rating, industry, maturity, and region.

Prices for public equity securities are readily available and are acquired from independent market data providers or established security dealer associations.

The pricing data and market quotes the Company obtains from outside sources, including third party pricing services, are reviewed internally for reasonableness. If a fair value appears unreasonable, the Company will re-examine the inputs and assess the reasonableness of the pricing data with the ~~vendor.~~provider. Additionally, the Company may compare the inputs to relevant market indices and other performance measurements. Based on management's analysis, the valuation is confirmed or may be revised if there is evidence of a more appropriate estimate of fair value based on available market

data. The Company has performed verification of the inputs and calculations in any valuation models, including independent validations and back testing, to confirm that the valuations represent reasonable estimates of fair value.

For the periods presented, the Company has not adjusted the quotes or prices it obtains from the pricing services and brokers it uses.

The following tables present the pricing sources for the fair values of the Company's fixed maturity and equity securities.

4146


		March 31, 2022													March 31, 2023
(In millions)	(In millions)	Quoted Prices in Active Markets for Identical Assets (Level 1)			Significant Observable Inputs (Level 2)			Significant Unobservable Inputs (Level 3)			Total Fair Value			(In millions)	Quoted Prices in Active Markets for Identical Assets (Level 1)			Significant Observable Inputs (Level 2)			Significant Unobservable Inputs (Level 3)			Total Fair Value
Securities available for sale, carried at fair value:	Securities available for sale, carried at fair value:													Securities available for sale, carried at fair value:
Fixed maturity securities:	Fixed maturity securities:													Fixed maturity securities:
Government and agencies:	Government and agencies:													Government and agencies:
Third party pricing vendor	Third party pricing vendor		$	29,547		$	730		$	0		$	30,277	Third party pricing vendor		$	24,903		$	610		$	0		$	25,513
Internal	Internal		0			435			0			435		Internal		0			380			0			380

Total government and agencies	Total government and agencies		29,547			1,165			0			30,712		Total government and agencies		24,903			990			0			25,893
Municipalities:	Municipalities:													Municipalities:
Third party pricing vendor	Third party pricing vendor		0			2,035			0			2,035		Third party pricing vendor		0			2,108			0			2,108
Internal	Internal		0			741			0			741		Internal		0			308			0			308

Broker/other														Broker/other		0			0			0			0
Total municipalities	Total municipalities		0			2,776			0			2,776		Total municipalities		0			2,416			0			2,416
Mortgage- and asset-backed securities:	Mortgage- and asset-backed securities:													Mortgage- and asset-backed securities:
Third party pricing vendor	Third party pricing vendor		0			981			0			981		Third party pricing vendor		0			2,038			0			2,038

Internal														Internal		0			53			0			53
Broker/other	Broker/other		0			67			318			385		Broker/other		0			58			418			476
Total mortgage- and asset-backed securities	Total mortgage- and asset-backed securities		0			1,048			318			1,366		Total mortgage- and asset-backed securities		0			2,149			418			2,567
Public utilities:	Public utilities:													Public utilities:
Third party pricing vendor	Third party pricing vendor		0			4,066			0			4,066		Third party pricing vendor		0			3,898			0			3,898
Internal	Internal		0			4,537			0			4,537		Internal		0			3,685			0			3,685
Broker/other	Broker/other		0			1			585			586		Broker/other		0			0			350			350
Total public utilities	Total public utilities		0			8,604			585			9,189		Total public utilities		0			7,583			350			7,933
Sovereign and supranational:	Sovereign and supranational:													Sovereign and supranational:
Third party pricing vendor	Third party pricing vendor		0			257			0			257		Third party pricing vendor		0			232			0			232
Internal	Internal		0			737			0			737		Internal		0			459			0			459
Broker/other	Broker/other		0			0			41			41		Broker/other		0			0			37			37
Total sovereign and supranational	Total sovereign and supranational		0			994			41			1,035		Total sovereign and supranational		0			691			37			728
Banks/financial institutions:	Banks/financial institutions:													Banks/financial institutions:
Third party pricing vendor	Third party pricing vendor		0			4,922			0			4,922		Third party pricing vendor		0			4,690			0			4,690
Internal	Internal		0			5,704			18			5,722		Internal		0			4,569			108			4,677
Broker/other	Broker/other		0			0			42			42		Broker/other		0			0			53			53
Total banks/financial institutions	Total banks/financial institutions		0			10,626			60			10,686		Total banks/financial institutions		0			9,259			161			9,420
Other corporate:	Other corporate:													Other corporate:
Third party pricing vendor	Third party pricing vendor		0			26,989			0			26,989		Third party pricing vendor		0			22,726			0			22,726
Internal	Internal		0			6,922			24			6,946		Internal		0			5,663			289			5,952
Broker/other	Broker/other		0			0			266			266		Broker/other		0			0			464			464
Total other corporate	Total other corporate		0			33,911			290			34,201		Total other corporate		0			28,389			753			29,142
Total securities available for sale	Total securities available for sale		$	29,547		$	59,124		$	1,294		$	89,965	Total securities available for sale		$	24,903		$	51,477		$	1,719		$	78,099
Equity securities, carried at fair value:	Equity securities, carried at fair value:													Equity securities, carried at fair value:
Third party pricing vendor	Third party pricing vendor		$	1,166		$	83		$	0		$	1,249	Third party pricing vendor		$	806		$	60		$	0		$	866

Broker/other	Broker/other		0			0			166			166		Broker/other		0			0			221			221
Total equity securities	Total equity securities		$	1,166		$	83		$	166		$	1,415	Total equity securities		$	806		$	60		$	221		$	1,087

4247


		March 31, 2022													March 31, 2023
(In millions)	(In millions)	Quoted Prices in Active Markets for Identical Assets (Level 1)			Significant Observable Inputs (Level 2)			Significant Unobservable Inputs (Level 3)			Total Fair Value			(In millions)	Quoted Prices in Active Markets for Identical Assets (Level 1)			Significant Observable Inputs (Level 2)			Significant Unobservable Inputs (Level 3)			Total Fair Value
Securities held to maturity, carried at amortized cost:	Securities held to maturity, carried at amortized cost:													Securities held to maturity, carried at amortized cost:
Fixed maturity securities:	Fixed maturity securities:													Fixed maturity securities:
Government and agencies:	Government and agencies:													Government and agencies:
Third party pricing vendor	Third party pricing vendor		$	23,315		$	211		$	0		$	23,526	Third party pricing vendor		$	20,517		$	183		$	0		$	20,700

Total government and agencies	Total government and agencies		23,315			211			0			23,526		Total government and agencies		20,517			183			0			20,700
Municipalities:	Municipalities:													Municipalities:
Third party pricing vendor	Third party pricing vendor		0			398			0			398		Third party pricing vendor		0			341			0			341

Total municipalities	Total municipalities		0			398			0			398		Total municipalities		0			341			0			341

Public utilities:	Public utilities:													Public utilities:
Third party pricing vendor	Third party pricing vendor		0			50			0			50		Third party pricing vendor		0			42			0			42

Total public utilities	Total public utilities		0			50			0			50		Total public utilities		0			42			0			42
Sovereign and supranational:	Sovereign and supranational:													Sovereign and supranational:
Third party pricing vendor	Third party pricing vendor		0			283			0			283		Third party pricing vendor		0			246			0			246

Broker/other	Broker/other		0			301			0			301		Broker/other		0			264			0			264
Total sovereign and supranational	Total sovereign and supranational		0			584			0			584		Total sovereign and supranational		0			510			0			510

Other corporate:	Other corporate:													Other corporate:
Third party pricing vendor	Third party pricing vendor		0			27			0			27		Third party pricing vendor		0			23			0			23

Total other corporate	Total other corporate		0			27			0			27		Total other corporate		0			23			0			23
Total securities held to maturity	Total securities held to maturity		$	23,315		$	1,270		$	0		$	24,585	Total securities held to maturity		$	20,517		$	1,099		$	0		$	21,616

4348


		December 31, 2021													December 31, 2022
(In millions)	(In millions)	Quoted Prices in Active Markets for Identical Assets (Level 1)			Significant Observable Inputs (Level 2)			Significant Unobservable Inputs (Level 3)			Total Fair Value			(In millions)	Quoted Prices in Active Markets for Identical Assets (Level 1)			Significant Observable Inputs (Level 2)			Significant Unobservable Inputs (Level 3)			Total Fair Value
Securities available for sale, carried at fair value:	Securities available for sale, carried at fair value:													Securities available for sale, carried at fair value:
Fixed maturity securities:	Fixed maturity securities:													Fixed maturity securities:
Government and agencies:	Government and agencies:													Government and agencies:
Third party pricing vendor	Third party pricing vendor		$	32,532		$	808		$	0		$	33,340	Third party pricing vendor		$	24,158		$	582		$	0		$	24,740
Internal	Internal		0			480			0			480		Internal		0			374			0			374
Total government and agencies	Total government and agencies		32,532			1,288			0			33,820		Total government and agencies		24,158			956			0			25,114
Municipalities:	Municipalities:													Municipalities:
Third party pricing vendor	Third party pricing vendor		0			2,222			0			2,222		Third party pricing vendor		0			2,021			0			2,021
Internal	Internal		0			814			0			814		Internal		0			299			0			299
Total municipalities	Total municipalities		0			3,036			0			3,036		Total municipalities		0			2,320			0			2,320
Mortgage- and asset-backed securities:	Mortgage- and asset-backed securities:													Mortgage- and asset-backed securities:
Third party pricing vendor	Third party pricing vendor		0			955			0			955		Third party pricing vendor		0			1,798			0			1,798
Internal														Internal		0			3			0			3
Broker/other	Broker/other		0			0			291			291		Broker/other		0			2			343			345
Total mortgage- and asset-backed securities	Total mortgage- and asset-backed securities		0			955			291			1,246		Total mortgage- and asset-backed securities		0			1,803			343			2,146
Public utilities:	Public utilities:													Public utilities:
Third party pricing vendor	Third party pricing vendor		0			4,527			0			4,527		Third party pricing vendor		0			3,786			0			3,786
Internal	Internal		0			5,031			0			5,031		Internal		0			3,383			0			3,383
Broker/other	Broker/other		0			0			493			493		Broker/other		0			0			497			497
Total public utilities	Total public utilities		0			9,558			493			10,051		Total public utilities		0			7,169			497			7,666
Sovereign and supranational:	Sovereign and supranational:													Sovereign and supranational:
Third party pricing vendor	Third party pricing vendor		0			273			0			273		Third party pricing vendor		0			232			0			232
Internal	Internal		0			799			0			799		Internal		0			565			0			565
Broker/other	Broker/other		0			0			43			43		Broker/other		0			0			37			37
Total sovereign and supranational	Total sovereign and supranational		0			1,072			43			1,115		Total sovereign and supranational		0			797			37			834
Banks/financial institutions:	Banks/financial institutions:													Banks/financial institutions:
Third party pricing vendor	Third party pricing vendor		0			5,237			0			5,237		Third party pricing vendor		0			4,622			0			4,622
Internal	Internal		0			6,309			0			6,309		Internal		0			4,518			105			4,623
Broker/other	Broker/other		0			0			45			45		Broker/other		0			0			54			54
Total banks/financial institutions	Total banks/financial institutions		0			11,546			45			11,591		Total banks/financial institutions		0			9,140			159			9,299
Other corporate:	Other corporate:													Other corporate:
Third party pricing vendor	Third party pricing vendor		0			29,495			0			29,495		Third party pricing vendor		0			22,268			0			22,268
Internal	Internal		0			7,916			0			7,916		Internal		0			5,352			200			5,552
Broker/other	Broker/other		0			0			426			426		Broker/other		0			0			542			542
Total other corporate	Total other corporate		0			37,411			426			37,837		Total other corporate		0			27,620			742			28,362
Total securities available for sale	Total securities available for sale		$	32,532		$	64,866		$	1,298		$	98,696	Total securities available for sale		$	24,158		$	49,805		$	1,778		$	75,741
Equity securities, carried at fair value:	Equity securities, carried at fair value:													Equity securities, carried at fair value:
Third party pricing vendor	Third party pricing vendor		$	1,340		$	90		$	0		$	1,430	Third party pricing vendor		$	822		$	60		$	0		$	882
Broker/other	Broker/other		0			0			173			173		Broker/other		0			0			209			209
Total equity securities	Total equity securities		$	1,340		$	90		$	173		$	1,603	Total equity securities		$	822		$	60		$	209		$	1,091

4449


		December 31, 2021													December 31, 2022
(In millions)	(In millions)	Quoted Prices in Active Markets for Identical Assets (Level 1)			Significant Observable Inputs (Level 2)			Significant Unobservable Inputs (Level 3)			Total Fair Value			(In millions)	Quoted Prices in Active Markets for Identical Assets (Level 1)			Significant Observable Inputs (Level 2)			Significant Unobservable Inputs (Level 3)			Total Fair Value
Securities held to maturity, carried at amortized cost:	Securities held to maturity, carried at amortized cost:													Securities held to maturity, carried at amortized cost:
Fixed maturity securities:	Fixed maturity securities:													Fixed maturity securities:
Government and agencies:	Government and agencies:													Government and agencies:
Third party pricing vendor	Third party pricing vendor		$	25,469		$	230		$	0		$	25,699	Third party pricing vendor		$	20,132		$	180		$	0		$	20,312
Total government and agencies	Total government and agencies		25,469			230			0			25,699		Total government and agencies		20,132			180			0			20,312
Municipalities:	Municipalities:													Municipalities:
Third party pricing vendor	Third party pricing vendor		0			436			0			436		Third party pricing vendor		0			335			0			335
Total municipalities	Total municipalities		0			436			0			436		Total municipalities		0			335			0			335

Public utilities:	Public utilities:													Public utilities:
Third party pricing vendor	Third party pricing vendor		0			55			0			55		Third party pricing vendor		0			41			0			41
Total public utilities	Total public utilities		0			55			0			55		Total public utilities		0			41			0			41
Sovereign and supranational:	Sovereign and supranational:													Sovereign and supranational:
Third party pricing vendor	Third party pricing vendor		0			313			0			313		Third party pricing vendor		0			242			0			242
Broker/other	Broker/other		0			337			0			337		Broker/other		0			258			0			258
Total sovereign and supranational	Total sovereign and supranational		0			650			0			650		Total sovereign and supranational		0			500			0			500

Other corporate:	Other corporate:													Other corporate:
Third party pricing vendor	Third party pricing vendor		0			29			0			29		Third party pricing vendor		0			22			0			22

Total other corporate	Total other corporate		0			29			0			29		Total other corporate		0			22			0			22
Total securities held to maturity	Total securities held to maturity		$	25,469		$	1,400		$	0		$	26,869	Total securities held to maturity		$	20,132		$	1,078		$	0		$	21,210

The following is a discussion of the determination of fair value of the Company's remaining financial instruments.

Derivatives

The Company uses derivative instruments to manage the risk associated with certain assets. However, the derivative instrument may not be classified in the same fair value hierarchy level as the associated asset. The significant inputs to pricing derivatives are generally observable in the market or can be derived by observable market data. When these inputs are observable, the derivatives are classified as Level 2.

The Company uses present value techniques to value non-option based derivatives. It also uses option pricing models to value option based derivatives. Key inputs are as follows:


Instrument Type						Level 2
Interest rate derivatives						Swap yield curves ~~Basic~~Basis curves Interest rate volatility (1)
Foreign currency exchange rate derivatives - Non-VIES (forwards, swaps and options)						Foreign currency forward rates Swap yield curves Basis curves Foreign currency spot rates Cross foreign currency basis curves Foreign currency volatility (1)
Foreign currency exchange rate derivatives - VIEs (swaps)						Foreign currency spot rates Swap yield curves Credit default swap curves Basis curves Recovery rates Foreign currency forward rates Foreign cross currency basis curves

(1) Option-based only

4550

The fair values of the foreign currency forwards and options are based on observable market inputs, therefore they are classified as Level 2.

The Parent Company has cross-currency swap agreements related to certain of its U.S. dollar-denominated senior notes to effectively convert a portion of the interest on the notes from U.S dollar to Japanese yen. Their fair values are based on observable market inputs, therefore they are classified as Level 2.

To determine the fair value of its interest rate derivatives, the Company uses inputs that are generally observable in the market or can be derived from observable market data. Interest rate swaps are cleared trades. In a cleared swap contract, the clearinghouse provides benefits to the counterparties similar to contracts listed for investment traded on an exchange since it maintains a daily margin to mitigate counterparties' credit risk. These derivatives are priced using observable inputs, accordingly, they are classified as Level 2. ~~For its interest rate swaptions, the Company estimates their fair values using observable market data, including interest rate curves and volatility. Their fair values are also classified as Level 2.~~

For derivatives associated with VIEs where the Company is the primary beneficiary, the Company is not the direct counterparty to the swap contracts. Nevertheless, the Company has full transparency into the contracts to properly value the swaps for reporting purposes. ~~Prior to October 1, 2021,~~For these derivatives, ~~were~~the Company utilizes valuation models developed by independent valuation analytics providers. The models are market standard DCF models and all associated processes and controls are executed by Company personnel. These models take into consideration any unique characteristics of the derivatives in determining the appropriate valuation methodology to estimate expected cash flows. The fair values of these swaps are based on observable market inputs and are classified as Level 3 because certain significant inputs were determined to be unobservable, primarily due to the long duration of the swaps which required extrapolation beyond the observable limits of the curve(s). However, due to the natural aging of the swap portfolio and the continued evolution of capital market inputs, especially the availability of long-term interest rates with tenors beyond 30 years, the Company has concluded that all significant inputs are now observable. As a result, effective October 1, 2021, the Company transferred the derivatives associated with its consolidated VIEs to Level 2 ofwithin the fair value hierarchy.

For forward bond purchase commitments with VIEs, the fair value of the derivative is based on the difference in the fixed purchase price and the current market value of the related bond prior to the settlement date. Since the bond is typically a public bond with readily available pricing, the derivatives associated with the forward purchase commitment are classified as Level 2 ofwithin the fair value hierarchy.

Commercial mortgage and other loans

Commercial mortgage and other loans include TREs, CMLs and MMLs. The Company's loan receivables do not have readily determinable market prices and generally lack market liquidity. Fair values for loan receivables are determined based on the present value of expected future cash flows discounted at the applicable U.S. Treasury or floating-rate benchmark yield plus an appropriate spread that considers other risk factors, such as credit and liquidity risk. The spreads are a significant component of the pricing inputs and are generally considered unobservable. Therefore, these investments ~~have been assigned a~~are classified as Level 3 within the fair value hierarchy.

Other investments

Other investments includes short-term investments that are measured at fair value where amortized cost approximates fair value.

Other policyholders' funds

The largest component of the other policyholders' funds liability is the Company's annuity line of business in Aflac Japan. The Company's annuities have fixed benefits and premiums. For this product, the Company estimates the fair value to be equal to the cash surrender value. This is analogous to the value paid to policyholders on the valuation date if they were to surrender their policy. The Company periodically checks the cash value against discounted cash flow projections for reasonableness. The Company considers its inputs for this valuation to be unobservable and have accordingly classified this valuation as Level 3.

Notes payable

The fair values of the Company's publicly issued notes payable are determined by utilizing available sources of observable inputs from third party pricing vendors and are classified as Level 2. The fair values of the Company's yen-denominated loans approximate their carrying values and are classified as Level 3.

4651

Transfers between Hierarchy Levels and Level 3 Rollforward

Assets and liabilities are transferred into Level 3 when a significant input cannot be corroborated with market observable data. This occurs when market activity decreases significantly and underlying inputs cannot be observed, current prices are not available, and/or when there are significant variances in quoted prices, thereby affecting transparency. Assets and liabilities are transferred out of Level 3 when circumstances change such that a significant input can be corroborated with market observable data. This may be due to a significant increase in market activity, a specific event, or one or more significant input(s) becoming observable. Effective October 1, 2021, the foreign exchange swaps discussed above were transferred from Level 3 to Level 2 because the significant inputs used for their valuation that were previously unobservable are now observable.

The following tables present the changes in fair value of the Company's investments ~~and derivatives~~ carried at fair value classified as Level 3. ~~Derivative assets and liabilities are presented as a net value.~~


Three Months Ended March 31, 2023
	Fixed Maturity Securities										Equity Securities
(In millions)	Mortgage- and Asset- Backed Securities		Public Utilities		Sovereign and Supranational		Banks/ Financial Institutions		Other Corporate				Total
Balance, beginning of period	$	343	$	497	$	37	$	159	$	742	$	209	$	1,987
Net investment gains (losses) included in earnings	0		0		0		0		0		2		2
Unrealized gains (losses) included in other comprehensive income (loss)	3		10		0		2		30		0		45
Purchases, issuances, sales and settlements:
Purchases	192		0		0		0		75		10		277
Issuances	0		0		0		0		0		0		0
Sales	0		0		0		0		0		0		0
Settlements	(120)		(7)		0		0		(2)		0		(129)
Transfers into Level 3	0		18		0		0		0		0		18
Transfers out of Level 3	0		(168)		0		0		(92)		0		(260)
Balance, end of period	$	418	$	350	$	37	$	161	$	753	$	221	$	1,940
Changes in unrealized gains (losses) relating to Level 3 assets and liabilities still held at the end of the period included in earnings	$	0	$	0	$	0	$	0	$	0	$	3	$	3

Three Months Ended
March 31, 2022
Fixed Maturity Securities Equity
Securities Derivatives
(In millions) Mortgage-
and
Asset-
Backed
Securities Public
Utilities Sovereign
and
Supranational Banks/
Financial
Institutions Other
Corporate Foreign
Currency
Swaps Total
Balance, beginning of period $ 291 $ 493 $ 43 $ 45 $ 426 $ 173 $ 0 $ 1,471
Net investment gains (losses) included
  in earnings 0 0 0 0 0 7 0 7
Unrealized gains (losses) included in
  other comprehensive income (loss) (15) (37) (2) 0 (18) 0 0 (72)
Purchases, issuances, sales
  and settlements:
Purchases 76 9 0 0 0 10 0 95
Issuances 0 0 0 0 0 0 0 0
Sales 0 0 0 0 0 0 0 0
Settlements (2) (8) 0 (3) (1) (7) 0 (21)
Transfers into Level 3 0 128 0 18 24 0 0 170
Transfers out of Level 3 (32) 0 0 0 (141) (17) 0 (190)
Balance, end of period $ 318 $ 585 $ 41 $ 60 $ 290 $ 166 $ 0 $ 1,460
Changes in unrealized gains
  (losses) relating to Level 3 assets
  and liabilities still held at the end
  of the period included in earnings $ 0 $ 0 $ 0 $ 0 $ 0 $ 4 $ 0 $ 4


Three Months Ended March 31, 2022
	Fixed Maturity Securities										Equity Securities
(In millions)	Mortgage- and Asset- Backed Securities		Public Utilities		Sovereign and Supranational		Banks/ Financial Institutions		Other Corporate				Total
Balance, beginning of period	$	291	$	493	$	43	$	45	$	426	$	173	$	1,471
Net investment gains (losses) included in earnings	0		0		0		0		0		7		7
Unrealized gains (losses) included in other comprehensive income (loss)	(15)		(37)		(2)		0		(18)		0		(72)
Purchases, issuances, sales and settlements:
Purchases	76		9		0		0		0		10		95
Issuances	0		0		0		0		0		0		0
Sales	0		0		0		0		0		0		0
Settlements	(2)		(8)		0		(3)		(1)		(7)		(21)
Transfers into Level 3	0		128		0		18		24		0		170
Transfers out of Level 3	(32)		0		0		0		(141)		(17)		(190)
Balance, end of period	$	318	$	585	$	41	$	60	$	290	$	166	$	1,460
Changes in unrealized gains (losses) relating to Level 3 assets and liabilities still held at the end of the period included in earnings	$	0	$	0	$	0	$	0	$	0	$	4	$	4

Three Months Ended
March 31, 2021
Fixed Maturity Securities Equity
Securities Derivatives
(In millions) Mortgage-
and
Asset-
Backed
Securities Public
Utilities Sovereign
and
Supranational Banks/
Financial
Institutions Other
Corporate Foreign
Currency
Swaps Total
Balance, beginning of period $ 224 $ 422 $ 48 $ 24 $ 299 $ 102 $ (98) $ 1,021
Net investment gains (losses) included
  in earnings 0 0 0 0 0 9 19 28
Unrealized gains (losses) included in
  other comprehensive income (loss) (15) (18) (3) (1) (12) 0 (1) (50)
Purchases, issuances, sales and
  settlements:
Purchases 10 78 0 5 0 11 0 104
Issuances 0 0 0 0 0 0 0 0
Sales 0 0 0 0 0 0 0 0
Settlements 0 (3) 0 0 0 0 0 (3)
Transfers into Level 3 0 0 23 0 32 0 0 55
Transfers out of Level 3 (15) 0 0 0 0 0 0 (15)
Balance, end of period $ 204 $ 479 $ 68 $ 28 $ 319 $ 122 $ (80) $ 1,140
Changes in unrealized gains
  (losses) relating to Level 3 assets
  and liabilities still held at the end
  of the period included in earnings $ 0 $ 0 $ 0 $ 0 $ 0 $ 0 $ 19 $ 19

4852

Fair Value Sensitivity

Level 3 Significant Unobservable Input Sensitivity

The following tables summarize the significant unobservable inputs used in the valuation of the Company's Level 3 investments carried at fair value. Included in the tables are the inputs or range of possible inputs that have an effect on the overall valuation of the financial instruments.

~~March 31, 2022~~

~~(In millions)~~

~~Fair Value~~

~~Valuation Technique(s)~~

~~Unobservable Input~~

Range
(Weighted Average)

~~Assets:~~

~~Securities available for sale, carried at fair value:~~

~~Fixed maturity securities:~~

~~Mortgage- and asset-backed securities~~

~~318~~

~~Consensus pricing~~

~~Offered quotes~~

~~N/A~~

~~(a)~~

~~Public utilities~~

~~585~~

~~Discounted cash flow~~

~~Credit spreads~~

~~N/A~~

~~(a)~~

~~Sovereign and supranational~~

~~Discounted cash flow~~

~~Historical volatility~~

~~N/A~~

~~(a)~~

~~Banks/financial institutions~~

~~Consensus pricing~~

~~Offered quotes~~

~~N/A~~

~~(a)~~

~~Other corporate~~

~~290~~

~~Discounted cash flow~~

~~Credit spreads~~

~~N/A~~

~~(a)~~

~~Equity securities~~

~~166~~

~~Net asset value~~

~~Offered quotes~~

~~N/A~~

~~(a)~~

~~Total assets~~

~~1,460~~

March 31, 2023

(In millions)

Fair Value

Valuation Technique(s)

Unobservable Input

Range

Weighted Average

Assets:

Securities available for sale, carried at fair value:

Fixed maturity securities:

Mortgage- and asset-backed securities

418

Consensus pricing

Offered quotes

82.69

107.62

(a)

100.39

Public utilities

350

Discounted cash flow

Credit spreads

170 bps

268 bps

(b)

206 bps

Sovereign and supranational

Consensus pricing

Offered quotes

N/A

(c)

N/A

Banks/financial institutions

161

Discounted cash flow

Credit spreads

67 bps

188 bps

(b)

111 bps

Other corporate

753

Discounted cash flow

Credit spreads

66 bps

295 bps

(b)

187 bps

Equity securities

221

Adjusted cost

Private financials

N/A

(d)

N/A

Total assets

1,940

(a) ~~N/A represents~~Represents prices for securities where the Company receives unadjusted broker quotes and for which there is no transparency into the providers' valuation ~~techniques~~techniques.

(b) Actual or ~~unobservable inputs.~~equivalent credit spreads in basis points.

(d) Prices do not utilize credit spreads; therefore, range is not applicable.

~~December 31, 2021~~

~~(In millions)~~

~~Fair Value~~

~~Valuation Technique(s)~~

~~Unobservable Input~~

Range
(Weighted Average)

~~Assets:~~

~~Securities available for sale, carried at fair value:~~

~~Fixed maturity securities:~~

~~Mortgage- and asset-backed securities~~

~~291~~

~~Consensus pricing~~

~~Offered quotes~~

~~N/A~~

~~(a)~~

~~Public utilities~~

~~493~~

~~Discounted cash flow~~

~~Credit spreads~~

~~N/A~~

~~(a)~~

~~Sovereign and supranational~~

~~Discounted cash flow~~

~~Historical volatility~~

~~N/A~~

~~(a)~~

~~Banks/financial institutions~~

~~Consensus pricing~~

~~Offered quotes~~

~~N/A~~

~~(a)~~

~~Other corporate~~

~~426~~

~~Discounted cash flow~~

~~Credit spreads~~

~~N/A~~

~~(a)~~

~~Equity securities~~

~~173~~

~~Net asset value~~

~~Offered quotes~~

~~N/A~~

~~(a)~~

~~Total assets~~

~~1,471~~

December 31, 2022

(In millions)

Fair Value

Valuation Technique(s)

Unobservable Input

Range

Weighted Average

Assets:

Securities available for sale, carried at fair value:

Fixed maturity securities:

Mortgage- and asset-backed securities

343

Consensus pricing

Offered quotes

97.38

106.71

(a)

102.98

Public utilities

497

Discounted cash flow

Credit spreads

128 bps

286 bps

(b)

192 bps

Sovereign and supranational

Consensus pricing

Offered quotes

N/A

(c)

N/A

Banks/financial institutions

159

Discounted cash flow

Credit spreads

67 bps

188 bps

(b)

113 bps

Other corporate

742

Discounted cash flow

Credit spreads

66 bps

647 bps

(b)

191 bps

Equity securities

209

Adjusted cost

Private financials

N/A

(d)

N/A

Total assets

1,987

(b) Actual or ~~unobservable inputs.~~equivalent credit spreads in basis points.

(d) Prices do not utilize credit spreads; therefore, range is not applicable

5053

The following is a discussion of the significant unobservable inputs or valuation techniques used in determining the fair value of securities ~~and derivatives~~ classified as Level 3.

~~Net Asset Value~~Credit Spreads

The Company holds certain ~~unlisted equity securities whose fair value is derived based on the financial statements published by the investee. These securities~~assets that are of a unique, specialized, and/or securitized nature that do not trade on a regular basis in an active market, which makes their fair values difficult to estimate. Most of these assets are managed by external asset managers and the ~~valuations derived~~Company utilizes these managers for their expertise when evaluating various inputs used to determine the fair values for these assets, including identifying the appropriate credit or risk spread over risk-free interest rates that incorporates the unique nature or structure of the asset in the valuations. For those assets of a similar nature but not managed by external asset managers, the Company internally estimates the spreads and risk adjustments over risk-free interest rates that reflect the unique nature or structure of the asset as well as the current pricing environment and market conditions for comparable or related investments. Credit or risk spreads are ~~dependent~~an important input needed to complete the discounted cash flow analyses used to estimate an investment’s fair value. Credit or risk spreads underlying these fair values are a significant, unobservable input whose derivation is based on the ~~availability~~Company’s evaluation of ~~timely financial reporting~~a combination of the ~~investee. Net asset value is an unobservable input in~~external manager’s expertise and knowledge, the ~~determination of fair value ofequity securities.~~current pricing environment, and market conditions for the specific asset.

Offered Quotes

In circumstances where the Company's valuation model price is overridden because it implies a value that is not consistent with current market conditions, the Company will solicit bids from a limited number of brokers. The Company also receives unadjusted prices from brokers for certain of its mortgage and asset-backed securities. These quotes are non-binding but are reflective of valuation best estimates at that particular point in time. Offered quotes are an unobservable input in the determination of fair value of mortgage- and asset-backed securities, certain banks/financial institutions, certain other corporate, and equity securities investments.

~~Interest Rates and CDS Spreads~~Private Financials

The Company invests in the debt and equity securities of private companies operating in the cancer, healthtech, insurtech, finance, internet of things, big data and analytics sectors. Due to their private and often small, startup nature, these companies rely on capital provided by institutional and private equity investors for their ongoing operations. They do not have public securities that trade on a regular basis in an active market, which makes their fair values difficult to estimate. The Company values these investments on a cost basis with appropriate adjustments made based on monitoring private financial information provided by these companies. Adjustments to valuations are generally made as new funding tranches are executed or if the financial information provided significantly changes indicating the need for impairment. This private financial information is unobservable and is a significant ~~drivers of~~determinant in the valuation of the foreign exchange swaps are interest rates and CDS spreads. Some of the Company's swaps have long maturities that increase the sensitivity of the swaps to interest rate fluctuations. For the Company's foreign exchange or cross currency swaps that are in a net asset position, an increase in yen interest rates (all other factors held constant) will decrease the presentfair value of ~~the yen final settlement receivable (receive leg), thus decreasing the value of the swap as long as the derivative remains in a net asset position.~~

Foreign exchange swaps also have a lump-sum final settlement of foreign exchange principal amounts at the termination of the swap. Assuming all other factors are held constant, an increase in yen interest rates will decrease the receive leg and decrease the net value of the swap. Likewise, holding all other factors constant, an increase in U.S. dollar interest rates will increase the swap's net value due to the decrease in the present value of the dollar final settlement payable (pay leg).

The extinguisher feature in most of the Company's VIE swaps results in a cessation of cash flows and no further payments between the parties to the swap in the event of a default on the referenced or underlying collateral. To price this feature, the Company applies the survival probability of the referenced entity to the projected cash flows. The survival probability uses the CDS spreads and recovery rates to adjust the present value of the cash flows. For extinguisher swaps with positive values, an increase in CDS spreads decreases the likelihood of receiving the final exchange payments and reduces the value of the swap.

Effective October 1, 2021, the foreign exchange swaps mentioned above were transferred from Level 3 to Level 2 because the significant inputs used for their valuation that were previously unobservable are now observable.these corporate venture investments.

For additional information on the Company's investments and financial instruments, see the accompanying Notes 1, 3 and 4 and Notes 1, 3 and 4 of the Notes to the Consolidated Financial Statements in the ~~2021~~2022 Annual Report.

6. DEFERRED POLICY ACQUISITION COSTS

The following tables present a rollforward of deferred policy acquisition costs by reporting segment and disaggregated by product type.


	March 31, 2023
	Aflac Japan								Aflac U.S.
(In millions)	Cancer		Medical and Other Health		Life Insurance		Other		Accident		Disability		Critical Care		Hospital Indemnity		Dental/Vision		Life Insurance		Other		Total
Deferred policy acquisition costs:
Balance at December 31, 2022	$	3,035	$	2,161	$	525	$	55	$	904	$	613	$	1,304	$	418	$	88	$	135	$	1	$	9,239
Capitalization	76		33		9		4		39		31		41		21		2		14		0		270
Amortization expense	(48)		(28)		(9)		0		(34)		(28)		(34)		(16)		(3)		(6)		1		(205)

Foreign currency translation and other	(19)		(13)		(3)		(1)		0		0		0		0		0		0		(1)		(37)
Balance at March 31, 2023	$	3,044	$	2,153	$	522	$	58	$	909	$	616	$	1,311	$	423	$	87	$	143	$	1	$	9,267


	December 31, 2022
	Aflac Japan								Aflac U.S.
(In millions)	Cancer		Medical and Other Health		Life Insurance		Other		Accident		Disability		Critical Care		Hospital Indemnity		Dental/Vision		Life Insurance		Other		Total
Deferred policy acquisition costs:
Balance at December 31, 2021	$	3,464	$	2,372	$	595	$	51	$	887	$	604	$	1,270	$	399	$	90	$	115	$	1	$	9,848
Capitalization	291		161		33		12		147		117		160		80		11		40		0		1,052
Amortization expense	(188)		(112)		(35)		(3)		(130)		(108)		(126)		(61)		(13)		(20)		4		(792)

Foreign currency translation and other	(532)		(260)		(68)		(5)		0		0		0		0		0		0		(4)		(869)
Balance at December 31, 2022	$	3,035	$	2,161	$	525	$	55	$	904	$	613	$	1,304	$	418	$	88	$	135	$	1	$	9,239

The Company uses the following constant level bases to amortize deferred policy acquisition costs:


Policy Type						Constant-level Basis
Life Products (U.S.)						Face Value
Health Products (U.S.)						Policy Count
Health & Life Products (Japan)						Units in Force

Face value is the stated dollar amount that the policy’s beneficiaries receive upon the death of the insured. For life and health products issued in Japan, the constant-level basis used is units in force, which is a proxy for face amount and insurance in force, respectively. Future DAC amortization is impacted by persistency.

There were no changes to the inputs, judgements, assumptions and methods used to determine amortization amounts during the three-month periods ended March 31, 2023 and 2022.

See Note 1 of the Notes to the Consolidated Financial Statements for more information on deferred policy acquisition costs.

7. POLICY LIABILITIES

Future Policy Benefits

The liability for future policy benefits is determined as the present value of future benefits to be paid to or on the behalf of policyholders and certain related expenses less the present value of future net premiums receivable under the Company's insurance contracts, where future net premiums receivable are future gross premiums receivable under the contract multiplied by the NPR.

The following tables present the changes in the present value of expected net premiums and the present value of expected future policy benefits by reporting segment and disaggregated by product type.


	March 31, 2023
	Aflac Japan								Aflac U.S.
(In millions)	Cancer		Medical and Other Health		Life Insurance		Other		Accident		Disability		Critical Care		Hospital Indemnity		Dental/Vision		Life Insurance		Other
Present value of expected premiums:
Balance at December 31, 2022	$	19,298	$	16,714	$	7,485	$	1,256	$	2,534	$	1,635	$	4,486	$	1,220	$	211	$	724	$	110
Beginning balance at original discount rate	18,221		16,195		7,284		1,242		2,760		1,775		5,050		1,365		231		799		118
Effect of changes in cash flow assumptions	0		0		0		0		0		0		0		0		0		0		0
Effect of actual variances from expected experience	(120)		(25)		(14)		(2)		(48)		(20)		(104)		(39)		(7)		(4)		(1)
Adjusted beginning of period balance	18,101		16,170		7,270		1,240		2,712		1,755		4,946		1,326		224		795		117
Issuances	229		104		111		8		117		120		192		103		10		49		14
Interest accrual	111		92		33		5		25		15		46		11		2		7		1
Net premiums earned (1)	(420)		(344)		(286)		(31)		(118)		(95)		(147)		(62)		(10)		(33)		(4)
Foreign currency translation	(109)		(100)		(44)		(8)		0		0		0		0		0		0		0
Other	0		0		0		0		0		0		0		0		2		4		9
Ending balance at original discount rate	17,912		15,922		7,084		1,214		2,736		1,795		5,037		1,378		228		822		137
Effect of changes in discount rate assumptions	1,542		1,045		319		42		(173)		(112)		(444)		(117)		(15)		(60)		(6)
Balance at March 31, 2023	$	19,454	$	16,967	$	7,403	$	1,256	$	2,563	$	1,683	$	4,593	$	1,261	$	213	$	762	$	131
Present value of expected future policy benefits:
Balance at December 31, 2022	$	54,766	$	27,419	$	31,954	$	5,582	$	3,098	$	2,445	$	11,489	$	2,074	$	488	$	1,526	$	622
Beginning balance at original discount rate	47,677		27,566		32,800		5,940		3,391		2,636		12,846		2,300		532		1,778		624
Effect of changes in cash flow assumptions	0		0		0		0		0		0		0		0		0		0		0
Effect of actual variances from expected experience	(136)		(24)		(14)		0		(55)		(24)		(120)		(48)		(9)		(6)		(2)
Adjusted beginning of period balance	47,541		27,542		32,786		5,940		3,336		2,612		12,726		2,252		523		1,772		622
Issuances	232		108		112		9		124		127		201		111		12		53		13
Interest accrual	396		163		166		27		31		23		133		21		5		16		8
Benefit payments	(825)		(367)		(493)		(61)		(115)		(118)		(224)		(69)		(15)		(29)		(11)
Foreign currency translation	(295)		(171)		(201)		(35)		0		0		0		0		0		0		0
Other	0		0		0		0		0		0		0		0		2		4		9
Ending balance at original discount rate	47,049		27,275		32,370		5,880		3,376		2,644		12,836		2,315		527		1,816		641
Effect of changes in discount rate assumptions	8,750		1,164		344		(110)		(227)		(149)		(1,019)		(176)		(33)		(210)		15
Balance at March 31, 2023	55,799		28,439		32,714		5,770		3,149		2,495		11,817		2,139		494		1,606		656
Net liability for future policy benefits	36,345		11,472		25,311		4,514		586		812		7,224		878		281		844		525
Less: reinsurance recoverable	0		1,643		0		0		0		0		0		0		0		10		0
Net liability for future policy benefits after reinsurance recoverable	$	36,345	$	9,829	$	25,311	$	4,514	$	586	$	812	$	7,224	$	878	$	281	$	834	$	525

(1) Net premiums earned represent the portion of gross premiums collected from policyholders that is used to fund expected benefit payments.


	December 31, 2022
	Aflac Japan								Aflac U.S.
(In millions)	Cancer		Medical and Other Health		Life Insurance		Other		Accident		Disability		Critical Care		Hospital Indemnity		Dental/Vision		Life Insurance		Other
Present value of expected premiums:
Balance at December 31, 2021	$	25,893	$	21,174	$	10,847	$	1,586	$	3,283	$	1,862	$	6,023	$	1,467	$	264	$	834	$	153
Beginning balance at original discount rate	22,470		18,681		10,064		1,461		2,999		1,760		5,391		1,380		241		780		135
Effect of changes in cash flow assumptions	(639)		317		(494)		25		(52)		5		(38)		42		10		(1)		(12)
Effect of actual variances from expected experience	(284)		61		(81)		(10)		(152)		(43)		(421)		(111)		(20)		(16)		6
Adjusted beginning of period balance	21,547		19,059		9,489		1,476		2,795		1,722		4,932		1,311		231		763		129
Issuances	947		639		221		62		355		384		537		273		33		146		0
Interest accrual	459		364		146		22		105		57		193		45		9		27		5
Net premiums earned (1)	(1,734)		(1,376)		(1,229)		(123)		(496)		(382)		(612)		(261)		(42)		(131)		(17)
Foreign currency translation	(2,997)		(2,488)		(1,343)		(195)		0		0		0		0		0		0		0
Other	(1)		(3)		0		0		1		(6)		0		(3)		0		(6)		1
Ending balance at original discount rate	18,221		16,195		7,284		1,242		2,760		1,775		5,050		1,365		231		799		118
Effect of changes in discount rate assumptions	1,077		519		201		14		(226)		(140)		(564)		(145)		(20)		(75)		(8)
Balance at December 31, 2022	$	19,298	$	16,714	$	7,485	$	1,256	$	2,534	$	1,635	$	4,486	$	1,220	$	211	$	724	$	110
Present value of expected future policy benefits:
Balance at December 31, 2021	$	72,747	$	36,021	$	42,720	$	7,322	$	3,949	$	2,871	$	15,388	$	2,552	$	616	$	1,843	$	837
Beginning balance at original discount rate	56,807		31,398		39,002		6,787		3,594		2,670		13,079		2,300		549		1,694		645
Effect of changes in cash flow assumptions	(721)		352		(550)		96		(70)		5		(43)		40		13		(1)		(15)
Effect of actual variances from expected experience	(333)		83		(91)		(10)		(177)		(48)		(465)		(130)		(23)		(21)		7
Adjusted beginning of period balance	55,753		31,833		38,361		6,873		3,347		2,627		12,571		2,210		539		1,672		637
Issuances	960		646		222		68		364		397		550		282		34		149		0
Interest accrual	1,599		642		670		106		128		94		539		85		21		62		32
Benefit payments	(3,050)		(1,375)		(1,248)		(202)		(456)		(483)		(823)		(277)		(62)		(103)		(45)
Foreign currency translation	(7,585)		(4,180)		(5,205)		(905)		0		0		0		0		0		0		0
Other	0		0		0		0		8		1		9		0		0		(2)		0
Ending balance at original discount rate	47,677		27,566		32,800		5,940		3,391		2,636		12,846		2,300		532		1,778		624
Effect of changes in discount rate assumptions	7,089		(147)		(846)		(358)		(293)		(191)		(1,357)		(226)		(44)		(252)		(2)
Balance at December 31, 2022	54,766		27,419		31,954		5,582		3,098		2,445		11,489		2,074		488		1,526		622
Net liability for future policy benefits	35,468		10,705		24,469		4,326		564		810		7,003		854		277		802		512
Less: reinsurance recoverable	0		1,579		0		0		0		0		0		0		0		9		0
Net liability for future policy benefits after reinsurance recoverable	$	35,468	$	9,126	$	24,469	$	4,326	$	564	$	810	$	7,003	$	854	$	277	$	793	$	512

(1) Net premiums earned represent the portion of gross premiums collected from policyholders that is used to fund expected benefit payments.

~~6. POLICY LIABILITIES~~

The following tables present the weighted-average interest rates and weighted-average liability duration (calculated using the original discount rate) by reporting segment and disaggregated by product type.


	March 31, 2023
	Aflac Japan				Aflac U.S.
	Cancer	Medical and Other Health	Life Insurance	Other	Accident	Disability	Critical Care	Hospital Indemnity	Dental/Vision	Life Insurance	Other
Weighted-average interest, original discount rate (1)	3.9 %	2.6 %	2.1 %	1.8 %	3.9 %	4.2 %	4.6 %	4.4 %	4.3 %	3.7 %	5.4 %
Weighted-average interest, current discount rate (1)	1.7 %	2.2 %	1.7 %	2.0 %	5.0 %	5.0 %	5.1 %	5.1 %	5.0 %	5.0 %	5.1 %
Weighted-average liability duration (years)	13.7	26.7	17.3	18.0	8.5	5.6	11.8	9.6	8.0	12.9	9.5

(1) The weighted-average interest rates are calculated using the reserve balances as the weights. No adjustments were made to observable market information.

~~Changes~~


	December 31, 2022
	Aflac Japan				Aflac U.S.
	Cancer	Medical and Other Health	Life Insurance	Other	Accident	Disability	Critical Care	Hospital Indemnity	Dental/Vision	Life Insurance	Other
Weighted-average interest, original discount rate (1)	4.1 %	2.6 %	2.1 %	1.8 %	3.8 %	4.2 %	4.6 %	4.4 %	4.3 %	3.7 %	5.4 %
Weighted-average interest, current discount rate (1)	1.6 %	2.2 %	1.6 %	1.9 %	4.8 %	4.7 %	4.8 %	4.8 %	4.8 %	4.8 %	4.8 %
Weighted-average liability duration (years)	13.7	26.9	17.3	18.2	8.5	5.6	12.0	9.4	8.1	13.1	9.6

(1) The weighted-average interest rates are calculated using the reserve balances as the weights. No adjustments were made to observable market information.

The following table presents a reconciliation of the disaggregated rollforwards above to the ending future policy benefits presented in the Consolidated Balance Sheets. The deferred profit liability for limited-payment contracts and the deferred profit liability for reinsurance is presented together with the liability for ~~unpaid~~future policy ~~claims were~~benefits in the Consolidated Balance Sheets and has been included as ~~follows:~~a reconciling item in the table below.

Three Months Ended
March 31,
(In millions) 2022 2021
Unpaid supplemental health claims, beginning of period $ 4,067 $ 4,389
Less reinsurance recoverables 37 39
Net balance, beginning of period 4,030 4,350
Add claims incurred during the period related to:
Current year 1,737 1,859
Prior years (208) (320)
Total incurred 1,529 1,539
Less claims paid during the period on claims incurred during:
Current year 468 511
Prior years 987 1,061
Total paid 1,455 1,572
Effect of foreign exchange rate changes on unpaid claims (135) (162)
Net balance, end of period 3,969 4,155
Add reinsurance recoverables 40 37
Unpaid supplemental health claims, end of period 4,009 4,192
Unpaid life claims, end of period 745 756
Total liability for unpaid policy claims $ 4,754 $ 4,948


(In millions)	March 31, 2023			December 31, 2022
Balances included in future policy benefits rollforward:
Aflac Japan
Cancer		$	36,345		$	35,468
Medical and other health		11,472			10,705
Life insurance		25,311			24,469
Other		4,514			4,326
Aflac U.S.
Accident		586			564
Disability		812			810
Critical care		7,224			7,003
Hospital indemnity		878			854
Dental/vision		281			277
Life insurance		844			802
Other		525			512
Corporate and other		31			19
Deferred profit liability - limited-payment contracts		1,788			1,740
Deferred profit liability - reinsurance		682			692
Total		$	91,293		$	88,241

~~The incurred claims development related to prior years reflects favorable claims experience compared to previous estimates. The favorable claims development of $208 million for~~Discount rates are determined using upper-medium grade (low-credit-risk) fixed-income instrument yields that reflect the ~~three-month period ended March 31, 2022 comprises approximately $114 million from Japan and $94 million from the U.S., representing approximately 55% and 45%~~duration characteristics of the ~~total, respectively. Excluding~~liability. Locked-in discount rates are determined as a weighted average of monthly upper-medium grade (low-credit-risk) fixed-income instrument forward curves, where the ~~impact of foreign exchange of a loss of approximately $7 million from December 31, 2021 to March 31, 2022,~~weights are the ~~favorable claims development in Japan would have been approximately $122 million, representing approximately 59%~~annualized premiums issued for each month of the ~~total.~~cohort. Discount rates are updated each reporting period and require estimation techniques (e.g., interpolation, extrapolation) for determination of points on the curve for which there is limited or no observable market data.

~~The~~More specifically, the Company ~~has experienced continued favorable claim trends in 2022~~constructs a discount rate curve separately for ~~its core health products in Japan. During the first quarter~~discounting cash flows used to calculate each of ~~2022, there were impacts from lower utilization of healthcare services, due to the COVID-19 pandemic. This impacted both cancer and medical products, as~~ the Japan ~~population was avoiding doctor~~ and ~~hospital visits~~U.S. liabilities for future policy benefits, reflective of the characteristics of the corresponding insurance liabilities, such as currency and staying home more. This resulted in lower sickness, accident, and cancer incurred claims. In addition, dating back to before the pandemic, cancer treatment patterns in Japan are continuing to be influenced by significant advances in early-detection techniques and by the increased use of pathological diagnosis rather than clinical exams. Additionally, follow-up radiation and chemotherapy treatments are occurring more often on an outpatient basis. Such changes in treatment not only increase the quality of life and initial outcomes for the patients, but also decrease the average length of each hospital stay, resulting in favorable claims development. Even though overall experience is favorable, during the first quarter of 2022, there has been an increase in medical hospitalization claims related to COVID-19, due to the Omicron variant surge in Japan. The Company is monitoring the experience of this benefit, and will additionally adjust claim reserves as needed.tenor.

In the ~~first quarter~~Aflac Japan segment, all long-duration insurance policies are denominated in yen. A significant portion of policies are characterized by tenors exceeding the availability of liquid market data in Japan for single-A rated (as a proxy for upper-medium grade) corporate yen-denominated debt. The discount rate curve is designed to prioritize the observable inputs where available, while past the last liquid point, the data is derived based on estimation techniques consistent with the fair value guidance in ASC 820. The Aflac Japan segment curve utilizes liquid market indices tracking publicly traded yen-denominated single-A corporate debt for the initial 10-year tenor. For the bonds within these market indices where only local ratings are available, the Company prioritizes the bonds with local ratings that are equivalent to a single-A rating based on international rating standards.

For the discount rates applicable to tenors for which the Japan single-A debt market is not liquid but there is sufficient observable market data and/or the observable market data is available for similar instruments (between 10 and 30 years), the Company estimates tenor-specific single-A credit spreads and applies them to risk-free government rates. Lastly, for the tenors where there is limited or no observable single-A or similar market data or risk-free government rates (beyond 30 years), the discount curve is derived by extrapolation of risk free rates beyond their last liquid point following the Smith-Wilson method and grading of the estimated forward credit spread anchored by the ultimate forward rate. The ultimate forward rate is based on the economic value-based solvency regime, which is consistent with the International Association of Insurance Supervisors (IAIS) Insurance Capital Standards (ICS) (which is expected to be introduced in Japan in 2025), and is adjusted for credit and inflation components.

For the Aflac U.S. segment where all long-duration insurance policies are denominated in U.S. dollar and substantially all have cash flow duration within 30 years, for which the U.S. upper-medium grade fixed-income market is liquid and observable, the Company uses data from a liquid fixed-income market index tracking single-A U.S. corporate debt. For the insignificant portion of the policies with cash flow tenors exceeding 30 years, the discount curve beyond that tenor is extrapolated following the Smith-Wilson method from year 30 to the same ultimate forward rate calculated for the Japan discount curve at year 60 and held constant thereafter. The use of the same ultimate rate for U.S. and Japan segments is based on the assumption of long-term global economic convergence.

For the three-month periods ended March 31, 2023 and 2022, the Company recognized $(2.8) billion and $4.2 billion in other comprehensive income (loss) net of tax, respectively, due to changes in the future policy benefits estimate from updating the discount rate assumptions. There were no changes to the methods used to determine the discount rates during the three-month periods ended March 31, 2023 and 2022.

For the year ended December 31, 2022, the Company recognized $13.7 billion in other comprehensive income (loss) net of tax, due to changes in the future policy benefits estimate from updating the discount rate assumptions. There were no changes to the methods used to determine the discount rates during the year ended December 31, 2022.

Mortality rate assumptions are based on industry tables and adjusted for the Company's actual or expected experience where credible or appropriate. These assumptions typically will vary by age, gender, and other demographic characteristics such as ~~experienced in 2021~~smoking status.

Morbidity assumptions are based on the Company's internal data and ~~2020,~~consider emerging experience. These assumptions are reflective of the ~~incurred claims development related to prior years reflects favorable claims experience compared to previous estimates. The favorable claims~~coverage and benefits provided and generally vary by age, gender, duration, and any other material policyholder characteristics. In cases where a calendar-year trend ~~continued for~~is significant, future cash flow projections may include a trend adjustment.

In Japan, separate lapse assumptions are set based on actual or expected experience. These lapse and total termination rate assumptions will vary by line of business and with policyholder characteristics such as duration. In the U.S., the majority of the future cash flows are modeled using total termination rates (which include both lapse and mortality) and are adjusted for actual experience. Policy provisions, such as reaching premium paid-up status, are taken into account when setting assumptions.

During the three-month periods ended March 31, 2023 and 2022, the Company's ~~major U.S. accident~~adjustment for actual variances from expected experience resulted in reserve remeasurement gains of $53 million and ~~health~~$34 million in the consolidated statement of earnings, respectively. The variance of actual experience from expected experience was primarily due to favorable variances in morbidity assumptions as compared to actual experience. There were no changes to the inputs, judgments, assumptions and methods used in measuring the liability for future policy benefits during the three-month periods ended March 31, 2023 and 2022.

In 2022, the Company's annual review process resulted in favorable changes to its morbidityassumptions due to favorable claims experience, primarily. This, together with the variance of actual experience from expected experience, resulted in reserve remeasurement gains of $215 million in the consolidated statement of earnings for the year ended December 31, 2022.

The following table summarizes the amount of net earned premiums recognized in the Consolidated Statements of Earnings by reporting segment and disaggregated by product type.


	Three Months Ended March 31,
(In millions)		2023		2022
Net earned premiums:
Aflac Japan
Cancer		$	1,132	$	1,336
Medical and other health		689		828
Life insurance		399		524
Other		39		44
Aflac U.S.
Accident		329		337
Disability		309		296
Critical care		443		446
Hospital indemnity		184		185
Dental/vision		53		49
Life insurance		115		99
Other		10		10
Corporate and other		90		42
Reinsurance ceded		(104)		(117)
Total		$	3,688	$	4,079

The following table summarizes the amount of interest expense related to insurance contracts recognized in total benefits and claims, net in the Consolidated Statements of Earnings by reporting segment and disaggregated by product type.


	Three Months Ended March 31,
(In millions)		2023		2022
Interest expense:
Aflac Japan
Cancer		$	285	$	329
Medical and other health		71		80
Life insurance		133		149
Other		22		24
Aflac U.S.
Accident		6		5
Disability		8		9
Critical care		87		86
Hospital indemnity		10		10
Dental/vision		3		3
Life insurance		9		8
Other		7		7
Corporate and other		0		0
Total		$	641	$	710

The following tables summarize the amount of undiscounted expected future gross premiums and expected future benefits and expenses and discounted (discounted at the current period discount rate) expected future gross premiums and expected future benefits and expenses by reporting segment and disaggregated by product type. Future gross premiums represent the expected amount of future premiums to be received. For limited-payment policies, the premiums are collected over a shorter period than the policy term over which benefits are provided. As a result, once the policy reaches premium paid-up status, the future gross premiums can be significantly less than the future benefit payments. Further, benefits and expenses are generally greater in the later years of a policy. These are the primary factors that result in future gross premiums lower than future benefit and expense payments for certain lines of business ~~including accident, hospital indemnity, cancer, critical illness and short-term disability. Refinements to COVID-19 incurred estimates also contributed to the favorable development. The U.S. portion~~ of the ~~favorable claims development includes $32 million related to refinements in the estimates for COVID and non-COVID claims as experience emerges.~~Company.


	March 31, 2023						December 31, 2022
(In millions)	Gross Premiums			Benefits and Expenses			Gross Premiums			Benefits and Expenses
Undiscounted expected future gross premiums and expected future benefits and expenses:
Aflac Japan
Cancer		$	74,863		$	83,549		$	75,529		$	84,246
Medical and other health		50,153			50,573			50,720			50,778
Life insurance		16,690			52,993			16,946			53,271
Other		2,309			9,379			2,322			9,433
Aflac U.S.
Accident		9,467			4,621			9,481			4,636
Disability		5,889			3,286			5,858			3,267
Critical care		21,134			22,085			21,069			22,113
Hospital indemnity		5,213			3,360			5,164			3,338
Dental/vision		1,194			754			1,208			759
Life insurance		2,466			2,871			2,375			2,787
Other		359			1,165			333			1,147
Total		$	189,737		$	234,636		$	191,005		$	235,775


	March 31, 2023						December 31, 2022
(In millions)	Gross Premiums			Benefits and Expenses			Gross Premiums			Benefits and Expenses
Discounted expected future gross premiums and expected future benefits and expenses:
Aflac Japan
Cancer		$	53,806		$	55,799		$	53,278		$	54,766
Medical and other health		35,030			28,439			34,693			27,419
Life insurance		12,875			32,714			12,951			31,954
Other		1,712			5,770			1,697			5,582
Aflac U.S.
Accident		6,625			3,149			6,510			3,098
Disability		4,554			2,495			4,468			2,445
Critical care		13,013			11,817			12,659			11,489
Hospital indemnity		3,592			2,139			3,483			2,074
Dental/vision		826			494			821			488
Life insurance		1,756			1,606			1,663			1,526
Other		252			656			228			622
Total		$	134,041		$	145,078		$	132,451		$	141,463

Loss expense as a result of net premium ratio capping for the three-month periods ended March 31, 2023 and 2022 was immaterial.

Other Policyholders' Funds

As of March 31, 2023 and December 31, 2022, the largest component of the other policyholders' funds liability was the Company's annuity line of business in Aflac Japan. The Company's annuities have fixed benefits and premiums.

The following table presents the changes in other policyholders’ funds.


(In millions)	March 31, 2023		December 31, 2022
Other policyholders' funds:
Fixed annuities account balance, beginning of period (1)	$	6,423	$	7,410
Premiums received	39		150
Transfers from WAYS conversions	58		214
Surrenders and withdrawals	(14)		(52)
Benefit payments	(104)		(367)
Interest credited	14		57
Foreign currency translation and other	(40)		(989)
Fixed annuities account balance, end of period	6,376		6,423
Other deposit type reserves	292		220
Total	$	6,668	$	6,643

(1) Aflac Japan fixed annuities

The following table presents other policyholders’ funds balances by range of guaranteed crediting rates.

March 31, 2023

December 31, 2022

(In millions)

Range of Guaranteed Minimum Crediting Rates (2)

At Guaranteed Minimum

Cash Surrender Value

Range of Guaranteed Minimum Crediting Rates (2)

At Guaranteed Minimum

Cash Surrender Value

Fixed annuities (1)

0.5% - 2.3%

$6,376

$6,281

0.5% - 2.3%

$6,423

$6,326

(1) Aflac Japan fixed annuities

(2) Weighted-average crediting rate of 1.5% at March 31, 2023 and December 31, 2022, respectively.

Aflac Japan’s fixed annuities have guaranteed fixed crediting rates which results in the policyholders' funds balances being able to cover all guaranteed benefit amounts. The reserves are adequate to fully fund future benefits at any given time.

See Note 1 of the Notes to the Consolidated Financial Statements for additional information on policy liabilities.

8. REINSURANCE

The Company periodically enters into fixed quota-share coinsurance agreements ~~with other companies~~ in the normal course of business. For each of its reinsurance agreements, the Company determines whether the agreement provides indemnification against loss or liability relating to insurance risk in accordance with applicable accounting standards. Reinsurance premiums and benefits paid or provided are accounted for on bases consistent with those used in

accounting for the original policies issued and the terms of the reinsurance contracts. Premiums and benefits are reported net of insurance ceded.

In January 2023, ALIJ entered into a coinsurance transaction whereby it ceded 28% of the liabilities associated with certain cancer insurance policies and riders to Aflac Re. This transaction transferred approximately $2.1 billion of reserves associated with these policies. Approximately $1.9 billion of assets were transferred from ALIJ to Aflac Re as preliminary consideration for assuming the reinsurance risk, and final settlement is expected in the second quarter of 2023. This internal reinsurance transaction with Aflac Re has no financial statement impact on a consolidated basis, except for the effect of foreign currency accounting.

In January 2023, ALIJ also entered into an external coinsurance transaction to cede 1.5% of the liabilities associated with the same cancer insurance policies and riders, in connection with which ALIJ transferred cash consideration to the reinsurer.

The Company has recorded a deferred profit liability related to reinsurance transactions. The remaining deferred profit liability of ~~$793~~$682 million and ~~$859~~$692 million as of March 31, ~~2022~~2023 and December 31, ~~2021,~~2022, respectively, is included in future policy benefits in the consolidated balance sheet and is being amortized into income over the expected lives of the policies. The Company has also recorded a reinsurance recoverable for reinsurance transactions, which is included in other assets in the consolidated balance sheet and had a remaining balance of ~~$883 million~~$1.1 billion and ~~$937~~$912 million as of March 31, ~~2022~~2023 and December 31, ~~2021,~~2022, respectively. ~~The spot yen/dollar exchange rate weakened by approximately 6.0% and ceded reserves decreased approximately 5.7% from December 31, 2021 to March 31, 2022.~~

The following table reconciles direct premiums and direct benefits and claims to net amounts after the effect of reinsurance which also includes the elimination of inter-segment amounts associated with affiliated reinsurance.


		Three Months Ended March 31,						Three Months Ended March 31,
(In millions)	(In millions)		2022	2021			(In millions)					2023	2022
Direct earned premiums	Direct earned premiums				$	4,214			$	4,652	Direct earned premiums			$	3,738	$	4,115
Ceded to other companies:	Ceded to other companies:										Ceded to other companies:
Ceded Aflac Japan closed blocks	Ceded Aflac Japan closed blocks				(98)				(114)		Ceded Aflac Japan closed blocks			(82)		(98)
Other	Other				(19)				(19)		Other			(25)		(19)
Assumed from other companies:	Assumed from other companies:										Assumed from other companies:
Retrocession activities	Retrocession activities				41				48		Retrocession activities			34		41
Other	Other				40				26		Other			23		40
Net earned premiums	Net earned premiums				$	4,178			$	4,593	Net earned premiums			$	3,688	$	4,079

Direct benefits and claims					$	2,505			$	2,776
Direct benefits and claims, excluding reserve remeasurement											Direct benefits and claims, excluding reserve remeasurement			$	2,256	$	2,334
Reserve remeasurement (gains) losses											Reserve remeasurement (gains) losses			(53)		(34)
Total direct benefits and claims											Total direct benefits and claims			2,203		2,300
Ceded benefits and change in reserves for future benefits:	Ceded benefits and change in reserves for future benefits:										Ceded benefits and change in reserves for future benefits:
Ceded Aflac Japan closed blocks	Ceded Aflac Japan closed blocks				(91)				(99)		Ceded Aflac Japan closed blocks			(100)		(88)
Eliminations	Eliminations				6				8		Eliminations			14		5
Other	Other				(4)				(8)		Other			(18)		(5)
Assumed from other companies:	Assumed from other companies:										Assumed from other companies:
Retrocession activities	Retrocession activities				38				42		Retrocession activities			5		37
Eliminations	Eliminations				(6)				(8)		Eliminations			10		(5)
Other	Other				39				24		Other			36		239
Benefits and claims, net					$	2,487			$	2,735
Total benefits and claims, net											Total benefits and claims, net			$	2,150	$	2,483

Prior-year amounts have been adjusted for the adoption of accounting guidance on January 1, 2023 related to accounting for long-duration insurance contracts.

These reinsurance transactions are indemnity reinsurance that do not relieve the Company from its obligations to policyholders. In the event that the reinsurer is unable to meet their obligations, the Company remains liable for the reinsured claims.

As a part of its capital contingency plan, the Company entered into a committed reinsurance facility agreement on December 1, 2015, with reserves of approximately ¥120 billion as of March 31, ~~2022.~~2023. This reinsurance facility agreement was renewed in ~~2021~~2022 and is effective until December 31, ~~2022.~~2023. There are also additional commitment periods of a one-year duration, each of which are automatically extended unless notification is received from the reinsurer within 60 days prior to the expiration. The reinsurer can withdraw from the committed facility if Aflac's Standard and Poor's (S&P) rating drops below BBB-. As of March 31, ~~2022,~~2023, the Company has not executed a reinsurance treaty under this committed reinsurance facility.

9. NOTES PAYABLE AND LEASE OBLIGATIONS

A summary of notes payable and lease obligations follows:


(In millions)	(In millions)	March 31, 2022			December 31, 2021			(In millions)	March 31, 2023			December 31, 2022
3.625% senior notes due November 2024			$	748		$	748
3.25% senior notes due March 2025			448			448
1.125% senior sustainability notes due March 2026	1.125% senior sustainability notes due March 2026		397			397		1.125% senior sustainability notes due March 2026		$	398		$	397
2.875% senior notes due October 2026	2.875% senior notes due October 2026		298			298		2.875% senior notes due October 2026		298			298
3.60% senior notes due April 2030	3.60% senior notes due April 2030		992			991		3.60% senior notes due April 2030		992			992
6.90% senior notes due December 2039	6.90% senior notes due December 2039		221			221		6.90% senior notes due December 2039		221			221
6.45% senior notes due August 2040	6.45% senior notes due August 2040		255			255		6.45% senior notes due August 2040		254			254
4.00% senior notes due October 2046	4.00% senior notes due October 2046		394			394		4.00% senior notes due October 2046		394			394
4.750% senior notes due January 2049	4.750% senior notes due January 2049		541			541		4.750% senior notes due January 2049		542			541
Yen-denominated senior notes and subordinated debentures:	Yen-denominated senior notes and subordinated debentures:							Yen-denominated senior notes and subordinated debentures:
.300% senior notes due September 2025 (principal amount ¥12.4 billion)	.300% senior notes due September 2025 (principal amount ¥12.4 billion)		101			107		.300% senior notes due September 2025 (principal amount ¥12.4 billion)		93			93
.932% senior notes due January 2027 (principal amount ¥60.0 billion)	.932% senior notes due January 2027 (principal amount ¥60.0 billion)		489			520		.932% senior notes due January 2027 (principal amount ¥60.0 billion)		448			450
1.075% senior notes due September 2029 (principal amount ¥33.4 billion)								1.075% senior notes due September 2029 (principal amount ¥33.4 billion)		249			250
.500% senior notes due December 2029 (principal amount ¥12.6 billion)	.500% senior notes due December 2029 (principal amount ¥12.6 billion)		103			109		.500% senior notes due December 2029 (principal amount ¥12.6 billion)		94			95
.550% senior notes due March 2030 (principal amount ¥13.3 billion)	.550% senior notes due March 2030 (principal amount ¥13.3 billion)		108			115		.550% senior notes due March 2030 (principal amount ¥13.3 billion)		99			99
1.159% senior notes due October 2030 (principal amount ¥29.3 billion)	1.159% senior notes due October 2030 (principal amount ¥29.3 billion)		238			254		1.159% senior notes due October 2030 (principal amount ¥29.3 billion)		218			220
.633% senior notes due April 2031 (principal amount ¥30.0 billion)	.633% senior notes due April 2031 (principal amount ¥30.0 billion)		244			259		.633% senior notes due April 2031 (principal amount ¥30.0 billion)		224			225
.843% senior notes due December 2031 (principal amount ¥9.3 billion)	.843% senior notes due December 2031 (principal amount ¥9.3 billion)		76			81		.843% senior notes due December 2031 (principal amount ¥9.3 billion)		69			70
.750% senior notes due March 2032 (principal amount ¥20.7 billion)	.750% senior notes due March 2032 (principal amount ¥20.7 billion)		168			179		.750% senior notes due March 2032 (principal amount ¥20.7 billion)		154			155
1.320% senior notes due December 2032 (principal amount ¥21.1 billion)								1.320% senior notes due December 2032 (principal amount ¥21.1 billion)		157			158
.844% senior notes due April 2033 (principal amount ¥12.0 billion)	.844% senior notes due April 2033 (principal amount ¥12.0 billion)		97			104		.844% senior notes due April 2033 (principal amount ¥12.0 billion)		89			90
1.488% senior notes due October 2033 (principal amount ¥15.2 billion)	1.488% senior notes due October 2033 (principal amount ¥15.2 billion)		123			131		1.488% senior notes due October 2033 (principal amount ¥15.2 billion)		113			114
.934% senior notes due December 2034 (principal amount ¥9.8 billion)	.934% senior notes due December 2034 (principal amount ¥9.8 billion)		80			85		.934% senior notes due December 2034 (principal amount ¥9.8 billion)		73			73
.830% senior notes due March 2035 (principal amount ¥10.6 billion)	.830% senior notes due March 2035 (principal amount ¥10.6 billion)		86			91		.830% senior notes due March 2035 (principal amount ¥10.6 billion)		79			79
1.039% senior notes due April 2036 (principal amount ¥10.0 billion)	1.039% senior notes due April 2036 (principal amount ¥10.0 billion)		81			86		1.039% senior notes due April 2036 (principal amount ¥10.0 billion)		74			75
1.594% senior notes due September 2037 (principal amount ¥6.5 billion)								1.594% senior notes due September 2037 (principal amount ¥6.5 billion)		48			49
1.750% senior notes due October 2038 (principal amount ¥8.9 billion)	1.750% senior notes due October 2038 (principal amount ¥8.9 billion)		72			77		1.750% senior notes due October 2038 (principal amount ¥8.9 billion)		66			66
1.122% senior notes due December 2039 (principal amount ¥6.3 billion)	1.122% senior notes due December 2039 (principal amount ¥6.3 billion)		51			54		1.122% senior notes due December 2039 (principal amount ¥6.3 billion)		47			47
1.264% senior notes due April 2041 (principal amount ¥10.0 billion)	1.264% senior notes due April 2041 (principal amount ¥10.0 billion)		81			86		1.264% senior notes due April 2041 (principal amount ¥10.0 billion)		74			75
2.108% subordinated debentures due October 2047 (principal amount ¥60.0 billion)	2.108% subordinated debentures due October 2047 (principal amount ¥60.0 billion)		486			517		2.108% subordinated debentures due October 2047 (principal amount ¥60.0 billion)		445			448
.963% subordinated bonds due April 2049 (principal amount ¥30.0 billion)	.963% subordinated bonds due April 2049 (principal amount ¥30.0 billion)		244			260		.963% subordinated bonds due April 2049 (principal amount ¥30.0 billion)		224			226
1.560% senior notes due April 2051 (principal amount ¥20.0 billion)	1.560% senior notes due April 2051 (principal amount ¥20.0 billion)		162			172		1.560% senior notes due April 2051 (principal amount ¥20.0 billion)		148			149
2.144% senior notes due September 2052 (principal amount ¥12.0 billion)								2.144% senior notes due September 2052 (principal amount ¥12.0 billion)		89			90
Yen-denominated loans:	Yen-denominated loans:							Yen-denominated loans:
Variable interest rate loan due September 2026 (.42% in 2022 and .41% in 2021, principal amount ¥5.0 billion)			41			43
Variable interest rate loan due September 2029 (.57% in 2022 and .56% in 2021, principal amount ¥25.0 billion)			203			216
Finance lease obligations payable through 2028			10			12
Variable interest rate loan due August 2027 (.35% in 2023 and .33% in 2022, principal amount ¥11.7 billion)								Variable interest rate loan due August 2027 (.35% in 2023 and .33% in 2022, principal amount ¥11.7 billion)		87			88
Variable interest rate loan due August 2029 (.45% in 2023 and .43% in 2022, principal amount ¥25.3 billion)								Variable interest rate loan due August 2029 (.45% in 2023 and .43% in 2022, principal amount ¥25.3 billion)		188			190
Variable interest rate loan due August 2032 (.60% in 2023 and .58% in 2022, principal amount ¥70.0 billion)								Variable interest rate loan due August 2032 (.60% in 2023 and .58% in 2022, principal amount ¥70.0 billion)		522			524
Finance lease obligations payable through 2030								Finance lease obligations payable through 2030		8			8
Operating lease obligations payable through 2049	Operating lease obligations payable through 2049		130			105		Operating lease obligations payable through 2049		142			139
Total notes payable and lease obligations	Total notes payable and lease obligations		$	7,768		$	7,956	Total notes payable and lease obligations		$	7,420		$	7,442

Amounts in the table above are reported net of debt issuance costs and issuance premiums or discounts, if applicable, that are being amortized over the life of the notes.

5466

A summary of the Company's lines of credit as of March 31, ~~2022~~2023 follows:

Borrower(s)

Type

Term

Expiration Date

Capacity

Amount Outstanding

Interest Rate on Borrowed Amount

Maturity Period

Commitment Fee

Business Purpose

Aflac Incorporated
and Aflac

uncommitted bilateral

364 days

December ~~30, 2022~~28, 2023

$100 million

$0 million

The rate quoted by the bank and agreed upon at the time of borrowing

Up to 3 months

None

General corporate purposes

Aflac Incorporated

unsecured revolving

5 years

~~March 29,~~

~~2024,~~May 9,
2027, or the date commitments are terminated pursuant to an event of default

¥100.0 billion

¥0.0 billion

A rate per annum equal to (a) Tokyo ~~interbank market rate~~Interbank Market Rate (TIBOR) plus, the alternative applicable TIBOR margin during the availability period from the closing date to the commitment termination date or (b) the TIBOR rate offered by the agent to major banks in yen for the applicable period plus, the applicable alternative TIBOR margin during the term out period

No later than
~~March 29, 2024~~May 10, 2027

~~.30%~~.28% to ~~.50%~~.45%, depending on the Parent Company's debt ratings as of the date of determination

General corporate purposes, including a capital contingency plan for the operations of the Parent Company

Aflac Incorporated
and Aflac

unsecured revolving

5 years

November ~~18, 2024,~~15, 2027, or the date commitments are terminated pursuant to an event of default

$1.0 billion

$0.0 billion

A rate per annum equal to, at the
Company's option, either, (a) ~~USD London Interbank Offered~~Secured
Overnight Financing Rate ~~(LIBOR)~~(SOFR) for U.S.
dollar denominated borrowings or TIBOR
for Japanese yen denominated borrowings,
in either case adjusted for certain costs, or
(b) a base rate determined by reference to
the highest of (1) the federal funds rate
plus 1/2 of 1%, (2) the rate of interest for
such day announced by ~~Mizuho Bank, Ltd.~~the agent as its
prime rate, or (3) ~~the eurocurrency rate~~SOFR for an interest
period of one month plus 1.00%, in each
case plus an applicable margin

No later than November ~~18, 2024~~15, 2027

~~.085%~~.08% to

~~.225%~~.20%, depending on the Parent Company's debt ratings as of the date of determination

General corporate purposes, including a capital contingency plan for the operations of the Parent Company

Aflac Incorporated
and Aflac

uncommitted bilateral

None specified

$50 million

$0 million

A rate per annum equal to, at the Parent
Company's option, either (a) a rate
determined by reference to USD LIBOR for
the interest period relevant to such
borrowing or (b) the base rate determined
by reference to the highest of (a) the
lender's ~~U.S. dollar~~USD short-term commercial loan
rate, (b) the federal funds rate plus 1/2 of
1% and (c) USD one-month LIBOR plus
1%. USD LIBOR is subject to replacement
with ~~Secured Overnight Financing Rate (SOFR)~~SOFR under certain circumstances

Up to 3 months

None

General corporate purposes

Aflac(1)

uncommitted revolving

364 days

November 30, ~~2022~~2023

$250 million

$0 million

USD three-month LIBOR plus 75 basis points per annum

~~3 months~~No later than December 1, 2023

None

General corporate purposes

Aflac Incorporated(1)

(Tranche 1)

uncommitted revolving

364 days

November ~~25, 2022~~27, 2023

¥50.0 billion

¥0.0 billion

Three-month yen TIBOR plus 7045 basis points per annum

~~3 months~~No later than November 28, 2023

None

General corporate purposes

Aflac Incorporated(1)

(Tranche 2)

uncommitted revolving

364 days

November ~~25, 2022~~27, 2023

¥50.0 billion

¥0.0 billion

Three-month yen TIBOR plus 7045 basis points per annum

~~3 months~~No later than November 28, 2023

None

General corporate purposes

Aflac New York(1)

uncommitted revolving

364 days

April ~~8, 2022~~10, 2023(2)

$25 million

$0 million

USD three-month LIBOR plus 75 basis points per annum

~~3 months~~No later than
April 11, 2023

None

General corporate purposes

CAIC(1)

uncommitted revolving

364 days

March 21, ~~2023~~
2024

$15 million

$0 million

USD three-month LIBOR plus 75 basis points per annum

No later than
March 22, ~~2023~~2024

None

General corporate purposes

(1) Intercompany credit agreement

(2) Renewed in April ~~2022~~2023 with an expiration date of April ~~10, 2023~~8, 2024

(continued)

5567

~~(continued)~~

Borrower(s)

Type

Term

Expiration Date

Capacity

Amount Outstanding

Interest Rate on Borrowed Amount

Maturity Period

Commitment Fee

Business Purpose

Tier One Insurance Company(1)

uncommitted revolving

364 days

March 21, ~~2023~~
2024

$0.3 million

$0 million

USD three-month LIBOR plus 75 basis points per annum

No later than March 22, ~~2023~~2024

None

General corporate purposes

Aflac Ventures Japan K.K.(1)

uncommitted revolving

364 days

May 2, ~~2022~~
2023

¥500 million

¥~~350~~0 million

A rate per annum equal to the short-term prime lending rates of banks appearing on the website for the Bank of Japan on the first day of the applicable period

No later than
May ~~2, 2022~~3, 2023

None

General corporate purposes

Hatch Healthcare K.K.(1)

uncommitted revolving

364 days

January 3, ~~2023~~
2024

¥900 million

¥0 million

A rate per annum equal to the short-term prime lending rates of banks appearing on the website for the Bank of Japan on the first day of the applicable period

No later than January 4, ~~2023~~2024

None

General corporate purposes

Hatch Insight K.K.(1)

uncommitted revolving

364 days

January 3, ~~2023~~
2024

¥600 million

¥0 million

A rate per annum equal to the short-term prime lending rates of banks appearing on the website for the Bank of Japan on the first day of the applicable period

No later than January 4, ~~2023~~2024

None

General corporate purposes

Aflac GI Holdings LLC(1)

uncommitted revolving

364 days

July ~~18, 2022~~17,
2023

$30 million

$0 million

USD three-month LIBOR plus 75 basis points per annum

No later than July 18, ~~2022~~2023

None

General corporate purposes

Aflac Incorporated(1)

uncommitted revolving

364 days

January 2,
2024

$400 million

$0 million

A rate per annum equal to three-month term SOFR plus 10 basis points for U.S. dollar denominated borrowings or three-month TIBOR for Japanese yen denominated borrowings

No later than January 3, 2024

None

General corporate purposes

Aflac Re Bermuda Ltd.(1)

uncommitted revolving

364 days

January 2,
2024

$400 million

$0 million

A rate per annum equal to three-month term SOFR plus 10 basis points for U.S. dollar denominated borrowings or three-month TIBOR for Japanese yen denominated borrowings

No later than January 3, 2024

None

General corporate purposes

(1) Intercompany credit agreement

The Company was in compliance with all of the covenants of its notes payable and lines of credit at March 31, ~~2022.~~2023. No events of default or defaults occurred during the three-month period ended March 31, ~~2022.~~2023.

For additional information, see Notes 4 and 9 of the Notes to the Consolidated Financial Statements in the ~~2021~~2022 Annual Report.

5668

9.10. SHAREHOLDERS’ EQUITY

The following table is a reconciliation of the number of shares of the Company's common stock for the three-month periods ended March 31.


(In thousands of shares)	(In thousands of shares)	2022	2021	(In thousands of shares)	2023	2022
Common stock - issued:	Common stock - issued:			Common stock - issued:
Balance, beginning of period	Balance, beginning of period	1,352,739	1,351,018	Balance, beginning of period	1,354,079	1,352,739
Exercise of stock options and issuance of restricted shares	Exercise of stock options and issuance of restricted shares	1,041	1,261	Exercise of stock options and issuance of restricted shares	933	1,041
Balance, end of period	Balance, end of period	1,353,780	1,352,279	Balance, end of period	1,355,012	1,353,780
Treasury stock:	Treasury stock:			Treasury stock:
Balance, beginning of period	Balance, beginning of period	700,607	658,564	Balance, beginning of period	738,823	700,607
Purchases of treasury stock:	Purchases of treasury stock:			Purchases of treasury stock:
Share repurchase program	Share repurchase program	8,007	13,440	Share repurchase program	10,348	8,007
Other	Other	343	378	Other	347	343
Dispositions of treasury stock:	Dispositions of treasury stock:			Dispositions of treasury stock:
Shares issued to AFL Stock Plan	Shares issued to AFL Stock Plan	(259)	(387)	Shares issued to AFL Stock Plan	(239)	(259)
Exercise of stock options	Exercise of stock options	(58)	(211)	Exercise of stock options	(48)	(58)
Other	Other	(209)	(212)	Other	(171)	(209)
Balance, end of period	Balance, end of period	708,431	671,572	Balance, end of period	749,060	708,431
Shares outstanding, end of period	Shares outstanding, end of period	645,349	680,707	Shares outstanding, end of period	605,952	645,349

Outstanding share-based awards are excluded from the calculation of weighted-average shares used in the computation of basic earnings per share (EPS). The following table presents the approximate number of share-based awards to purchase shares, on a weighted-average basis, that were considered to be anti-dilutive and were excluded from the calculation of diluted EPS for the following periods.


		Three Months Ended March 31,				Three Months Ended March 31,
(In thousands)	(In thousands)		2022	2021			(In thousands)		2023		2022
Anti-dilutive share-based awards	Anti-dilutive share-based awards				249			1		Anti-dilutive share-based awards		164	249

Share Repurchase Program

During the first three months of 2023, the Company repurchased 10.3 million shares of its common stock for $700 million as part of its share repurchase program. During the first three months of 2022, the Company repurchased 8.0 million shares of its common stock for $500 million as part of its share repurchase program. ~~During the first three months of 2021, the Company repurchased 13.4 million shares of its common stock for $650 million as part of its share repurchase program.~~ As of March 31, ~~2022,~~2023, a remaining balance of ~~47.8~~106.3 million shares of the Company's common stock was available for purchase under share repurchase authorizations by its board of directors.

Reclassifications from Accumulated Other Comprehensive Income

The tables below are reconciliations of accumulated other comprehensive income by component for the following periods.

Changes in Accumulated Other Comprehensive Income


Three Months Ended March 31, 2023
(In millions)	Unrealized Foreign Currency Translation Gains (Losses)			Unrealized Gains (Losses) on Fixed Maturity Securities			Unrealized Gains (Losses) on Derivatives			Effect of Changes in Discount Rate Assumptions			Pension Liability Adjustment			Total
Balance at December 31, 2022		$	(3,564)		$	(702)		$	(27)		$	(2,100)		$	(36)		$	(6,429)


Other comprehensive income (loss) before reclassification		(54)			2,036			0			(2,794)			7			(805)
Amounts reclassified from accumulated other comprehensive income (loss)		0			(45)			1			0			0			(44)
Net current-period other comprehensive income (loss)		(54)			1,991			1			(2,794)			7			(849)
Balance at March 31, 2023		$	(3,618)		$	1,289		$	(26)		$	(4,894)		$	(29)		$	(7,278)

All amounts in the table above are net of tax.

Prior-year amounts have been adjusted for the adoption of accounting guidance on January 1, 2023 related to accounting for long-duration insurance contracts.

~~Changes in Accumulated Other Comprehensive Income~~


Three Months Ended March 31, 2022	Three Months Ended March 31, 2022																Three Months Ended March 31, 2022
(In millions)	(In millions)	Unrealized Foreign Currency Translation Gains (Losses)			Unrealized Gains (Losses) on Fixed Maturity Securities			Unrealized Gains (Losses) on Derivatives			Pension Liability Adjustment			Total			(In millions)	Unrealized Foreign Currency Translation Gains (Losses)			Unrealized Gains (Losses) on Fixed Maturity Securities			Unrealized Gains (Losses) on Derivatives			Effect of Changes in Discount Rate Assumptions			Pension Liability Adjustment			Total
Balance at December 31, 2021	Balance at December 31, 2021		$	(2,013)		$	9,602		$	(30)		$	(166)		$	7,393	Balance at December 31, 2021		$	(1,985)		$	9,602		$	(30)		$	(15,832)		$	(166)		$	(8,411)

Other comprehensive income (loss) before reclassification	Other comprehensive income (loss) before reclassification		(469)			(3,754)			0			(2)			(4,225)		Other comprehensive income (loss) before reclassification		(453)			(3,754)			0			4,224			(2)			15
Amounts reclassified from accumulated other comprehensive income (loss)	Amounts reclassified from accumulated other comprehensive income (loss)		0			(61)			1			5			(55)		Amounts reclassified from accumulated other comprehensive income (loss)		0			(61)			1			0			5			(55)
Net current-period other comprehensive income (loss)	Net current-period other comprehensive income (loss)		(469)			(3,815)			1			3			(4,280)		Net current-period other comprehensive income (loss)		(453)			(3,815)			1			4,224			3			(40)
Balance at March 31, 2022	Balance at March 31, 2022		$	(2,482)		$	5,787		$	(29)		$	(163)		$	3,113	Balance at March 31, 2022		$	(2,438)		$	5,787		$	(29)		$	(11,608)		$	(163)		$	(8,451)

All amounts in the table above are net of tax.

Prior-year amounts have been adjusted for the adoption of accounting guidance on January 1, 2023 related to accounting for long-duration insurance contracts.

Three Months Ended
March 31, 2021
(In millions) Unrealized Foreign
Currency Translation
Gains (Losses) Unrealized
Gains (Losses)
on Fixed Maturity Securities Unrealized
Gains (Losses)
on Derivatives Pension Liability Adjustment Total
Balance at December 31, 2020 $ (1,109) $ 10,361 $ (34) $ (284) $ 8,934
Other comprehensive
   income (loss) before
   reclassification (565) (1,583) 1 (4) (2,151)
Amounts reclassified from
   accumulated other
   comprehensive income
  (loss) 0 16 0 8 24
Net current-period other
   comprehensive
   income (loss) (565) (1,567) 1 4 (2,127)
Balance at March 31, 2021 $ (1,674) $ 8,794 $ (33) $ (280) $ 6,807

~~All amounts in the table above are net of tax.~~

The tables below summarize the amounts reclassified from each component of accumulated other comprehensive income into net earnings for the following periods.

Reclassifications Out of Accumulated Other Comprehensive Income

~~Reclassifications Out of Accumulated Other Comprehensive Income~~

(In millions)

Three Months Ended

March 31, ~~2022~~2023

Details about Accumulated Other Comprehensive Income Components

Amount Reclassified from Accumulated Other Comprehensive Income

Affected Line Item in the
Statements of Earnings

Unrealized gains (losses) on available-for-sale
securities

7757

Net investment gains (losses)

~~(16)~~(12)

Tax (expense) or benefit(1)

6145

Net of tax

Unrealized gains (losses) on derivatives

(1)

Net investment gains (losses)

Tax (expense) or benefit(1)

(1)

Net of tax

Amortization of defined benefit pension items:

Actuarial gains (losses)

~~(6)~~0

Acquisition and operating expenses(2)

Prior service (cost) credit

Acquisition and operating expenses(2)

Tax (expense) or benefit(1)

~~(5)~~0

Net of tax

Total reclassifications for the period

5544

Net of tax

(1) Based on 21% tax rate

(2) These accumulated other comprehensive income components are included in the computation of net periodic ~~pension~~benefit cost (see Note 1112 for additional details).

(In millions)

Three Months Ended

March 31, ~~2021~~2022

Details about Accumulated Other Comprehensive Income Components

Amount Reclassified from Accumulated Other Comprehensive Income

Affected Line Item in the
Statements of Earnings

Unrealized gains (losses) on available-for-sale
securities

~~(20)~~77

Net investment gains (losses)

4 (16)

Tax (expense) or benefit(1)

~~(16)~~61

Net of tax

Unrealized gains (losses) on derivatives

(1)

Net investment gains (losses)

Tax (expense) or benefit(1)

(1)

Net of tax

Amortization of defined benefit pension items:

Actuarial gains (losses)

~~(10)~~(6)

Acquisition and operating expenses(2)

Prior service (cost) credit

Acquisition and operating expenses(2)

Tax (expense) or benefit(1)

~~(8)~~(5)

Net of tax

Total reclassifications for the period

~~(24)~~55

Net of tax

(1) Based on 21% tax rate

(2) These accumulated other comprehensive income components are included in the computation of net periodic ~~pension~~benefit cost (see Note 1112 for additional details).

~~10.~~

11. SHARE-BASED COMPENSATION

As of March 31, ~~2022,~~2023, the Company has outstanding share-based awards under the Aflac Incorporated Long-Term Incentive Plan (As Amended and Restated February 14, 2017), as further amended on August 9, 2022 (the Plan). Share-based awards are designed to reward employees for their long-term contributions to the Company and provide incentives for them to remain with the Company. The number and frequency of share-based awards are based on competitive practices, operating results of the Company, government regulations, and other factors.

The Plan, ~~as amended on February 14, 2017,~~ allows for a maximum number of shares issuable over its term of 75 million shares including 38 million shares that may be awarded in respect of awards other than options or stock appreciation rights. If any awards granted under the Plan are forfeited or are terminated before being exercised or settled for any reason other than tax forfeiture, then the shares underlying the awards will again be available under the Plan.

The Plan allows awards to Company employees for incentive stock options (ISOs), non-qualifying stock options (NQSOs), restricted stock, restricted stock units, and stock appreciation rights. Non-employee directors are eligible for grants of NQSOs, restricted stock, and stock appreciation rights. As of March 31, ~~2022,~~2023, approximately ~~35.8~~34.8 million shares were available for future grants under this plan. The ISOs and NQSOs have a term of 10 years, and the share-based awards generally vest upon time-based conditions or time and performance-based conditions. Time-based vesting generally occurs after three years. Performance-based vesting conditions generally include the attainment of goals related to Company financial performance. As of March 31, ~~2022,~~2023, the only performance-based awards issued and outstanding were restricted stock awards and units.

Stock options and stock appreciation rights granted under the amended Plan have an exercise price of at least the fair market value of the underlying stock on the grant date and have an expiration date no later than 10 years from the grant date. Time-based restricted stock awards, restricted stock units and stock options granted after January 1, 2017 generally vest on a ratable basis over three years, and awards granted prior to the amendment vest on a cliff basis over three years. The Compensation Committee of the Board of Directors has the discretion to determine vesting schedules.

Share-based awards granted to U.S.-based grantees are settled with authorized but unissued Company stock, while those issued to Japan-based grantees are settled with treasury shares.

The following table provides information on stock options outstanding and exercisable at March 31, ~~2022.~~2023.


		Stock Option Shares (in thousands)		Weighted-Average Remaining Term (in years)		Aggregate Intrinsic Value (in millions)			Weighted-Average Exercise Price Per Share				Stock Option Shares (in thousands)		Weighted-Average Remaining Term (in years)		Aggregate Intrinsic Value (in millions)			Weighted-Average Exercise Price Per Share
Outstanding	Outstanding		1,843		3.3		$	61		$	31.48	Outstanding		1,414		2.8		$	45		$	32.56
Exercisable	Exercisable		1,843		3.3		61			31.48		Exercisable		1,414		2.8		45			32.56

The Company received cash from the exercise of stock options in the amount of $8$4 million during the first three months of ~~2022,~~2023, compared with ~~$15~~$8 million in the first three months of ~~2021.~~2022. The tax benefit realized as a result of stock option exercises and restricted stock releases was $17 million in the first three months of 2023, compared with $16 million in the first three months of ~~2022, compared with $14 million in the first three months of 2021.~~2022.

As of March 31, ~~2022,~~2023, total compensation cost not yet recognized in the Company's consolidated financial statements related to restricted stock awards and units was ~~$76~~$75 million, of which $43 million (1.8 million shares) was related to restricted stock awards and units with a performance-based vesting condition. The Company expects to recognize these amounts over a weighted-average period of approximately 1.9 years. There are no other contractual terms covering restricted stock awards once vested.

The following table summarizes restricted stock activity during the three-month period ended March 31, ~~2022.~~2023.

(In thousands of shares) Shares Weighted-Average
Grant-Date Fair Value
Per Share
Restricted stock at December 31, 2021 2,557 $ 49.38
Granted in 2022 978 67.67
Canceled in 2022 (20) 50.73
Vested in 2022 (1,064) 49.49
Restricted stock at March 31, 2022 2,451 $ 55.91


(In thousands of shares)	Shares	Weighted-Average Grant-Date Fair Value Per Share
Restricted stock at December 31, 2022	2,414		$	56.21
Granted in 2023	1,066		70.52
Canceled in 2023	(41)		57.33
Vested in 2023	(1,080)		52.66
Restricted stock at March 31, 2023	2,359		$	62.34

In February ~~2022,~~2023, the Company granted ~~390~~454 thousand performance-based stock awards and units, which are contingent on the achievement of the Company's financial performance metrics and its market-based conditions. On the date of grant, the Company estimated the fair value of restricted stock awards and units with market-based conditions using a Monte Carlo simulation model. The model discounts the value of the stock at the assumed vesting date based on the risk-free interest rate. Based on estimates of actual performance versus the vesting thresholds, the calculated fair value percentage pay-out estimate will be updated each quarter.

The Company uses third-party analyses to assist in developing the assumptions used in, as well as calibrating, a Monte Carlo simulation model. The Company is responsible for determining the assumptions used in estimating the fair value of its share-based payment awards.

For additional information on the Company's long-term share-based compensation plans and the types of share-based awards, see Note 12 of the Notes to the Consolidated Financial Statements included in the ~~2021~~2022 Annual Report.

~~11.~~12. BENEFIT PLANS

The Company has funded defined benefit plans in Japan and the U.S., however the U.S. plan was frozen to new participants effective October 1, 2013. The Company also maintains non-qualified, unfunded supplemental retirement plans that provide defined pension benefits in excess of limits imposed by federal tax law for certain Japanese, U.S. and former employees, however the U.S. plan was frozen to new participants effective January 1, 2015. U.S. employees who are not participants in the defined benefit plan receive a nonelective 401(k) employer contribution.

The Company provides certain health care benefits for eligible U.S. retired employees, their beneficiaries and covered dependents (other postretirement benefits). The health care plan is contributory and unfunded. Effective January 1, 2014, employees eligible for benefits included the following: (1) active employees whose age plus service, in years, equaled or exceeded 80 (rule of 80); (2) active employees who were age 55 or older and have met the 15 years of service requirement; (3) active employees who would meet the rule of 80 in the next five years; (4) active employees who were age 55 or older and who would meet the 15 years of service requirement within the next five years; and (5) current retirees. For certain employees and former employees, additional coverage is provided for all medical expenses for life.

Pension and other postretirement benefit expenses are included in acquisition and operating expenses in the consolidated statements of earnings, which includes other components of net periodic pension cost and postretirement costs (other than service costs) of $4$2 million and $7$4 million for the three-month periods ended March 31, ~~2022~~2023 and ~~2021,~~2022, respectively. Total net periodic benefit cost includes the following components:


		Three Months Ended March 31,																		Three Months Ended March 31,
		Pension Benefits												Other							Pension Benefits												Other
		Japan						U.S.						Postretirement Benefits							Japan						U.S.						Postretirement Benefits
(In millions)	(In millions)	2022			2021			2022			2021			2022			2021			(In millions)	2023			2022			2023			2022			2023			2022
Components of net periodic benefit cost:	Components of net periodic benefit cost:																			Components of net periodic benefit cost:
Service cost	Service cost		$	5		$	6		$	6		$	7		$	0		$	0	Service cost		$	4		$	5		$	4		$	6		$	0		$	0
Interest cost	Interest cost		2			1			9			8			0			0		Interest cost		2			2			11			9			0			0
Expected return on plan assets	Expected return on plan assets		(2)			(2)			(11)			(10)			0			0		Expected return on plan assets		(2)			(2)			(9)			(11)			0			0
Amortization of net actuarial loss	Amortization of net actuarial loss		0			1			5			8			1			1		Amortization of net actuarial loss		0			0			0			5			0			1

Net periodic (benefit) cost	Net periodic (benefit) cost		$	5		$	6		$	9		$	13		$	1		$	1	Net periodic (benefit) cost		$	4		$	5		$	6		$	9		$	0		$	1

During the three months ended March 31, ~~2022,~~2023, Aflac Japan contributed approximately $9$6 million (using the weighted-average yen/dollar exchange rate for the three-month period ended March 31, ~~2022)~~2023) to the Japanese funded defined benefit plan, and Aflac U.S. did not make a contribution to the U.S. funded defined benefit plan.

For additional information regarding the Company's Japanese and U.S. benefit plans, see Note 14 of the Notes to the Consolidated Financial Statements in the ~~2021~~2022 Annual Report.

~~12.~~13. COMMITMENTS AND CONTINGENT LIABILITIES

~~Effective for 2022,~~In February 2023, the Company renewed an outsourcing agreement with ~~an information~~a management consulting and technology ~~and data~~ services company to provide application maintenance and development services for Aflac Japan. As of March 31, ~~2022,~~2023, the agreement has a remaining term of ~~four~~five years and an aggregate remaining cost of ~~¥8.0~~¥20.9 billion ($65157 million using the March 31, ~~2022~~2023 exchange rate).

The Company is a defendant in various lawsuits and receives various regulatory inquiries considered to be in the normal course of business. Members of the Company's senior legal and financial management teams review litigation and regulatory inquiries on a quarterly and annual basis. The final results of any litigation or regulatory inquiries cannot be predicted with certainty. Although some of this litigation is pending in states where large punitive damages, bearing little relation to the actual damages sustained by plaintiffs, have been awarded in recent years, the Company believes the outcome of pending litigation will not have a material adverse effect on its financial position, results of operations, or cash flows.

See Note 3 of the Notes to the Consolidated Financial Statements for details on certain investment commitments.

Guaranty Fund Assessments

The U.S. insurance industry has a policyholder protection system that is monitored and regulated by state insurance departments. These life and health insurance guaranty associations are state entities (in all 50 states as well as Puerto Rico and the District of Columbia) created to protect policyholders of an insolvent insurance company. All insurance companies (with limited exceptions) licensed to sell life or health insurance in a state must be members of that state’s guaranty association. Under state guaranty association laws, certain insurance companies can be assessed (up to prescribed limits) for certain obligations to the policyholders and claimants of impaired or insolvent insurance companies that write the same line or similar lines of business.

In 2009, the Pennsylvania Insurance Commissioner placed long-term care insurer Penn Treaty Network America Insurance Company and its subsidiary American Network Insurance Company (collectively referred to as Penn Treaty), neither of which is affiliated with Aflac, in rehabilitation and petitioned a state court for approval to liquidate Penn Treaty. A final order of liquidation was granted by a recognized judicial authority on March 1, 2017, and as a result, Penn Treaty is in the process of liquidation. The Company estimated and recognized the impact of its share of guaranty fund assessments resulting from the liquidation using a discounted rate of 4.25%. The Company recognized a discounted liability for the assessments of $62 million (undiscounted $94 million), offset by discounted premium tax credits of $48 million (undiscounted $74 million), for a net $14 million impact to net income in the quarter ended March 31, 2017. The Company paid a majority of these assessments by March 31, 2022. The Company used the cost estimate provided as of the liquidation date by the National Organization of Life and Health Guaranty Associations (NOLHGA) to calculate its estimated assessments and tax credits.

Guaranty fund assessments for the three-month periods ended March 31, ~~2022~~2023 and ~~2021~~2022 were immaterial.

6274

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations (MD&A)

FORWARD-LOOKING INFORMATION

The Private Securities Litigation Reform Act of 1995 provides a safe harbor to encourage companies to provide prospective information, so long as those informational statements are identified as forward-looking and are accompanied by meaningful cautionary statements identifying important factors that could cause actual results to differ materially from those included in the forward-looking statements. Aflac Incorporated (the Parent Company) and its subsidiaries (collectively with the Parent Company, the Company) desire to take advantage of these provisions. This report contains cautionary statements identifying important factors that could cause actual results to differ materially from those projected herein, and in any other statements made by Company officials in communications with the financial community and contained in documents filed with the Securities and Exchange Commission (SEC). Forward-looking statements are not based on historical information and relate to future operations, strategies, financial results or other developments. Furthermore, forward-looking information is subject to numerous assumptions, risks and uncertainties. In particular, statements containing words such as the ones listed below or similar words, as well as specific projections of future results, generally qualify as forward-looking. The Company undertakes no obligation to update such forward-looking statements.

• expect

• anticipate

• believe

• goal

• objective

• may

• should

• estimate

• intends

• projects

• will

• assumes

• potential

• target

• outlook

The Company cautions readers that the following factors, in addition to other factors mentioned from time to time, could cause actual results to differ materially from those contemplated by the forward-looking statements:

•difficult conditions in global capital markets and the economy, including ~~those~~inflation and the continued effects caused by COVID-19

•defaults and credit downgrades of investments

•global fluctuations in interest rates and exposure to significant interest rate risk

•concentration of business in Japan

•limited availability of acceptable yen-denominated investments

•foreign currency fluctuations in the yen/dollar exchange rate

•differing ~~judgments~~interpretations applied to investment valuations

•significant valuation judgments in determination of expected credit losses recorded on the Company's investments

•decreases in the Company's financial strength or debt ratings

•decline in creditworthiness of other financial institutions

•concentration of the Company's investments in any particular single-issuer or sector

•~~the effects of~~major public health issues, including COVID-19 ~~and its variants (both known and emerging),~~ and any resulting or coincidental economic effects, ~~and government interventions,~~ on the Company's business and financial results

•the Company's ability to attract and retain qualified sales associates, brokers, employees, and distribution partners

•deviations in actual experience from pricing and reserving assumptions

•ability to continue to develop and implement improvements in information technology systems and on successful execution of revenue growth and expense management initiatives

•interruption in telecommunication, information technology and other operational systems, or a failure to maintain the security, confidentiality or privacy of sensitive data residing on such systems

•subsidiaries' ability to pay dividends to the Parent Company

•inherent limitations to risk management policies and procedures

•operational risks of third party vendors

•tax rates applicable to the Company may change

•failure to comply with restrictions on policyholder privacy and information security

•extensive regulation and changes in law or regulation by governmental authorities

•competitive environment and ability to anticipate and respond to market trends

•catastrophic events, including, but not limited to, as a result of climate change, epidemics, pandemics (such as ~~the coronavirus~~ COVID-19), tornadoes, hurricanes, earthquakes, tsunamis, war or other military action, terrorism or other acts of violence, and damage incidental to such events

•ability to protect the Aflac brand and the Company's reputation

•ability to effectively manage key executive succession

•changes in accounting standards

•level and outcome of litigation

•allegations or determinations of worker misclassification in the United States

6375

MD&A OVERVIEW

MD&A is intended to inform the reader about matters affecting the financial condition and results of operations of Aflac Incorporated and its subsidiaries for the three-month periods ended March 31, ~~2022~~2023 and ~~2021,~~2022, respectively. Results of operations for interim periods are not necessarily indicative of results for the entire year. As a result, the following discussion should be read in conjunction with the consolidated financial statements and notes that are included in the Company's annual report on Form 10-K for the year ended December 31, ~~2021 (2021~~2022 (2022 Annual Report). In this MD&A, amounts may not foot due to rounding.

This MD&A is divided into the following sections:

6476

EXECUTIVE SUMMARY

Company Overview

Aflac Incorporated (the Parent Company) and its subsidiaries (collectively, the Company) provide financial protection to ~~more than 50 million people worldwide.~~millions of policyholders and customers in Japan and the U.S. The Company’s principal business is supplemental health and life insurance products with the goal to provide customers the best value in supplemental insurance products in the United States (U.S.) and Japan. The Company's insurance business consists of two reporting segments: Aflac Japan and Aflac U.S. The Parent Company’s primary insurance subsidiaries are Aflac Life Insurance Japan Ltd. in Japan (Aflac Japan) and American Family Life Assurance Company of Columbus (Aflac); Continental American Insurance Company (CAIC), branded as Aflac Group Insurance (AGI); American Family Life Assurance Company of New York (Aflac New York); Tier One Insurance Company (TOIC) and ~~Argus Dental & Vision,~~Aflac Benefits Solutions, Inc. ~~(Argus)~~(ABS), which provides a platform for Aflac Dental and Vision in the U.S. (collectively, Aflac U.S.). The Parent Company, other operating business units that are not individually reportable, and business activities, including reinsurance activities, not included in Aflac Japan or Aflac U.S. are included in Corporate and other.

~~Market Conditions~~

~~The impact of the Coronavirus Disease 2019 (COVID-19) global pandemic on~~In 2022, the Company ~~continues~~established Aflac Re Bermuda Ltd. (Aflac Re), a Bermuda domiciled insurer that reinsures certain policies issued by ALIJ. Aflac Re is subject to ~~evolve~~regulation in Bermuda, where the Bermuda Monetary Authority (BMA) has broad administrative powers relating to granting and revoking licenses to transact reinsurance business, approval of specific reinsurance transactions, capital requirements and solvency standards, limitations on dividends to shareholders, the nature of and limitations on investments, and the ~~continued path~~filing of ~~the global economic recovery remains uncertain given the potential longer term impacts of the pandemic. For example, economic conditions have acted as headwinds to sales~~financial statements in ~~the first quarter of 2022, particularly~~accordance with prescribed or permitted accounting practices. Financial results from Aflac Re are included in ~~Japan, pressuring premium growth rates. Further, in the U.S., supply shortages, upward pressure on wages to attract employees~~Corporate and higher commodity prices have all driven near-term increases in inflation. Central bank and government efforts to control inflation, as well the impacts of the Russia-Ukraine conflict, including volatility in energy prices and additional disruptions in the global supply chain, could lead to slower economic growth in Japan and the U.S. Additionally, rising energy prices, along with increased widening of the differential between U.S. and Japan interest rates, have contributed to a weakening of the yen, which has the effect of suppressing the Company's current period results in relation to the comparable prior period.

In the first quarter of 2022, sales for Aflac Japan in yen terms decreased 14.8%, compared to the first quarter of 2021, reflecting ongoing pandemic conditions and a first quarter of 2021 that included the launch of a new medical product. In the first quarter of 2022, sales for Aflac U.S. increased 19.0%, compared to the first quarter of 2021, reflecting continued improvement in pandemic conditions in the U.S. and investment in growth initiatives.

other.

Performance Highlights

Total revenues were ~~$5.3~~$4.8 billion in the first ~~quarter~~three months of ~~2022,~~2023, compared with ~~$5.9~~$5.2 billion in the first ~~quarter~~three months of ~~2021.~~2022. Net earnings were ~~$1.0~~$1.2 billion, or ~~$1.58~~$1.94 per diluted share in the first ~~quarter~~three months of ~~2022,~~2023, compared with ~~$1.3~~$1.0 billion, or ~~$1.87~~$1.60 per diluted share, in the first ~~quarter~~three months of ~~2021.~~

2022.

Results in the first quarter of ~~2022~~2023 included pretax net investment gains of ~~$122~~$123 million, compared with pretax net investment gains of ~~$307~~$122 million in the first ~~quarter~~three months of ~~2021.~~2022. Net investment gains in the first ~~quarter~~three months of ~~2022~~2023 included ~~a decrease~~an increase in credit loss allowances of ~~$25~~$30 million; ~~$167~~$99 million of net gains from certain derivative and foreign currency gains or losses; ~~$156~~$3 million of net losses on equity securities; and ~~$86~~$57 million of net gains from sales and redemptions.

The average yen/dollar exchange rate(1) for the three-month period ended March 31, ~~2022~~2023 was ~~116.18,~~132.30, or ~~8.9%~~12.2% weaker than the average yen/dollar exchange rate(1) of ~~105.88~~116.18 for the same period in ~~2021.~~

2022.

Adjusted earnings(2) in the first quarter of ~~2022~~2023 were ~~$927 million,~~$1.0 billion, or ~~$1.42~~$1.55 per diluted share, compared with ~~$1.1 billion,~~$942 million, or ~~$1.53~~$1.44 per diluted share, in the first quarter of ~~2021.~~2022. The weaker yen/dollar exchange rate negatively impacted adjusted earnings per diluted share by ~~$.06.~~

$.07.

Total investments and cash at March 31, ~~2022~~2023 were ~~$132.6~~$120.5 billion, compared with ~~$143.0~~$117.4 billion at December 31, ~~2021.~~2022. In the first quarter of ~~2022,~~2023, Aflac Incorporated repurchased ~~$500~~$700 million, or ~~8.0~~10.3 million of its common shares. At March 31, ~~2022,~~2023, the Company had ~~47.8~~106.3 million remaining shares authorized for repurchase.

Shareholders’ equity was ~~$29.5~~$19.8 billion, or ~~$45.75~~$32.65 per share, at March 31, ~~2022,~~2023, compared with ~~$33.3~~$20.1 billion, or ~~$50.99~~$32.73 per share, at December 31, ~~2021.~~2022. Shareholders’ equity at March 31, 2023 included a cumulative decrease of $4.9 billion from the effect of changes in discount rate assumptions on insurance contracts, driven by the adoption of the new accounting guidance for long-duration insurance contracts, compared with a corresponding cumulative decrease of $2.1 billion at December 31, 2022, ~~included~~and a net unrealized gain on investment securities and derivatives of ~~$5.8~~$1.3 billion, compared with a net unrealized ~~gain~~loss of ~~$9.6 billion~~$729 million at December 31, ~~2021.~~2022. Shareholders’ equity at March 31, ~~2022~~2023 also included an unrealized foreign currency translation loss of ~~$2.5~~$3.6 billion, compared with an unrealized foreign currency translation loss of ~~$2.0~~$3.6 billion at December 31, ~~2021.~~2022. The annualized return on average shareholders’ equity in the first quarter of ~~2022~~2023 was ~~13.2%~~23.8%.

Shareholders’ equity excluding accumulated other comprehensive income (AOCI)(2) (adjusted book value) was ~~$26.4~~$27.1 billion, or ~~$40.93~~$44.66 per share at March 31, ~~2022,~~2023, compared with ~~$25.9~~$26.6 billion, or ~~$39.65~~$43.18 per share, at December 31, ~~2021.~~2022. The annualized adjusted return on equity (ROE) excluding foreign currency impact(2) in the first quarter of ~~2022~~2023 was ~~14.7%~~14.8%.

(1) Yen/U.S. dollar exchange rates are based on the published MUFG Bank, Ltd. telegraphic transfer middle rate (TTM).

(2) See the Results of Operations section of this MD&A for a definition of this non-U.S. GAAP financial measure.

RESULTS OF OPERATIONS

The Company earns its revenues principally from insurance premiums and investments. The Company’s operating expenses primarily consist of insurance benefits provided and reserves established for anticipated future insurance benefits, general business expenses, commissions and other costs of selling and servicing its products. Profitability for the Company depends principally on its ability to price its insurance products at a level that enables the Company to earn a margin over the costs associated with providing benefits and administering those products. Profitability also depends on, among other items, actuarial and policyholder behavior experience on insurance products, and the Company's ability to attract and retain customer assets, generate and maintain favorable investment results, effectively deploy capital and utilize tax capacity, and manage expenses.

This document includes references to the Company’s financial performance measures which are not calculated in accordance with United States generally accepted accounting principles (U.S. GAAP) (non-U.S. GAAP). The financial measures exclude items that the Company believes may obscure the underlying fundamentals and trends in insurance operations because they tend to be driven by general economic conditions and events or related to infrequent activities not directly associated with insurance operations.

Due to the size of Aflac Japan, where the functional currency is the Japanese yen, fluctuations in the yen/dollar exchange rate can have a significant effect on reported results. In periods when the yen weakens, translating yen into dollars results in fewer dollars being reported. When the yen strengthens, translating yen into dollars results in more dollars being reported. Consequently, yen weakening has the effect of suppressing current period results in relation to the comparable prior period, while yen strengthening has the effect of magnifying current period results in relation to the comparable prior period. A significant portion of the Company’s business is conducted in yen and never converted into dollars but translated into dollars for U.S. GAAP reporting purposes, which results in foreign currency impact to earnings, cash flows and book value on a U.S. GAAP basis. Management evaluates the Company's financial performance both including and excluding the impact of foreign currency translation to monitor, respectively, cumulative currency impacts and the currency-neutral operating performance over time. The average yen/dollar exchange rate is based on the published MUFG Bank, Ltd. telegraphic transfer middle rate (TTM).

The Company defines the non-U.S. GAAP financial measures included in this document as follows:

•Adjusted earnings are adjusted revenues less benefits and adjusted expenses. Adjusted earnings per share (basic or diluted) are the adjusted earnings for the period divided by the weighted average outstanding shares (basic or diluted) for the period presented. The adjustments to both revenues and expenses account for certain items that cannot be predicted or that are outside management’s control. Adjusted revenues are U.S. GAAP total revenues excluding adjusted net investment gains and losses. Adjusted expenses are U.S. GAAP total acquisition and operating expenses including the impact of interest cash flows from derivatives associated with notes payable but excluding any nonrecurring or other items not associated with the normal course of the Company’s insurance operations and that do not reflect the Company's underlying business performance. Management uses adjusted earnings and adjusted earnings per diluted share to evaluate the financial performance of the Company’s insurance operations on a consolidated basis and believes that a presentation of these financial measures is vitally important to an understanding of the underlying profitability drivers and trends of the Company’s insurance business. The most comparable U.S. GAAP financial measures for adjusted earnings and adjusted earnings per share (basic or diluted) are net earnings and net earnings per share, respectively.

•Adjusted net investment gains and losses are net investment gains and losses adjusted for i) amortized hedge cost/income related to foreign currency exposure management strategies and certain derivative activity, ii) net interest cash flows from foreign currency and interest rate derivatives associated with certain investment strategies, which are both reclassified to net investment income, and iii) the impact of interest cash flows from derivatives associated with notes payable, which is reclassified to interest expense as a component of total adjusted expenses. The Company considers adjusted net investment gains and losses important as it represents

the remainder amount that is considered outside management’s control, while excluding the components that are within management’s control and are accordingly reclassified to net investment income and interest expense. The most comparable U.S. GAAP financial measure for adjusted net investment gains and losses is net investment gains and losses.

•Amortized hedge costs/income represent costs/income incurred or recognized as a result of using foreign currency derivatives to hedge certain foreign exchange risks in the Company's Japan segment or in Corporate and other. These amortized hedge costs/ income are estimated at the inception of the derivatives based on the specific terms of each contract and are recognized on a straight-line basis over the term of the hedge. The Company believes that amortized hedge costs/income measure the periodic currency risk management costs/

income related to hedging certain foreign currency exchange risks and are an important component of net investment income. There is no comparable U.S. GAAP financial measure for amortized hedge costs/ income.

•Adjusted earnings excluding current period foreign currency impact are computed using the average foreign currency exchange rate for the comparable prior-year period, which eliminates fluctuations driven solely by foreign currency exchange rate changes. Adjusted earnings per diluted share excluding current period foreign currency impact is adjusted earnings excluding current period foreign currency impact divided by the weighted average outstanding diluted shares for the period presented. The Company considers adjusted earnings excluding current period foreign currency impact and adjusted earnings per diluted share excluding current period foreign currency impact important because a significant portion of the Company's business is conducted in Japan and foreign exchange rates are outside management’s control; therefore, the Company believes it is important to understand the impact of translating foreign currency (primarily Japanese yen) into U.S. dollars. The most comparable U.S. GAAP financial measures for adjusted earnings excluding current period foreign currency impact and adjusted earnings per diluted share excluding current period foreign currency impact are net earnings and net earnings per share, respectively.

•Adjusted book value is the U.S. GAAP book value (representing total shareholders’ equity), less AOCI as recorded on the U.S. GAAP balance sheet. Adjusted book value per common share is adjusted book value at the period end divided by the ending outstanding common shares for the period presented. The Company considers adjusted book value and adjusted book value per common share important as they exclude AOCI, which fluctuates due to market movements that are outside management’s control. The most comparable U.S. GAAP financial measures for adjusted book value and adjusted book value per common share are total book value and total book value per common share, respectively.

•Adjusted return on equity excluding foreign currency impact is adjusted earnings excluding the current period foreign currency impact divided by average shareholders’ equity, excluding AOCI. The Company considers adjusted return on equity excluding foreign currency impact important as it excludes changes in foreign currency and components of AOCI, which fluctuate due to market movements that are outside management's control. The most comparable U.S. GAAP financial measure for adjusted return on equity excluding foreign currency impact is ROE as determined using net earnings and average total shareholders’ equity.

•U.S. dollar-denominated investment income excluding foreign currency impact represents amounts excluding foreign currency impact on U.S. dollar-denominated investment income using the average foreign currency exchange rate for the comparable prior year period. The Company considers U.S. dollar-denominated investment income excluding foreign currency impact important as it eliminates the impact of foreign currency changes on the Aflac Japan segment results, which are outside management’s control. The most comparable U.S. GAAP financial measure for U.S. dollar-denominated investment income excluding foreign currency impact is the corresponding net investment income amount from the U.S. dollar denominated investments translated to yen.

6779

The following table is a reconciliation of items impacting adjusted earnings and adjusted earnings per diluted share to the most directly comparable U.S. GAAP financial measures of net earnings and net earnings per diluted share, respectively.

Reconciliation of Net Earnings to Adjusted Earnings


			In Millions	Per Diluted Share										In Millions	Per Diluted Share
		Three Months Ended March 31,								Three Months Ended March 31,
				2022		2021		2022			2021					2023		2022		2023		2022
Net earnings	Net earnings			$	1,032	$	1,293	$	1.58		$	1.87	Net earnings			$	1,188	$	1,047	$	1.94	$	1.60
Items impacting net earnings:	Items impacting net earnings:												Items impacting net earnings:
Adjusted net investment (gains) losses (1)	Adjusted net investment (gains) losses (1)			(134)		(304)		(.21)			(.44)		Adjusted net investment (gains) losses (1)			(209)		(134)		(.34)		(.21)
Other and non-recurring (income) loss	Other and non-recurring (income) loss			1		6		.00			.01		Other and non-recurring (income) loss			0		1		.00		.00
Income tax (benefit) expense on items excluded from adjusted earnings				28		62		.04			.09
Income tax (benefit) expense on items excluded from adjusted earning													Income tax (benefit) expense on items excluded from adjusted earning			(26)		28		(.04)		.04

Adjusted earnings	Adjusted earnings			927		1,058		1.42			1.53		Adjusted earnings			953		942		1.55		1.44
Current period foreign currency impact (2)	Current period foreign currency impact (2)			37		N/A		.06			N/A		Current period foreign currency impact (2)			41		N/A		.07		N/A
Adjusted earnings excluding current period foreign currency impact	Adjusted earnings excluding current period foreign currency impact			$	963	$	1,058	$	1.48		$	1.53	Adjusted earnings excluding current period foreign currency impact			$	994	$	942	$	1.62	$	1.44

(1) See reconciliation of net investment (gains) losses to adjusted net investment (gains) losses below.

(2) Prior period foreign currency impact reflected as “N/A” to isolate change for current period only.

Prior-year amounts have been adjusted for the adoption of accounting guidance on January 1, 2023 related to accounting for long-duration insurance contracts.

Reconciling Items

Net Investment Gains and Losses

Reconciliation of Net Investment (Gains) Losses to Adjusted Net Investment (Gains) Losses


		Three Months Ended March 31,						Three Months Ended March 31,
(In millions)	(In millions)		2022		2021		(In millions)		2023		2022
Net investment (gains) losses	Net investment (gains) losses		$	(122)	$	(307)	Net investment (gains) losses		$	(123)	$	(122)
Items impacting net investment (gains) losses:	Items impacting net investment (gains) losses:						Items impacting net investment (gains) losses:
Amortized hedge costs	Amortized hedge costs		(26)		(19)		Amortized hedge costs		(58)		(26)
Amortized hedge income	Amortized hedge income		11		17		Amortized hedge income		29		11
Net interest cash flows from derivatives associated with certain investment strategies	Net interest cash flows from derivatives associated with certain investment strategies		(9)		(8)		Net interest cash flows from derivatives associated with certain investment strategies		(69)		(9)
Interest rate component of the change in fair value of foreign currency swaps on notes payable	Interest rate component of the change in fair value of foreign currency swaps on notes payable		13		14		Interest rate component of the change in fair value of foreign currency swaps on notes payable		12		13
Adjusted net investment (gains) losses	Adjusted net investment (gains) losses		$	(134)	$	(304)	Adjusted net investment (gains) losses		$	(209)	$	(134)

The Company's investment strategy is to invest primarily in fixed maturity securities to provide a reliable stream of investment income, which is one of the drivers of the Company’s profitability. This investment strategy incorporates asset-liability matching (ALM) to align the expected cash flows of the portfolio to the needs of the Company's liability structure. The Company does not purchase securities with the intent of generating investment gains or losses. However, investment gains and losses may be realized as a result of changes in the financial markets and the creditworthiness of specific issuers, tax planning strategies, and/or general portfolio management and rebalancing. The realization of investment gains and losses is independent of the underwriting and administration of the Company's insurance products.

Net investment gains and losses excluded from adjusted earnings include the following:

•Securities Transactions

•Credit Losses

•Changes in the Fair Value of Equity Securities

•Certain Derivative and Foreign Currency Activities.

6880

Securities Transactions, Credit Losses and Changes in the Fair Value of Equity Securities

Securities transactions include gains and losses from sales and redemptions of investments where the amount received is different from the amortized cost of the investment. Credit losses include losses for held-to-maturity fixed maturity securities, available-for-sale fixed maturity securities, loan receivables, loan commitments and reinsurance recoverables. Changes in the fair value of equity securities are the result of gains or losses driven by fluctuations in market prices.

Certain Derivative and Foreign Currency Activities

The Company's derivative activities include:

•foreign currency forwards and options used to economically hedge certain portions of forecasted cash flows denominated in yen and hedge the Company's long term exposure to a weakening ~~yen~~yen;

•cross-currency interest rate swaps, also referred to as foreign currency swaps, associated with certain senior notes and subordinated ~~debentures~~debentures;

•interest rate swaps used to economically hedge interest rate fluctuations in certain variable-rate ~~investments~~investments;

•bond purchase commitments at the inception of investments in consolidated VIEs.

Gains and losses are recognized as a result of valuing these derivatives, net of the effects of hedge accounting. The Company also excludes from adjusted earnings the accounting impacts of remeasurement associated with changes in the foreign currency exchange rate.

For additional information regarding net investment gains and losses, including details of reported amounts for the periods presented, see Notes 3 and 4 of the Notes to the Consolidated Financial Statements.

Other and Non-recurring Items

The U.S. insurance industry has a policyholder protection system that provides funds for the policyholders of insolvent insurers. The system can result in periodic charges to the Company as a result of insolvencies/bankruptcies that occur with other companies in the life insurance industry. Some states permit member insurers to recover assessments paid through full or partial premium tax offsets. These charges neither relate to the ordinary course of the Company’s business nor reflect the Company’s underlying business performance, but result from external situations not controlled by the Company. The Company excludes any charges associated with U.S. guaranty fund assessments and the corresponding tax benefit or expense from adjusted earnings.

In Japan, the government also requires the insurance industry to contribute to a policyholder protection corporation that provides funds for the policyholders of insolvent insurers; however, these costs are calculated and administered differently than in the U.S. In Japan, these costs are not directly related to specific insolvencies or bankruptcies, but are rather a regular operational cost for an insurance company. Based on this structure, the Company does not remove the Japan policyholder protection expenses from adjusted earnings.

The Company considers the costs associated with the early redemption of its debt to be unrelated to the underlying fundamentals and trends in its insurance operations. Additionally, these costs are driven by changes in interest rates subsequent to the issuance of the debt, and the Company considers these interest rate changes to represent economic conditions not directly associated with its insurance operations.

Other items excluded from adjusted earnings include integration costs related to the Company's acquisition of Zurich North America's U.S. Corporate Life and Pensions business; these costs primarily consist of expenditures for legal, accounting, consulting, integration of systems and processes and other similar services. These integration costs are excluded from adjusted earnings for one year following the acquisition and amounted to $6 million for the three-month period ended March 31, 2021.

Income Taxes

The Company's combined U.S. and Japanese effective income tax rate on pretax earnings was ~~19.1%~~11.5% for the three-month period ended March 31, ~~2022,~~2023, compared with ~~19.4%~~19.1% for the same period in ~~2021.~~2022. The combined effective tax rate differs from the U.S. statutory rate primarily due to ~~solar,~~ historic and solar tax credits and the exclusion of foreign ~~tax credits.~~currency translation gains and losses held in the Delaware Statutory Trust. For additional information, see the Critical Accounting Estimates - Income Taxes section of Item 7. MD&A in the ~~2021~~2022 Annual Report.

The Company expects that its effective tax rate on adjusted earnings for future periods will be approximately 20%. The effective tax rate continues to be subject to future tax law changes both in the U.S. and in foreign jurisdictions. See the risk factor entitled "Tax rates applicable to the Company may change" in Item 1A. Risk Factors of the ~~2021~~2022 Annual Report for more information.

Foreign Currency Translation

Aflac Japan’s premiums and a significant portion of its investment income are received in yen, and its claims and most expenses are paid in yen. Aflac Japan purchases yen-denominated assets and U.S. dollar-denominated assets, which may be hedged to yen, to support yen-denominated policy liabilities. Yen-denominated income statement accounts are translated to U.S. dollars using the weighted average Japanese yen/U.S. dollar foreign exchange rate for the reporting period, except realized gains and losses on securities transactions which are translated at the exchange rate on the trade date of each transaction. Yen-denominated balance sheet accounts are translated to U.S. dollars using the spot Japanese yen/U.S. dollar foreign exchange rate at the end of the reporting period.

RESULTS OF OPERATIONS BY SEGMENT

U.S. GAAP financial reporting requires that a company report financial and descriptive information about operating segments in its annual and interim period financial statements. Furthermore, the Company is required to report a measure of segment profit or loss, certain revenue and expense items, and segment assets. The Company's insurance business consists of two segments: Aflac Japan and Aflac U.S. Aflac Japan is the principal contributor to consolidated earnings. In addition, the Parent Company, other business units that are not individually reportable, and business activities, including reinsurance ~~retrocession~~ activities, not included in Aflac Japan or Aflac U.S. are included in Corporate and other. See Item 1. Business in the ~~2021~~2022 Annual Report for a summary of each segment's products and distribution channels.

Consistent with U.S. GAAP guidance for segment reporting, pretax adjusted earnings is the Company's U.S. GAAP measure of segment performance. The Company believes that a presentation of this measure is vitally important to an understanding of the underlying profitability drivers and trends of its business. Additional performance measures used to evaluate the financial condition and performance of the Company's segments are listed below.

•Operating Ratios

•New Annualized Premium Sales

•New Money Yield

•Return on Average Invested Assets

•Average Weekly Producer

•Premium Persistency

For additional information on the Company’s performance measures included in this MD&A, see the Glossary of Selected Terms found directly following Part II. Other Information. See Note 2 of the Notes to the Consolidated Financial Statements for the reconciliation of segment results to the Company's consolidated U.S. GAAP results and additional information.

7082

AFLAC JAPAN SEGMENT

Aflac Japan Pretax Adjusted Earnings

Changes in Aflac Japan’s pretax adjusted earnings and profit margins are primarily affected by morbidity, mortality, expenses, persistency and investment yields. The following table presents a summary of operating results for Aflac Japan.

Aflac Japan Summary of Operating Results


		Three Months Ended March 31,						Three Months Ended March 31,
(In millions)	(In millions)		2022		2021		(In millions)		2023		2022
Net earned premiums	Net earned premiums		$	2,724	$	3,123	Net earned premiums		$	2,170	$	2,625
Net investment income: (1)	Net investment income: (1)						Net investment income: (1)
Yen-denominated investment income	Yen-denominated investment income		299		328		Yen-denominated investment income		263		299
U.S. dollar-denominated investment income	U.S. dollar-denominated investment income		406		397		U.S. dollar-denominated investment income		407		406
Net investment income	Net investment income		705		724		Net investment income		669		705
Amortized hedge costs related to certain foreign currency exposure management strategies	Amortized hedge costs related to certain foreign currency exposure management strategies		26		19		Amortized hedge costs related to certain foreign currency exposure management strategies		(58)		26
Adjusted net investment income	Adjusted net investment income		680		705		Adjusted net investment income		611		680
Other income (loss)	Other income (loss)		9		13		Other income (loss)		9		9
Total adjusted revenues	Total adjusted revenues		3,413		3,841		Total adjusted revenues		2,790		3,314
Benefits and claims, net			1,827		2,135
Benefits and claims:							Benefits and claims:
Benefits and claims, excluding reserve remeasurement							Benefits and claims, excluding reserve remeasurement		1,466		1,793
Reserve remeasurement (gains) losses							Reserve remeasurement (gains) losses		(13)		(14)
Total benefits and claims, net							Total benefits and claims, net		1,453		1,779
Adjusted expenses:	Adjusted expenses:						Adjusted expenses:
Amortization of deferred policy acquisition costs	Amortization of deferred policy acquisition costs		154		172		Amortization of deferred policy acquisition costs		85		94
Insurance commissions	Insurance commissions		161		187		Insurance commissions		138		161
Insurance and other expenses	Insurance and other expenses		410		460		Insurance and other expenses		326		409
Total adjusted expenses	Total adjusted expenses		725		818		Total adjusted expenses		549		664
Total benefits and adjusted expenses	Total benefits and adjusted expenses		2,551		2,954		Total benefits and adjusted expenses		2,002		2,443
Pretax adjusted earnings	Pretax adjusted earnings		$	862	$	887	Pretax adjusted earnings		$	788	$	870
Weighted-average yen/dollar exchange rate	Weighted-average yen/dollar exchange rate		116.18		105.88		Weighted-average yen/dollar exchange rate		132.30		116.18


			In Dollars						In Yen							In Dollars				In Yen
Percentage change over previous period:	Percentage change over previous period:	Three Months Ended March 31,						Three Months Ended March 31,	Percentage change over previous period:			Three Months Ended March 31,				Three Months Ended March 31,
				2022		2021				2022			2021		Percentage change over previous period:	2023		2022		2023		2022
Net earned premiums	Net earned premiums			(12.8)	%	(.9)	%			(4.3)	%		(3.6)	%		(17.3)	%	(11.5)	%	(5.9)	%	(2.8)	%
Adjusted net investment income	Adjusted net investment income			(3.5)		9.8				5.9			6.9		Adjusted net investment income	(10.1)		(3.6)		2.4		5.9
Total adjusted revenues	Total adjusted revenues			(11.1)		1.0				(2.5)			(1.8)		Total adjusted revenues	(15.8)		(10.0)		(4.1)		(1.2)
Pretax adjusted earnings	Pretax adjusted earnings			(2.8)		3.7				6.8			.9		Pretax adjusted earnings	(9.4)		(5.0)		3.2		4.7

(1) Net interest cash flows from derivatives associated with certain investment strategies of ~~$(10)~~$(62) and ~~$(8)~~$(10) for the three-month periods ended March 31, ~~2022~~2023 and ~~2021,~~2022, respectively, have been reclassified from net investment gains (losses) and included in adjusted earnings as a component of net investment income.

Prior-year amounts have been adjusted for the adoption of accounting guidance on January 1, 2023 related to accounting for long-duration insurance contracts.

In the three-month period ended March 31, ~~2022,~~2023, Aflac Japan's net earned premiums decreased, in yen terms, mainly due to limited-pay products reaching premium paid-up status and ~~constrained sales from~~ the ~~impact~~implementation of ~~pandemic conditions. In yen terms, adjusted~~the Aflac Re global reinsurance strategy. Adjusted net investment income, in yen terms, increased in the three-month period ended March 31, ~~2022,~~2023, primarily due to ~~higher alternative and floating rate income as well as~~ the impact of ~~a weaker yen~~foreign exchange on U.S. dollar-denominated ~~investment income.~~investments offset by higher hedge costs. The increase in pretax adjusted earnings in yen for the ~~quarter~~three-month period ended March 31, 2023 was primarily due to ~~continued favorable claim trends~~a decrease in total benefits and ~~higher~~ adjusted ~~net investment income.~~expenses.

Annualized premiums in force decreased ~~4.6%~~4.8% to ¥1.28 trillion as of March 31, 2023, compared with ¥1.35 trillion as of March 31, ~~2022, compared with ¥1.41 trillion as of March 31, 2021.~~2022. The decrease in annualized premiums in force in yen was driven primarily by limited-pay products

reaching premium paid-up status and lower ~~sales during the COVID-19 pandemic.~~sales. Annualized premiums in force, translated into dollars at respective period-end exchange rates, were $9.6 billion at March 31, 2023, compared with $11.0 billion at March 31, ~~2022, compared with $12.7 billion at~~2022. As of March 31, ~~2021.~~2023, Aflac Japan exceeded 23 million individual policies in force in Japan, with more than 14 million cancer policies in force in Japan.

Aflac Japan's investment portfolios include U.S. dollar-denominated securities and reverse-dual currency securities (yen-denominated debt securities with dollar coupon payments). In years when the yen strengthens in relation to the dollar, translating Aflac Japan's U.S. dollar-denominated investment income into yen lowers growth rates for net investment income, total adjusted revenues, and pretax adjusted earnings in yen terms. In years when the yen weakens, translating U.S. dollar-denominated investment income into yen magnifies growth rates for net investment income, total adjusted revenues, and pretax adjusted earnings in yen terms.

The following table illustrates the effect of translating Aflac Japan’s U.S. dollar-denominated investment income and related items into yen by comparing certain segment results with those that would have been reported had foreign currency exchange rates remained unchanged from the comparable period in the prior year. Amounts excluding foreign currency impact on U.S. dollar-denominated investment income were determined using the average foreign currency exchange rate for the comparable prior year period. See non-U.S. GAAP financial measures defined above.

Aflac Japan Percentage Changes Over Previous Period

(Yen Operating Results)

For the Periods Ended March 31,


			Including Foreign Currency Changes						Excluding Foreign Currency Changes						Including Foreign Currency Changes				Excluding Foreign Currency Changes
		Three Months						Three Months			Three Months				Three Months
				2022		2021				2022		2021			2023		2022			2023		2022
Adjusted net investment income	Adjusted net investment income			5.9	%	6.9	%			.3		8.5	%	Adjusted net investment income	2.4	%	5.9	%		(5.9)	%	.3	%
Total adjusted revenues	Total adjusted revenues			(2.5)		(1.8)				(3.5)		(1.5)		Total adjusted revenues	(4.1)		(1.2)			(5.8)		(2.3)
Pretax adjusted earnings	Pretax adjusted earnings			6.8		.9				2.5		2.1		Pretax adjusted earnings	3.2		4.7			(3.0)		.5

Prior-year amounts have been adjusted for the adoption of accounting guidance on January 1, 2023 related to accounting for long-duration insurance contracts.

The following table presents a summary of operating ratios in yen terms for Aflac Japan.


		Three Months Ended March 31,						Three Months Ended March 31,
Ratios to total adjusted revenues:	Ratios to total adjusted revenues:		2022		2021		Ratios to total adjusted revenues:		2023		2022
Benefits and claims, net			53.5	%	55.6	%
Total benefits and claims, net							Total benefits and claims, net		52.1	%	53.7	%
Adjusted expenses:	Adjusted expenses:						Adjusted expenses:
Amortization of deferred policy acquisition costs	Amortization of deferred policy acquisition costs		4.5		4.5		Amortization of deferred policy acquisition costs		3.1		2.8
Insurance commissions	Insurance commissions		4.7		4.9		Insurance commissions		4.9		4.8
Insurance and other expenses	Insurance and other expenses		12.0		12.0		Insurance and other expenses		11.7		12.4
Total adjusted expenses	Total adjusted expenses		21.2		21.3		Total adjusted expenses		19.7		20.0
Pretax adjusted earnings	Pretax adjusted earnings		25.3		23.1		Pretax adjusted earnings		28.2		26.2
Ratios to total premiums:	Ratios to total premiums:						Ratios to total premiums:
Benefits and claims, net			67.1	%	68.4	%
Total benefits and claims, net							Total benefits and claims, net		67.0	%	67.9	%
Adjusted expenses:	Adjusted expenses:						Adjusted expenses:
Amortization of deferred policy acquisition costs	Amortization of deferred policy acquisition costs		5.7		5.5		Amortization of deferred policy acquisition costs		3.9		3.6

Prior-year amounts have been adjusted for the adoption of accounting guidance on January 1, 2023 related to accounting for long-duration insurance contracts.

In the three-month period ended March 31, ~~2022,~~2023, the ~~benefit~~total benefits and claims ratio to total premiums decreased, compared with the same period in the prior ~~year. This is~~year, primarily due to a decrease in the third sector benefit ratio due to favorable experience and the continued change in the mix of first and third sector ~~business and lower benefits in Aflac Japan's third sector~~ business. In the three-month period ended March 31, ~~2022,~~2023, the total adjusted expense ratio decreased slightly, compared ~~to 2021~~with the same period in the prior year, reflecting the decrease in total adjusted revenues and an offsetting decrease in total adjusted ~~expenses.~~expenses due to expense control efforts as well as the reinsurance transaction with Aflac Re. In total, the pretax adjusted profit margin

increased in the three-month period ended March 31, ~~2022~~2023 primarily due to a lower benefit ~~ratios~~ratio and ~~higher~~a lower expense ratio and an offsetting decrease in total adjusted ~~net investment income.~~

revenues.

The following table presents Aflac Japan's premium persistency on a 12-month rolling basis as of March 31.


	2023		2022
Premium persistency	93.9	%	94.3	%

Aflac Japan Sales

The following table presents Aflac Japan’s new annualized premium sales for the periods ended March 31.


			In Dollars								In Yen								In Dollars						In Yen
		Three Months								Three Months						Three Months		Three Months
(In millions of dollars and billions of yen)	(In millions of dollars and billions of yen)			2022			2021				2022			2021			(In millions of dollars and billions of yen)		2023			2022			2023			2022
New annualized premium sales	New annualized premium sales			$	103		$	132			¥	11.9		¥	14.0		New annualized premium sales		$	100		$	103		¥	13.2		¥	11.9
Increase (decrease) over prior period	Increase (decrease) over prior period			(22.4)		%	2.6		%		(14.8)		%	(.2)		%	Increase (decrease) over prior period		(3.2)		%	(22.4)		%	10.8		%	(14.8)		%

In 2023, the new annualized premium sales on a yen basis increased, compared with 2022, due primarily to sales of Aflac Japan's new cancer insurance product and updated first sector products, all of which were launched in the second half of 2022. Further, these products were launched at Dai-ichi Life and other financial institutions in January 2023.

The following table details the contributions to Aflac Japan's new annualized premium sales by major insurance product for the periods ended March 31.


		Three Months						Three Months
			2022		2021				2023		2022
Cancer	Cancer		53.0	%	45.4	%	Cancer		59.9	%	53.0	%
Medical and other health:							Medical and other health:
Medical	Medical		31.4		43.3		Medical		20.8		31.4
Income support	Income support		1.1		.6		Income support		.6		1.1
Ordinary life:
Life insurance:							Life insurance:
Traditional life (1)							Traditional life (1)		7.3		9.0
WAYS	WAYS		.7		.7		WAYS		8.9		.7
Child endowment	Child endowment		.3		.3		Child endowment		.6		.3
Other ordinary life (1)			9.0		8.9
Other	Other		4.5		.8		Other		1.9		4.5
Total	Total		100.0	%	100.0	%	Total		100.0	%	100.0	%

(1) Includes term and whole life

The foundation of Aflac Japan's product portfolio has been, and continues to be, third sector products, which include cancer, medical, ~~and~~ income support, ~~insurance products. Aflac Japan has been focusing more on promotion of cancer~~ and ~~medical~~nursing care insurance ~~products in this low-interest-rate environment. These products are less interest-rate sensitive and more profitable compared to first sector savings~~ products. With continued cost pressure on Japan’s health care system, the Company expects the need for third sector products will continue to rise in the future and that the medical and cancer insurance products Aflac Japan provides will continue to be an important part of its product portfolio.

~~Sales of protection-type~~ Moreover, in November 2022, Aflac Japan refreshed its first sector savings-type products WAYS and Child Endowment and began to actively promote sales of these products after having curtailed sales of both products beginning in 2013. The refreshment of these first sector products position Aflac Japan for potential future long-term sales opportunities by marketing these products to a younger demographic as well as potential cross-selling opportunities of Aflac Japan's third sector products on a yen basis decreased 14.9% in the first quarter of 2022, compared with the first quarter of 2021, reflecting ongoing pandemic conditions and a first quarter of 2021 that included the launch of a new medical product.products.

Sales of Aflac Japan cancer insurance products in the Japan Post Group channel experienced a material decline beginning in August 2019. Japan Post Group resumed proactive sales of cancer insurance policies in April 2021 and Aflac Japan continues to strengthen the strategic alliance. In April ~~2022, approximately 10,000 employees of Japan Post Co. were transferred to Japan Post Insurance.~~2023, Japan Post Group ~~has informed~~began selling Aflac Japan that the transferred employees' responsibilities will include sales of Japan Post Insurance products and Aflac Japan cancer products but will not include sales of other financial products. The Company expects continued collaboration to further position both companies for long-term growth and a gradual improvement of Japan Post GroupJapan's new cancer insurance ~~sales~~product that was launched in the intermediate term. For example, during 2021 Aflac Japan observed an increase in the number of proposals to potential customers in the Japan Post Group channel, and the Japan Post Group continues to conduct a nationwide campaign to improve certain sales process practices.August 2022. For additional information, see the risk factor entitled "Sales of the Company's products and services are dependent on its ability to attract, retain and support a network of qualified sales associates, brokers and employees in the U.S. and sales associates and other distribution partners in Japan," in Item 1A. Risk Factors in the ~~2021~~2022 Annual Report.

~~In response to the COVID-19 pandemic,~~ Aflac Japan continues to promote digital and web-based sales to groups and use of its system that enables smart device-based insurance application by allowing the customer and an Aflac Japan operator to see the same screen through their smart devices. Further, Aflac Japan continues to utilize its virtual sales tool that enables online consultations and policy applications to be completed entirely online.

The following table details the contributions to Aflac Japan's new annualized premium sales by agency type for the three-month periods ended March 31.


		2022		2021			2023		2022
Independent corporate and individual	Independent corporate and individual	48.9	%	54.3	%	Independent corporate and individual	50.9	%	48.9	%
Affiliated corporate (1)	Affiliated corporate (1)	46.5		40.6		Affiliated corporate (1)	45.4		46.5
Bank	Bank	4.6		5.1		Bank	3.7		4.6
Total	Total	100.0	%	100.0	%	Total	100.0	%	100.0	%

(1) Includes Japan Post Group, Dai-ichi Life and Daido Life

During the three-month period ended March 31, ~~2022,~~2023, Aflac Japan recruited 64 new sales agencies. At March 31, ~~2022,~~2023, Aflac Japan was represented by approximately ~~7,700~~7,300 sales agencies, with approximately 110,000 licensed sales associates employed by those agencies. The number of sales agencies has declined in recent years due to Aflac Japan's focus on supporting agencies with strong management frameworks, high productivity and more producing agents.

At March 31, ~~2022,~~2023, Aflac Japan had agreements to sell its products at ~~360~~359 banks, approximately 90% of the total number of banks in Japan.

Aflac Japan Investments

The level of investment income in yen is affected by available cash flow from operations, the timing of investing the cash flow, yields on new investments, the effect of yen/dollar exchange rates on U.S. dollar-denominated investment income, and other factors.

As part of the Company's portfolio management and asset allocation process, Aflac Japan invests in yen and U.S. dollar-denominated investments. Yen-denominated investments primarily consist of JGBs, public and private fixed maturity securities and public equity securities. Aflac Japan's U.S. dollar-denominated investments include fixed maturity investments and growth assets, including alternative investments in limited partnerships or similar investment vehicles. Aflac Japan has been investing in both ~~publicly-traded~~publicly traded and privately originated U.S. dollar-denominated investment-grade and below-investment-grade fixed maturity securities and loan receivables, and has entered into foreign currency forwards and options to hedge the currency risk on the fair value of a portion of the U.S. dollar investments.

7486

The following table details the investment purchases for Aflac Japan.


		Three Months Ended March 31,						Three Months Ended March 31,
(In millions)	(In millions)		2022		2021		(In millions)		2023		2022
Yen-denominated:	Yen-denominated:						Yen-denominated:
Fixed maturity securities:	Fixed maturity securities:						Fixed maturity securities:
Japan government and agencies	Japan government and agencies		$	0	$	1,181	Japan government and agencies		$	151	$	0
Private placements	Private placements		307		196		Private placements		273		307
Other fixed maturity securities	Other fixed maturity securities		17		107		Other fixed maturity securities		77		17
Equity securities	Equity securities		91		117		Equity securities		123		91
Other investments	Other investments		3		2		Other investments		6		3
Total yen-denominated	Total yen-denominated		$	418	$	1,603	Total yen-denominated		$	630	$	418

U.S. dollar-denominated:	U.S. dollar-denominated:						U.S. dollar-denominated:
Fixed maturity securities:	Fixed maturity securities:						Fixed maturity securities:
Other fixed maturity securities	Other fixed maturity securities		$	85	$	606	Other fixed maturity securities		$	376	$	85

Collateralized loan obligations	Collateralized loan obligations		67		117		Collateralized loan obligations		0		67

Commercial mortgage and other loans:	Commercial mortgage and other loans:						Commercial mortgage and other loans:
Transitional real estate loans	Transitional real estate loans		507		61		Transitional real estate loans		53		507

Middle market loans	Middle market loans		311		783		Middle market loans		150		311
Other investments	Other investments		48		56		Other investments		137		48
Total U.S. dollar-denominated	Total U.S. dollar-denominated		$	1,018	$	1,623	Total U.S. dollar-denominated		$	716	$	1,018
Total Aflac Japan purchases	Total Aflac Japan purchases		$	1,436	$	3,226	Total Aflac Japan purchases		$	1,346	$	1,436

See the Investments section of this MD&A for further discussion of these investment programs, and see Notes 3 and 4 of the Notes to the Consolidated Financial Statements and Notes 1, 3 and 4 of the Notes to the Consolidated Financial Statements in the ~~2021~~2022 Annual Report for more information regarding loans and loan receivables.

The following table presents the results of Aflac Japan’s investment yields for the periods ended March 31.


		Three Months						Three Months
			2022			2021					2023			2022
Total purchases for the period (in millions) (1)	Total purchases for the period (in millions) (1)		$	1,385		$	3,168			Total purchases for the period (in millions) (1)	$	1,203		$	1,385
New money yield (1), (2)			3.90		%	2.72			%
New money yield (1),(2)										New money yield (1),(2)	5.18		%	3.90		%
Return on average invested assets (3)	Return on average invested assets (3)		2.54			2.47				Return on average invested assets (3)	2.57			2.54
Portfolio book yield, including U.S. dollar-denominated investments, end of period (1)			2.62		%	2.58			%
Portfolio book yield, including U.S. dollar-denominated investments, end of period (1),(2)										Portfolio book yield, including U.S. dollar-denominated investments, end of period (1),(2)	3.13		%	2.62		%

(1) Includes fixed maturity securities, commercial mortgage and other loans, equity securities, and excludes alternative investments in limited partnerships

(2) Reported on a gross yield basis; excludes investment expenses, external management fees, and amortized hedge costs

(3) Net of investment expenses and amortized hedge costs, year-to-date number reflected on a quarterly average basis

The increase in the Aflac Japan new money yield in the three-month period ended March 31, ~~2022~~2023 was primarily due to ~~increased allocations to higher yielding floating rate asset classes.~~increases in U.S. interest rates. See Notes 3, 4 and 5 of the Notes to the Consolidated Financial Statements and the Investments and Hedging Activities sections of this MD&A for additional information on the Company's investments and hedging strategies.

AFLAC U.S. SEGMENT

Aflac U.S. Pretax Adjusted Earnings

Changes in Aflac U.S. pretax adjusted earnings and profit margins are primarily affected by morbidity, mortality, expenses, persistency and investment yields. The following table presents a summary of operating results for Aflac U.S.

7587

Aflac U.S. Summary of Operating Results


		Three Months Ended March 31,								Three Months Ended March 31,
(In millions)	(In millions)		2022			2021			(In millions)		2023			2022
Net earned premiums	Net earned premiums		$	1,413		$	1,422		Net earned premiums		$	1,428		$	1,413
Adjusted net investment income (1)	Adjusted net investment income (1)		184			176			Adjusted net investment income (1)		197			184
Other income	Other income		42			30			Other income		35			42
Total adjusted revenues	Total adjusted revenues		1,639			1,628			Total adjusted revenues		1,660			1,639
Benefits and claims			622			556
Benefits and claims:									Benefits and claims:
Benefits and claims, excluding reserve remeasurement									Benefits and claims, excluding reserve remeasurement		691			686
Reserve remeasurement (gains) losses									Reserve remeasurement (gains) losses		(40)			(20)
Total benefits and claims									Total benefits and claims		651			666
Adjusted expenses:	Adjusted expenses:								Adjusted expenses:
Amortization of deferred policy acquisition costs	Amortization of deferred policy acquisition costs		168			139			Amortization of deferred policy acquisition costs		119			114
Insurance commissions	Insurance commissions		140			139			Insurance commissions		142			140
Insurance and other expenses	Insurance and other expenses		384			347			Insurance and other expenses		395			387
Total adjusted expenses	Total adjusted expenses		692			626			Total adjusted expenses		657			640
Total benefits and adjusted expenses	Total benefits and adjusted expenses		1,314			1,182			Total benefits and adjusted expenses		1,308			1,306
Pretax adjusted earnings	Pretax adjusted earnings		$	325		$	445		Pretax adjusted earnings		$	352		$	333
Percentage change over previous period:	Percentage change over previous period:								Percentage change over previous period:
Net earned premiums	Net earned premiums		(.6)		%	(4.1)		%	Net earned premiums		1.1		%	(.6)		%
Adjusted net investment income	Adjusted net investment income		4.5			(.6)			Adjusted net investment income		7.1			4.5
Total adjusted revenues	Total adjusted revenues		.7			(3.5)			Total adjusted revenues		1.3			.7
Pretax adjusted earnings	Pretax adjusted earnings		(27.0)			36.5			Pretax adjusted earnings		5.7			.6

(1) Net interest cash flows from derivatives associated with certain investment strategies of $(7) and $1 for the three-month ~~period~~periods ended March 31, 2023 and 2022, respectively, have been reclassified from net investment gains (losses) and included in adjusted earnings as a component of net investment income.

Prior-year amounts have been adjusted for the adoption of accounting guidance on January 1, 2023 related to accounting for long-duration insurance contracts.

In the three-month period ended March 31, ~~2022,~~2023, net earned premiums for Aflac U.S. ~~decreased~~increased primarily ~~due to lower persistency.~~driven by continued investments in growth initiatives. Adjusted net investment income increased in the three-month period ended March 31, ~~2022,~~2023 primarily ~~impacted by higher variable net investment income. Other income increased in the three-month period ended March 31, 2022~~ due to anhigher floating rate income due to higher volumes and rates. The increase ~~in fee income. The decrease~~ in pretax adjusted earnings in the three-month period ended March 31, ~~2022,~~2023 was driven primarily by lower benefits and higher revenues, partially offset by higher ~~incurred benefits as benefits approach pre-pandemic levels, and elevated adjusted~~ expenses.

Annualized premiums in force ~~decreased~~increased 1.4% to $6.0 billion at March 31, 2023, compared with $5.9 billion at March 31, ~~2022, compared with $6.0 billion at March 31, 2021.~~2022.

The following table presents a summary of operating ratios for Aflac U.S.


		Three Months Ended March 31,						Three Months Ended March 31,
Ratios to total adjusted revenues:	Ratios to total adjusted revenues:		2022		2021		Ratios to total adjusted revenues:		2023		2022
Benefits and claims			37.9	%	34.2	%
Total benefits and claims							Total benefits and claims		39.2	%	40.7	%
Adjusted expenses:	Adjusted expenses:						Adjusted expenses:
Amortization of deferred policy acquisition costs	Amortization of deferred policy acquisition costs		10.3		8.5		Amortization of deferred policy acquisition costs		7.2		7.0
Insurance commissions	Insurance commissions		8.5		8.5		Insurance commissions		8.6		8.5
Insurance and other expenses	Insurance and other expenses		23.4		21.3		Insurance and other expenses		23.8		23.5
Total adjusted expenses	Total adjusted expenses		42.2		38.5		Total adjusted expenses		39.6		39.0
Pretax adjusted earnings	Pretax adjusted earnings		19.8		27.3		Pretax adjusted earnings		21.2		20.3
Ratios to total premiums:	Ratios to total premiums:						Ratios to total premiums:
Benefits and claims			44.0	%	39.1	%
Total benefits and claims							Total benefits and claims		45.6	%	47.1	%
Adjusted expenses:	Adjusted expenses:						Adjusted expenses:
Amortization of deferred policy acquisition costs	Amortization of deferred policy acquisition costs		11.9		9.8		Amortization of deferred policy acquisition costs		8.3		8.1

Prior-year amounts have been adjusted for the adoption of accounting guidance on January 1, 2023 related to accounting for long-duration insurance contracts.

For the three-month period ended March 31, ~~2022,~~2023, the ~~benefit~~total benefits and claims ratio to total premiums ~~increased~~decreased compared with the same period in ~~2021,~~2022, reflecting ~~higher incurred claims, partially offset by~~assumption updates in the third quarter of 2022 and reserve ~~releases~~remeasurement gains related to ~~lower persistency.~~experience. The total adjusted expense ratio increased in the three-month period ended March 31, ~~2022,~~2023, when compared with the same period in ~~2021,~~2022, primarily due to higher ~~DAC amortization associated with lower persistency and~~ planned spending, reflecting ongoing investments in the U.S. ~~platform.~~platform and higher DAC amortization associated with lower persistency. The pretax adjusted profit margin ~~decreased~~increased in the three-month period ended March 31, ~~2022,~~2023, compared with the same period in ~~2021,~~2022, primarily due to the ~~higher adjusted expense and~~lower benefit ~~ratios.~~ratio.

The following table presents premium persistency for Aflac U.S. on a 12-month rolling basis as of March 31.


	2023		2022
Premium persistency	77.9	%	78.7	%

Aflac U.S. Sales

The following table presents Aflac's U.S. new annualized premium sales for the periods ended March 31.


		Three Months							Three Months
(In millions)	(In millions)		2022			2021				(In millions)	2023			2022
New annualized premium sales	New annualized premium sales		$	299		$	251			New annualized premium sales	$	315		$	299
Increase (decrease) over prior period	Increase (decrease) over prior period		19.0		%	(22.1)		%		Increase (decrease) over prior period	5.3		%	19.0		%

New annualized premium sales for accident insurance ~~the leading Aflac U.S. product category, increased 14.1%~~decreased 1.8%; disability sales increased ~~21.5%~~13.8%; critical care insurance sales (including cancer insurance) increased ~~11.6%~~1.8%; hospital indemnity insurance sales increased ~~18.6%~~.2%; ~~and~~ dental/vision sales increased ~~47.8%~~22.7%; and life sales increased 10.3% in the first quarter of ~~2022,~~2023, compared with the first quarter of ~~2021.~~2022. The increase in sales for Aflac U.S. in the first quarter of ~~2022~~2023 reflects continued improvement ~~in pandemic conditions in the U.S and~~from investment in growth ~~initiatives. For the full year of 2022, Aflac U.S. expects this trend of increasing sales to continue.~~initiatives as well as productivity gains.

The following table details the contributions to Aflac's U.S. new annualized premium sales by major insurance product category for the periods ended March 31.


		Three Months					Three Months
			2022		2021				2023		2022
Accident	Accident		25.3	%	26.3	%		Accident	23.5	%	25.3	%
Disability	Disability		23.3		23.1			Disability	25.2		23.3
Critical care(1)	Critical care(1)		21.2		22.6			Critical care(1)	20.5		21.2
Hospital indemnity	Hospital indemnity		16.7		16.7			Hospital indemnity	15.9		16.7
Dental/vision	Dental/vision		5.6		4.6			Dental/vision	6.6		5.6
Life	Life		7.9		6.7			Life	8.3		7.9
Total	Total		100.0	%	100.0	%		Total	100.0	%	100.0	%

(1) Includes cancer, critical illness, and hospital intensive care products

In the first quarter of ~~2022,~~2023, the Aflac U.S. sales force included an average of approximately 6,100 U.S. agents, including brokers, who were actively producing business on a weekly basis. The Company believes that this average weekly producer equivalent metric allows sales management to monitor progress and needs, as well as serve as a leading indicator of future production capacity. Aflac U.S. believes that during 2021 and continuing into 2022, constraints in the labor market have limited its recruiting of new sales agents, and that limitations on face-to-face sales opportunities during the COVID-19 pandemic suppressed the development of newly recruited agents into business producers and the productivity of veteran agents and brokers. Aflac U.S. believes that the above factors have acted as a headwind to sales and to growth in the number of average weekly producers. Aflac U.S. remains focused on mitigating and reversing these trends as the U.S. economy continues to recover from the pandemic.

In response to the COVID-19 pandemic, Aflac U.S. remains focused on supporting its agency channel, most of which are small businesses, by offering financial support and an extended value proposition. The Aflac U.S. sales team has pivoted to accommodate preferred enrollment conditions which include realizing sales at the worksite through in-person enrollment, an enrollment call center, video enrollment through co-browsing and self-enrollment. The traditional agent sales team is also using virtual recruiting and training through video conferencing in order to maintain or increase the recruiting pipeline. The Aflac U.S. broker sales team is focused on product enhancements due to COVID-19 as well as leveraging technology based solutions to drive enrollment.

Aflac U.S. Investments

The level of investment income is affected by available cash flow from operations, the timing of investing the cash flow, yields on new investments, and other factors.

As part of the Company's portfolio management and asset allocation process, Aflac U.S. invests in fixed maturity investments and growth assets, including public equity securities and alternative investments in limited partnerships. Aflac U.S. has been investing in both publicly traded and privately originated investment-grade and below-investment-grade fixed maturity securities and loan receivables.

The following table details the investment purchases for Aflac U.S.


		Three Months Ended March 31,						Three Months Ended March 31,
(In millions)	(In millions)		2022		2021		(In millions)		2023		2022
Fixed maturity securities:	Fixed maturity securities:						Fixed maturity securities:
Other fixed maturity securities	Other fixed maturity securities		$	232	$	246	Other fixed maturity securities		$	209	$	232
Infrastructure debt	Infrastructure debt		9		0		Infrastructure debt		0		9
Collateralized loan obligations			0		11

Equity securities	Equity securities		9		0		Equity securities		0		9
Other investments:
Commercial mortgage and other loans:							Commercial mortgage and other loans:
Transitional real estate loans	Transitional real estate loans		107		24		Transitional real estate loans		14		107
Commercial mortgage loans			0		34

Middle market loans	Middle market loans		166		58		Middle market loans		19		166
Limited partnerships			5		6
Other investments							Other investments		15		5
Total Aflac U.S. Purchases	Total Aflac U.S. Purchases		$	528	$	379	Total Aflac U.S. Purchases		$	257	$	528

See Note 3 of the Notes to the Consolidated Financial Statements and Notes 1 and 3 of the Notes to the Consolidated Financial Statements in the ~~2021~~2022 Annual Report for more information regarding loans and loans receivables.

The following table presents the results of Aflac's U.S. investment yields for the periods ended March 31.


		Three Months						Three Months
			2022			2021					2023			2022
Total purchases for period (in millions) (1)	Total purchases for period (in millions) (1)		$	523		$	373			Total purchases for period (in millions) (1)	$	242		$	523
New money yield (1), (2)			4.60		%	3.22			%
New money yield (1),(2)										New money yield (1),(2)	7.01		%	4.60		%
Return on average invested assets (3)	Return on average invested assets (3)		4.61			4.69				Return on average invested assets (3)	4.74			4.61
Portfolio book yield, end of period (1)			4.95		%	5.12			%
Portfolio book yield, end of period (1),(2)										Portfolio book yield, end of period (1),(2)	5.46		%	4.95		%

(1) Includes fixed maturity securities, commercial mortgage and other loans, equity securities, and excludes alternative investments in limited partnerships

(2) Reported on a gross yield basis; excludes investment expenses and external management fees

(3) Net of investment expenses, year-to-date number reflected on a quarterly average basis

The increase in the Aflac U.S. new money yield ~~for~~in the three-month period ended March 31, ~~2022~~2023 was primarily due to ~~increased allocations to higher yielding floating rate asset classes.~~increases in U.S. interest rates. See Notes 3 and 5 of the Notes to the Consolidated Financial Statements and the Investments section of this MD&A for additional information on the Company's investments.

CORPORATE AND OTHER

Changes in the pretax adjusted earnings of Corporate and other are primarily affected by investment income. The following table presents a summary of results for Corporate and other.

Corporate and Other Summary of Operating Results


		Three Months Ended March 31,						Three Months Ended March 31,
(In millions)	(In millions)		2022		2021		(In millions)		2023		2022
Net earned premiums	Net earned premiums		$	41	$	48	Net earned premiums		$	91	$	41
Net investment income (loss) (1)	Net investment income (loss) (1)		4		16		Net investment income (loss) (1)		7		4
Amortized hedge income related to certain foreign currency management strategies	Amortized hedge income related to certain foreign currency management strategies		11		17		Amortized hedge income related to certain foreign currency management strategies		29		11
Adjusted net investment income	Adjusted net investment income		15		33		Adjusted net investment income		36		15
Other income	Other income		18		2		Other income		2		18
Total adjusted revenues	Total adjusted revenues		74		83		Total adjusted revenues		129		74
Benefits and claims, net			39		43
Total benefits and claims, net							Total benefits and claims, net		46		37
Adjusted expenses:	Adjusted expenses:						Adjusted expenses:
Interest expense	Interest expense		40		44		Interest expense		33		40
Other adjusted expenses	Other adjusted expenses		39		22		Other adjusted expenses		57		40
Total adjusted expenses	Total adjusted expenses		79		66		Total adjusted expenses		90		80
Total benefits and adjusted expenses	Total benefits and adjusted expenses		118		109		Total benefits and adjusted expenses		136		116
Pretax adjusted earnings	Pretax adjusted earnings		$	(44)	$	(26)	Pretax adjusted earnings		$	(7)	$	(42)

(1) The change in value of federal historic rehabilitation and solar investments in partnerships of $51 and $12 for the three-month ~~period~~periods ended March 31, 2023, and 2022, respectively, is included as a reduction to net investment income. Tax credits on these investments of $52 and $16 for the three-month ~~period~~periods ended March 31, 2023, and 2022, respectively, have been recorded as an income tax benefit in the consolidated statement of earnings. See Note 3 of the Notes to the Consolidated Financial Statements for additional information on these investments.

Prior-year amounts have been adjusted for the adoption of accounting guidance on January 1, 2023 related to accounting for long-duration insurance contracts.

In the three-month period ended March 31, ~~2022, the decrease in~~2023, total adjusted revenues ~~was~~increased compared to the same period in 2022 primarily ~~driven by a decline~~due to higher total premiums associated with the Aflac Re global reinsurance strategy and an increase in adjusted net investment ~~income, partially offset by an increase in other income due~~income. Total adjusted expenses increased compared to the ~~receipt of interest on a tax refund and a gain on the sale of a parcel of non-core real estate. The decline~~same period in ~~adjusted net investment income was~~2022 primarily due to expenses associated with the Aflac Re global reinsurance strategy. These results also reflect the impact of ~~federal tax credit investments discussed below~~foreign currency on total net earned premiums and ~~lower amortized hedge income as a result of changing market conditions. The decrease in pretax~~the corresponding benefits. Pretax adjusted earnings ~~for~~increased in the three-month period ended March 31, 2023 when compared to the same period in 2022 ~~primarily reflects lower~~reflecting the increase in total adjusted ~~revenues and increases in~~revenue, partially offset by higher other adjusted ~~expenses.~~expenses, net benefits and claims.

limited partnerships and included in other investments in the consolidated balance sheet. The change in value of each investment is recorded as a reduction to net investment income. Tax credits generated by these investments are recorded as an income tax benefit in the consolidated statement of earnings.

INVESTMENTS

The Company’s investment strategy utilizes disciplined asset and liability management while seeking long-term risk-adjusted investment returns and the delivery of stable income within regulatory and capital objectives, and preserving shareholder value. In attempting to optimally balance these objectives, the Company seeks to maintain on behalf of Aflac Japan a diversified portfolio of yen-denominated investment assets, U.S. dollar-denominated investment portfolio hedged back to yen and a portfolio of unhedged U.S. dollar-denominated assets. As part of the Company's portfolio management and asset allocation process, Aflac U.S. invests in fixed maturity investments and growth assets, including public equity securities and alternative investments in limited partnerships. Aflac U.S. invests in both publicly traded and privately originated investment-grade and below-investment-grade fixed maturity securities and loans. ~~Additionally, in November 2021, the~~The Company ~~became~~is also a signatory to the Principles for Responsible Investment, a global framework for incorporating environmental, social and governance (ESG) considerations into investment and ownership decisions.

For additional information concerning the Company's investments, see Notes 3, 4, and 5 of the Notes to the Consolidated Financial Statements.

The following tables detail investments by segment.

Investment Securities by Segment


		March 31, 2022									March 31, 2023
(In millions)	(In millions)	Aflac Japan		Aflac U.S.		Corporate and Other		Total		(In millions)	Aflac Japan		Aflac U.S.		Corporate and Other		Total
Available for sale, fixed maturity securities, at fair value	Available for sale, fixed maturity securities, at fair value	$	74,352	$	13,720	$	1,893	$	89,965	Available for sale, fixed maturity securities, at fair value	$	61,628	$	12,661	$	3,810	$	78,099
Held to maturity, fixed maturity securities, at amortized cost (1)	Held to maturity, fixed maturity securities, at amortized cost (1)	20,672		0		0		20,672		Held to maturity, fixed maturity securities, at amortized cost (1)	18,936		0		0		18,936
Equity securities	Equity securities	677		217		521		1,415		Equity securities	655		51		381		1,087
Commercial mortgage and other loans:	Commercial mortgage and other loans:									Commercial mortgage and other loans:
Transitional real estate loans (1)	Transitional real estate loans (1)	4,359		1,071		109		5,539		Transitional real estate loans (1)	5,277		1,158		200		6,635
Commercial mortgage loans (1)	Commercial mortgage loans (1)	1,210		653		8		1,871		Commercial mortgage loans (1)	1,134		624		0		1,758
Middle market loans (1)	Middle market loans (1)	4,457		445		0		4,902		Middle market loans (1)	4,474		461		0		4,935
Other investments:	Other investments:									Other investments:
Policy loans	Policy loans	203		21		0		224		Policy loans	189		25		0		214
Short-term investments (2)	Short-term investments (2)	469		291		987		1,747		Short-term investments (2)	1,334		172		1,055		2,561
Limited partnerships	Limited partnerships	1,623		179		162		1,964		Limited partnerships	2,034		222		176		2,432
Other	Other	0		25		0		25		Other	0		34		0		34
Investment in affiliate (3)										Investment in affiliate (3)	0		119		(119)		0
Total investments	Total investments	108,022		16,622		3,680		128,324		Total investments	95,661		15,527		5,503		116,691
Cash and cash equivalents	Cash and cash equivalents	1,626		583		2,066		4,275		Cash and cash equivalents	1,517		701		1,591		3,809
Total investments and cash	Total investments and cash	$	109,648	$	17,205	$	5,746	$	132,599	Total investments and cash	$	97,178	$	16,228	$	7,094	$	120,500

(1) Net of allowance for credit losses

(2) Includes securities lending collateral

(3) For consolidated reporting, Aflac U.S.'s investment in Aflac Re is eliminated in Corporate and other

December 31, 2021
(In millions) Aflac Japan Aflac U.S. Corporate and Other Total
Available for sale, fixed maturity securities,
   at fair value $ 81,793 $ 14,910 $ 1,993 $ 98,696
Held to maturity, fixed maturity securities,
   at amortized cost (1)
22,000 0 0 22,000
Equity securities 714 226 663 1,603
Commercial mortgage and other loans:
Transitional real estate loans (1)
4,226 1,020 45 5,291
Commercial mortgage loans (1)
1,217 669 8 1,894
Middle market loans (1)
4,297 304 0 4,601
Other investments:
Policy loans 216 20 0 236
Short-term investments (2)
590 302 834 1,726
Limited partnerships 1,534 169 155 1,858
Other 0 22 0 22
     Total investments 116,587 17,642 3,698 137,927
Cash and cash equivalents 2,053 681 2,317 5,051
              Total investments and cash $ 118,640 $ 18,323 $ 6,015 $ 142,978


	December 31, 2022
(In millions)	Aflac Japan		Aflac U.S.		Corporate and Other		Total
Available for sale, fixed maturity securities, at fair value	$	61,615	$	12,231	$	1,895	$	75,741
Held to maturity, fixed maturity securities, at amortized cost (1)	19,056		0		0		19,056
Equity securities	650		51		390		1,091
Commercial mortgage and other loans:
Transitional real estate loans (1)	5,133		1,140		182		6,455
Commercial mortgage loans (1)	1,269		729		15		2,013
Middle market loans (1)	4,557		471		0		5,028
Other investments:
Policy loans	190		24		0		214
Short-term investments (2)	319		184		1,029		1,532
Limited partnerships	1,900		208		182		2,290
Other	0		34		0		34
Investment in affiliate (3)	0		195		(195)		0
Total investments	94,689		15,267		3,498		113,454
Cash and cash equivalents	1,601		720		1,622		3,943
Total investments and cash	$	96,290	$	15,987	$	5,120	$	117,397

(1) Net of allowance for credit losses

(2) Includes securities lending collateral

(3) For consolidated reporting, Aflac U.S.'s investment in Aflac Re is eliminated in Corporate and other

The ratings of the Company's securities referenced in the table below are based on the ratings designations provided by major rating organizations such as Moody's, Standard & Poor's and Fitch or, if not rated, are determined based on the Company's internal analysis of such securities. When the ratings issued by the rating agencies differ, the Company utilizes

the second lowest rating when three or more rating agency ratings are available or the lowest rating when only two rating agency ratings are available.

The distributions of fixed maturity securities the Company owns, by credit rating, were as follows:

Composition of Fixed Maturity Securities by Credit Rating


			March 31, 2022						December 31, 2021							March 31, 2023						December 31, 2022
		Amortized Cost			Fair Value			Amortized Cost			Fair Value				Amortized Cost			Fair Value			Amortized Cost			Fair Value
AAA	AAA		1.0	%		0.9	%		1.0	%		.9	%	AAA		1.7	%		1.6	%		1.6	%		1.5	%
AA	AA		5.2			5.3			5.1			5.2		AA		5.3			5.4			5.2			5.3
A	A		68.5			68.5			68.9			68.5		A		67.9			68.0			68.0			68.1
BBB	BBB		22.9			22.9			22.5			22.8		BBB		23.0			22.8			23.0			22.9
BB or lower	BB or lower		2.4			2.4			2.5			2.6		BB or lower		2.1			2.2			2.2			2.2
Total	Total		100.0	%		100.0	%		100.0	%		100.0	%	Total		100.0	%		100.0	%		100.0	%		100.0	%

As of March 31, ~~2022,~~2023, the Company's direct and indirect exposure to securities in its investment portfolio that were guaranteed by third parties was immaterial both individually and in the aggregate.

The following table presents the 10 largest unrealized loss positions in the Company's portfolio as of March 31, ~~2022.~~2023.

(In millions) Credit
Rating Amortized
Cost Fair
Value Unrealized Loss
KLM Royal Dutch Airlines B $ 139 $ 120 $ (19)
Banco de Chile A 163 149 (14)
Kommunal Landspensjonskasse (KLP) BBB 123 113 (10)
Lloyds Banking Group PLC A 188 178 (10)
JPMORGAN CHASE & CO A 224 215 (9)
ORACLE CORP BBB 195 186 (9)
Heathrow Funding Ltd. BBB 82 73 (9)
DANSKE BANK A/S BBB 135 126 (9)
Intesa Sanpaolo Spa BBB 127 119 (8)
Nippon Prologis REIT Inc. A 82 74 (8)


(In millions)	Credit Rating		Amortized Cost			Fair Value			Unrealized Loss
KLM Royal Dutch Airlines		B		$	136		$	103		$	(33)
GLP Pte Ltd.		BBB		112			80			(32)
Autostrade Per Litalia Spa		BBB		148			116			(32)
Prologis LP		A		171			141			(30)
JP Morgan Chase and Co.		A		200			171			(29)
Banco de Chile		A		150			122			(28)
Investcorp Capital Limited		BB		327			306			(21)
Credit Suisse Group AG		BBB		75			55			(20)
Grand City Properties SA		BBB		56			37			(19)
Urban Renaissance Agency		A		183			164			(19)

Generally, declines in fair values can be a result of changes in interest rates, yen/dollar exchange rate, and changes in net spreads driven by a broad market move or a change in the issuer's underlying credit quality. The Company believes these issuers have the ability to continue making timely payments of principal and interest. See the Unrealized Investment Gains and Losses section in Note 3 of the Notes to the Consolidated Financial Statements for further discussions of unrealized losses related to financial institutions and other corporate investments.

Below-Investment-Grade Securities

The Company's portfolio of below-investment-grade securities includes debt securities purchased while the issuer was rated investment grade plus other loans and bonds purchased as part of an allocation to that segment of the market. The following is the Company's below-investment-grade exposure.

Below-Investment-Grade Investments


		March 31, 2022									March 31, 2023
(In millions)	(In millions)	Par Value		Amortized Cost (1)		Fair Value		Unrealized Gain (Loss)		(In millions)	Par Value		Amortized Cost (1)		Fair Value		Unrealized Gain (Loss)
Investcorp Capital Limited	Investcorp Capital Limited	$	352	$	352	$	355	$	3	Investcorp Capital Limited	$	327	$	327	$	306	$	(21)
Pemex Project Funding Master Trust	Pemex Project Funding Master Trust	245		245		248		3		Pemex Project Funding Master Trust	225		225		228		3
Commerzbank	Commerzbank	204		152		224		72		Commerzbank	187		145		205		60
Telecom Italia SpA										Telecom Italia SpA	150		150		183		33
KLM Royal Dutch Airlines	KLM Royal Dutch Airlines	163		139		120		(19)		KLM Royal Dutch Airlines	150		136		103		(33)
Telecom Italia SpA		163		163		191		28
Autostrade Per Litalia Spa		163		162		175		13
Apache Corporation	Apache Corporation	138		116		156		40		Apache Corporation	138		110		130		20
Howmet Aerospace Inc.										Howmet Aerospace Inc.	100		70		101		31
IKB Deutsche Industriebank AG	IKB Deutsche Industriebank AG	106		50		94		44		IKB Deutsche Industriebank AG	97		48		77		29
Arconic Inc.		100		76		107		31
Generalitat de Catalunya	Generalitat de Catalunya	65		26		78		52		Generalitat de Catalunya	60		25		60		35
National Gas Co. Trinidad & Tobago										National Gas Co. Trinidad & Tobago	52		50		46		(4)
Other Issuers	Other Issuers	281		284		298		14		Other Issuers	63		64		51		(13)
Subtotal (2)	Subtotal (2)	1,980		1,765		2,046		281		Subtotal (2)	1,549		1,350		1,490		140

High yield corporate bonds	High yield corporate bonds	830		754		802		48		High yield corporate bonds	736		622		668		46
Middle market loans	Middle market loans	4,722		4,586		4,632		46		Middle market loans	4,642		4,454		4,456		2
Grand Total	Grand Total	$	7,532	$	7,105	$	7,480	$	375	Grand Total	$	6,927	$	6,426	$	6,614	$	188

(1) Net of allowance for credit losses

(2) Securities initially purchased as investment grade, but have subsequently been downgraded to below investment grade

The Company invests in middle market loans primarily to U.S. corporate borrowers, most of which have below-investment-grade ratings. The objectives of this program include enhancing the yield on invested assets, achieving further diversification of credit risk, and mitigating the risk of rising interest rates and hedge costs through the acquisition of floating rate assets.

The Company maintains an allocation to higher yielding corporate bonds within the Aflac Japan and Aflac U.S. portfolios. Most of these securities were rated below-investment-grade at the time of purchase, but the Company also purchased several that were rated investment grade which, because of market pricing, offer yields commensurate with below-investment-grade risk profiles. The objective of this allocation was to enhance the Company's yield on invested assets and further diversify credit risk. All investments in this program must have a minimum rating at purchase of low BB using the Company's above described rating methodology and are managed by the Company's internal credit portfolio management team.

Fixed Maturity Securities by Sector

The Company maintains diversification in investments by sector to avoid concentrations to any one sector, thus managing exposure risk. The following table shows the distribution of fixed maturities by sector classification.


		March 31, 2022											March 31, 2023
(In millions)	(In millions)	Amortized Cost (1)		Gross Unrealized Gains		Gross Unrealized Losses		Fair Value		% of Total		(In millions)	Amortized Cost (1)		Gross Unrealized Gains		Gross Unrealized Losses		Fair Value		% of Total
Government and agencies	Government and agencies	$	48,466	$	6,120	$	(348)	$	54,238	47.4	%	Government and agencies	$	43,595	$	4,082	$	(1,084)	$	46,593	46.3	%
Municipalities	Municipalities	2,751		454		(31)		3,174		2.7		Municipalities	2,593		261		(97)		2,757		2.8
Mortgage- and asset-backed securities	Mortgage- and asset-backed securities	1,335		57		(26)		1,366		1.3		Mortgage- and asset-backed securities	2,545		99		(77)		2,567		2.7
Public utilities	Public utilities	8,063		1,222		(46)		9,239		7.9		Public utilities	7,495		671		(191)		7,975		7.9
Electric	Electric	6,571		1,009		(29)		7,551		6.4		Electric	6,074		551		(134)		6,489		6.4
Natural Gas	Natural Gas	270		41		(3)		308		.3		Natural Gas	844		69		(32)		882		.9
Other	Other	580		84		(8)		656		.6		Other	577		51		(25)		604		.6
Utility/Energy		642		88		(6)		724		.6
Sovereign and Supranational		1,410		217		(8)		1,619		1.4
Sovereign and supranational												Sovereign and supranational	1,118		134		(14)		1,238		1.2
Banks/financial institutions	Banks/financial institutions	9,824		1,056		(194)		10,686		9.6		Banks/financial institutions	9,279		653		(512)		9,420		9.8
Banking	Banking	5,693		691		(113)		6,270		5.6		Banking	5,571		455		(295)		5,732		5.9
Insurance	Insurance	1,853		255		(40)		2,069		1.8		Insurance	1,716		143		(67)		1,791		1.8
Other	Other	2,278		110		(41)		2,347		2.2		Other	1,992		55		(150)		1,897		2.1
Other corporate	Other corporate	30,287		4,225		(284)		34,228		29.7		Other corporate	27,617		2,655		(1,107)		29,165		29.3
Basic Industry	Basic Industry	2,714		498		(27)		3,186		2.7		Basic Industry	2,444		307		(83)		2,669		2.6
Capital Goods	Capital Goods	3,317		359		(27)		3,649		3.2		Capital Goods	3,275		231		(147)		3,359		3.5
Communications	Communications	3,057		541		(14)		3,584		3.0		Communications	2,906		375		(66)		3,214		3.1
Consumer Cyclical	Consumer Cyclical	2,594		353		(13)		2,934		2.5		Consumer Cyclical	2,136		219		(50)		2,305		2.3
Consumer Non-Cyclical	Consumer Non-Cyclical	6,730		818		(63)		7,486		6.6		Consumer Non-Cyclical	6,148		522		(240)		6,429		6.5
Energy	Energy	3,137		572		(14)		3,695		3.1		Energy	2,556		359		(60)		2,855		2.7
Other	Other	1,220		149		(24)		1,345		1.2		Other	1,343		95		(113)		1,325		1.4
Technology	Technology	4,066		333		(62)		4,337		4.0		Technology	3,701		185		(171)		3,716		3.9
Transportation	Transportation	3,452		602		(40)		4,012		3.4		Transportation	3,108		362		(177)		3,293		3.3
Total fixed maturity securities	Total fixed maturity securities	$	102,136	$	13,351	$	(937)	$	114,550	100.0	%	Total fixed maturity securities	$	94,242	$	8,555	$	(3,082)	$	99,715	100.0	%

(1) Net of allowance for credit losses

Securities by Type of Issuance

The Company has investments in both publicly and privately issued securities. The Company's ability to sell either type of security is a function of overall market liquidity which is impacted by, among other things, the amount of outstanding securities of a particular issuer or issuance, trading history of the issue or issuer, overall market conditions, and idiosyncratic events affecting the specific issue or issuer.

8395

The following table details investment securities by type of issuance.

Investment Securities by Type of Issuance


			March 31, 2022						December 31, 2021							March 31, 2023						December 31, 2022
(In millions)	(In millions)	Amortized Cost (1)			Fair Value			Amortized Cost (1)			Fair Value			(In millions)	Amortized Cost (1)			Fair Value			Amortized Cost (1)			Fair Value
Publicly issued securities:	Publicly issued securities:													Publicly issued securities:
Fixed maturity securities	Fixed maturity securities		$	84,260		$	94,175		$	88,552		$	103,034	Fixed maturity securities		$	76,825		$	81,310		$	77,176		$	79,090
Equity securities	Equity securities		1,236			1,235			950			950		Equity securities		866			866			882			882
Total publicly issued	Total publicly issued		85,496			95,410			89,502			103,984		Total publicly issued		77,691			82,176			78,058			79,972
Privately issued securities: (2)	Privately issued securities: (2)													Privately issued securities: (2)
Fixed maturity securities (3)	Fixed maturity securities (3)		17,876			20,375			18,817			22,531		Fixed maturity securities (3)		17,417			18,405			17,349			17,861
Equity securities	Equity securities		179			180			653			653		Equity securities		221			221			209			209
Total privately issued	Total privately issued		18,055			20,555			19,470			23,184		Total privately issued		17,638			18,626			17,558			18,070
Total investment securities	Total investment securities		$	103,551		$	115,965		$	108,972		$	127,168	Total investment securities		$	95,329		$	100,802		$	95,616		$	98,042

(1) Net of allowance for credit losses

(2) Primarily consists of securities owned by Aflac Japan

(3) Excludes Rule 144A securities

The following table details the Company's reverse-dual currency securities.

Reverse-Dual Currency Securities(1)


(Amortized cost, in millions)	(Amortized cost, in millions)	March 31, 2022				December 31, 2021				(Amortized cost, in millions)	March 31, 2023				December 31, 2022
Privately issued reverse-dual currency securities	Privately issued reverse-dual currency securities		$	4,500			$	4,784		Privately issued reverse-dual currency securities		$	4,028			$	4,049
Publicly issued collateral structured as reverse-dual currency securities	Publicly issued collateral structured as reverse-dual currency securities		1,500				1,596			Publicly issued collateral structured as reverse-dual currency securities		1,374				1,383
Total reverse-dual currency securities	Total reverse-dual currency securities		$	6,000			$	6,380		Total reverse-dual currency securities		$	5,402			$	5,432
Reverse-dual currency securities as a percentage of total investment securities	Reverse-dual currency securities as a percentage of total investment securities		5.8		%		5.9		%	Reverse-dual currency securities as a percentage of total investment securities		5.7		%		5.7		%

(1) Principal payments in yen and interest payments in dollars

Aflac Japan has a portfolio of privately issued securities to better match liability characteristics and secure higher yields than those available on Japanese government or other public corporate bonds. Aflac Japan’s investments in yen-denominated privately issued securities consist primarily of non-Japanese issuers, are rated investment grade at purchase and have longer maturities, thereby allowing the Company to improve asset/liability matching and overall investment returns. These securities are generally either privately negotiated arrangements or issued under medium-term note programs and have standard documentation commensurate with credit ratings of the issuer, except when internal credit analysis indicates that additional protective and/or event-risk covenants were required. Many of these investments have protective covenants appropriate to the specific investment. These may include a prohibition of certain activities by the borrower, maintenance of certain financial measures, and specific conditions impacting the payment of the Company's notes.

HEDGING ACTIVITIES

The Company uses derivative contracts to hedge foreign currency exchange rate risk and interest rate risk. The Company uses various strategies, including derivatives, to manage these risks. See Item 7A. Quantitative and Qualitative Disclosures About Market Risk in the ~~2021~~2022 Annual Report for more information about market risk and the Company’s use of derivatives.

Derivatives are designed to reduce risk on an economic basis while minimizing the impact on financial results. The Company’s derivatives programs vary depending on the type of risk being hedged. See Note 4 of the Notes to the Consolidated Financial Statements for:

•A description of the Company's derivatives, hedging strategies and underlying risk ~~exposure~~.exposure.

•Information about the notional amount and fair market value of the Company's derivatives.

8496

•The unrealized and realized gains and losses impact on adjusted earnings of derivatives in cash flow, fair value, net investments in foreign operations, or non-qualifying hedging relationships.

Foreign Currency Exchange Rate Risk Hedge Program

The Company has deployed the following hedging strategies to mitigate exposure to foreign currency exchange rate risk:

•Aflac Japan hedges U.S. dollar-denominated investments back to yen (see Aflac Japan’s U.S. Dollar-Denominated Hedge Program below).

•Aflac Japan maintains certain unhedged U.S. dollar-denominated securities, which serve as an economic currency hedge of a portion of the Company's investment in Aflac Japan (see Aflac Japan’s U.S. Dollar-Denominated Hedge Program below).

•The Parent Company designates yen-denominated liabilities (notes payable and loans) as non-derivative hedging instruments and designates certain foreign currency forwards and options as derivative hedges of the Company’s net investment in Aflac Japan (see Enterprise Corporate Hedging Program below).

•The Parent Company enters into forward and option contracts to accomplish a dual objective of hedging foreign currency exchange rate risk related to dividend payments by its subsidiary, ALIJ, and reducing enterprise-wide hedge ~~costs.~~costs (see Enterprise Corporate Hedging Program below).

The following table presents metrics related to Aflac Japan's U.S. dollar-denominated hedge program and the Parent Company's enterprise corporate hedging program, including associated amortized hedge costs/income, for the ~~three-month~~ periods ended March 31. See the Results of Operations section of this MD&A for the Company's definition of amortized hedge costs/income.


		Three Months			Three Months
		2022	2021			2023	2022
Aflac Japan:	Aflac Japan:			Aflac Japan:
FX Forwards	FX Forwards			FX Forwards
FX forward (sell USD, buy yen) notional at end of period (in billions) (1)	FX forward (sell USD, buy yen) notional at end of period (in billions) (1)	$4.5	$6.4	FX forward (sell USD, buy yen) notional at end of period (in billions) (1)		$3.7	$4.5
Weighted average remaining tenor (in months) (2)	Weighted average remaining tenor (in months) (2)	9.9	9.7	Weighted average remaining tenor (in months) (2)		9.8	9.9
Amortized hedge income (cost) for period (in millions)	Amortized hedge income (cost) for period (in millions)	$(13)	$(17)	Amortized hedge income (cost) for period (in millions)		$(39)	$(13)
FX Options	FX Options			FX Options
FX option notional at the end of period (in billions) (1)	FX option notional at the end of period (in billions) (1)	$13.5	$11.5	FX option notional at the end of period (in billions) (1)		$13.5	$13.5
Weighted average remaining tenor (in months) (2)	Weighted average remaining tenor (in months) (2)	6.6	4.6	Weighted average remaining tenor (in months) (2)		7.4	6.6
Amortized hedge income (cost) for period (in millions)	Amortized hedge income (cost) for period (in millions)	$(13)	$(3)	Amortized hedge income (cost) for period (in millions)		$(19)	$(13)
Corporate and Other (Parent Company):
Corporate and other (Parent Company):				Corporate and other (Parent Company):
FX Forwards	FX Forwards			FX Forwards
FX forward (buy USD, sell yen) notional at end of period (in billions) (1)	FX forward (buy USD, sell yen) notional at end of period (in billions) (1)	$5.0	$5.0	FX forward (buy USD, sell yen) notional at end of period (in billions) (1)		$5.0	$5.0
Weighted average remaining tenor (in months) (2)	Weighted average remaining tenor (in months) (2)	10.9	11.5	Weighted average remaining tenor (in months) (2)		10.4	10.9
Amortized hedge income (cost) for period (in millions)	Amortized hedge income (cost) for period (in millions)	$12	$18	Amortized hedge income (cost) for period (in millions)		$31	$12
FX Options	FX Options			FX Options
FX option notional at the end of period (in billions) (1)	FX option notional at the end of period (in billions) (1)	$1.9	$1.9	FX option notional at the end of period (in billions) (1)		$2.2	$1.9
Weighted average remaining tenor (in months) (2)	Weighted average remaining tenor (in months) (2)	7.6	7.6	Weighted average remaining tenor (in months) (2)		7.4	7.6
Amortized hedge income (cost) for period (in millions)	Amortized hedge income (cost) for period (in millions)	$(1)	$(1)	Amortized hedge income (cost) for period (in millions)		$(2)	$(1)

(1) Notional is reported net of any offsetting positions within Aflac Japan or the Parent Company, respectively.

(2) Tenor based on period reporting date to settlement date

Amortized hedge costs/income can fluctuate based upon many factors, including the derivative notional amount, the length of time of the derivative contract, changes in both U.S. and Japan interest rates, and supply and demand for dollar funding. Amortized hedge costs/income have fluctuated in recent periods due to changes in the previously mentioned factors.

Aflac Japan’s U.S. Dollar-Denominated Hedge Program (U.S. Dollar Program)

Aflac Japan buys U.S. dollar-denominated investments, typically corporate bonds, and hedges them back to yen with foreign currency forwards and options to hedge foreign currency exchange rate risk. This economically creates yen assets that match yen liabilities during the life of the derivative and provides favorable capital treatment under the Japan solvency margin ratio (SMR) calculations. The currency risk being hedged is generally based on fair value of hedged investments. The following table summarizes the U.S. dollar-denominated investments held by Aflac Japan.


		March 31, 2022				December 31, 2021					March 31, 2023				December 31, 2022
(In millions)	(In millions)	Amortized Cost (1)		Fair Value		Amortized Cost (1)		Fair Value		(In millions)	Amortized Cost (1)		Fair Value		Amortized Cost (1)		Fair Value
Available-for-sale securities:	Available-for-sale securities:									Available-for-sale securities:
Fixed maturity securities (excluding bank loans)		$	16,543	$	18,715	$	17,615	$	20,478
Fixed maturity securities										Fixed maturity securities	$	12,817	$	14,176	$	14,321	$	15,191

Equity securities	Equity securities	22		22		24		24		Equity securities	33		33		33		33
Commercial mortgage and other loans:	Commercial mortgage and other loans:									Commercial mortgage and other loans:
Transitional real estate loans (floating rate)	Transitional real estate loans (floating rate)	4,359		4,406		4,226		4,293		Transitional real estate loans (floating rate)	5,277		5,207		5,133		5,088
Commercial mortgage loans		1,211		1,172		1,217		1,265
Commercial mortgage and other loans										Commercial mortgage and other loans	1,134		1,013		1,269		1,129
Middle market loans (floating rate)	Middle market loans (floating rate)	4,457		4,504		4,297		4,352		Middle market loans (floating rate)	4,474		4,468		4,557		4,545
Other investments	Other investments	1,622		1,622		1,534		1,534		Other investments	2,033		2,033		1,899		1,899
Total U.S. Dollar Program	Total U.S. Dollar Program	28,214		30,441		28,913		31,946		Total U.S. Dollar Program	25,768		26,930		27,212		27,885
Available-for-sale securities:	Available-for-sale securities:									Available-for-sale securities:
Fixed maturity securities - economically converted to yen	Fixed maturity securities - economically converted to yen	2,340		3,231		2,236		3,328		Fixed maturity securities - economically converted to yen	2,236		2,928		2,209		2,795
Total U.S. dollar-denominated investments in Aflac Japan	Total U.S. dollar-denominated investments in Aflac Japan	$	30,554	$	33,672	$	31,149	$	35,274	Total U.S. dollar-denominated investments in Aflac Japan	$	28,004	$	29,858	$	29,421	$	30,680

(1) Net of allowance for credit losses

The U.S. Dollar Program includes all U.S. dollar-denominated investments in Aflac Japan other than the investments in certain consolidated VIEs where the instrument is economically converted to yen as a result of a derivative in the consolidated VIE. The Company uses one-sided foreign currency put options to mitigate the settlement risk on U.S. dollar-denominated assets related to extreme foreign currency rate changes. From time to time, Aflac Japan also maintains a collar program on a portion of its U.S. Dollar Program to mitigate against more extreme moves in foreign exchange and therefore support SMR. As of March 31, ~~2022,~~2023, there were no collars in Aflac Japan, and none of the Company's foreign currency options hedging Aflac Japan's U.S. dollar-denominated assets were in-the-money.

In 2021, the Company moved to a strategy that contains one-sided put options, fewer foreign currency forwards and no collars. The Company believes that the new strategy will reduce its exposure to pricing volatility and the related risk of negative settlements should there be a material weakening in the yen. Depending on further developments, including the possibility of further market volatility, there may be additional costs associated with maintaining the options program. The Company is continually evaluating other adjustments, including the possibility of changing the level of hedging employed with the U.S. dollar-denominated investments.

As of March 31, ~~2022,~~2023, the fair value of Aflac Japan's unhedged U.S. dollar-denominated portfolio was ~~$9.9~~$9.7 billion (excluding certain U.S. dollar-denominated assets shown in the table above as a result of consolidation that have been economically converted to yen using derivatives).

Foreign exchange derivatives used for hedging are periodically settled, which results in cash receipt or payment at maturity or early termination. The following table presents the settlements associated with the Company's currency derivatives used for hedging Aflac Japan’s U.S. dollar-denominated investments.


		Three Months Ended March 31,							Three Months Ended March 31,
(In millions)	(In millions)	2022			2021			(In millions)		2023		2022
Net cash inflows (outflows)	Net cash inflows (outflows)		$	(619)		$	108				Net cash inflows (outflows)		$	(579)	$	(619)

Enterprise Corporate Hedging Program

The Company has designated certain yen-denominated liabilities and foreign currency forwards and options of the Parent Company as accounting hedges of its net investment in Aflac Japan. The Company's consolidated yen-denominated net asset position was partially hedged at ~~$10.0~~$11.1 billion as of March 31, ~~2022,~~2023, with hedging instruments comprised of ~~$3.1~~$3.9 billion of yen-denominated debt and ~~$6.9~~$7.2 billion of foreign currency forwards and options, compared with ~~$10.2~~$11.6 billion as of December 31, ~~2021,~~2022, with hedging instruments comprised of ~~$3.3~~$4.0 billion of yen-denominated debt and ~~$6.9~~$7.6 billion of foreign currency forwards and options.

8798

The Company makes its accounting designation of net investment hedge at the beginning of each quarter. If the total of the designated Parent Company non-derivative and derivative notional is equal to or less than the Company's net investment in Aflac Japan, the hedge is deemed to be effective, and the currency exchange effect on the yen-denominated liabilities and the change in estimated fair value of the derivatives are reported in the unrealized foreign currency component of other comprehensive income. The Company's net investment hedge was effective during the three-month periods ended March 31, ~~2022~~2023 and ~~2021,~~2022, respectively. For additional information on the Company's net investment hedging strategy, see Note 4 of the Notes to the Consolidated Financial Statements.

In order to economically mitigate risks associated with the enterprise-wide exposure to the yen and the level and volatility of hedge costs, the Parent Company enters into foreign exchange forward and option contracts. By buying U.S. dollars and selling yen, the Parent Company is effectively lowering its overall economic exposure to the yen, while Aflac Japan's U.S. dollar exposure remains reduced as a result of Aflac Japan's U.S. Dollar Program that economically creates yen assets. Among other objectives, this strategy is intended to offset the enterprise-wide amortized hedge costs by generating amortized hedge income. This activity is reported in Corporate and ~~Other.~~other. The Company continually evaluates the program’s efficacy.

As part of the Company’s internal reinsurance platform, Aflac Re enters into foreign currency forwards with the Parent Company to economically manage the currency mismatch between Aflac Re's assets, which are mostly denominated in U.S. dollars, and liabilities, which are mostly denominated in yen, in order to support and optimize BMA capital requirements. For additional information on the Company's internal reinsurance platform, see Note 8 of the Notes to the Consolidated Financial Statements and the Liquidity and Capital Resources section of this MD&A.

Interest Rate Risk Hedge Program

Aflac Japan and Aflac U.S. use interest rate swaps from time to time to mitigate the risk of investment income volatility for certain variable-rate investments. Additionally, to manage interest rate risk associated with its U.S. dollar-denominated investments held by Aflac Japan, from time to time the Company utilizes interest rate swaptions.

For additional discussion of the risks associated with the foreign currency exposure refer to the Currency Risk section in Item 7A., Quantitative and Qualitative Disclosures about Market Risk, and Item 1A, specifically to the Risk Factors titled “The Company is exposed to foreign currency fluctuations in the yen/dollar exchange rate" and “Lack of availability of acceptable yen-denominated investments could adversely affect the Company's results of operations, financial position or liquidity" in the ~~2021~~2022 Annual Report.

See Note 4 of the Notes to the Consolidated Financial Statements for additional information on the Company's hedging activities.

DEFERRED POLICY ACQUISITION COSTS

The following table presents deferred policy acquisition costs by segment.


(In millions)	(In millions)	March 31, 2022			December 31, 2021			% Change				(In millions)	March 31, 2023			December 31, 2022			% Change
Aflac Japan	Aflac Japan		$	5,842		$	6,233		(6.3)	%	(1)	Aflac Japan		$	5,776		$	5,776		.0	%	(1)
Aflac U.S.	Aflac U.S.		3,240			3,292			(1.6)			Aflac U.S.		3,491			3,463			.8

Total	Total		$	9,082		$	9,525		(4.7)	%		Total		$	9,267		$	9,239		.3	%

(1) Aflac Japan’s deferred policy acquisition costs ~~decreased .3%~~increased .6% in yen during the three months ended March 31, ~~2022.~~2023.

Prior-year amounts have been adjusted for the adoption of accounting guidance on January 1, 2023 related to accounting for long-duration insurance contracts.

See Note 6 of the Notes to the Consolidated Financial Statements ~~in the 2021 Annual Report~~ for additional information on the Company's deferred policy acquisition costs.

POLICY LIABILITIES

The following table presents policy liabilities by segment.


(In millions)	(In millions)	March 31, 2022			December 31, 2021			% Change				(In millions)	March 31, 2023			December 31, 2022			% Change
Aflac Japan	Aflac Japan		$	88,089		$	93,613		(5.9)	%	(1)	Aflac Japan		$	88,944		$	86,088		3.3	%	(1)
Aflac U.S.	Aflac U.S.		11,976			11,916			.5			Aflac U.S.		11,542			11,187			3.2
Other			266			276			(3.6)
Corporate and other												Corporate and other		1,874			302			100.0
Intercompany eliminations(2)	Intercompany eliminations(2)		(688)			(733)			(6.1)			Intercompany eliminations(2)		(2,427)			(667)			100.0
Total	Total		$	99,643		$	105,072		(5.2)	%		Total		$	99,933		$	96,910		3.1	%

(1) Aflac Japan’s policy liabilities increased ~~.1%~~4.0% in yen during the three months ended March 31, ~~2022.~~2023.

(2) Elimination entry necessary due to the internal reinsurance transaction with Aflac Re and to recapture of a portion of policy liabilities ceded externally as a result of the reinsurance retrocession ~~transaction as described in~~transaction. See Note 8 of the Notes to the Consolidated Financial Statements.

Prior-year amounts have been adjusted for the adoption of accounting guidance on January 1, 2023 related to accounting for long-duration insurance contracts.

See Note 7 of the Notes to the Consolidated Financial ~~Statements.~~

Statements for additional information on the Company's policy liabilities.

BENEFIT PLANS

Aflac Japan and Aflac U.S. have various benefit plans. For additional information on the Company's Japanese and U.S. plans, see Note 1112 of the accompanying Notes to the Consolidated Financial Statements and Note 14 of the Notes to the Consolidated Financial Statements in the ~~2021~~2022 Annual Report.

POLICYHOLDER PROTECTION

Policyholder Protection Corporation

The Japanese insurance industry has a policyholder protection system that provides funds for the policyholders of insolvent insurers. Legislation enacted regarding the framework of the Life Insurance Policyholder Protection Corporation (LIPPC) included government fiscal measures supporting the LIPPC. In March 2022, Japan's Diet passed legislation that extended the government's fiscal support of the LIPPC through March 2027. ~~Effective April 2014,~~In March 2022, the ~~annual~~ LIPPC ~~contribution amount~~reached the required balance for the total life industry ~~was lowered from ¥40~~of ¥400 billion as specified by its Articles of Incorporation. As a result, additional contributions are not expected to ~~¥33 billion.~~be required unless the balance is reduced due to payments made by the LIPPC to the policyholders of insolvent insurers. Accordingly, Aflac Japan did not recognize an expense for LIPPC assessments for the three-month period ended March 31, 2023. Aflac Japan recognized an expense for LIPPC assessments of ¥.9 billion for ~~both of~~ the three-month ~~periods~~period ended March 31, ~~2022 and 2021 for LIPPC assessments.~~2022.

Guaranty Fund Assessments

Under U.S. state guaranty association laws, certain insurance companies can be assessed (up to prescribed limits) for certain obligations to the policyholders and claimants of impaired or insolvent insurance companies that write the same line or similar lines of business. The amount of the guaranty fund assessment that an insurer is assessed is based on its proportionate share of premiums in that state. Guaranty fund assessments for the three-month periods ended March 31, ~~2022~~2023 and ~~2021~~2022 were immaterial.

LIQUIDITY AND CAPITAL RESOURCES

Liquidity refers to the ability to generate sufficient cash resources to meet the payment obligations of the Company. Capital refers to the long-term financial resources available to support the operations of the businesses, fund business growth and provide for an ability to withstand adverse circumstances. Financial leverage (leverage) refers to an investment strategy of using debt to increase the potential ROE. The Company targets and actively manages liquidity, capital and leverage in the context of a number of considerations, including:

•business investment and growth needs

•strategic growth objectives

•financial flexibility and obligations

100

•capital support for hedging activity

•a constantly evolving business and economic environment

•a balanced approach to capital allocation and shareholder deployment.

The governance framework supporting liquidity, capital and leverage includes global senior management and board committees that review and approve all significant capital related decisions.

The Company's cash and cash equivalents include unrestricted cash on hand, money market instruments, and other debt instruments with a maturity of 90 days or less when purchased, all of which ~~has~~have minimal market, settlement or other risk exposure. The target minimum amount for the Parent Company’s cash and cash equivalents is approximately ~~$2.0~~$1.8 billion to provide a capital buffer and liquidity support at the holding company. This amount excludes $400 million of proceeds from the issuance of senior sustainability notes in 2021, unallocated proceeds of which contribute to total cash but are not intended to support holding company liquidity. The Company remains committed to prudent liquidity and capital management. At March 31, ~~2022,~~2023, the Company held ~~$4.3~~$3.8 billion in cash and cash equivalents for stress conditions, which includes the Parent Company's target minimum amount of ~~$2.0~~$1.8 billion.

Aflac Japan and Aflac U.S. generate cash flows from their operations and provide the primary sources of liquidity to the Parent Company through management fees and dividends, with Aflac Japan being the largest contributor. The primary uses of cash by the Parent Company are shareholder dividends, the repurchase of its common stock, interest on its outstanding indebtedness and operating expenses.

The following table presents the amounts provided to the Parent Company for the three-month periods ended March 31.

Liquidity Provided by Subsidiaries to Parent Company


(In millions)	(In millions)	2022		2021		(In millions)	2023		2022
Management fees paid by subsidiaries	Management fees paid by subsidiaries	$	33	$	32	Management fees paid by subsidiaries	$	38	$	33
Dividends declared or paid by subsidiaries	Dividends declared or paid by subsidiaries	514		427		Dividends declared or paid by subsidiaries	780		514

The following table details Aflac Japan remittances, which are included in the totals above, for the three-month periods ended March 31.

Aflac Japan Remittances


(In millions of dollars and billions of yen)	(In millions of dollars and billions of yen)	2022		2021		(In millions of dollars and billions of yen)	2023		2022
Aflac Japan management fees paid to Parent Company	Aflac Japan management fees paid to Parent Company	$	15	$	15	Aflac Japan management fees paid to Parent Company	$	16	$	15

Aflac Japan dividends declared or paid to Parent Company (in dollars)	Aflac Japan dividends declared or paid to Parent Company (in dollars)	339		377		Aflac Japan dividends declared or paid to Parent Company (in dollars)	505		339
Aflac Japan dividends declared or paid to Parent Company (in yen)	Aflac Japan dividends declared or paid to Parent Company (in yen)	¥	41.1	¥	41.0	Aflac Japan dividends declared or paid to Parent Company (in yen)	¥	67.3	¥	41.1

The Company intends to maintain higher than historical levels of liquidity and capital at the Parent Company for stress conditions and with the goals of addressing the Company’s hedge costs and related potential need for collateral and mitigating against long-term weakening of the Japanese yen. Further, the Company plans to continue to maintain a portfolio of unhedged U.S. dollar-denominated investments at Aflac Japan and to consider whether the amount of such investments should be increased or decreased relative to the Company’s view of economic equity surplus in Aflac Japan in light of potentially rising hedge costs and other factors. See the Hedging Activity subsection of this MD&A for more information.

The Company believes that its balance of cash and cash equivalents and cash generated by operations will be sufficient to satisfy both its short-term and long-term cash requirements and plans for cash, including material cash requirements from known contractual obligations and returning capital to shareholders through share repurchases and dividends. For additional information, see the Liquidity and Capital Resources section of Item 7. MD&A in the ~~2021~~2022 Annual Report.

In addition to cash and cash equivalents, the Company also maintains credit facilities, both intercompany and with external partners, and a number of other available tools to support liquidity needs on a global basis. In September 2021, the Parent Company filed a shelf registration statement with the SEC that allows the Company to issue an indefinite amount of debt securities, in one or more series, from time to time until September 2024. The Company believes outside sources for additional debt and equity capital, if needed, will continue to be available. Additionally, as of March 31, ~~2022,~~2023, the Parent Company and Aflac had four lines of credit with third parties and ~~ten~~twelve intercompany lines of credit. The Company was in compliance with all of the covenants of its notes payable and lines of credit at March 31, ~~2022.~~2023. For additional information, see Note 9 of the Notes to the Consolidated Financial Statements.

101

As part of enterprise-wide capital management and optimization, the Company also utilizes the newly-created intercompany reinsurance platform to execute internal reinsurance transactions with Aflac Re. For additional information, see Note 8 of the Notes to the Consolidated Financial Statements.

The Company's consolidated financial statements convey its financing arrangements during the periods presented. The Company has not engaged in material intra-period short-term financings during the periods presented that are not otherwise reported in its balance sheet or disclosed therein. As of March 31, ~~2022,~~2023, the Company had no material letters of credit, standby letters of credit, guarantees or standby repurchase obligations. The Company has not entered into transactions involving the transfer of financial assets with an obligation to repurchase financial assets that have been accounted for as a sale under applicable accounting standards, including securities lending transactions. See Notes 3 and 4 of the Notes to the Consolidated Financial Statements and Notes 1, 3, and 4 of the Notes to the Consolidated Financial Statements in the ~~2021~~2022 Annual Report for more information on the Company's securities lending and derivative activities. See Note 15 of the Notes to the Consolidated Financial Statements in the ~~2021~~2022 Annual Report for information on material unconditional purchase obligations that are not recorded on the Company's balance sheet. With the exception of disclosed activities in those referenced footnotes and the Risk Factors in the ~~2021~~2022 Annual Report entitled, "The Company is exposed to foreign currency fluctuations in the yen/dollar exchange rate" and "Lack of availability of acceptable yen-denominated investments could adversely affect the Company's results of operations, financial position or liquidity," the Company is not aware of any trend, demand, commitment, event or uncertainty that would reasonably result in its liquidity increasing or decreasing by a material amount.

Consolidated Cash Flows

The Company consistently generates positive cash flows from operations, and has the ability to adjust cash flow management from other sources of liquidity including reinvestment cash flows and selling investments in order to meet short-term cash needs.

The Company translates cash flows for Aflac Japan’s yen-denominated items into U.S. dollars using weighted-average exchange rates. In periods when the yen weakens, translating yen into dollars causes fewer dollars to be reported. When the yen strengthens, translating yen into dollars causes more dollars to be reported.

The following table summarizes consolidated cash flows by activity for the three-month periods ended March 31.


(In millions)	(In millions)	2022		2021		(In millions)	2023		2022
Operating activities	Operating activities	$	1,260	$	1,366	Operating activities	$	708	$	1,260
Investing activities	Investing activities	(1,210)		(969)		Investing activities	105		(1,210)
Financing activities	Financing activities	(737)		(470)		Financing activities	(933)		(737)
Exchange effect on cash and cash equivalents	Exchange effect on cash and cash equivalents	(89)		(78)		Exchange effect on cash and cash equivalents	(14)		(89)
Net change in cash and cash equivalents	Net change in cash and cash equivalents	$	(776)	$	(151)	Net change in cash and cash equivalents	$	(134)	$	(776)

Operating Activities

The principal cash inflows for the Company's insurance activities come from insurance premiums and investment income. The principal cash outflows are the result of policy claims, operating expenses, income tax, as well as interest expense. As a result of policyholder aging, claims payments are expected to gradually increase over the life of a policy. Therefore, future policy benefit reserves are accumulated in the early years of a policy and are designed to help fund future claims payments.

The Company expects its future cash flows from premiums and investment portfolios to be sufficient to meet its cash needs for benefits and expenses.

Investing Activities

The Company's investment objectives provide for liquidity primarily through the purchase of publicly traded investment-grade debt securities. Prudent portfolio management dictates that the Company attempts to match the duration of its assets with the duration of its liabilities. Currently, when the Company's fixed maturity securities mature, the proceeds may be reinvested at a yield below that required for the accretion of policy benefit liabilities on policies issued in earlier years. However, the long-term nature of the Company's business and its strong cash flows provide the Company with the ability to minimize the effect of mismatched durations and/or yields identified by various asset adequacy analyses. From time to time or when market opportunities arise, the Company disposes of selected fixed maturity securities that are available for

102

sale to improve the duration matching of assets and liabilities, improve future investment yields, and/or re-balance its portfolio. As a result, dispositions before maturity can vary significantly from year to year.

As part of its overall corporate strategy, the Company has committed $400 million to Aflac Ventures, LLC (Aflac Ventures), as opportunities emerge. Aflac Ventures is a subsidiary of Aflac Global Ventures, LLC (Aflac Global Ventures) which is reported in Corporate and other. The central mission of Aflac Global Ventures is to support the organic growth and business development needs of Aflac Japan and Aflac U.S. with an emphasis on digital applications designed to improve the customer experience, gain efficiencies, and develop new markets in an effort to enhance and defend long-term shareholder value. Investments are included in equity securities or the other investments line in the consolidated balance sheets.

As part of an arrangement with Federal Home Loan Bank of Atlanta (FHLB), Aflac U.S. obtains low-cost funding from FHLB supported by acceptable forms of collateral pledged by Aflac U.S. In the first three months of ~~2022,~~2023, Aflac U.S. borrowed and repaid ~~$171~~$37 million under this program. As of March 31, ~~2022,~~2023, Aflac U.S. had outstanding borrowings of ~~$471~~$591 million reported in its balance sheet.

See Note 3 of the Notes to the Consolidated Financial Statements for details on certain investment commitments.

Financing Activities

Cash flows from financing activities consist primarily of share repurchases, dividends to shareholders and from time to time debt issuances and redemptions.

Cash returned to shareholders through treasury stock purchases and dividends was $948 million during the three-month period ended March 31, 2023, compared with $750 million during the three-month period ended March 31, ~~2022, compared with $869 million during the three-month period ended March 31, 2021.~~2022.

The following tables present a summary of treasury stock activity during the three-month periods ended March 31.

Treasury Stock Purchased


(In millions of dollars and thousands of shares)	(In millions of dollars and thousands of shares)	2022		2021		(In millions of dollars and thousands of shares)	2023		2022
Treasury stock purchases	Treasury stock purchases	$	500	$	650	Treasury stock purchases	$	700	$	500
Number of shares purchased:	Number of shares purchased:					Number of shares purchased:
Share repurchase program	Share repurchase program	8,007		13,440		Share repurchase program	10,348		8,007
Other	Other	343		378		Other	347		343
Total shares purchased	Total shares purchased	8,350		13,818		Total shares purchased	10,695		8,350

Treasury Stock Issued


(In millions of dollars and thousands of shares)	(In millions of dollars and thousands of shares)	2022		2021		(In millions of dollars and thousands of shares)	2023		2022
Stock issued from treasury:	Stock issued from treasury:					Stock issued from treasury:
Cash financing	Cash financing	$	9	$	9	Cash financing	$	2	$	9
Noncash financing	Noncash financing	17		19		Noncash financing	18		17
Total stock issued from treasury	Total stock issued from treasury	$	26	$	28	Total stock issued from treasury	$	20	$	26
Number of shares issued	Number of shares issued	526		810		Number of shares issued	458		526

As of March 31, ~~2022,~~2023, a remaining balance of ~~47.8~~106.3 million shares of the Company's common stock was available for purchase under share repurchase authorizations by its board of directors.

Cash dividends paid to shareholders were $.42 per share in the first quarter of 2023, compared with $.40 per share in the first quarter of ~~2022, compared with $.33 per share in the first quarter of 2021.~~2022. The following table presents the dividend activity for the three-month periods ended March 31.


(In millions)	(In millions)	2022		2021		(In millions)	2023		2022
Dividends paid in cash	Dividends paid in cash	$	250	$	219	Dividends paid in cash	$	248	$	250
Dividends through issuance of treasury shares	Dividends through issuance of treasury shares	9		8		Dividends through issuance of treasury shares	9		9
Total dividends to shareholders	Total dividends to shareholders	$	259	$	227	Total dividends to shareholders	$	257	$	259

103

In April ~~2022,~~2023, the board of directors declared the second quarter cash dividend of ~~$.40~~$.42 per share, an increase of ~~21.2%~~5.0% compared with the same period in ~~2021.~~2022. The dividend is payable on June 1, ~~2022~~2023 to shareholders of record at the close of business on May ~~18, 2022.~~17, 2023.

Regulatory Restrictions

Aflac Japan

Aflac Japan is required to meet certain financial criteria as governed by Japanese corporate law in order to provide dividends to the Parent Company. Under these criteria, dividend capacity at the Japan subsidiary is basically defined as total equity excluding common stock ~~accumulated other comprehensive income amounts,~~and capital reserves (representing statutorily required amounts in Japan) but reduced for net after-tax unrealized losses on available-for-sale securities. These dividend capacity requirements are generally aligned with the SMR. Japan's ~~FSA~~Financial Services Agency (FSA) maintains its own solvency standard which is quantified through the SMR. Aflac Japan's SMR is sensitive to interest rate, credit spread, and foreign exchange rate ~~changes,~~changes; therefore, the Company continues to evaluate alternatives for reducing this sensitivity, including the reduction of subsidiary dividends paid to the Parent Company and Parent Company capital contributions. In the event

of a rapid change in market risk conditions causing SMR to decline, the Company has one senior unsecured revolving credit facility in the amount of ¥100 billion and a committed reinsurance facility in the amount of approximately ¥120 billion as a capital contingency plan. Additionally, subject to market conditions, the Company expects that it could take action to enter into derivatives on unhedged U.S. dollar-denominated investments with foreign currency options or ~~forwards.~~forwards or execute additional internal reinsurance transactions with Aflac Re. See Notes 78 and 89 of the Notes to the Consolidated Financial Statements for additional information.

The Company has already undertaken various measures to mitigate the sensitivity of Aflac Japan's SMR. For example, the Company employs policy reserve matching (PRM) investment strategies, which is a Japan-specific accounting treatment that reduces SMR interest rate sensitivity since PRM-designated investments are carried at amortized cost consistent with corresponding liabilities. In order for a PRM-designated asset to be held at amortized cost, there are certain criteria that must be maintained. The primary criterion relates to maintaining the duration of designated assets and liabilities within a specified tolerance range. If the duration difference is not maintained within the specified range without rebalancing, then a certain portion of the assets must be re-classified as available for sale and held at fair value with any associated unrealized gain or loss recorded in surplus. To rebalance, assets may need to be sold in order to maintain the duration with the specified range, resulting in realizing a gain or loss from the sale. For U.S. GAAP, PRM investments are categorized as available for sale. The Company also uses foreign currency derivatives to hedge a portion of its U.S. dollar-denominated investments. See Notes 3, 4 and 8 of the Notes to the Consolidated Financial Statements in the ~~2021~~2022 Annual Report for additional information on the Company's investment strategies, hedging activities, and reinsurance, respectively.

As of March 31, ~~2022,~~2023, Aflac Japan's SMR remains high and reflects a strong capital and surplus position. The Company is committed to maintaining strong capital levels, consistent with maintaining current insurance financial strength and credit ratings.

The FSA is considering the introduction of an economic value-based solvency regime based on the Insurance Capital Standards (ICS) for insurance companies in Japan. The FSA continues to conduct field testing with insurance companies in Japan for the purpose of investigating the impact of the introduction of such regulations. Final specifications are expected to be decided in 2024, and a new capital regime to replace the current solvency regime is expected to be introduced in 2025.

Aflac U.S.

A life insurance company’s statutory capital and surplus is determined according to rules prescribed by the National Association of Insurance Commissioners (NAIC), as modified by the insurance department in the insurance company’s state of domicile. Statutory accounting rules are different from U.S. GAAP and are intended to emphasize policyholder protection and company solvency. The continued long-term growth of the Company's business may require increases in the statutory capital and surplus of its insurance operations. The Company's insurance operations may secure additional statutory capital through various sources, such as internally generated statutory earnings, reduced dividends paid to the Parent Company, capital contributions by the Parent Company from funds generated through debt or equity offerings, or reinsurance transactions. The NAIC’s Risk-based capital (RBC) formula is used by insurance regulators to help identify inadequately capitalized insurance companies. The RBC formula quantifies insurance risk, business risk, asset risk and

104

interest rate risk by weighing the types and mixtures of risks inherent in the insurer’s operations. As of March 31, ~~2022, Aflac’s~~2023, Aflac U.S.'s combined RBC ratio remains high and reflects a strong capital and surplus position.

Aflac, CAIC and TOIC are domiciled in Nebraska and are subject to its regulations. The maximum amount of dividends that can be paid to the Parent Company by Aflac, CAIC and TOIC without prior approval of Nebraska's director of insurance is the greater of the net income from operations, which excludes net investment gains, for the previous year determined under statutory accounting principles, or 10% of statutory capital and surplus as of the previous year-end. Dividends declared by Aflac during ~~2022~~2023 in excess of $1.1 billion would be considered extraordinary and require such approval. Similar laws apply in New York, the domiciliary jurisdiction of Aflac New York.

Privacy and Cybersecurity Governance

The Company’s Board of Directors has adopted an information security policy directing management to establish and operate a global information security program with the goals of monitoring existing and emerging threats and ensuring that the Company’s information assets and data, and the data of its customers, are appropriately protected from loss or theft. The Board has delegated oversight of the Company’s information security program to the Audit and Risk Committee. The Company’s senior officers, including its Global ~~Security and~~ Chief Information Security Officer, are responsible for the operation of the global information security program and ~~communicates~~communicate quarterly with the Audit and Risk Committee on the program, including with respect to the state of the program, compliance with applicable regulations, current and evolving threats, and recommendations for changes in the information security program. The global information security program also includes a cybersecurity incident response plan that is designed to provide a management framework across Company functions for a coordinated assessment and response to potential security incidents. This framework establishes a protocol to report certain incidents to the Global ~~Security and~~ Chief Information Security Officer and other senior officers, with the goal of timely assessing such incidents, determining applicable disclosure requirements and

communicating with the Audit and Risk Committee. The incident response plan directs the executive officers to report certain incidents immediately and directly to the Lead Non-Management Director.

Other

For information regarding commitments and contingent liabilities, see Note 1213 of the Notes to the Consolidated Financial Statements.

Additional Information

Investors should note that the Company announces material financial information in its SEC filings, press releases and public conference calls. In accordance with SEC guidance, the Company may also use the Investor Relations section of the Company's website (http://investors.aflac.com) to communicate with investors about the Company. It is possible that the financial and other information the Company posts there could be deemed to be material information. The information on the Company's website is not part of this document. Further, the Company's references to website URLs are intended to be inactive textual references only.

CRITICAL ACCOUNTING ESTIMATES

The Company prepares its financial statements in accordance with U.S. GAAP. These principles are established primarily by the Financial Accounting Standards Board (FASB). In this MD&A, references to U.S. GAAP issued by the FASB are derived from the FASB Accounting Standards Codification™ (ASC). The preparation of financial statements in conformity with U.S. GAAP requires the Company to make estimates based on currently available information when recording transactions resulting from business operations. The estimates that the Company deems to be most critical to an understanding of its results of operations and financial condition are those related to the valuation of investments and derivatives, DAC, liabilities for future policy benefits, and ~~unpaid policy claims, and~~ income taxes. The preparation and evaluation of these critical accounting estimates involve the use of various assumptions developed from management’s analyses and judgments. Calculations of DAC and the liability for future policy benefits require the use of estimates based on actuarial valuation techniques. The application of these critical accounting estimates determines the values at which 93% of the Company's assets and 80% of its liabilities are reported as of March 31, ~~2022,~~2023, and thus has a direct effect on net earnings and shareholders’ equity. Subsequent experience or use of other assumptions could produce significantly different results.

On January 1, 2023, the Company adopted Accounting Standards Update (ASU) 2018-12, Financial Services - Insurance: Targeted Improvements to the Accounting for Long-Duration Contracts (LDTI). The update significantly changes how insurers account for long-duration contracts and amends existing recognition, measurement, presentation, and disclosure requirements applicable to the Company related to liabilities for future policy benefits and DAC. As part of this adoption,

105

the Company measures together all payments under an insurance contract including future expected claims and unpaid policy claims and related expenses, as an integrated reserve. This resulted in unpaid policy claims on long-duration insurance contracts and accrued claim adjustment expenses that were presented separately in the Company’s consolidated balance sheet pre-adoption to now be presented as part of liabilities for future policy benefits.

For additional information, see Note 1 of the Notes to the Consolidated Financial Statements in this document and in the 2022 Annual Report.

Deferred Policy Acquisition Costs

Amortization of DAC is computed using the same contract groupings (also referred to as cohorts) and mortality and termination assumptions that are used in computing the liability for future policy benefits, and these assumptions are reviewed and updated at least annually. The effects of changes in assumptions are recognized prospectively over the remaining contract term as a revision of future amortization pattern, while current period amortization is calculated based on the actual experience during the quarter. For additional information, see Note 6 of the Notes to the Consolidated Financial Statements.

Future Policy Benefits

The Company's liabilities for future policy benefits are determined in accordance with applicable guidelines as defined under U.S. GAAP and Actuarial Standards of Practice and represent claims that are expected to occur in the future and already incurred claims (which represent claims that have been incurred and are in the process of payment as well as an estimate of those claims that have been incurred but have not yet been reported to the Company) and are measured using the net level premium method. Future policy benefits are calculated using assumptions and estimates including mortality, morbidity, termination (also referred to as lapses), expense, and discount rates. The assumptions and estimates that the Company uses depend on its judgment regarding the likelihood of future events and are inherently uncertain.

Cash flow assumptions (mortality, morbidity, and termination) are established at policy inception and are evaluated each quarter to determine if an update is needed. To facilitate a more detailed review of cash flow assumptions, experience studies are performed annually during the third quarter. Changes in cash flow assumptions are recognized in reserve remeasurement (gains) losses in the consolidated statement of earnings. Expense assumptions are established at policy inception and are not updated. Actual experience is reflected in the calculation of future policy benefits each quarter, and changes in the liability due to actual experience are recognized in reserve remeasurement (gains) losses in the consolidated statement of earnings.

Discount rates used to calculate net premiums are locked in at policy inception and represent the basis to recognize interest expense in the consolidated statement of earnings. Discount rates used to measure the carrying value of liability for future policy benefits in the consolidated balance sheet are updated each reporting period, and the differences between the liability balances calculated using the locked-in discount rates and the updated discount rates are recognized in other comprehensive income (loss) (OCI). The discount rate methodology is designed to prioritize observable inputs based on market data available in the local debt markets where the respective policies were issued in the currency in which the policies are denominated. For the discount rates applicable to tenors for which the single-A debt market is not liquid or there is little or no observable market data, the Company uses various estimation techniques consistent with the fair value guidance in ASC 820, which include, but are not limited to: (i) for tenors where there is less observable market data and/or the observable market data is available for similar instruments, estimating tenor-specific single-A credit spreads and applying them to risk-free government rates; (ii) for tenors where there is very limited or no observable single-A or similar market data, interpolation and extrapolation techniques.

Upon adoption, if interest rates increased by 100 basis points the Company's FPB balance as of December 31, 2022, would decrease by $13.3 billion, and if interest rates decreased by 100 basis points the Company's FPB balance as of December 31, 2022 would increase by $10.4 billion.

See Note 7 of the Notes to the Consolidated Financial Statements for details of future policy benefits activity.

There have been no other changes in the items the Company has identified as critical accounting estimates during the ~~three months~~three-month period ended March 31, ~~2022.~~2023. For additional information, see the Critical Accounting Estimates section of Item 7. MD&A included in the ~~2021~~2022 Annual Report.

106

New Accounting Pronouncements

On January 1, 2023, the Company adopted LDTI employing a modified retrospective transition method, which requires the amended guidance be applied as of the beginning of the earliest period presented beginning on the January 1, 2021 transition date (Transition Date). The Transition Date impact from adoption resulted in a decrease in AOCI of approximately $18.6 billion and a decrease in retained earnings of approximately $0.3 billion.

For information on new accounting pronouncements and the impact, if any, on the Company's financial position or results of operations, see Note 1 of the Notes to the Consolidated Financial Statements.

Item 3.Quantitative and Qualitative Disclosures about Market Risk

The Company is exposed primarily to the following types of market risks: currency risk, interest rate risk, credit risk and equity risk. The Company regularly monitors its market risks and uses a variety of strategies to manage its exposure to these market risks. A description of the Company's market risk exposures may be found under “Quantitative and Qualitative Disclosures About Market Risk” in Part II, Item 7A, of the ~~2021~~2022 Annual Report. There have been no material changes to the Company's market risk exposures from the market risk exposures previously disclosed in the ~~2021~~2022 Annual Report.

Item 4.Controls and Procedures

Disclosure Controls and Procedures

The Company’s management, with the participation of the Company’s Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of the Company’s disclosure controls and procedures (as such term is defined in Rule 13a-15(e) under the Securities Exchange Act of 1934, as amended (the Exchange Act)) as of the end of the period covered by this quarterly report (the Evaluation Date). Based on such evaluation, the Company’s Chief Executive Officer and Chief Financial Officer have concluded that, as of the Evaluation Date, the Company’s disclosure controls and procedures are effective.

Changes in Internal Control Over Financial Reporting

During the first fiscal quarter of ~~2022,~~2023, the Company executed internal controls associated with new processes supporting the implementation of Accounting Standards Update (ASU) 2018-12 for long-duration insurance contracts (LDTI)~~. These controls provide assurance over~~, which the ~~reasonableness of the estimated impact to the Company's accumulated other comprehensive income and retained earnings that is expected upon adoption of LDTI~~Company adopted on January 1, 2023 ~~as disclosed in~~using a modified retrospective method. For additional information, see Note 1 of the accompanying Notes to the Consolidated Financial Statements and Note 1 of the Notes to the Consolidated Financial ~~Statements. The Company will continue to refine and maturate~~Statements in the ~~internal controls associated with LDTI until adoption on January 1, 2023.~~ 2022 Annual Report.

Except for the change in controls over the Company's ~~implementation~~adoption of LDTI, there have not been any changes in the Company’s internal control over financial reporting (as such term is defined in Rule 13a-15(f) under the Exchange Act) during the first fiscal quarter of ~~2022~~2023 that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.

~~PART II. OTHER INFORMATION~~

~~Item 1A.Risk Factors~~

Major public health issues, including COVID-19 and any resulting economic effects could have an adverse impact on the Company's financial condition and results of operations and other aspects of its business.

The Company continues to closely monitor developments related to COVID-19 to assess its impact on the Company's business. Due to the evolving nature of this event, including fluctuations in infection, hospitalization and death rates in the United States, Japan and other regions of the world, COVID-19 could continue to impact the Company's business, financial condition, results of operations, capital position, liquidity or prospects in a number of ways. The pandemic may cause changes to estimates of future earnings, capital deployment and other guidance the Company has provided to the markets in the "2022 Outlook" section of Item 7. MD&A in the 2021 Annual Report.

The continuing effects of the pandemic and the effort by governmental entities, public health authorities and private entities to contain the impact of COVID-19 in the U.S. and Japan, among other factors, result in continuing uncertainty about the severity and duration of the pandemic’s effects on the U.S., Japan and global economies and on the Company's business. The extent to which the pandemic will continue to impact the Company's business, results of operations or financial condition, as well as those of its customers, agents, brokers and other distribution partners, vendors and counterparties, will depend on future developments that are highly uncertain and cannot be predicted, including new information that may emerge concerning the severity of COVID-19, including its variants, and the actions taken to contain or treat its and their impact.

As a result of the COVID-19 pandemic and its effects on the U.S. economy, Aflac U.S. has experienced lower sales and may experience elevated lapse rates due to factors including the proportionately higher concentration of Aflac U.S. policies in force being associated with small businesses that may be disproportionately negatively impacted by the economic uncertainty surrounding COVID-19. Such results may also occur due to economic and other factors affecting larger businesses and individuals. For example, lapse rates experienced by Aflac U.S. during the quarter ended March 31, 2022 were higher than recent historical norms within the large business customer base.

Policies issued by Aflac Japan and Aflac U.S. are primarily sold and enrolled in person through face-to-face interaction. Likewise, recruiting of new agents and brokers largely occurs through in-person contact. The ability of individual agents and agencies, strategic alliance partners, brokers and other distribution partners to make sales in Japan and the U.S. and the ability to conduct agent and broker recruiting has been significantly reduced by efforts to mitigate the effects of the pandemic, including social distancing orders, requirements or guidelines issued by government or public health authorities, and adoption of social distancing techniques and remote working by employees, which may hinder sales of the Company’s products in Japan and the U.S. The Company cannot predict with certainty the continuing impact of these events on its distribution channels and financial results, but the impact to date has been more acute for Aflac U.S. due to the higher number of confirmed COVID-19 cases and deaths in the U.S. to date compared with Japan, both in absolute terms and in proportion to national populations, as well as the historically lower rate of persistency in the Aflac U.S. business. The Company also considers that most Aflac U.S. business customers, and most of the independent agents in its agency channel, are small businesses who may lack the financial resources to weather an economic downturn and may be disproportionately negatively impacted by the economic uncertainty surrounding COVID-19. These factors may continue to negatively impact sales throughout 2022. See the risk factors entitled “Sales of the Company's products and services are dependent on its ability to attract, retain and support a network of qualified sales associates, brokers and employees in the U.S. and sales associates and other distribution partners in Japan” and “Difficult conditions in global capital markets and the economy, including those caused by COVID-19, could have a material adverse effect on the

107

~~Company's investments, capital position, revenue, profitability, and liquidity and harm the Company's business” in Item 1A. Risk Factors in the 2021 Annual Report for more information.~~

Further, the Company's operations, as well as those of its vendors, service providers and counterparties, may also be adversely affected by the COVID-19 pandemic or the mitigation efforts outlined above. In both the U.S. and Japan, the Company has over 50% of its employees working remotely. The Company has begun to implement return to work plans for Aflac Japan and Aflac U.S. that are adaptable and based upon multiple factors including government orders, guidelines issued by public health authorities, the location and job responsibilities of specific Company personnel, rates of COVID-19 vaccinations, cases and deaths in various localities and other factors. The Company may nevertheless experience operational disruptions when employees return to work.

The assumptions and estimates that the Company uses in establishing premiums and reserves depend on the Company's judgment regarding the likelihood of future events and are inherently uncertain, including without limitation in regard to the effects of COVID-19. See the risk factor entitled “If future policy benefits, claims or expenses exceed those anticipated in establishing premiums and reserves, the Company's financial results would be adversely affected” in Item 1A. Risk Factors and the "Executive Summary" section of Item 7. MD&A in the 2021 Annual Report for more information.

For more information on the effects of the COVID-19 pandemic on markets and investments, see the risk factor entitled, “Difficult conditions in global capital markets and the economy, including those caused by the COVID-19, could have a material adverse effect on the Company's investments, capital position, revenue, profitability, and liquidity and harm the Company's business” in Item 1A. Risk Factors in the 2021 Annual Report.PART II. OTHER INFORMATION

Item 2.Unregistered Sales of Equity Securities and Use of Proceeds

Issuer Purchases of Equity Securities

During the first three months of ~~2022,~~2023, the Parent Company repurchased shares of its common stock as follows:


Period	Period	Total Number of Shares Purchased		Average Price Paid Per Share		Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs	Maximum Number of Shares that May Yet Be Purchased Under the Plans or Programs	Period	Total Number of Shares Purchased		Average Price Paid Per Share		Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs	Maximum Number of Shares that May Yet Be Purchased Under the Plans or Programs
January 1 - January 31	January 1 - January 31	1,933,400		$	61.87	1,933,400	53,895,617	January 1 - January 31	2,440,300		$	72.15	2,440,300	114,201,523
February 1 - February 28	February 1 - February 28	3,183,212		63.58		2,845,206	51,050,411	February 1 - February 28	3,542,907		69.48		3,200,100	111,001,423
March 1 - March 31	March 1 - March 31	3,233,866		61.93		3,228,600	47,821,811	March 1 - March 31	4,711,768		64.20		4,707,900	106,293,523

Total	Total	8,350,478	(1)	$	62.55	8,007,206	47,821,811	Total	10,694,975	(1)	$	67.76	10,348,300	106,293,523	(2)

(1) During the first three months of ~~2022, 343,272~~2023, 346,675 shares were purchased in connection with income tax withholding obligations related to the vesting of restricted-share-based awards during the period.

(2) The total remaining shares available for purchase at March 31, 2023, consisted of 6,293,523 shares related to a 100,000,000 share repurchase authorization by the board of directors announced in August 2020 and 100,000,000 shares related to a 100,000,000 share repurchase authorization by the board of directors announced in November 2022.

96108

Item 6. Exhibits


(a)	EXHIBIT INDEX
	3.0	-	Articles of Incorporation, as amended – incorporated by reference from Form 10-Q for June 30, 2008, Exhibit 3.0.
	3.1	-	Bylaws of the Corporation, as amended and restated – incorporated by reference from Form 8-K dated February 11, 2022, Exhibit 3.1.
	10.1*	-	~~U.S. Form of Employee Restricted Stock Award Agreement under the~~ Aflac Incorporated ~~Long-Term~~2023 Management Incentive Plan ~~as amended and restated February 14, 2017~~ – incorporated by reference from Form 8-K dated February ~~11, 2022,~~10, 2023, Exhibit 10.1.
	10.2*	-	~~Japan Form of Employee Restricted Stock Award Agreement under the~~ Aflac Incorporated ~~Long-Term Incentive~~Executive Officer Severance Plan ~~as amended and restated February 14, 2017 – incorporated by reference from Form 8-K dated February 11, 2022, Exhibit 10.2.~~
	31.1	-	Certification of CEO dated ~~April 29, 2022,~~May 1, 2023, required by Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934.
	31.2	-	Certification of CFO dated ~~April 29, 2022,~~May 1, 2023, required by Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934.
	32	-	Certification of CEO and CFO dated ~~April 29, 2022,~~May 1, 2023, pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
	101.INS	-	XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
	101.SCH	-	Inline XBRL Taxonomy Extension Schema.
	101.CAL	-	Inline XBRL Taxonomy Extension Calculation Linkbase.
	101.DEF	-	Inline XBRL Taxonomy Extension Definition Linkbase.
	101.LAB	-	Inline XBRL Taxonomy Extension Label Linkbase.
	101.PRE	-	Inline XBRL Taxonomy Extension Presentation Linkbase.
	104	-	Cover Page Interactive Data File - formatted as Inline XBRL and contained in Exhibit 101.

Management contract or compensatory plan or arrangement required to be filed as an exhibit pursuant to Item 6 of this report

97109

~~Defined Terms~~

~~Throughout this Quarterly Report on Form 10-Q, the Company may use abbreviations, acronyms and defined terms which are defined below.~~


~~ALM~~			~~Asset-Liability Matching~~
~~AOCI~~			~~Accumulated Other Comprehensive Income~~
~~ASC~~			~~Accounting Standards Codification~~
~~ASU~~			~~Accounting Standards Update~~
~~CDS~~			~~Credit Default Swap~~
~~CML~~			~~Commercial Mortgage Loan~~
~~CSA~~			~~Credit Support Annex~~
~~DAC~~			~~Deferred Policy Acquisition Costs~~
~~DSCR~~			~~Debt Service Coverage Ratios~~
~~EPS~~			~~Earnings Per Share~~
~~FASB~~			~~Financial Accounting Standard Board~~
~~FHLB~~			~~Federal Home Loan Bank of Atlanta~~
~~FSA~~			~~Japanese Financial Services Agency~~
~~ISDA~~			~~International Swaps and Derivatives Association, Inc.~~
~~ISO~~			~~Incentive Stock Option~~
~~Japan Post Group~~			~~Japan Post Holdings, Japan Post Co. and Japan Post Insurance, collectively~~
~~Japan Post Holdings~~			~~Japan Post Holdings Co., Ltd.~~
~~Japan Post Co.~~			~~Japan Post Co. Ltd~~
~~Japan Post Insurance~~			~~Japan Post Insurance Co., Ltd.~~
~~JGB~~			~~Japan Government Bond~~
~~LDTI~~			~~Long-Duration Targeted Improvements~~
~~LGD~~			~~Loss-Given-Default~~
~~LIBOR~~			~~London Interbank Offered Rate~~
~~LIPPC~~			~~Life Insurance Policyholder Protection Corporation~~
~~LTV~~			~~Loan-to-Value~~
~~MD&A~~			~~Management's Discussion and Analysis of Financial Condition and Results of Operations~~
~~MML~~			~~Middle Market Loan~~
~~NAIC~~			~~National Association of Insurance Commissioners~~
~~NOLHGA~~			~~National Organization of Life and Health Guaranty Associations~~
~~NQSO~~			~~Non-qualifying Stock Option~~
~~NRSRO~~			~~Nationally Recognized Statistical Rating Organization~~
~~OTC~~			~~Over-the-Counter~~
PD			~~Probability-of-Default~~
~~PRM~~			~~Policy Reserve Matching~~
~~RBC~~			~~Risk-Based Capital~~
~~ROE~~			~~Return on Equity~~
~~S&P~~			~~Standard & Poor's~~
~~SEC~~			~~Securities and Exchange Commission~~
~~SMR~~			~~Solvency Margin Ratio~~
~~SOFR~~			~~Secured Overnight Financing Rate~~
~~The Plan~~			~~Aflac Incorporated Long-Term Incentive Plan~~
~~TIBOR~~			~~Tokyo Interbank Market Rate~~
~~TDR~~			~~Troubled Debt Restructuring~~
~~TRE~~			~~Transitional Real Estate Loan~~
~~TTM~~			~~Telegraphic Transfer Middle Rate~~
~~U.S. GAAP~~			~~U.S. Generally Accepted Accounting Principles~~
~~VIE~~			~~Variable Interest Entity~~

Glossary of Selected Terms

Throughout this Quarterly Report on Form 10-Q, the Company may use certain performance metrics and other terms which are defined below.

Adjusted Net Investment Income - Net Investment Income adjusted for i) amortized hedge cost/income related to foreign currency exposure management strategies and certain derivative activity and ii) net interest cash flows from foreign currency and interest rate derivatives associated with certain investment strategies, which are reclassified from net investment gains and (losses) to net investment income. The Company considers adjusted net investment income important because it provides a more comprehensive understanding of the costs and income associated with the Company's investments and related hedging strategies. The metric is used in segment reporting as a component of segment profitability.

Affiliated Corporate Agency – Agency in Japan directly affiliated with a specific corporation that sells insurance policies primarily to its employees.

Annualized Premiums in Force – the amount of gross premium that a policyholder must pay over a full year in order to keep coverage. The growth of net earned premiums (defined below) is directly affected by the change in premiums in force and by the change in weighted-average yen/dollar exchange rates.

Average Weekly Producer – The total number of writing agents who have produced greater than $0.00 during the production week - excluding any manual adjustments divided by the number of weeks in the time period. The Company believes this metric allows sales management to monitor progress and needs, as well as serve as a leading indicator of future production capacity.

Capital Buffer – Established dollar amount of liquidity at the Parent Company reserved for injecting capital into the insurance entities or general liquidity support for general expenses at the Parent Company. Currently, the capital buffer is $1.0 billion and is part of ~~$2.0~~the $1.8 billion target minimum balance at the Parent Company.

Earnings Per Basic Share – Net earnings divided by weighted-average number of shares outstanding for the period.

Earnings Per Diluted Share – Net earnings divided by the weighted-average number of shares outstanding for the period plus the weighted-average shares for the dilutive effect of share-based awards outstanding.

Group Insurance – Insurance issued to a group, such as an employer or trade association, that covers

employees or association members and their dependents through certificates of coverage.

Individual Insurance – Insurance issued to an individual with the policy designed to cover that person and his or her dependents.

~~In-force~~In force Policies – A count of policies that are active contracts at the end of a period.

Liquidity Support – Internally defined and established dollar amount of liquidity reserved for supporting potential collateral and settlements of derivatives at the Parent Company. Currently, the liquidity support is ~~$1.0~~$0.8 billion and is part of the ~~$2.0~~$1.8 billion target minimum balance at the Parent Company.

Net Investment Income – The income derived from interest and dividends on invested assets, after deducting investment expenses.

Net Earned Premiums – is a financial measure that appears on the Company's Consolidated Statements of Earnings and in its segment reporting. This measure reflects collected or due premiums that have been earned ratably on policies in force during the reporting period, reduced by premiums that have been ceded to third parties and increased by premiums assumed through reinsurance.

New Annualized Premium Sales – (sometimes referred to as new sales or sales) An operating measure that is not reflected on the Company's financial statements. New annualized premium sales generally represent annual premiums on policies and riders the Company sold and incremental increases from policy conversions that would be collected over a 12-month period assuming the policies remain in force for that entire period. For Aflac Japan, new annualized premium sales are determined by applications submitted during the reporting period. For Aflac U.S., new annualized premium sales are determined by applications. that are issued during the reporting period. Policy conversions are defined as the positive difference in the annualized premium when a policy upgrades in the current reporting period.

New Money Yield – Gross yields earned on purchases of fixed maturities, loan receivables, and equities. Purchases exclude capitalized interest, securities lending/repurchase agreements, short-term/cash activity, and alternatives. New money yield for equities is based on the assumed dividend yield at the time of purchase. The new money yield for Aflac Japan excludes the impact of any derivatives and associated amortized hedge costs associated with USD-denominated investments. Management uses this metric as a leading indicator of future investment earning potential.

110

Operating Ratios – Used to evaluate the Company's financial condition and profitability. Examples include:

(1) Ratios to total adjusted revenues, which present expenses as a percentage of total revenues and (2) Ratios to total premium, including benefit ratio.

Premium Persistency – Percentage of premiums remaining in force at the end of a period, usually one ~~year.~~year, and presented on a trailing 12-month basis. For example, 95% persistency would mean that 95% of the premiums in force at the beginning of the period were still in force at the end of the period. The Company believes that this metric is a key driver of in force levels, which is a key measure of the size of the Company's business and future sources of earnings.

Pretax Adjusted Earnings – Earnings as adjusted earnings before the application of income taxes. This measure is used in the Company's segment reporting.

Pretax Adjusted Profit Margin – Adjusted earnings divided by adjusted revenues, before taxes are applied. This measure is used in the Company's segment reporting.

Return on Average Invested Assets – Net investment income as a percentage of average invested assets during the period. Management uses this metric to demonstrate how our actual net investment income results represent an overall return on the portfolio to provide a more comparative metric as the size of our investment portfolio changes over time.

Risk-based Capital (RBC) Ratio – Statutory adjusted capital divided by statutory required capital. This insurance ratio is based on rules prescribed by the National Association of Insurance Commissioners (NAIC) and provides an indication of the amount of statutory capital the insurance company maintains, relative to the inherent risks in the insurer’s operations.

Solvency Margin Ratio (SMR) – Solvency margin total divided by one half of the risk total. This insurance ratio is prescribed by the Japan Financial Services Agency (FSA) and is used for all life insurance companies in Japan to measure the adequacy of the company’s ability to pay policyholder claims in the event actual risks exceed expected levels.

Statutory Earnings – Earnings determined according to accounting rules prescribed by the National Association of Insurance Commissioners (NAIC), as modified by the insurance department in the insurance company’s state of domicile. These statutory accounting rules are different from U.S. GAAP and are intended to emphasize policyholder protection and company solvency.

Weighted-Average Foreign Currency Exchange Rate – Japan segment operating earnings for the period (excluding hedge costs) in yen divided by Japan

segment operating earnings for the period (excluding hedge costs) in dollars. Management uses this metric to evaluate and determine consolidated results on foreign currency effective basis.

~~100~~111

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


						Aflac Incorporated

~~April 29, 2022~~May 1, 2023						/s/ Max K. Brodén
						(Max K. Brodén)
						Executive Vice President; Chief Financial Officer

~~April 29, 2022~~May 1, 2023						/s/ June Howard
						(June Howard)
						Senior Vice President, Financial Services; Chief Accounting Officer

~~101~~112


Three Months Ended March 31, 2021
	Fixed Maturity Securities										Equity Securities		Derivatives
(In millions)	Mortgage- and Asset- Backed Securities		Public Utilities		Sovereign and Supranational		Banks/ Financial Institutions		Other Corporate				Foreign Currency Swaps		Total
Balance, beginning of period	$	224	$	422	$	48	$	24	$	299	$	102	$	(98)	$	1,021
Net investment gains (losses) included in earnings	0		0		0		0		0		9		19		28
Unrealized gains (losses) included in other comprehensive income (loss)	(15)		(18)		(3)		(1)		(12)		0		(1)		(50)
Purchases, issuances, sales and settlements:
Purchases	10		78		0		5		0		11		0		104
Issuances	0		0		0		0		0		0		0		0
Sales	0		0		0		0		0		0		0		0
Settlements	0		(3)		0		0		0		0		0		(3)
Transfers into Level 3	0		0		23		0		32		0		0		55
Transfers out of Level 3	(15)		0		0		0		0		0		0		(15)
Balance, end of period	$	204	$	479	$	68	$	28	$	319	$	122	$	(80)	$	1,140
Changes in unrealized gains (losses) relating to Level 3 assets and liabilities still held at the end of the period included in earnings	$	0	$	0	$	0	$	0	$	0	$	0	$	19	$	19


			Page
Executive Summary			6577
Results of Operations			6678
Investments			7992
Hedging Activities			8496
Deferred Policy Acquisition Costs			8899
Policy Liabilities			88100
Benefit Plans			89100
Policyholder Protection			89100
Liquidity and Capital Resources			89100
Critical Accounting Estimates			94105